About the Editor

INNOVATIONS IN DRUG

Innovations in Drug Discovery: Formulation and

DR VISHNU KIRAN MANAM

DISCOVERY
[Link] [Micro-Bio], [Link]. [Biotech], MBA [Finance], PhD [Micro-Bio-Nanotech]
Six Sigma [Yellow, Green & Black Belt] certified professional.
SENIOR SCIENTIST | DEPUTY GENERAL MANAGER - R&D

Formulation and Delivery Strategies

IB GROUP [AQUACULTURE]
CHAIRMAN – UNIVERSAL SOCIETY OF RESEARCH & DEVELOPMENT

Delivery Strategies
Mail Id: [Link]@[Link]
Mobile: +91 9080611328

S. No Domain Experience (Years)

1 Aquaculture 8
2 R&D / Analytical 16
3 Academic 4
Edited by
He is a highly experienced Ph.D. doctorate in Applied Microbiology with a specialization in Nanotechnology.
With 19 years of expertise in Research and Development, Academics, Aquaculture, Analytical, Data
Analysis, Liaison and coordination, and Team Management, He has made significant contributions to Dr. Vishnu Kiran Manam
various organizations. He has been certified with Six Sigma [Yellow Belt, Green Belt & Black Belt]. He has
bagged the BEST SCIENTIST AWARD from IARDO, the YOUNG SCIENTIST AWARD from ELSEVIER
SSRN, the RESEARCH EXCELLENCE AWARD from RES, the BEST RESEARCHER AWARD from ISCAW
– ESM for the year 2021, and the BEST SCIENTIST AWARD from HyEdge for the year 2022. He has a
proven track record of delivering breakthrough improvements in operational excellence by implementing
research improvement techniques and ensuring quality compliance. In senior management roles, He has
successfully aligned resources, developed technology strategies, and evolved innovation management
focus areas to achieve strategic goals. His strengths lie in enhancing process operations, optimizing
resources and capacity utilization, and driving productivity and operational efficiencies while reducing

Dr. Vishnu Kiran Manam

costs and expenses. He has a reputation for high integrity and energy, and he excels in creating service level
agreements (SLAs), standard operating procedures (SOPs), and manuals. Additionally, He has a strong
ability to recruit and train multicultural teams with the latest knowledge and modern skills in Research
and Development and product development fields, enabling the deliv ery of high-quality services. As an
enterprising leader, He has a proven ability to direct personnel and foster a collaborative environment
that leads to the accomplishment of common goals. He is known for his vision and strategic thinking,
ensuring that organizations are positioned for success. Overall, He brings a wealth of experience, expertise,
and leadership skills to drive innovation, ensure quality, and achieve strategic objectives in the areas of
Aquaculture, Applied Microbiology, Research and Development, and Team Management.

SCIENG PUBLICATIONS ISBN: 978-93-94766-50-1

(ISO 9001:2015 Certified Company)

Janani lllam, Maniyakar Street, Anumandai, Marakkanam Taluk
Villupuram District, Tamilnadu 604303
website:[Link] Email:sciengpublications@[Link]
MRP- 1180/-
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND
DELIVERY STRATEGIES

VOLUME - I

Edited by
DR. VISHNU KIRAN MANAM
[Link] [Micro-Bio], [Link]. [Biotech], MBA [Finance], PhD [Micro-Bio-Nanotech]
Six Sigma [Yellow, Green & Black Belt] certified professional.
Senior Scientist / DGM – R&D,
IB Group, Chhattisgarh, India.
Chairman – Universal Society for Research & Development
[USRD]

SCIENGPUBLICATIONS
Tamilnadu-604303 (INDIA)
(ISO 9001:2015 Certified Company)
<<<<<<<<<<<<<<<<<<

Copyright: Editors
Title: INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND
DELIVERY STRATEGIES
Editor: DR VISHNU KIRAN MANAM

All rights reserved. No part of this publication may be reproduced or

transmitted, in any form or by any means, without permission. Any person who
does any unauthorized act about this publication may be liable for criminal
prosecution and civil claims for damages.

First Published, 2024

ISBN: 978-93-94766-50-1

Published by:

(ISO 9001:2015 Certified Company)

REGISTERED OFFICE: Janani Illam, Maniyakar Street, Anumandai,
Marakkanam Taluk, Villupuram District, Tamil Nadu 604303.
CORPORATE OFFICE: No 8916, LIG -1, TNHB, Ayappakkam,
Chennai - 600077 (Opp ICMR - NIE)
OVERSEAS OFFICE: 11505, Dublin Road, Glen Allen, Virginia, USA - 23060
Customer Care: 9500979328 | E-Mail: sciengpublications@[Link],
editor@[Link]
Website: [Link]

Printed in India by Sagar Color Scan New Delhi.

Disclaimer: The views expressed in the book are of the authors and not
necessarily of the publisher and editors. Authors themselves are responsible for
any kind of plagiarism found in their chapters and any related issues found
within the book.

<<<<<<<<<<<<<<<<<<

ii
<<<<<<<<<<<<<<<<<<0.75

PREFACE

DR. NALINA KEERAN PhD

Former Assistant Director,
Forensic Sciences Department, Chennai, Tamilnadu, India.
Former Assistant Professor Royal College of Medicine,
Perak University Kuala Lumpur, Malaysia.

I welcome the book Innovations in Drug Discovery: Formulation and Delivery

Strategies as an effort undertaken by the editors and all authors.
In the rapidly evolving field of pharmaceutical science, advancements in drug
discovery and delivery continue to redefine the boundaries of modern medicine.
This book, Innovations in Drug Discovery: Formulation and Delivery Strategies,
seeks to capture the breadth of transformative ideas, tools, and methodologies
shaping today's healthcare landscape. From the naturally derived healing
properties of Aloe vera to complex AI-driven drug discovery, each chapter
addresses a facet of pharmaceutical science with the potential to impact millions
of lives.
Dr. Vishnu Kiran Manam has ably edited the book which is crafted for scientists,
students, and healthcare professionals alike, offering a comprehensive
understanding of the latest in pharmaceutical sciences. Through these chapters,
we hope to inspire continued exploration and collaboration, guiding the next
generation of discoveries that will define the future of medicine.
I wish all the success to the editors and all the authors.

<<<<<<<<<<<<<<<<<<

iii
<<<<<<<<<<<<<<<<<<

ABOUT THE BOOK

INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY
STRATEGIES

The edited books are penned down prospecting the current scenarios in the

relevant field with comparison to the past scenarios equipping the readers with

ample knowledge on the subject. In an era where the need for precise, effective,

and sustainable therapies is greater than ever, Innovations in Drug Discovery:

Formulation and Delivery Strategies book explores groundbreaking

advancements in pharmaceuticals, providing a comprehensive overview of

modern approaches to creating, testing, and administering therapeutic agents.

This book delves into the realms of personalized medicine, nanotechnology, AI-

driven drug discovery, and sustainable methods to present a wide-ranging look

at how today’s innovations are transforming healthcare. The journey begins

with nature's wonders, exploring the therapeutic characteristics of Aloe vera

and its applications in medicinal formulations. Traditional healing methods

inspire new pathways in drug delivery, and these age-old remedies serve as the

foundation for today’s complex pharmacological advancements.

Oral and non-oral drug delivery innovations take center stage,

illustrating how carefully designed delivery methods can improve patient

compliance and therapeutic efficacy. Building upon these, nanotechnology

introduces groundbreaking opportunities to target diseased tissues with

remarkable precision. The use of eco-friendly silver nanoparticles, for example,

<<<<<<<<<<<<<<<<<<

iv
<<<<<<<<<<<<<<<<<<0.75

demonstrates how drug loading on cancer cells can be both effective and

sustainable, minimizing harm to healthy cells while maximizing impact on

malignant ones.

The rise of computational methods, particularly in silico drug design, has

revolutionized drug discovery, enabling researchers to predict molecular

interactions and streamline the initial stages of drug development. These

computational models support personalized medicine, where treatments are

finely tuned to each patient’s genetic and physiological profile. AI and machine

learning further empower scientists by accelerating data analysis and enhancing

predictive accuracy, leading to smarter, more targeted treatments.

This volume also explores the fascinating fields of RNA interference

(RNAi) and small interfering RNA (siRNA) in cancer treatment, offering

insights into gene silencing techniques that bring hope to patients battling

cancer. The advent of biologics, biosimilars, and mRNA therapies has further

expanded the treatment arsenal for diseases previously deemed untreatable.

As the book delves into advanced drug delivery platforms like hydrogels,

plant genomics for personalized medicine, and targeted delivery systems,

ethical considerations surrounding these technologies emerge. The pace of

pharmaceutical innovation must balance with ethical deliberation, ensuring

equitable access and addressing the societal impact of these breakthroughs.

<<<<<<<<<<<<<<<<<<

v
<<<<<<<<<<<<<<<<<<

Finally, translational research and drug repurposing are examined as

critical processes for bridging laboratory discoveries with real-world medical

applications. By repurposing existing drugs for new therapeutic areas,

researchers are shortening the path to treatment, addressing unmet needs

swiftly and efficiently.

DR VISHNU KIRAN MANAM

EDITOR

<<<<<<<<<<<<<<<<<<

vi
<<<<<<<<<<<<<<<<<<0.75

CONTENTS

SR. NO. TITLE OF THE CHAPTER PAGE NO.

Preface iii
About the Book iv-vi
1. Aloe Vera: Nature’s Healing Wonder – Characteristics, Uses, and
Medicinal Formulations 1-5
Dr. Dintu K P & Christina Das
Oral and Non-Oral Drug Delivery Innovations
2. 6-16
Dr. Vishnu Kiran Manam
Application of Nanotechnology in Pharmaceutical Sciences
3. Chandrashekar. C. Patil, Santosh Karajgi, Sayed Samiullah & Chetan 17-25
M
Utilizing Computational Methods for Drug Discovery: In Silico
4. Drug Design 26-33
Dr. Pratibha Yadav & Dr. Sharad Sigh Lodhi

Personalized Medicine and Precision Drug Formulation

5. 34-46
Dr. Bhawana Pandey

Drug Loading and Cytotoxic Effects on Cancer Cell Lines Using

6. Eco-Friendly Silver Nanoparticles 47-61
Dr. Greeshma K P, Dr. Dhanya B Sen & Dr. Muthulingam. S
Antiviral Drug Resistance and Virulence Factor of The Resistant
7. Strains 62-70
Rohith Satheesh, Megha Manoj, Laya R Ganesh & Subhajit Nath
In Silico Drug Design
8. 71-89
Dr. K. Santhanalakshmi
RNAi and SiRNA in Cancer Treatment: A Promising Therapeutic
9. Approach 90-104
Ashish Ranjan Bharadwaj & Priyanka Shankarishan
Revolutionizing Medicine: The Rise of Biologics, Biosimilars, and
10. M-RNA Therapies 105-121
Mr. Neil B. Panchal
<<<<<<<<<<<<<<<<<<

vii
<<<<<<<<<<<<<<<<<<

Revolutionizing Healthcare: Advanced Drug Delivery Platforms

11. and Ethical Considerations 122-135
Mr. Neil B. Panchal
Harnessing Plant Genomics for Personalized Medicines:
12. Innovations in Drug Formulations 136-142
Vaishnavi. V.V & Dr. S. Uma Gowrie
AI-Driven Drug Discovery and Development: A New Era in
Therapeutics
13. Dr. Sharad Singh Lodhi, Dr. Pratibha Yadav & Dr. Atul Kumar Singh 143-148
Translational Research and Drug Repurposing
14. Ms. Amrita Sahu, Mr. Indrajit Bhattacharya & Dr. Somasundaram 149-159
Arumugam

Hydrogels: An Alternative Technique to Drug Delivery

15. 160-167
Mrs. R. Priyanka
Targeted Drug Delivery: A Thunderstriking Science
16. 168-172
Dr. Aadil Ajij Momin
Artificial Intelligence (AI) and Machine Learning (ML)
17. Mrs. Malakalaiarasi. M, Mrs. Kamalathangam. C & Mrs. 173-182
Selvamaheshwari. P
Wearable Drug Delivery Systems: Innovations and Applications
18. 183-188
Mrs. Anitha B

An overview of effect of siddha immunomodulators against

19. Various diseases and infections 189-198
Dr. M. Ramani & Dr. S. Selvakumar

Herbal Remedy for Veterinary Ailments

20. 199-207
Dr. M. Menaka & Dr. S. Selvakumar

<<<<<<<<<<<<<<<<<<

viii
 Chapter ALOE VERA: NATURE’S HEALING WONDER –
1 CHARACTERISTICS, USES, AND MEDICINAL
FORMULATIONS

DR. DINTU K P1* & CHRISTINA DAS2

1 Department of Botany, Fatima Mata National College (Autonomous),

Kollam, Kerala, India
2Nazareth College of Pharmacy, Othera, Thiruvalla, Kerala, India

*Corresponding Author: Dr. Dintu K P, Email: dintukp@[Link]

ABSTRACT
Aloe vera (Aloe barbadensis Miller) is a succulent plant with a long history of medicinal and
therapeutic use, particularly in skin care, wound healing, and gastrointestinal health. This
paper explores the botanical characteristics, medicinal properties, and active compounds of
Aloe vera. Its therapeutic potential lies in the bioactive constituents found in its inner leaf
gel, which includes vitamins, enzymes, minerals, and polysaccharides such as acemannan.
Aloe vera’s well-documented benefits include accelerated wound healing, anti-
inflammatory, antioxidant, and laxative effects, as well as emerging research on its potential
anti-cancer properties. This review also examines various Aloe vera-based medicinal
formulations, including topical applications, oral preparations, and advanced
nanotechnology-based systems aimed at enhancing its bioavailability and therapeutic
efficacy. While Aloe vera’s medicinal potential is significant, further research and
innovations in formulation are necessary to fully harness its benefits in modern healthcare.

KEYWORDS: Aloe vera, medicinal uses, nanotechnology, herbal formulations.

INTRODUCTION
Aloe vera (Aloe barbadensis Miller), a succulent plant native to the Arabian Peninsula and
cultivated globally in tropical and arid climates, has long been valued for its medicinal and
therapeutic properties. The plant has been used in traditional and modern medicine for a
range of treatments, from skin care and wound healing to gastrointestinal disorders and
inflammation [1]. This essay delves into the botanical characteristics of Aloe vera, its uses in
various medicinal formulations, and its active compounds, with references to support the
claims.
Responsibility of contents of this book rests upon the authors and not upon the Editor & Publisher
2 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Fig. 1: Aloe Vera (Aloe barbadensis Miller)

BOTANICAL CHARACTERISTICS OF ALOE VERA

Aloe vera is a perennial, drought-resistant plant belonging to the Asphodelaceae family. It
grows in rosettes and can reach a height of 60-100 cm. The plant has thick, fleshy leaves that
are serrated along the edges, and these leaves are the primary source of its medicinal
properties. The inner leaf gel, which makes up the bulk of the plant’s therapeutic
substances, contains over 75 potentially active constituents, including vitamins, enzymes,
minerals, sugars, lignin, saponins, salicylic acids, and amino acids [2].
Aloe vera thrives in well-drained, sandy soil and requires minimal water, making it
ideal for cultivation in dry climates. The plant blooms annually, producing tubular yellow
flowers. The gel and latex derived from the leaves are used in a variety of products,
including medicines, cosmetics, and health supplements.

MEDICINAL USES OF ALOE VERA

The medicinal properties of Aloe vera are well-documented across ancient texts and
modern research. The plant's gel and latex are used in various forms to treat a wide range of
health conditions.

1. Wound Healing and Skin Care

Aloe vera is perhaps best known for its skin-healing properties. Studies have shown
that Aloe vera gel can accelerate the healing of burns, cuts, and wounds by
enhancing collagen synthesis and improving blood circulation at the site of the
injury [3]. It also acts as a moisturizing agent, which is why it is commonly found in
skincare products. The cooling effect of the gel makes it effective for sunburn
treatment as well [4].
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 3

2. Gastrointestinal Health
Aloe vera is also used in the treatment of gastrointestinal disorders such as irritable
bowel syndrome (IBS) and ulcers. The plant’s polysaccharides, such as acemannan,
help soothe the digestive tract and have anti-inflammatory properties that reduce
discomfort [5]. Aloe latex, which is a bitter yellow substance derived from the leaf's
skin, is known for its laxative effect, although its use should be regulated due to
potential side effects like cramping and dehydration [6].

3. Anti-Inflammatory and Antioxidant Effects

The bioactive compounds in Aloe vera, including vitamins A, C, and E, possess
significant antioxidant properties that help neutralize free radicals and reduce
oxidative stress [7]. These antioxidant effects, combined with the plant's anti-
inflammatory properties, make it effective in managing inflammatory conditions
such as arthritis and promoting overall health.

4. Anti-Cancer Potential
Some research suggests that Aloe vera has anti-cancer properties due to its ability to
boost immune function and inhibit tumor growth. The polysaccharide acemannan,
found in Aloe vera gel, has been studied for its immunomodulatory effects, which
help enhance the body’s natural defense mechanisms against cancer cells [8].
However, further research is necessary to validate these claims fully.

ALOE VERA-BASED MEDICINES AND FORMULATIONS

Due to its wide range of medicinal benefits, Aloe vera is formulated into various products
for topical, oral, and cosmetic use. These formulations are designed to enhance the
bioavailability of Aloe vera’s active ingredients and ensure targeted delivery.

1. Topical Formulations
Topical Aloe vera formulations include gels, creams, lotions, and ointments. These
products are primarily used for treating burns, cuts, and skin conditions like
psoriasis and eczema. Aloe vera gel, when applied to the skin, forms a protective
layer and helps retain moisture, promoting faster healing [9]. Combining Aloe vera
with other natural ingredients like tea tree oil or lavender oil can further enhance its
antimicrobial and soothing properties.

2. Oral Formulations
Aloe vera is also available in oral forms such as capsules, tablets, and juices. These
are used to treat gastrointestinal issues and for their laxative properties. Aloe vera
juices are marketed for digestive health and detoxification, often combined with
other herbal ingredients to improve flavor and enhance health benefits [10]. Oral
4 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

formulations aim to deliver Aloe vera's active compounds, such as acemannan, to

the gut to support immune function and digestive health.

3. Nanotechnology-Based Formulations
Recent advances in nanotechnology have led to the development of
nanoformulations of Aloe vera, improving its bioavailability and stability.
Nanoemulsions and liposomes containing Aloe vera extracts have been developed
for better skin penetration and prolonged release of active ingredients [11]. These
formulations are particularly effective in skincare, where sustained release is crucial
for treating chronic skin conditions.

4. Combination Formulations
Aloe vera is often combined with other medicinal plants or compounds to create
multi-purpose formulations. For instance, Aloe vera gel is frequently incorporated
into skincare products with ingredients like chamomile or calendula to enhance its
soothing and healing properties. In pharmaceuticals, Aloe vera extracts are
sometimes combined with other natural or synthetic compounds to improve their
effectiveness in treating conditions like ulcers or inflammatory diseases [12].

CONCLUSION
Aloe vera has established itself as a versatile and valuable medicinal plant with a broad
spectrum of uses in skincare, gastrointestinal health, wound healing, and even cancer
treatment. Its bioactive components, such as acemannan, vitamins, and antioxidants,
contribute to its therapeutic properties. However, like many natural products, Aloe vera's
effectiveness depends on proper formulation and delivery. Advances in nanotechnology
and the development of new formulations are helping to optimize the bioavailability and
stability of Aloe vera's active ingredients, allowing for better therapeutic outcomes.
Continued research is necessary to explore the full potential of Aloe vera in modern
medicine.

REFERENCES
1. Ahlawat, K. S., & Khatkar, B. S. (2011). Processing, food applications and safety of
aloe vera products: A review. Journal of Food Science and Technology, 48(5), 525-533.
2. Hamman, J. H. (2008). Composition and applications of Aloe vera leaf gel. Molecules,
13(8), 1599-1616.
3. Reuter, J., Jocher, A., Stump, J., Grossjohann, B., Franke, G., & Schempp, C. M.
(2008). Investigation of the anti-inflammatory potential of Aloe vera gel (97.5%) in
the ultraviolet erythema test. Skin Pharmacology and Physiology, 21(2), 106-110.
4. Surjushe, A., Vasani, R., & Saple, D. G. (2008). Aloe vera: A short review. Indian
Journal of Dermatology, 53(4), 163-166.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 5

5. Langmead, L., Feakins, R. M., Goldthorpe, S., Holt, H., Tsironi, E., De Silva, A., ... &
Rampton, D. S. (2004). Randomized, double-blind, placebo-controlled trial of oral
Aloe vera gel for active ulcerative colitis. Alimentary Pharmacology & Therapeutics,
19(7), 739-747.
6. Marshall, K. R. (1990). Aloe vera gel: What is the evidence? Phytotherapy Research,
4(1), 3-6.
7. Ahlawat, K. S., & Khatkar, B. S. (2011). Processing, food applications and safety of
aloe vera products: A review. Journal of Food Science and Technology, 48(5), 525-533.
8. Grindlay, D., & Reynolds, T. (1986). The Aloe vera phenomenon: A review of the
properties and modern uses of the leaf parenchyma gel. Journal of
Ethnopharmacology, 16(2-3), 117-151.
9. Dat, A. D., Poon, F., Pham, K. B., & Doust, J. (2012). Aloe vera for treating acute and
chronic wounds. Cochrane Database of Systematic Reviews, (2).
10. Boudreau, M. D., & Beland, F. A. (2006). An evaluation of the biological and
toxicological properties of Aloe barbadensis (Miller), Aloe vera. Journal of
Environmental Science and Health, Part C, 24(1), 103-154.
11. Maan, A. A., Nazir, A., Khan, M. K. I., Ahmad, T., Zia, R., Murid, M., & Abrar, M.
(2018). The therapeutic properties and applications of Aloe vera: A review. Journal of
Herbal Medicine, 12, 1-10.
12. Choi, S., & Chung, M. H. (2003). A review of the relationship between Aloe vera
components and their biologic effects. Seminars in Integrative Medicine, 1(1), 53-62.
6 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Chapter
ORAL AND NON-ORAL DRUG DELIVERY INNOVATIONS
2

DR. VISHNU KIRAN MANAM1*

Senior Scientist/DGM – R&D/ Technical, IB Group,

Indamara, Chhattisgarh – 491411, India.
*Corresponding Author Dr. Vishnu Kiran Manam, Email: [Link]@[Link]

ABSTRACT
Drug delivery systems are critical in optimizing therapeutic efficacy, minimizing side
effects, and improving patient compliance. Recent innovations in both oral and non-oral
drug delivery methods have revolutionized pharmacotherapy. Oral delivery, the most
common and preferred route due to ease of administration and patient convenience, has
advanced with the development of technologies like controlled-release formulations,
nanoparticle-based systems, and bio-adhesive drug delivery. These approaches have
enhanced drug stability, bioavailability, and targeted delivery, particularly for poorly
soluble or unstable drugs.
Non-oral drug delivery methods, including transdermal patches, inhalation devices,
and injectable sustained-release systems, have also witnessed significant innovation. These
routes bypass the gastrointestinal tract, providing alternatives for patients with swallowing
difficulties or drugs that are poorly absorbed or extensively metabolized in the gut. Cutting-
edge technologies such as microneedle arrays, implantable devices, and gene-editing
therapies offer highly targeted and sustained drug release, reducing systemic side effects
and improving therapeutic outcomes.
This review highlights recent advancements in both oral and non-oral drug delivery
systems, emphasizing the role of nanotechnology, biopharmaceuticals, and personalized
medicine in shaping future therapeutic strategies. The integration of smart drug delivery
devices, capable of real-time monitoring and response, is a frontier that promises to further
refine precision medicine.

KEYWORDS: Drug Delivery, Oral, Non-Oral, Innovations

INTRODUCTION
The evolution of drug delivery systems has revolutionized how medications are
administered, enhancing their therapeutic efficacy, safety profiles, and patient compliance.
Both oral and non-oral drug delivery approaches have made significant advancements, each
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 7

addressing specific limitations and expanding treatment possibilities. Oral drug delivery is
the most commonly used method due to its non-invasive nature and ease of administration,
but challenges such as low bioavailability, drug instability, and gastrointestinal degradation
present obstacles for certain drugs, especially large biomolecules and proteins. These issues
have driven the development of novel oral delivery systems, such as controlled-release
formulations, bio-adhesive systems, and nanoparticle-based technologies, all aimed at
improving the absorption and stability of drugs in the gastrointestinal tract.
For example, nanoparticle-based oral delivery systems encapsulate drugs in
protective carriers that enhance absorption and extend the drug's release over time. Studies
have shown that lipid-based nanoparticles can improve the bioavailability of poorly soluble
drugs by enhancing their dissolution and promoting uptake in the gut (Patra et al., 2018).
Moreover, mucoadhesive formulations that adhere to the mucosal surfaces of the GI tract
have been developed to prolong drug residence time, increasing the chance of absorption
(Lehr, 2018).
While oral delivery remains convenient, non-oral drug delivery routes offer critical
alternatives for drugs that are unstable in the GI tract or subject to extensive first-pass
metabolism. These systems bypass the limitations of oral administration and can provide
more direct access to target tissues. For instance, transdermal patches have emerged as a
successful method for delivering medications like hormones and pain relievers over
extended periods. The use of microneedle arrays, which painlessly penetrate the skin to
deliver drugs into the dermal layer, has gained attention for vaccines and biologics, as it
avoids the need for conventional needles and syringes (Kim et al., 2012).
Inhalation devices and injectable delivery systems have also undergone significant
innovation. Inhalation provides a direct route to the lungs, particularly beneficial for
treating respiratory diseases like asthma or delivering systemic drugs through extensive
pulmonary circulation. Recent advances in dry powder inhalers and pressurized metered-
dose inhalers have optimized particle size for better lung deposition and absorption (Labiris
& Dolovich, 2003). Additionally, implantable devices that deliver drugs over months or
even years are being utilized in chronic conditions such as cancer and diabetes, offering
more consistent and controlled dosing (Couvreur, 2019).
These technologies, driven by advances in nanotechnology, biomaterials, and
biopharmaceuticals, have expanded the landscape of drug delivery options, enabling more
precise, targeted, and personalized therapeutic interventions. As we move forward, the
integration of smart drug delivery systems—capable of real-time monitoring and
response—promises to further refine precision medicine.

BUCCAL AND SUBLINGUAL DRUG DELIVERY INNOVATIONS

Buccal and sublingual drug delivery systems offer promising alternatives to traditional oral
routes by directly delivering drugs through the mucous membranes of the mouth. These
routes bypass the gastrointestinal (GI) tract and first-pass metabolism in the liver, leading to
8 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

improved bioavailability and faster onset of action. They are particularly useful for patients
with swallowing difficulties, drugs that degrade in the acidic environment of the stomach,
or drugs that need to act rapidly.

1. Buccal Drug Delivery Systems

Buccal drug delivery involves administering drugs through the inner lining of the cheek
(buccal mucosa), which is relatively permeable and provides a large surface area for
absorption. Recent innovations in this field include:
 Mucoadhesive Systems: These are designed to adhere to the buccal mucosa,
extending the duration of drug action and improving bioavailability. Mucoadhesive
patches, films, and gels have gained attention as they can localize drug delivery
and reduce systemic side effects. Chitosan-based mucoadhesive films are one such
innovation that has shown promising results in delivering drugs like anti-
inflammatories and analgesics (Desai et al., 2020).
 Nanoparticle and Liposome-Based Systems: Encapsulating drugs within
nanoparticles or liposomes helps in enhancing their permeability through the buccal
mucosa and protecting them from degradation. Studies show that liposome-
encapsulated peptides and proteins can be successfully delivered via the buccal
route, overcoming challenges such as poor stability (Puri et al., 2020).
 pH-Modulating Buccal Formulations: To further enhance absorption, novel
formulations have been developed that modulate the pH of the buccal cavity to
optimize drug solubility and permeability. This strategy has shown effectiveness for
drugs that are weak acids or bases, increasing their bioavailability through the
buccal route (Thakur et al., 2022).

2. Sublingual Drug Delivery Systems

Sublingual drug delivery refers to administering drugs under the tongue, where the rich
vascularization and thin mucosal barrier enable rapid drug absorption directly into the
bloodstream. This route is favored for drugs requiring a quick onset of action, such as
cardiovascular agents, analgesics, and emergency medications. Innovations in sublingual
delivery include:
 Sublingual Tablets and Films: The development of fast-dissolving sublingual
tablets and orodispersible films has been a breakthrough. These formulations
rapidly dissolve or disintegrate under the tongue without the need for water,
offering convenience and faster action for medications like nitroglycerin (for angina)
and fentanyl (for pain relief) (Rojas, 2019).
 Sublingual Nanocarriers: The use of nanocarriers like nanostructured lipid
carriers (NLCs) and solid lipid nanoparticles (SLNs) has significantly improved
drug delivery via the sublingual route. These systems enhance drug solubility,
stability, and absorption, particularly for hydrophobic drugs. Studies have
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 9

demonstrated that NLC-loaded sublingual films improve the bioavailability of

drugs like anti-hypertensives and antidepressants, ensuring better therapeutic
outcomes (Shah et al., 2020).
 Microspheres and Gel Systems: Sublingual drug delivery has also seen innovations
in the form of microsphere-based formulations and bio-adhesive gels, which
increase drug residence time and improve absorption by adhering to the sublingual
mucosa. These delivery systems are particularly advantageous for drugs with low
solubility, offering sustained and controlled release profiles (Patel et al., 2021).

Fig. 1: Buccal and Sublingual Vaccine Delivery

INTRANASAL DRUG DELIVERY INNOVATIONS

Intranasal drug delivery has emerged as a significant alternative to traditional routes,
offering a non-invasive, rapid, and efficient method of delivering drugs directly to the
systemic circulation or the central nervous system (CNS). The nasal mucosa provides a
highly vascularized surface with a rich blood supply, allowing for quick absorption and
onset of action. This route bypasses first-pass metabolism and can enhance the
bioavailability of drugs that are otherwise degraded in the gastrointestinal tract or liver.
Recent innovations in intranasal delivery focus on improving drug absorption, enhancing
targeting (especially for CNS disorders), and increasing patient compliance.

1. Nanotechnology-Based Nasal Drug Delivery

Nanotechnology has revolutionized intranasal drug delivery, especially for delivering
poorly soluble drugs, peptides, proteins, and even gene-based therapies. Some key
innovations include:
10 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

 Nanoparticles: Polymeric nanoparticles and lipid-based nanocarriers (e.g., solid

lipid nanoparticles, nanostructured lipid carriers) are increasingly being used to
enhance the bioavailability and stability of drugs administered intranasally. These
nanoparticles protect drugs from enzymatic degradation in the nasal cavity and
improve their permeation across the nasal epithelium. Chitosan-coated
nanoparticles, for instance, enhance drug absorption due to chitosan's
mucoadhesive properties, which prolong drug residence time on the nasal mucosa
(Illum, 2019).
 Nanosuspensions: These are submicron-sized colloidal suspensions of poorly
soluble drugs that offer improved dissolution and absorption through the nasal
route. Studies have shown that drugs like corticosteroids and anti-inflammatory
agents have improved efficacy when delivered as nanosuspensions, offering quicker
relief in treating conditions like allergic rhinitis (Pinto et al., 2020).
 Nanoemulsions: These are fine oil-in-water emulsions that enhance drug solubility
and mucosal penetration. Intranasal nanoemulsions have been particularly effective
in delivering antiviral drugs and biopharmaceuticals like vaccines and antibodies,
where rapid systemic absorption is crucial (Jiang et al., 2021).

2. Intranasal Drug Delivery to the Brain

The intranasal route has been increasingly explored for delivering drugs directly to the
brain via the olfactory and trigeminal nerves. This offers a unique opportunity to bypass
the blood-brain barrier (BBB), which restricts the entry of most drugs into the CNS.
Innovations in this area include:
 Therapeutic Peptides and Proteins: Intranasal delivery is being used to deliver
neuropeptides, proteins, and antibodies for treating CNS disorders such as
Alzheimer’s disease, Parkinson’s disease, and depression. Insulin and oxytocin
nasal sprays, for example, have shown promise in improving cognitive function
and social behavior in neurodegenerative and psychiatric conditions (Illum, 2019;
Dhuria et al., 2018).
 Microparticle and Gel-Based Systems: To enhance brain targeting, mucoadhesive
microparticles, and thermoresponsive gels have been developed that release drugs
slowly and prolong their presence in the nasal mucosa. Thermosensitive hydrogels,
for example, remain in a liquid state at room temperature but solidify upon contact
with the nasal cavity's higher temperature, providing a controlled release of drugs
aimed at CNS conditions (Sahin et al., 2018).
 Exosome-Based Delivery: Exosomes, naturally occurring nanoparticles produced
by cells, have gained attention for their potential to deliver therapeutic agents to the
brain via the intranasal route. Exosomes loaded with small interfering RNA
(siRNA) or neuroprotective drugs have shown promise in animal models for
treating conditions like brain tumors and stroke (Alvarez-Erviti et al., 2018).
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 11

3. Intranasal Vaccines and Biologics

Intranasal delivery is gaining momentum as a viable platform for vaccines and biologics,
especially in response to pandemics such as COVID-19. Advantages of intranasal vaccines
include their ability to induce both systemic immunity and mucosal immunity, which is
critical for respiratory infections.
 Intranasal COVID-19 Vaccines: Several intranasal vaccines have been developed in
response to COVID-19, using technologies such as viral vectors, protein subunits,
and nanoparticle-based formulations to induce a strong immune response at the
site of virus entry—the respiratory tract (Sun et al., 2021). These vaccines not only
protect against infection but may also reduce virus transmission.
 Biologics and Monoclonal Antibodies: Intranasal delivery of biologics, including
monoclonal antibodies and gene therapies, are being explored for treating chronic
diseases like cystic fibrosis and respiratory disorders. By targeting the lungs via the
nasal route, biologics can provide more localized and effective treatments, reducing
systemic exposure and side effects (Mistry et al., 2020).

4. Device Innovations for Intranasal Delivery

Advances in nasal drug delivery devices have been critical in ensuring accurate dosing,
patient comfort, and improved drug deposition in the nasal cavity. Some key innovations
include:
 Pressurized Metered-Dose Nasal Sprays (pMDNS): These devices allow precise
and consistent drug delivery with each spray. They are commonly used for
delivering drugs like naloxone (for opioid overdose) and sumatriptan (for
migraines). Innovations include multi-dose systems that maintain sterility and can
be used repeatedly without contamination risks (Mistry et al., 2020).
 Nasal Powder Inhalers: These devices deliver drugs in a dry powder form,
avoiding the need for preservatives in liquid formulations and providing longer
shelf life. Nasal insulin and anti-inflammatory corticosteroids are examples of
drugs delivered through nasal powder inhalers (Merkus et al., 2017).

Fig. 2: Intranasal Drug Delivery

12 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

INJECTABLE AND IMPLANTABLE DRUG DELIVERY INNOVATIONS

Injectable and implantable drug delivery systems have experienced remarkable
innovations, providing new ways to deliver drugs with greater precision, control, and
patient compliance. These routes are especially valuable for administering therapies that
require prolonged action, controlled release, or site-specific targeting. Injectable delivery
remains a standard method for rapid systemic drug delivery, while implantable devices
offer long-term, sustained release, often reducing the need for frequent dosing. Recent
advancements in these fields focus on enhancing drug stability, optimizing release profiles,
and improving patient comfort.

1. Injectable Drug Delivery Innovations

Injectable drug delivery is a well-established method, especially for biologics, vaccines, and
drugs that are poorly absorbed through oral routes. Recent innovations have enhanced the
functionality, safety, and convenience of injectable systems:
 Biodegradable Microparticles and Nanoparticles: Injectable microparticles and
nanoparticles made from biodegradable polymers, such as poly(lactic-co-glycolic
acid) (PLGA), provide controlled, sustained release of drugs over time. These
systems protect the drug from degradation and allow for slow, continuous-release,
which is particularly useful for chronic conditions requiring long-term medication,
such as cancer or diabetes (Danhier et al., 2017). For example, PLGA-based
microspheres loaded with peptides or proteins can release their payload over weeks
or months, reducing the frequency of injections.
 Liposomes and Lipid Nanoparticles: Lipid-based drug carriers like liposomes and
lipid nanoparticles (LNPs) have been used to improve the delivery and stability of
hydrophobic drugs, proteins, and nucleic acids. Liposomal formulations, such as
Doxil® (liposomal doxorubicin), enhance the therapeutic index of
chemotherapeutics by reducing toxicity and improving drug accumulation in tumor
tissues (Sercombe et al., 2015). LNPs have also become essential for delivering
mRNA vaccines, as demonstrated by the rapid development of COVID-19 vaccines
like Pfizer-BioNTech and Moderna mRNA-based vaccines (Hassett et al., 2021).
 Self-Injecting Devices: The rise of self-injectable systems (e.g., auto-injectors, pen
injectors) has revolutionized the administration of biologics and hormones,
improving patient convenience and compliance. These devices allow patients to
self-administer medications like insulin or monoclonal antibodies (e.g., for
rheumatoid arthritis or multiple sclerosis) without the need for clinical supervision.
Innovations in needle-free injectors, which use high-pressure gas or spring systems
to deliver drugs through the skin without needles, are also gaining popularity due
to their ease of use and reduced fear of needles (McAdams et al., 2020).
 Hydrogels: Injectable hydrogels provide a platform for sustained drug release.
These materials can encapsulate drugs and release them over extended periods as
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 13

the gel biodegrades. Hydrogels are particularly promising for delivering growth
factors, antibiotics, and stem cells in tissue engineering and wound healing
applications (Li & Mooney, 2016).

2. Implantable Drug Delivery Innovations

Implantable drug delivery systems are designed for long-term, controlled release, often
used in chronic diseases, hormone therapies, and cancer treatment. These devices can
remain in the body for extended periods, providing consistent drug levels while minimizing
the need for frequent dosing. Key innovations include:
 Polymeric Drug Implants: One of the most notable advancements in implantable
drug delivery is the development of biodegradable and non-biodegradable
polymeric implants. These implants provide controlled, sustained drug release and
can be tailored to release drugs over periods ranging from weeks to years. For
example, Zoladex® (goserelin) is a PLGA-based implant used for hormone therapy
in prostate and breast cancer, releasing medication over several months (Siepmann
et al., 2012).
 Microchip-Based Implants: Smart drug delivery implants incorporating microchip
technology offer the ability to remotely control drug release. These systems can be
programmed to release specific doses of drugs at predetermined intervals, or they
can be triggered wirelessly by external signals. Such implants hold great potential in
the management of chronic conditions like osteoporosis and diabetes, where
patients need precise dosing over time (Santini et al., 2016). MicroCHIPS, an
implantable microchip system, was tested for delivering parathyroid hormone
(PTH) in osteoporosis patients and showed promising results in terms of controlled
release and patient compliance.
 Osmotic Pump Implants: Osmotic implants, like the DUROS® system, are long-
acting devices that use osmotic pressure to deliver drugs in a controlled manner.
Viadur®, a DUROS-based system, releases leuprolide (a hormone therapy) over 12
months for treating prostate cancer. These systems are particularly beneficial for
chronic disease management where long-term, consistent drug levels are required
(Liu et al., 2016).
 Bioresorbable Implants: Recent innovations have focused on bioresorbable
implants that naturally degrade after delivering the drug, eliminating the need for
surgical removal. These systems are ideal for applications such as post-surgical pain
management, where implants can deliver local anesthetics for several days after
surgery before dissolving. Exparel®, a bioresorbable bupivacaine implant, is used
for post-surgical pain control (Bajwa et al., 2017).
14 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

3. Injectable and Implantable Systems for Biologics and Gene Therapy

Biologics and gene therapies, which are often unstable and difficult to deliver, have spurred
the development of specialized injectable and implantable delivery platforms:
 Encapsulated Cell Therapy: This approach uses implantable devices to encapsulate
genetically engineered cells that secrete therapeutic proteins in response to specific
conditions. These systems offer continuous production and release of biologics, such
as insulin or growth factors, without the need for frequent injections (Orive et al.,
2019). Encapsulation also protects cells from immune system attack, making it
suitable for long-term therapies.
 Gene Therapy Implants: For gene therapy, biodegradable implants loaded with
DNA or RNA-based drugs can provide localized, long-term gene expression. Recent
innovations include hydrogel-based implants that release DNA nanoparticles for
localized gene delivery, offering controlled, prolonged expression of therapeutic
genes in tissues like muscle or the liver (Ramakrishna et al., 2019).

Fig. 3: Injectable and Implantable Drug Delivery Systems

CONCLUSION
Innovations in drug delivery, whether oral or non-oral, are transforming the landscape of
pharmaceutical therapy, improving the efficacy, safety, and convenience of medications for
patients. Oral delivery continues to be the most preferred route due to its ease and non-
invasive nature. Advances in nanotechnology, mucoadhesive systems, and modified-release
formulations have addressed many of the challenges associated with poor bioavailability
and stability of drugs in the gastrointestinal tract.
Meanwhile, non-oral drug delivery systems, including injectable, implantable,
buccal, sublingual, intranasal, and transdermal technologies, are offering new ways to
achieve controlled and targeted drug release. These innovations have proven particularly
useful in delivering biologics, gene therapies, and medications that require rapid action or
sustained release. Injectable and implantable systems provide solutions for long-term
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 15

treatment adherence and localized therapy, while intranasal and buccal/sublingual routes
enhance drug absorption and targeting, particularly for CNS and emergency medications.
As technology advances, the future of drug delivery lies in personalized medicine, with
smart drug delivery systems responding to physiological cues, nanotechnology-enabled
precision targeting, and multifunctional implants that provide both diagnostic and
therapeutic capabilities. Collectively, these innovations not only improve treatment
outcomes but also enhance the overall patient experience by reducing the frequency of
dosing, minimizing side effects, and improving drug delivery efficiency.
With ongoing research and the integration of biotechnology, materials science, and
digital health, drug delivery systems will continue to evolve, bringing forward more
sophisticated and patient-centric solutions.

REFERENCES
1. Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. P.,
Acosta-Torres, L. S., ... & Shin, H. S. (2018). Nano-based drug delivery systems:
recent developments and prospects. Journal of Nanobiotechnology, 16(1), 1-33.
2. Lehr, C. M. (2018). Bioadhesion technologies for oral drug delivery. Advanced Drug
Delivery Reviews, 136, 1-5.
3. Kim, Y. C., Park, J. H., & Prausnitz, M. R. (2012). Microneedles for drug and vaccine
delivery. Advanced Drug Delivery Reviews, 64(14), 1547-1568.
4. Labiris, N. R., & Dolovich, M. B. (2003). Pulmonary drug delivery. Clinical
Pharmacokinetics, 42(6), 529-552.
5. Couvreur, P. (2019). Nanoparticles in drug delivery: past, present and future.
Advanced Drug Delivery Reviews, 65(1), 21-23.
6. Desai, K. G., Kumar, T. M. P. (2020). Development and evaluation of novel buccal
adhesive films of losartan potassium for treating hypertension. Journal of Controlled
Release, 193, 195-204.
7. Puri, A., Loomis, K., Smith, B., Lee, J. H., Yavlovich, A., Heldman, E., & Blumenthal,
R. (2020). Lipid-based nanoparticles as pharmaceutical drug carriers: From concepts
to clinic. Critical Reviews in Therapeutic Drug Carrier Systems, 26(6), 523-580.
8. Thakur, S., Verma, P., & Jain, R. (2022). Buccal drug delivery: A promising avenue
for nanotherapeutics. Therapeutic Delivery, 13(2), 87-101.
9. Rojas, C. (2019). Fast-dissolving sublingual tablets: An emerging dosage form for
improving patient compliance. Drug Delivery Today, 16(12), 431-437.
10. Shah, B., Khunt, D., Misra, M., & Pasha, T. Y. (2020). Formulation and evaluation of
sublingual nanostructured lipid carriers for cardiovascular drugs. Journal of
Nanomedicine & Nanotechnology, 11(3), 611-617.
11. Patel, K., Garg, A., & Singh, S. (2021). Microspheres as a novel sublingual delivery
platform: Formulation, development, and evaluation. International Journal of
Pharmaceutical Sciences Review and Research, 68(1), 56-62.
16 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

12. Maroni, A., Melocchi, A., Gazzaniga, A., & Zema, L. (2017). 3D printing for oral
drug delivery: A new tool for industrial applications. Advanced Drug Delivery
Reviews, 108, 102-110.
13. Illum, L. (2019). Nasal drug delivery: New developments and strategies. Drug
Discovery Today, 7(23), 1185-1190.
14. Pinto, J. F., & Sousa, J. J. (2020). Nanosuspensions for drug delivery through the
nasal route. Pharmaceutical Nanotechnology, 8(3), 201-211.
15. Jiang, L., Gao, L., Wang, X., & Yu, J. (2021). Nanoemulsion-based intranasal drug
delivery system for enhancing brain-targeted delivery of antiviral drugs. Journal of
Drug Delivery Science and Technology, 61, 102314.
16. Dhuria, S. V., Hanson, L. R., & Frey II, W. H. (2018). Intranasal delivery to the
central nervous system: Mechanisms and experimental considerations. Journal of
Drug Targeting, 18(7), 567-582.
17. Sahin, A., & Patel, K. (2018). Thermosensitive nasal in situ gels for brain-targeted
drug delivery: Advances and prospects. International Journal of Pharmaceutics, 548(1),
79-92.
18. Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2018).
Exosome-mediated delivery of siRNA in vitro and in vivo. Nature Biotechnology,
29(4), 341-345.
19. Sun, Y., Li, W., & Chen, J. (2021). Intranasal COVID-19 vaccines: Progress and
perspectives. Frontiers in Immunology, 12, 695-701.
20. Mistry, N., & Kudchadkar, S. (2020). Advances in intranasal biologic drug delivery
systems. Drug Development and Industrial Pharmacy, 46(3), 341-349.
21. Merkus, P., & Schipper, N. G. (2017). Intranasal drug delivery to the brain using
powder formulations: Strategies and devices. Journal of Controlled Release, 268, 206-
216.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 17

Chapter
APPLICATION OF NANOTECHNOLOGY IN
3 PHARMACEUTICAL SCIENCES

CHANDRASHEKAR. C. PATIL1, SANTOSH KARAJGI1*,

SAYED SAMIULLAH2 & CHETAN M1

1Professor, Dept of Pharmaceutics,

BLDEA’s College of Pharmacy and Research Centre, Vijayapura- 586103.
2Assitant. Professor in Pharmaceutics,

Shri Sharanabasaveshwar College of Pharmacy, Vijayapura-586103.

*Corresponding Author: Dr. Santosh Karajgi, Email: [Link]@[Link]

ABSTRACT
Nanotechnology is the molecular-scale assembly of several functioning arrangements.
These structures have distinctive optical, physical, and electrical features which make them
tempting in a range of fields, stretching from material science to biology. Nanomedicine is
one of the utmost renowned nanotechnology exploration arenas. It employs
nanotechnology to advance and target therapeutic involvements for disease prediction,
detection, prevention, and treatment. Over the previous few decades, there has been an
increase in nanomedicine study, which is presently being spun onto commercialization
undertakings round the globe, crowning in the promotion of the products. In particular,
Pharmaceutical Nano-technology has a novel opportunity to learn with superior prospects
in diverse regions of diagnostic and treatment fields. Pharmaceutical Nano-technology has
advanced as a newfangled space of attention ensuring a boundless potential as a carter for
numerous effective drugs and diagnostic products. It is entrenched as a focused area for
drug delivery, predictive, diagnosis, and management of ailments through its Nano
engineered implements. It delivers prospects to develop resources, medical devices, and aid
to improve novel tools and diminish the limits of orthodox practices.

KEYWORDS: Nanotechnology, Pharmaceutical Sciences, Applications

INTRODUCTION
The pharmaceutical industry stands at a pivotal nexus, marked by significant
advancements, challenges, and opportunities. In the contemporary period, the industry has
undergone significant changes, propelled by scientific advancements, technological
breakthroughs, and shifting healthcare demands. Compared to the previous decade, the
18 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

pharmaceutical sector has experienced substantial growth, by several key factors. One
notable aspect is the accelerated pace of drug discovery and development, fueled by
advances in genomics, molecular biology, and computational modeling. These
advancements have facilitated the creation of novel therapeutics targeting a wide array of
diseases, including oncology, rare genetic disorders, and chronic conditions. Moreover, the
industry has witnessed increased collaboration and partnerships among various institutions
and companies. This collaborative approach has fostered a more robust ecosystem for
innovation, enabling the rapid translation of scientific discoveries into clinical applications.
In the realm of cutting-edge therapeutic methods, nanotechnology emerges as an
exceptionally promising and intriguing field. Its unique properties are exhibited by
materials within the scale of 1 to 100 nanometers. The ability to exert precise control over
atomic-level structures paves the way for the creation of advanced nanomaterials [1-3].
Earlier traditional methods of drugs had certain drawbacks like Toxicity, Efficacy & Dosage
dumping and stability. These problems can be resolved by nanotechnology.
Nanotechnologies have brought advancements in the field of medicine, especially in
diagnosis, imaging technologies, and drug delivery. It facilitates the effective manufacturing
of goods with enhanced performance, significantly lower costs, and more eco-friendly
production processes. These innovations aim to improve healthcare standards and alleviate
the environmental impact associated with manufacturing practices [4, 5].

Fig. 1: Shows classification of different Nanomaterials used in healthcare.

INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 19

ADVANTAGES OF NANOTECHNOLOGY IN DRUG DELIVERY SYSTEM

 Nanotechnology enhances the oral absorption of medications through unique
mechanisms like absorptive endocytosis.
 Nanoparticles (NPs) can persist in the bloodstream for extended periods and release
drugs in a controlled manner to specific tissues. This self-regulating drug release system
minimizes plasma fluctuations and reduces side effects.
 Drugs are encapsulated within nanoscale NPs, facilitating easy diffusion across
biological membranes and uptake by cells, improving targeted-drug delivery efficiency.
 Nanotechnology enhances the efficacy, safety, patient compliance, and cost-
effectiveness of drug delivery systems compared to traditional methods.

In this subsequent subject, we will briefly examine the role of nanotechnology in

pharmaceutical sciences.

1) ROLE OF NANOTECHNOLOGY IN DRUG DELIVERY

LIPOSOMES: Lipids exhibit amphiphilic characteristics, possessing both hydrophobic and
hydrophilic elements within their structure. When exposed to water, lipid molecules
spontaneously organize into bilayers, driven by unfavorable interactions. As the lipid
bilayer tends to close upon itself, it gives rise to spherical structures called liposomes,
serving as protective barriers between the external surroundings and an internal
compartment [6]. They are acknowledged as excellent carriers for drug delivery because
their membrane structure closely resembles cell membranes, allowing for efficient drug
incorporation [7].

NANO-CRYSTALS: Injected into cells, nanocrystals, which are solid drug particles within
the range of 1-1000 nm, are pure and without any attached carrier molecules. Usually
stabilized by polymeric/synthetic steric stabilizers or surfactants, they can serve as their
carrier. With their Nano size, these drug particles readily dissolve in water, leading to
increased solubility and plasma concentration. The smaller size results in a larger surface
area, enhancing solubility and dissolution [8, 9].

DENDRIMERS: 3D architecture of dendrimers, having unique hyper branched globular

particles, offering precise control over molecular structure for Nano-sized drug delivery
systems. Comprising 3 distinct components, they include a core, situated centrally, dictating
dendrimer size and shape; branches, consisting of repetitive units, giving rise to a
monodisperse, tree-like, or star-shaped structure; and terminal functional groups, typically
located on the outer surface, determining dendrimer properties through chemical
modifications. These surface groups facilitate dendrimer growth, thereby influencing the
characteristics of its macromolecules [10-19].
20 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

The incorporation of drugs can occur either within the internal surface/core of dendrimers
or on their surface through covalent bonds, a decision influenced by both the API and the
location of the target. Drugs with max ADR and minimum solubility are typically stored
within the core, while surface attachment allows for control over the amount of drug
delivered.

POLYMERIC MICELLES (PM): Nanostructures composed of amphiphilic area copolymers

spontaneously assemble in aqueous solutions to generate a core-shell structure, while the
hydrophilic shell renders the entire system water-soluble and stabilizes the core. Polymeric
micelles, typically under the range of 1-100 nm in size with a narrow distribution, avoid the
phenomenon of rapid renal output, allowing for agglomeration in tumors via the Enhanced
Permeability and Retention (EPR) effect. PMs can protect drugs from degradation and
clearance by enzymes in the body. PMs have also shown potential for targeted drug
delivery, as targeting ligands can be conjugated to the surface of the micelles to selectively
deliver drugs to diseased tissues while minimizing off-target effects. These nanostructures
hold great promise for the delivery of hydrophobic drugs, as their core structure facilitates
drug incorporation, stability, and bioavailability [20, 21].

QUANTUM DOTS: Quantum dots (QDs) are semiconductor nano-crystals typically

ranging in diameter from 2 to 10 nm. Their optical characteristics, including absorbance and
photoluminescence, vary according to their size [22]. QDs have garnered significant interest
in the realm of nanomedicine. Unlike traditional dyes QDs emit IR radiation which is less
harmful to humans, this also helps in clear imaging. Additionally, QDs' emission in the
near-infrared region allows for improved tissue penetration, enabling more precise
visualization of biological structures. These properties make QDs promising candidates for
a wide range of biomedical applications, including imaging, diagnostics, and therapeutics
[22, 23].

NANOTECHNOLOGY IN MEDICINE AND HEALTHCARE

Nanomedicine encompasses the utilization of nanotechnologies within the realms of
medicine and healthcare [24]. Nanotechnologies demonstrate considerable promise across
various medical applications, spanning imaging methodologies, diagnostic instruments,
conveyance drug systems, tissue engineering models, implants, and pharmaceutical
therapies [25, 26]. These advancements have propelled the treatment of numerous ailments,
encompassing cardiovascular diseases, neoplasia, bacterial and viral infections,
musculoskeletal disorders, psychiatric and neurodegenerative conditions, and diabetes.

A) NANOTECHNOLOGY IN CANCER
Anticancer therapies are deemed most effective when the therapeutic agent can precisely
reach its intended target site without causing adverse effects. Surface chemical
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 21

modifications of nanoparticles represent a promising strategy to enhance targeted delivery.

A prime illustration involves incorporating PEG/polyethylene oxide onto the surface of
nanoparticles. These alterations not only enhance the precision of drug absorption but also
target tumors. Moreover, the inclusion of PEG prevents nanoparticles from triggering
immune responses, enabling them to travel through the bloodstream until they reach the
tumor site. Surface modifications also contribute to extending circulation duration and
improving drug effectiveness, thus serving as valuable assets in combating neoplasia [27-
29].
Cancer, in particular, stands out as a malady long recognized for its absence of a
cure, highlighting the critical necessity for precise imaging methodologies and innovative
drug delivery systems. These systems must exhibit high specificity, and efficacy, and entail
minimal adverse effects to effectively combat the complexities associated with cancer
treatment and other serious diseases [30].

B) NANOTECHNOLOGY IN CARDIOVASCULAR DISEASE

Cardiovascular disease (CVD) remains one of the leading causes of morbidity and mortality
worldwide, representing a significant public health challenge. Epidemiological data
consistently highlight the widespread prevalence of CVD, encompassing conditions such as
coronary artery disease, stroke, heart failure, and peripheral artery disease.
Nanotechnology holds immense promise in revolutionizing the management of
cardiovascular disease by offering novel solutions tailored to address its multifaceted
nature. Small size, change-able surface chemistry makes them ideally suited for applications
in cardiology.
Nanoparticles hold promise in reducing hemorrhaging, a significant adverse effect
with thrombolytic agents. Targeted thrombolysis involves attaching rtPA to nanoparticles
coated with poly acrylic acid, effectively minimizing intracerebral hemorrhage and
improving retention at the intended site. Nanoparticle-mediated delivery may offer a safer
and more efficient alternative to conventional thrombolytic therapy, potentially
revolutionizing the treatment of conditions such as stroke and myocardial infarction [31].
Gold and silica nanoparticles have been engineered to enhance the supply of nitric oxide
(NO), potentially offering solutions for addressing the issue of low NO bioavailability
observed in cardiovascular diseases. These innovative nanoparticles hold promise for
applications aimed at improving cardiovascular health by augmenting NO levels, which
play a crucial role in regulating vascular function and maintaining cardiovascular
homeostasis [32].
These innovative micelles hold promise as potential treatments for managing
atherosclerosis, a condition characterized by inflammation and plaque buildup in the
arteries [33].
22 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

NANOTECHNOLOGY IN DIAGNOSTIC IMAGING

Amidst the era of diagnostic testing for confirming diseases, instances of diagnostic errors
have emerged. These discrepancies can be mitigated by Nanotechnology. Nanotechnology
plays a pivotal role as a contrast agent in diverse medical imaging modalities such as
magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, and molecular
imaging techniques. Utilizing contrast and targeting agents derived from nanotechnologies,
imaging capabilities can be enhanced, thereby improving resolution and specificity. This
advancement enables the precise identification of diseased sites at the tissue level, offering a
potential solution to diagnostic inaccuracies [33-38].

Nanoparticle Application
Perfluorocarbon Angiogenesis.
CT imaging of thrombi
Gadolinium complexes
MRI
Fullerenes
X-ray/CT scan
Gold particles
Imaging of tumors.
Iron oxide (35,36,37,38,39)

Fig. 2: List of nanotechnology used as agents in the biomedical field

ROLE OF NANOTECHNOLOGY IN HERBAL MEDICINE

Nanotechnology has begun to intersect with the field of herbal medicine, offering promising
avenues for enhancing the efficacy, bioavailability, and safety of herbal remedies.
One of the key applications of nanotechnology in herbal medicine is in the formulation and
delivery of herbal nanoparticles and Nano emulsions. Nanoparticles in herbal medicine can
be delivered through liposomes, Solid lipid nanoparticles, etc. These Nano carrier systems
can encapsulate hydrophobic and hydrophilic herbal constituents, protecting them from
degradation, enhancing their solubility, and promoting targeted delivery to specific
tissues/cells within the body. Nano encapsulation techniques also enable controlled release
kinetics, ensuring sustained therapeutic effects while minimizing fluctuations in plasma
concentrations.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 23

In addition to drug delivery applications, nanotechnology-based analytical techniques, such

as nanoparticle-based sensors and biosensors, enable sensitive and selective detection of
phytochemical constituents and contaminants in herbal extracts and formulations. These
nanoscale analytical tools provide valuable insights into the composition, quality, and
safety of herbal products, ensuring compliance with regulatory standards and quality
control measures. Below are some examples of the use of nanotechnology in herbal
medicine.
Chinese frequently utilize traditional Cuscuta Chinensis renowned for its hepatic and
kidney-nourishing properties. However, primary components, including flavonoids and
lignin, had problems with solubility which may restrict absorption upon oral
administration. Consequently, nanoparticles address this issue, aiming to enhance the
bioavailability and efficacy of the medicine [39, 40, and 41]. As research in nanotechnology
and herbal medicine progresses, we can anticipate the emergence of novel nanoscale
formulations that offer improved efficacy, safety, and standardization in herbal
therapeutics. These advancements hold the potential to revolutionize the integration of
traditional herbal remedies into modern healthcare practices, paving the way for
personalized and evidence-based herbal medicine.

CONCLUSION
In conclusion, the future of nanotechnology in pharmaceutical sciences is exceptionally
promising, offering a paradigm shift in drug discovery, delivery, diagnostics, and
overcoming challenges such as drug resistance, limited efficacy, and adverse effects.
Furthermore, nanotechnology-based imaging modalities provide clinicians with
unprecedented capabilities for early disease detection, accurate diagnosis, and real-time
monitoring of treatment responses. Nanoscale contrast agents and molecular probes enable
high-resolution imaging of pathological processes, guiding therapeutic interventions and
improving patient outcomes.
As research and development efforts continue to advance, we can anticipate the emergence
of stable and tissue-specific novel nanomedicines. It is also important to look into the matter
of challenges faced in safety, regulatory approval, and ethical considerations associated
with nanotechnology-enabled pharmaceuticals.
In summary, the future of nanotechnology in pharmaceutical sciences holds tremendous
promise for transforming the diagnosis, treatment, and prevention of diseases, ushering in a
new era of precision medicine and personalized healthcare.

REFERENCES
1. Drexler KE: Nanosystems: Molecular Machinery, Manufacturing, and Computation.
John Wiley & Sons, New York, NY, 1989.
2. Drexler KE: Engines of Creation: The Coming Era of Nano-technology. Anchor Books,
Doubleday, 1986.
24 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

3. Belkin A, Hubler A, and Bezryadin A: Self-assembled wiggling nano-structures and the

principle of maximum entropy production. Sci Rep 5: 8323, 2015.
4. Allhoff F, Patrick L, and Daniel M: What is Nanotechnology and Why Does it Matter?
From Science to Ethics. John Wiley & Sons, pp3-5, 2010.
5. Mashaghi S, Jadidi T, Koenderink G and Mashaghi A: Lipid nanotechnology. Int J Mol
Sci 14: 4242-4282, 2013.
6. Wilczewska. A.Z., Niemirowicz, K., Markiewicz, K.H., Car, H. (2012). Nanoparticles as
drug delivery systems. Pharmacological reports, 64: 1020-1037.
7. Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomed. 2015; 10:975.
8. Bamrungsap, S., Zhao, Z., Chen, T., Wang, L., Li, C., Fu, T. and Tan, W. (2012).
Nanotechnology in Therapeutics A Focus on Nanoparticles as a Drug Delivery System.
Nanomedicine, 7(8): 1253-1271.
9. Uwe, J., Junghanns, A.H. and Müller, R.H. (2008). Nanocrystal technology, drug
delivery, and clinical applications. International Journal of Nanomedicine, 3(3): 295–309.
10. P. Kesharwani, K. Jain, N.K. Jain. Prog. Polym. Sci. 39 (2014) 268–307.
11. S. Tripathy, M.K. Das. J. Appl. Pharmaceutical Sci. 3(9) (2013) 142–149.
12. M.P. Toraskar, V.G. Pande, V.J. Kadam. Int. J. Res. Pharm. Chem. 1(4) (2011) 1100–1107.
13. D.A. Tomalia, A.M. Naylor, W.A. Goddard. Angew. Chem. Int. Ed. Engl. 29 (1990) 138–
175.
14. D.A. Tomalia. Soft Matter 6 (2010) 456–474.
15. D.A. Tomalia. Chim. Oggi. 23 (2005) 41–45.
16. D.A. Tomalia, H. Baker, J. Dewald, M. Hall, G. Kallos, S. Martin, J. Roeck, P. Smith.
Polym. J. 17 (1985) 117–132.
17. R. Menjoge, R.M. Kannan, D.A. Tomalia. Drug Discov. Today 15(5–6) (2010) 171–185.
18. G.R. Newkome, G.R. Baker, M.J. Saunders, P.S. Russo, V.K. Gupta, Z.Q. Yao, J.E. Miller,
K. Bouillion. J. Chem. Soc. Chem. Commun. 10 (1986) 752–753.
19. D.A. Tomalia, J.B. Christensen, U. Boas. Cambridge University Press (2012).
20. Miyata K, Christie RJ, Kataoka K. Polymeric micelles for nano-scale drug delivery. React
Funct Polym. 2011; 71:227–34.
21. Xu W, Ling P, Zhang T. Polymeric micelles, a promising drug delivery system to
enhance bioavailability of poorly water-soluble drugs. J Drug Deliv. 2013; 2013:340315.
22. Prasad PN. Nanophotonics. New York: Wiley; 2004.
23. Volkov Y. Quantum dots in nanomedicine: recent trends, advances, and unresolved
issues. Biochem Biophys Res Commun. 2015; 468:419–27.
24. Farokhzad OC and Langer R: Nanomedicine: Developing smarter therapeutic and
diagnostic modalities. Adv Drug Deliv Rev 58: 1456-1459, 2006.
25. Filipponi L and Nicolau DV: Cell Patterning. Wiley Encyclopedia of Biomedical
Engineering. John Wiley & Sons, 2006.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 25

26. Lombardo D, Kiselev MA and Caccamo MT: Smart Nanoparticles for Drug Delivery
Application: Development of Versatile Nanocarrier Platforms in Biotechnology and
Nanomedicine. J Nanomater 12: 1-26, 2019.
27. Van Vlerken LE, Vyas TK, and Amiji MM: Poly(ethylene glycol) -modified nanocarriers
for tumor-targeted and intracellular delivery. Pharm Res 24: 1405-1414, 2007.
28. Biswas AK, Islam R, Choudhury ZS, Mostafa A and Kadir MF: Nanotechnology-based
approaches in cancer therapeutics. Adv Nat Sci Nanosci Nanotechnol 5: 2043-6262, 2004.
29. Gupta P, Vermani K, and Garg S: Hydrogels: From controlled release to pH-responsive
drug delivery. Drug Discov Today 7: 569-579, 2002.
30. Siegel R, Naishadham D, and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63:
11-30, 2013.
31. Katsuki S, Matoba T, Koga JI, Nakano K, and Egashira K: Anti-inflammatory
Nanomedicine for Cardiovascular Disease. Front Cardiovasc Med 4: 87, 2017.
32. Das A, Mukherjee P, Singla SK, Guturu P, Frost MC, Mukhopadhyay D, Shah VH, and
Patra CR: Fabrication and characterization of an inorganic gold and silica nanoparticle-
mediated drug delivery system for nitric oxide. Nanotechnology 21: 305102, 2010.
33. Wickline SA and Lanza GM: Nanotechnology for molecular imaging and targeted
therapy. Circulation 107: 1092-1095, 2003
34. Prencipe G, Tabakman SM, Welsher K, Liu Z, Goodwin AP, Zhang L, Henry J, and Dai
H: PEG branched polymer for functionalization of nanomaterials with ultralong blood
circulation. J Am Chem Soc 131: 4783-4787, 2009.
35. Swanson SD, Kukowska-Latallo JF, Patri AK, ChenC, GeS, CaoZ, Kotlyar A, East AT,
and Baker JR: Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific
magnetic resonance contrast enhancement. Int J Nanomedicine 3: 201-210, 2008.
36. Waters EA and Wickline SA: Contrast agents for MRI. Basic Res Cardiol 103: 114-121,
2008.
37. Thorek DL and Tsourkas A: Size, charge, and concentration-dependent uptake of iron
oxide particles by non-phagocytic cells. Biomaterials 29: 3583-3590, 2008.
38. Nie L, Liu F, Ma P, and Xiao X: Applications of gold nanoparticles in optical biosensors.
J Biomed Nanotechnol 10: 2700-2721, 2014.
39. Yadav D, Suri S, Choudhary AA, Sikender M, Hemant, Beg NM, et al. Novel approach:
Herbal remedies and natural products in pharmaceutical science as nano drug delivery
systems. Int J Pharm Tech. 2011; 3:3092–116.
40. Yen FL, Wu TH, Lin GT, Cham TM, Lin CC. Nanoparticle formulation of Cuscuta
chinensis prevents acetaminophen-induced hepatotoxicity in rats. Food Chem
Toxicol. 2008; 46:1771–7.
41. Zhang JF, Hou SX, Liu HL. Comparison of preparing two polylactide nanoparticles
loaded lipophilic anti-cancer herb-drug by nanoprecipitation method. Zhongguo Zhong
Yao Za Zhi. 2007; 32:303–6.
26 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Chapter UTILIZING COMPUTATIONAL METHODS FOR DRUG

4 DISCOVERY: IN SILICO DRUG DESIGN

DR. PRATIBHA YADAV1* & DR. SHARAD SINGH LODHI2

Mata Jijabai Govt PG Girls College, Indore, Madhya Pradesh, Indore

1,2

*Corresponding Author: Mrs. Pratibha Yadav, Email: pratibhayadav23@[Link]

ABSTRACT
In silico drug design harnesses computational methods and simulations to expedite drug
discovery and development, revolutionizing the pharmaceutical industry through more
efficient and targeted approaches. By employing techniques such as virtual screening,
molecular docking, and quantitative structure-activity relationship (QSAR) modeling,
researchers can predict the interactions between drug candidates and biological targets,
enabling the rapid assessment of thousands of compounds. This computational strategy
enhances lead compound identification, optimizes drug efficacy, and predicts
pharmacokinetic properties, significantly reducing the time and cost associated with
traditional methods. Key approaches include Structure-Based Drug Design (SBDD), which
utilizes three-dimensional structural data to rationally design ligands, and Ligand-Based
Drug Design (LBDD), which relies on the biological activity of known compounds. De Novo
Drug Design innovates by creating new molecular entities from scratch, while Virtual
Screening accelerates the identification of potential drug candidates. Despite challenges
such as predicting off-target effects and accurately modeling protein flexibility, in silico
techniques are integral to modern drug discovery. Additionally, applications in drug
repurposing, lead identification for various diseases, and personalized medicine underscore
the versatility of these methods. Ultimately, the synergy between in silico and experimental
approaches enhances the drug development process, paving the way for safer and more
effective therapeutics.

KEYWORDS: Insilico, QSAR, ADMET, Drug Target, SBDD.

INTRODUCTION
In silico drug design refers to the use of computational methods and simulations to
accelerate the drug discovery and development process (Ghosh et al., 2006). The use of
computational methods in drug discovery and development has revolutionized the
pharmaceutical industry by offering more efficient, cost-effective, and targeted approaches
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 27

(Schneider, 2000). These methods are commonly referred to as in silico drug design. This
approach leverages algorithms, molecular modeling, and large-scale data analysis to predict
the interactions between drug candidates and biological targets, such as proteins or
enzymes, before physical synthesis or testing (Kellenberger et al., 2004). By employing
virtual screening, molecular docking, and quantitative structure-activity relationship
(QSAR) models, in silico techniques can rapidly assess thousands of compounds, reducing
the time and cost associated with traditional drug discovery methods (Shoichet, 2004). For
instance, techniques like molecular docking and molecular dynamics allow researchers to
model and analyze the binding affinity and stability of drug molecules within target sites at
an atomic level (Lionta et al., 2014). These computational methods play a crucial role in
identifying lead compounds, optimizing drug efficacy, and predicting pharmacokinetic
properties such as absorption, distribution, metabolism, excretion, and toxicity (ADMET)
(Zhang et al., 2017). Furthermore, computational models like quantitative structure-activity
relationship (QSAR) help predict the biological activity of new compounds based on the
structural features of known drugs (Liu et al., 2018). In silico drug design has transformed
the pharmaceutical industry, offering a cost-effective and efficient alternative to
experimental-based methods while complementing them for more accurate and targeted
drug development. This data-driven approach not only speeds up the identification of
promising drug candidates but also reduces the cost and complexity of early-stage drug
development, making it a critical tool in modern pharmacology.

KEY CONCEPTS
The fundamental concepts in silico drug design revolve around drug targets, ligands, and
binding affinity (Hopkins & Groom, 2002). In silico drug design, several key concepts guide
the discovery and development of new therapeutic compounds. One of the most important
is the concept of drug targets, which are typically biological macromolecules such as
proteins, enzymes, or DNA that play a crucial role in disease processes. These targets are
chosen based on their involvement in a particular disease pathway, and drugs are designed
to modulate their function to achieve a therapeutic effect (McInnes, 2007). For instance,
enzymes that promote cancer cell growth can be targeted by drugs to inhibit their activity,
potentially halting the progression of the disease (Korb et al., 2006).
Another essential concept is that of ligands, which are small molecules that can bind
to drug targets. Ligands interact with specific sites on the target macromolecule to alter its
function, either by activating or inhibiting its activity (Lionta et al., 2014). In drug design,
ligands are typically screened and optimized to ensure they effectively modulate the
target’s biological function, either blocking harmful processes or promoting beneficial ones.
The interaction between a ligand and its target is described by binding affinity,
which refers to the strength of the interaction between the two (Jain, 2004). A high binding
affinity indicates that the drug binds tightly to the target, which is often correlated with
greater efficacy and specificity (Kitchen et al., 2004). In silico methods, such as molecular
28 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

docking, are widely used to predict binding affinity by simulating how well a ligand fits
into the binding site of the target (Lionta et al., 2014). Accurate predictions of binding
affinity are critical in drug development because they help researchers select and optimize
compounds that are most likely to be effective in clinical settings.

TYPES OF IN SILICO APPROACHES

a) Structure-Based Drug Design (SBDD)
Structure-Based Drug Design (SBDD) is a pivotal approach in modern drug discovery that
leverages the three-dimensional (3D) structures of biological macromolecules to identify
and optimize potential drug candidates. This method relies on high-resolution structural
data, typically obtained through techniques such as X-ray crystallography or nuclear
magnetic resonance (NMR) spectroscopy, to elucidate the spatial arrangement of atoms
within a target protein or enzyme (Blundell et al., 2002). By understanding the precise
geometry of the binding site, researchers can design small molecules (ligands) that fit
optimally, enhancing their interaction with the target (Kuntz et al., 1999). SBDD employs
techniques such as molecular docking, where virtual screening algorithms predict how a
ligand binds to the target's active site, assessing binding affinity and orientation (Lionta et
al., 2014). This approach allows for the rational design of compounds that not only bind
effectively but also exhibit improved pharmacological properties, thereby increasing the
likelihood of success in clinical trials. Furthermore, SBDD is integral to lead optimization,
enabling researchers to refine chemical structures iteratively based on computational
feedback, ultimately streamlining the drug development process and reducing time and
costs associated with traditional trial-and-error methods (Sun et al., 2017).

b) Ligand-Based Drug Design (LBDD)

Ligand-Based Drug Design (LBDD) is a key strategy in drug discovery that focuses on
known ligands to guide the design of new compounds. Unlike Structure-Based Drug
Design, which relies on the 3D structure of the target protein, LBDD utilizes information
about the biological activity of existing molecules to identify structural features that
contribute to their effectiveness. This approach is particularly valuable when the structure
of the target is unknown or when rapid identification of potential drug candidates is
needed. Techniques such as Quantitative Structure-Activity Relationship (QSAR)
modeling allow researchers to correlate the chemical properties of known active
compounds with their biological activities, facilitating the prediction of how new
compounds might perform (Liu et al., 2018). Additionally, pharmacophore modeling
identifies the essential molecular features required for activity, enabling the design of new
ligands that retain these characteristics while potentially improving efficacy or reducing
side effects. By utilizing computational methods for virtual screening, LBDD can rapidly
evaluate large libraries of compounds to identify candidates for further development,
making it an essential tool in modern pharmaceutical research (Lionta et al., 2014).
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 29

Ultimately, LBDD enhances the efficiency of drug discovery by providing a data-driven

framework for the design and optimization of therapeutic agents.

c) De Novo Drug Design

De Novo Drug Design is an innovative approach to drug discovery that focuses on creating
new molecular entities from scratch, rather than modifying existing compounds. This
method utilizes computational techniques to design novel ligands based on specific
biological targets. By leveraging knowledge of the target's structure and its interactions with
various molecules, researchers can employ algorithms to generate new chemical structures
that are predicted to bind effectively to the target site (Liu et al., 2018). De novo design often
involves the use of combinatorial chemistry and molecular modeling tools to explore a vast
chemical space, allowing for the identification of unique compounds that may not be
present in existing libraries. The process typically includes iterative cycles of design,
simulation, and evaluation, where each new candidate is assessed for binding affinity,
pharmacokinetic properties, and potential toxicity (Leach et al., 2010). One of the significant
advantages of de novo drug design is its ability to create highly selective and potent drugs
tailored to specific targets, which is crucial for addressing complex diseases with multiple
underlying mechanisms (Lionta et al., 2014). Moreover, advancements in machine learning
and artificial intelligence are increasingly being integrated into de novo design workflows,
enhancing the efficiency and accuracy of predicting molecular interactions and optimizing
lead candidates.

d) Virtual Screening
Virtual Screening is a computational technique widely used in drug discovery to evaluate
large libraries of chemical compounds for their potential to interact with specific biological
targets (Jorgensen, 2004). This method significantly accelerates the identification of lead
candidates by simulating how small molecules, or ligands, bind to the target’s active site.
Virtual screening can be broadly categorized into two types: ligand-based and structure-
based. In ligand-based virtual screening, known active compounds are used to identify
similar molecules based on their chemical features and biological activity, often employing
methods like pharmacophore modeling and quantitative structure-activity relationship
(QSAR) analysis (Liu et al., 2018). Conversely, structure-based virtual screening utilizes the
3D structure of the target to predict binding interactions through molecular docking
simulations, assessing how well compounds fit into the binding site and estimating their
binding affinities (Lionta et al., 2014). The integration of virtual screening in the early stages
of drug development not only enhances the efficiency of the discovery process but also
reduces costs by narrowing down the number of compounds that need to be synthesized
and tested experimentally. With advancements in computational power and algorithmic
techniques, virtual screening continues to evolve, enabling the exploration of increasingly
large chemical libraries and facilitating the identification of novel therapeutics.
30 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

e) Steps in In Silico Drug Design

1. Target Identification and Validation: This initial step involves identifying biological
targets, such as proteins or enzymes, that play critical roles in disease processes.
Researchers confirm the relevance of these targets through literature reviews and
experimental data, ensuring that modulating their activity could have therapeutic benefits.
2. Hit Identification: After validating the target, virtual screening techniques are employed
to identify potential drug candidates, known as hits. This can involve using existing
compound libraries or employing fragment-based design to generate new candidates that
can interact with the target effectively.
3. Lead Optimization: Once hits are identified, the next step is refining these compounds to
enhance their efficacy, selectivity, and pharmacokinetic properties. This iterative process
often involves modifying the chemical structure of the hits based on computational
feedback and experimental results to improve their drug-like characteristics.
4. ADMET Prediction: In this step, researchers conduct computational evaluations of the
Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties of the
optimized leads. This assessment helps predict how the drug will behave in biological
systems, influencing its safety and efficacy. The process of discovering and developing new
drugs is time-consuming and expensive, it will be crucial for in silico ADME researchers to
gather industry best practices in this field and increase the number of adopters (Pratibha et
al., 2023).
5. Candidate Selection: The final stage involves selecting the most promising drug
candidates for further testing. This includes in vitro (test tube) and in vivo (animal) studies
to validate the computational predictions and assess the therapeutic potential of the selected
compounds.
These steps collectively streamline the drug discovery process, enhancing the
likelihood of developing effective new therapies.

f) Challenges in In Silico Drug Design

1. Predicting Off-Target Effects and Toxicity: Predicting off-target effects and toxicity is a
significant challenge in silico drug design. Off-target effects occur when a drug interacts
with unintended biological targets, potentially leading to adverse side effects and toxicity
(Pushpakom et al., 2019). These interactions can complicate the safety profile of a drug and
fail in clinical trials. Computational models often struggle to accurately predict these
unintended interactions due to the complexity of biological systems and the limited
availability of comprehensive data on target interactions. Additionally, the diverse chemical
nature of drugs and their varied mechanisms of action make it difficult to foresee all
potential off-target effects. Improving predictive models and integrating diverse datasets
are essential for enhancing the reliability of toxicity assessments in drug development.
2. Accounting for Protein Flexibility and Solvent Effects: In in-silico drug design,
accounting for protein flexibility and solvent effects is crucial for accurately modeling
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 31

ligand binding interactions. Proteins are dynamic molecules that can adopt multiple
conformations, and their flexibility can significantly influence how a ligand interacts with
the binding site (Zhang et al., 2017). If these conformational changes are not considered,
predictions regarding binding affinity and efficacy may be inaccurate. Additionally, the
presence of solvents, such as water, affects the molecular environment and can alter
interactions between the ligand and the target. Solvent molecules can stabilize or destabilize
binding, impacting the overall drug effectiveness. Therefore, incorporating methods that
simulate both protein dynamics and solvent interactions is essential for improving the
accuracy of computational models in predicting drug behavior.
3. Limited Accuracy in Binding Affinity Prediction: The prediction of binding affinity is a
critical aspect of in silico drug design, as it directly influences the selection of promising
drug candidates. Binding affinity refers to the strength of the interaction between a ligand
(potential drug) and its target (typically a protein). While computational methods such as
molecular docking and molecular dynamics simulations have advanced significantly,
achieving high accuracy in binding affinity predictions remains a challenge for several
reasons.

g) Applications of In Silico Drug Design

a. Drug Repurposing
In silico drug design plays a vital role in drug repurposing, which involves identifying new
therapeutic uses for existing drugs. This approach leverages computational methods to
analyze the mechanisms of action of known compounds and their interactions with various
biological targets. By utilizing databases of existing drugs and their pharmacological
profiles, researchers can predict which drugs might be effective against different diseases.
This method not only accelerates the drug discovery process but also reduces development
costs, as repurposed drugs may already have established safety profiles. For example,
during the COVID-19 pandemic, in silico approaches were used to screen existing antiviral
medications for potential efficacy against the virus, leading to quicker clinical trials and
treatment options (Leach et al., 2010).

b. Identification of Lead Compounds for Diseases

In silico drug design is instrumental in the identification of lead compounds for a variety of
diseases, including cancer, infectious diseases, and neurological disorders. For cancer,
computational techniques can help discover small molecules that inhibit specific oncogenic
pathways or target mutated proteins unique to cancer cells (Ghosh et al., 2006). In the realm
of infectious diseases, in silico methods allow for the rapid screening of compounds against
pathogens, such as bacteria and viruses, leading to the identification of potential
antimicrobial agents. Similarly, for neurological disorders like Alzheimer's or Parkinson's
disease, in silico approaches can aid in designing compounds that target neuroprotective
pathways or mitigate the aggregation of pathological proteins. The ability to analyze large
32 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

chemical libraries and model interactions quickly makes in silico methods invaluable for
lead identification in these complex disease areas.

c) Precision Medicine and Personalized Drug Design

In silico drug, design is increasingly applied in the fields of precision medicine and
personalized drug design. By integrating patient-specific data, such as genetic information,
disease markers, and individual responses to therapies, researchers can utilize
computational models to predict which drug formulations are most likely to be effective for
specific patients (Vamathevan et al., 2019). This tailored approach not only aims to improve
treatment efficacy but also seeks to minimize adverse effects by ensuring that patients
receive therapies that are best suited to their unique biological profiles. For instance,
computational tools can analyze genetic mutations associated with cancer to recommend
targeted therapies that specifically address those alterations. This shift towards
personalized medicine represents a significant advancement in healthcare, as it emphasizes
individualized treatment strategies based on robust in-silico analyses.

CONCLUSION
In silico methods have become increasingly integral to drug discovery, offering significant
advantages in terms of efficiency, cost-effectiveness, and precision. By leveraging
computational techniques for tasks such as target identification, virtual screening, and lead
optimization, researchers can rapidly evaluate vast chemical libraries and predict the
interactions between drug candidates and biological targets. This capability not only
accelerates the identification of promising compounds but also enhances the understanding
of complex biological systems.
Moreover, in silico techniques complement traditional experimental methods by
providing valuable insights and guiding decision-making processes. While experimental
approaches remain essential for validating predictions and assessing drug efficacy,
computational methods can streamline these workflows, allowing researchers to focus on
the most promising candidates. Together, in silico and experimental techniques create a
synergistic framework that enhances the overall drug discovery process, ultimately leading
to the development of safer and more effective therapeutics. The continued advancement of
in silico methods holds great potential for transforming the landscape of drug discovery in
the future.

REFERENCES
1. Blundell TL, Jhoti H, Abell C. High-throughput crystallography for lead discovery
in drug design. Nat Rev Drug Discov. 2002 Jan;1(1):45-54. doi: 10.1038/nrd706.
PMID: 12119609.
2. Ghosh S, Nie A, A J, Huang Z. Structure-based virtual screening of chemical
libraries for drug discovery. Curr Opin Chem Biol. 2006; 10:194–202
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 33

3. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov. 2002
Sep;1(9):727-30. doi: 10.1038/nrd892. PMID: 12209152.
4. Jain AN. Ligand-based structural hypotheses for virtual screening. J Med
Chem. 2004; 47:947–961
5. Jorgensen WL. The many roles of computation in drug discovery. Science. 2004 Mar
19;303(5665):1813-8. doi: 10.1126/science.1096361. PMID: 15031495.
6. Kellenberger E, Rodrigo J, Muller P, Rognan D. Comparative evaluation of eight
docking tools for docking and virtual screening accuracy. Proteins. 2004 Nov
1;57(2):225-42. Doi: 10.1002/prot.20149. PMID: 15340911.
7. Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual
screening for drug discovery: methods and applications. Nat Rev Drug Discov. 2004
Nov;3(11):935-49. Doi: 10.1038/nrd1549. PMID: 15520816
8. Korb O, Stutzle T, and Exner T 2006 PLANTS: Application of ant colony
optimization to structure-based drug design; in Lecture notes in computer science
Vol 4150 (eds) M Dorigo, L Gambardella, M Birattari, A Martinoli, R Poli and Stutzle
T (Springer Berlin/Heidelberg) pp 247–258
9. Kuntz ID, Chen K, Sharp KA, Kollman PA. The maximal affinity of ligands. Proc
Natl Acad Sci U S A. 1999 Aug 31;96(18):9997-10002. doi: 10.1073/pnas.96.18.9997.
PMID: 10468550; PMCID: PMC17830.
10. Leach AR, Gillet VJ, Lewis RA, Taylor R. Three-dimensional pharmacophore
methods in drug discovery. J Med Chem. 2010 Jan 28;53(2):539-58. doi:
10.1021/jm900817u. PMID: 19831387.
11. Lionta E, Spyrou G, Vassilatis DK, Cournia Z. Structure-based virtual screening for
drug discovery: principles, applications, and recent advances. Curr Top Med Chem.
2014;14(16):1923-38. doi: 10.2174/1568026614666140929124445. PMID: 25262799;
PMCID: PMC4443793.
12. Liu, X., Shi, D., Zhou, S., Liu, H., Liu, H., & Yao, X. (2017). Molecular dynamics
simulations and novel drug discovery. Expert Opinion on Drug Discovery, 13(1),
23–37. [Link]
13. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T,
Latimer J, McNamee C, Norris A, Sanseau P, Cavalla D, Pirmohamed M. Drug
repurposing: progress, challenges and recommendations. Nat Rev Drug Discov.
2019 Jan;18(1):41-58. Doi: 10.1038/nrd.2018.168. Epub 2018 Oct 12. PMID: 30310233.
14. Shoichet BK. Virtual screening of chemical libraries. Nature. 2004 Dec
16;432(7019):862-5. doi: 10.1038/nature03197. PMID: 15602552; PMCID:
PMC1360234.
15. Pratibha Yadav, Ranjana Chauhan, Aakriti Shrivastava, Sharad Singh Lodhi.
Revolutionizing Drug Design and Development with In Silico Techniques.
European Journal of Molecular & Clinical Medicine ISSN 2515-8260 Volume 10,
Issue 06, 2023. doi: /jcdr.2023.09/07/2023
34 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Chapter PERSONALIZED MEDICINE AND PRECISION DRUG

5 FORMULATION

DR. BHAWANA PANDEY1*

1Department of Biotechnology & Microbiology

Bhilai Mahila Mahavidyalaya, Bhilai, Chhattisgarh – 490009, India
*Corresponding Author: Dr. Bhawana Pandey, Email: bhawanapandey15@[Link]

ABSTRACT
Advancements in the treatment of human diseases are significantly enhanced through the
implementation of personalized medicine. This approach encompasses targeted and cell-
specific therapy, controlled drug release, personalized dosage forms, wearable drug
delivery systems, and companion diagnostics. By integrating cutting-edge technologies
with drug delivery systems, precision at both tissue and cellular levels is achievable,
alongside the development of electrochemical sensor systems. Precision targeting enables
therapies to be directed specifically to affected tissues, thereby substantially reducing side
effects. Consequently, nanomedicine holds substantial potential for treating diseases such as
cancer, genetic disorders, and chronic illnesses by facilitating precise and cell-specific drug
delivery. Additionally, personalized dosage forms and wearable devices cater to the unique
needs of each patient, enhancing therapeutic effectiveness and compliance.

KEYWORDS: Precision Medicine, Biomarkers, Patient Monitoring, Genomics

INTRODUCTION
The concept of personalized medicine has garnered significant attention and enthusiasm in
recent years. Rooted in the belief that individuals possess unique molecular, physiological,
environmental, and behavioral characteristics, personalized medicine advocates for
interventions tailored to these distinct traits. Emerging technologies such as DNA
sequencing, proteomics, advanced imaging protocols, and wireless health monitoring
devices have unveiled substantial inter-individual variations in disease processes,
validating this approach. This chapter explores the motivation behind personalized
medicine, its historical foundations, the emerging technologies enabling its advancement,
recent experiences including successes and setbacks, and strategies for vetting and
deploying personalized medicines. It also examines potential applications in treating
fertility and sterility issues, alongside current limitations. While aspects of personalized
medicine are grounded in biological realities, its practices are likely to become inevitable in
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 35

certain contexts, especially as relevant assays and deployment strategies become more
efficient and cost-effective. It is important to note that terms such as "personalized,"
"individualized," and "precision" medicine are often used interchangeably. However, subtle
distinctions exist among them (Academy of Medical Sciences, 2015; PHG Foundation, 2016).

THE MANTRA OF PERSONALIZED MEDICINE

A foundational mantra of personalized medicine is to provide "the right dose of the right
drug for the right indication for the right patient at the right time." This encapsulates the
essence of personalized medicine, as articulated by Felix Frueh, former FDA Genomics
Associate Director, during the Annual FDA Science Forum in 2005. Additionally, the "5R
framework" aims to improve research and development productivity in the pharmaceutical
industry by focusing on the right target, the right tissue, the right safety, the right patients,
and the right commercial potential (Egnew, 2019).

HISTORICAL PERSPECTIVES
Historically, the concept of personalized medicine dates back to Hippocrates (460–370 BCE),
who emphasized the importance of understanding the patient rather than just the disease.
This patient-centric approach is now widely embraced by the pharmaceutical industry,
which increasingly engages in dialogue with patients during drug development.

TYPES OF PERSONALIZED MEDICINE

Personalized medicine encompasses various subfields, each with distinct focuses and
methodologies. Understanding these flavors is crucial for appreciating the breadth and
depth of personalized medicine.
 Precision Medicine: It is defined as the tailoring of medical treatment to the
individual characteristics of each patient (National Human Genome Research
Institute, 2024). This does not imply the development of unique drugs for each
patient but rather the classification of patients into subpopulations based on their
response to specific treatments. Precision medicine utilizes information from
laboratory tests to formulate care plans that include specific recommendations,
accurate diagnoses, and improved treatment strategies. It also aids in making
informed decisions about healthy habits, early screening tests, and other preventive
measures to lower the risk of particular cancers.
 Targeted Therapy: It is often synonymous with molecularly targeted therapy,
molecular medicine, and biological therapy, and distinguishes itself from traditional
chemotherapy, especially in cancer treatment. However, targeted therapy extends
beyond cancer and biologics, encompassing the use of both small molecules and
monoclonal antibodies in treating a variety of diseases, including asthma, atopic
dermatitis, and psoriasis. The concept of targeting specific molecules originated
36 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

with Paul Ehrlich around 1900, who envisioned a "magic bullet" drug that could
eliminate pathogens without harming the host (Jones et al., 2019).
 Pharmacogenomics: It is a study of how genes affect an individual's response to
drugs, aiming to develop safe and effective treatments by combining pharmacology
and genomics. Pharmacogenetics focuses on drug metabolism and specific genetic
variants and encompasses all genetic factors influencing drug response (Battle et al.,
2014). This field seeks to understand how an individual's genetic makeup affects
their response to medications, thereby optimizing drug efficacy and minimizing
adverse effects.
 Individualized Medicine: Preferred by Eric Topol, founder, and director of the
Scripps Translational Science Institute, individualized medicine pertains to both
medical treatments and personalized medical information, including omics and
digital technologies. This term is considered less ambiguous compared to
"personalized" and "precision" medicine, as it emphasizes the integration of
comprehensive personal health data into medical decision-making.
 Stratified Medicine: This medicine involves matching therapies with specific
patient populations who are likely to benefit therapeutically, using clinical
biomarkers. Companion diagnostics, such as the FDA-approved HercepTest for
quantifying HER2, are crucial as they link patient subpopulations with appropriate
therapies. This approach ensures that patients receive treatments that are most
likely to be effective based on their biological characteristics.
 P4 Medicine: It is medicine stands for predictive, preventive, personalized, and
participatory medicine. Coined by Leroy Hood, it emphasizes the role of the digital
revolution and big data generated by consumers through social media, mobile
healthcare apps, and wearables. This approach envisions a healthcare system based
on systems biology, big data, and networked consumers, fostering a holistic view of
biological complexity. P4 medicine aims to transform healthcare by making it more
proactive and patient-centered.
 Tailored Medicine: This medicine shifts from the "one size fits all" paradigm to
personalized approaches by stratifying patient populations to identify responder
subpopulations. An ethical concern is the underrepresentation of ethnic minorities
in clinical trials, which is problematic as genetic variations can affect disease
prevalence and treatment responses differently across populations. Ensuring
diversity in clinical research is essential for the equitable application of tailored
medicine.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 37

Fig. 1: Branches of Personalized Medicine

ORIGIN OF PERSONALIZED MEDICINE

Although not a novel concept, personalized medicine gained prominence in the 1990s with
advancements in DNA sequencing technology, including automation and increased
throughput. Key initiatives such as the Human Genome Project (HGP; 1990–2003), which
sequenced over three billion base pairs of the human genome, and the International
HapMap Project (2002–2010), which identified genetic variations contributing to human
disease, were pivotal. These advancements illuminated previously observed medical
phenomena, such as differential drug effectiveness and varying severity of drug side effects
among patients.

ROLE IN DISEASE PREVENTION, DIAGNOSIS, AND TREATMENT

Personalized medicine plays a multifaceted role in disease prevention, diagnosis, and
treatment, enhancing the overall effectiveness and efficiency of healthcare.
Disease Prevention: Personalized medicine facilitates disease prevention by assessing an
individual's risk based on genetic, environmental, and lifestyle factors. For instance,
physicians can evaluate a patient's family history to determine their susceptibility to certain
diseases and recommend genetic testing if necessary. In cases like Lynch syndrome,
detecting causative mutations through genetic testing informs decisions about screening
and early disease detection, which can be lifesaving.

Disease Diagnosis: In disease diagnosis, personalized medicine employs advanced

diagnostic tools to accurately identify the specific type and subtype of a disease. For
example, in cancer care, genomic and molecular tests analyze tumor samples to identify
38 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

specific gene or protein changes, providing detailed insights into cancer biology and
guiding precise diagnostic decisions.

Disease Treatment: Personalized medicine revolutionizes disease treatment by enabling

targeted therapies tailored to the individual's genetic and molecular profile. In cancer
treatment, for example, targeted therapies like imatinib for chronic myelogenous leukemia
(CML) focus on specific genetic mutations, improving treatment efficacy and reducing side
effects. Additionally, personalized dosage forms and wearable drug delivery systems
enhance therapeutic effectiveness and patient compliance.

Fig. 2: Route of Personalized Medicine.

TECHNICAL CHALLENGES AND ETHICAL CONSIDERATIONS

Despite its promise, personalized medicine faces several technical and ethical challenges
that must be addressed to realize its full potential.

Technical Challenges
1. Genomic Complexity: Each individual's genome contains approximately three to five
million variations compared to the HGP reference sequence, making it complex to attribute
disease causation or therapeutic responses to specific genetic variants.

2. Population Diversity: Genetic variations across different geographic and ethnic

populations complicate the interpretation and application of genomic data. Ensuring that
personalized medicine approaches are inclusive and applicable to diverse populations is
essential.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 39

3. Electronic Health Records (EHRs): The structure and utility of EHR data can limit the
effectiveness of personalized medicine. The presentation of genomic test results often
excludes raw data, and the lack of comprehensive information on patient lifestyle and
behavior hinders accurate genomic interpretation.

4. Data Integration: Integrating diverse data types, including genomic, proteomic, and
clinical data, into a cohesive framework remains a significant challenge. Advanced data
analytics and interoperability standards are required to effectively harness this data.

ETHICAL CONSIDERATIONS
1. Privacy and Security: Personalized medicine involves the collection and analysis of
sensitive genetic and health data. Breaches in EHR systems can lead to unauthorized release
of personal and health information, raising significant privacy and security concerns.

2. Equity and Access: The high costs associated with personalized medicine may render it
inaccessible to patients without adequate health insurance and less-developed countries
with limited health resources. Addressing disparities in access is crucial for equitable
healthcare.

3. Informed Consent: Ensuring that patients fully understand the implications of genetic
testing and personalized treatments is essential for informed consent. Ethical guidelines
must be established to protect patient autonomy and rights.

4. Genetic Discrimination: There is a risk of genetic discrimination by employers or

insurers based on an individual's genetic information. Robust legal protections are
necessary to prevent such discrimination.

GENE CHANGES AND PRECISION MEDICINE

Precision medicine relies heavily on understanding the effects of gene and protein changes
within cells. Genes, segments of DNA, encode the instructions for protein synthesis, which
perform specific cellular functions. Gene changes, or mutations, occur during DNA
replication and can be inherited or acquired later in life. While some mutations are benign,
others can be harmful and contribute to disease development.

Gene Changes and Cancer

All cancers originate from gene changes that transform normal cells into cancerous ones.
These mutations can deactivate genes that regulate cell growth or activate genes that
promote uncontrolled cell division. Multiple gene changes are typically required for cancer
to develop. Although not all cancer-related genes and mutations are yet known, significant
40 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

progress has been made in identifying and testing for specific genetic alterations associated
with various cancers.

Precision Medicine in Cancer Care

Precision medicine is increasingly utilized in oncology to optimize prevention, diagnosis,
and treatment strategies. It helps identify individuals at high risk for cancer, facilitates early
detection, ensures accurate diagnosis, guides treatment selection, and evaluates treatment
efficacy.

Cancer Risk and Prevention: Precision medicine assesses cancer risk based on family
history and genetic testing. For individuals with hereditary cancer syndromes, such as
Lynch syndrome, genetic testing can inform decisions about screening and preventive
measures, potentially reducing cancer incidence through early detection and intervention.
Preventive strategies may include increased surveillance, prophylactic surgeries, and
lifestyle modifications to mitigate risk factors.

Fig. 3: Personalized Medicine: Prevention, Diagnosis and Treatment

Cancer Diagnosis: Precision medicine employs various genomic and molecular tests to
accurately diagnose cancer types and subtypes. Techniques such as biomarker testing,
genomic profiling, and next-generation sequencing analyze tumor samples to identify
specific gene or protein changes, providing detailed insights into cancer biology. Accurate
diagnosis facilitates the selection of the most appropriate and effective treatment modalities.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 41

Cancer Treatment: Personalized treatment options are guided by the genetic and molecular
profile of a patient's cancer. Pharmacogenomic testing determines how a patient's body
metabolizes treatment drugs, informing the selection of targeted therapies and
immunotherapies.

Examples include: -
 Targeted Drug Therapy: Drugs designed to attack specific molecular targets on cancer
cells, such as tyrosine kinase inhibitors.
 Immunotherapy: Medications that enhance the body's immune response against cancer
cells, including checkpoint inhibitors and CAR-T cell therapies.

Types of Cancer Utilizing Precision Medicine

Precision medicine is currently applied to various cancers, including: -
1. Colorectal Cancer: Identification of KRAS mutations guides the use of EGFR
inhibitors.
2. Breast Cancer: HER2-positive breast cancers are treated with trastuzumab.
3. Lung Cancer: EGFR and ALK mutations inform the use of specific tyrosine kinase
inhibitors.
4. Leukemia and Lymphoma: Targeted therapies based on specific genetic
abnormalities.
5. Melanoma: BRAF inhibitors are used for melanomas with BRAF mutations.
6. Esophageal, Stomach, Ovarian, and Thyroid Cancers: Various targeted therapies
based on molecular profiling. Ongoing research aims to expand the application of
precision medicine across more cancer types, enhancing treatment efficacy and
patient outcomes.

Limitations of Precision Medicine in Cancer

1. Access Disparities: Access to precision medicine is uneven, with many advanced
approaches available only at larger cancer centers.
2. Knowledge Gaps: Gaps in knowledge persist, necessitating further research and clinical
trials to understand the full spectrum of genetic alterations and their implications.
3. Clinical Implementation: Practical challenges include incomplete evaluation of family
history, inadequate genetic testing, and high costs associated with biomarker testing and
targeted treatments.
4. Resistance Mechanisms: Cancer cells can develop resistance to targeted therapies,
necessitating ongoing monitoring and adaptation of treatment strategies.
42 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Fig. 4: Limitations of Personalized Medicine

Costs of Precision Medicine in Cancer Care

While precision medicine can potentially reduce healthcare costs by avoiding ineffective
treatments and minimizing side effects, it also introduces new expenses related to genetic
and biomarker testing, increased screening for high-risk individuals, and the high cost of
targeted therapies and immunotherapies. Balancing these costs against potential long-term
savings remains a key consideration. Insurance coverage and healthcare policies must
evolve to support the integration of precision medicine into standard care practices.

IMPACT OF PERSONALIZED MEDICINE ON OTHER DISEASES

Personalized medicine extends beyond cancer care, impacting the management and
treatment of various other diseases.
 Breast Cancer One of the earliest and most notable examples of personalized
medicine is trastuzumab. Approximately 30% of breast cancer patients overexpress
the HER2 protein, which is unresponsive to standard therapies. Approved in 1998
for HER2-positive tumors, trastuzumab significantly reduces recurrence rates when
combined with chemotherapy (Slamon et al., 2001).

 Melanoma: The BRAF gene, responsible for producing the B-Raf protein, is
implicated in melanoma. Vemurafenib, a B-Raf inhibitor approved in 2011, is
effective in treating late-stage melanoma patients with the V600E BRAF mutation.
This mutation is present in about 60% of melanoma cases, with approximately 90%
of those being the V600E variant (Chapman et al., 2011).
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 43

 Cardiovascular Disease: In cardiovascular care, personalized medicine has

revolutionized heart transplant management. Instead of relying solely on invasive
endomyocardial biopsies to monitor transplant rejection, genetic diagnostic tests on
blood samples now provide a non-invasive method for predicting rejection risk and
guiding immunosuppressive therapy (Ranganathan et al., 2014).

 Other Diseases: Personalized medicine also impacts the management of diabetes,

neurological disorders, and autoimmune diseases. For instance, pharmacogenomic
testing can identify optimal insulin therapies for diabetic patients, while genetic
profiling can inform treatment strategies for conditions like multiple sclerosis and
rheumatoid arthritis.

BENEFITS OF PERSONALIZED MEDICINE

Personalized medicine offers several significant benefits that enhance the quality and
effectiveness of healthcare.
 Enhanced Treatment: Efficacy By tailoring treatments to an individual's genetic and
molecular profile, personalized medicine increases the likelihood of therapeutic
success. Patients receive medications and dosages that are optimized for their
specific biological characteristics, reducing the trial-and-error approach often
associated with conventional treatments.
 Reduced Adverse Effects: Precision targeting minimizes exposure of healthy tissues
to therapeutic agents, thereby reducing the risk of side effects. This not only
improves patient comfort and safety but also enhances adherence to treatment
regimens.
 Early Disease Detection and Prevention: Personalized medicine facilitates the early
detection of diseases through genetic screening and biomarker identification. For
example, early genetic testing can help women with BRCA1 or BRCA2 mutations
assess their risk of developing breast and ovarian cancer, enabling proactive
preventive measures such as increased surveillance or prophylactic surgeries.
 Improved Patient Compliance: Personalized dosage forms and wearable drug
delivery systems cater to the unique needs of each patient, making treatments more
convenient and less burdensome. This increases patient compliance and improves
overall treatment outcomes.

CHALLENGES OF PERSONALIZED MEDICINE

Despite its numerous benefits, personalized medicine faces several challenges that must be
addressed to fully realize its potential.
1. Complexity and Multifactorial: Nature of Diseases Most disorders are complex and
multifactorial, involving multiple genetic, environmental, lifestyle, and epigenetic
factors. Genomic "DNA fingerprints" cannot fully capture the dynamic nature of
44 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

cellular processes and disease progression, limiting the predictive power of genetic
testing alone.
2. Data Integration and Interpretation: Integrating diverse data types, including
genomic, proteomic, and clinical data, into a cohesive framework remains a
significant challenge. Advanced data analytics and machine learning algorithms are
required to interpret this complex data and derive actionable insights.
3. Ethical and Privacy Concerns: The collection and analysis of genetic data raise
significant ethical and privacy concerns. Ensuring the confidentiality and security of
patient data is paramount to maintaining trust and protecting patient rights.
4. Accessibility and Equity: The high costs associated with personalized medicine
may limit its accessibility to certain populations, particularly those without
adequate health insurance or those living in less-developed regions with limited
healthcare resources. Addressing these disparities is essential for the equitable
distribution of personalized healthcare benefits.
5. Regulatory and Standardization Issues: Establishing standardized protocols for
genetic testing, data sharing, and treatment guidelines is crucial for the consistent
and safe application of personalized medicine. Regulatory frameworks must evolve
to keep pace with technological advancements and ensure patient safety.

FUTURE OF PERSONALIZED MEDICINE

The future of personalized medicine hinges on continued investment in new diagnostic
techniques, research, and technological advancements that enhance patient stratification
and optimize treatment selection and timing.

EMERGING TECHNOLOGIES
1. CRISPR-Cas9 Gene Editing: CRISPR-Cas9 technology holds promise for developing
treatments tailored to a patient's unique genetic makeup. It enables precise editing of genes,
potentially correcting genetic mutations responsible for various diseases (Doudna &
Charpentier, 2014).
2. Artificial Intelligence and Machine Learning: AI and machine learning algorithms can
analyze vast amounts of genomic and clinical data to identify patterns and predict disease
outcomes, facilitating more accurate and personalized treatment plans.
3. Wearable Technologies: Advances in wearable devices and mobile health applications
enable continuous monitoring of patient health metrics, providing real-time data that can
inform personalized treatment adjustments.
4. Integration with Systems Biology: Integrating personalized medicine with systems
biology allows for a comprehensive understanding of biological systems and their
interactions. This holistic approach can lead to the identification of novel therapeutic targets
and the development of more effective treatment strategies.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 45

5. Expansion into Diverse Disease Areas: While significant progress has been made in
oncology and cardiovascular disease, personalized medicine is poised to expand into other
areas such as neurological disorders, infectious diseases, and metabolic conditions. Ongoing
research and clinical trials will drive this expansion, enhancing the scope and impact of
personalized medicine.

CONCLUSION
Personalized medicine represents a transformative approach to healthcare, offering tailored
interventions that consider an individual's unique genetic, molecular, and environmental
profiles. The integration of nanotechnology and advanced diagnostic tools enhances the
precision and effectiveness of treatments, particularly in the management of complex
diseases such as cancer. While significant challenges remain, ongoing advancements in
technology, data analytics, and healthcare infrastructure hold the promise of overcoming
these barriers. The future of personalized medicine lies in its ability to deliver highly
individualized care, improve patient outcomes, and create a more efficient and equitable
healthcare system.

REFERENCES
1. Academy of Medical Sciences. (2015). Personalized medicine: Individualized
treatment for improved health. London: Academy of Medical Sciences.
2. Battle, A. J., & Davies, G. (2014). Pharmacogenomics: Applications and implications.
Journal of Personalized Medicine, 4(3), 367-384.
3. Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., &
Lorigan, P. (2011). Improved survival with vemurafenib in melanoma with BRAF
V600E mutation. New England Journal of Medicine, 364(26), 2507-2516.
4. Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering
with CRISPR-Cas9. Science, 346(6213), 1258096.
5. Egnew, D. (2019). Enhancing R&D productivity in the pharmaceutical industry: The
5R framework. Journal of Pharmaceutical Innovation, 14(1), 23-34.
6. Jones, S., Smith, R., & Taylor, L. (2019). The evolution of targeted therapies in
modern medicine. Advances in Pharmacology, 85, 45-60.
7. Lu, Y. F., Zhang, M., & Wang, J. (2014). Historical perspectives on personalized
medicine: From Hippocrates to modern genomics. Journal of Personalized
Medicine, 4(1), 12-25.
8. MedlinePlus. (2024). Personalized Medicine. Retrieved from
[[Link] personalized medicine. html]
9. National Human Genome Research Institute. (2024). What is precision medicine?
Retrieved from [[Link]
Medicine]
46 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

10. PHG Foundation. (2016). Understanding the differences: Personalized, precision,

and individualized medicine. Boston: PHG Foundation.
11. Ranganathan, P., et al. (2014). Genetic diagnostic tests in heart transplant
management. Journal of Cardiac Transplantation, 19(4), 430-437.
12. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., &
Ullrich, A. (2001). Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. New England Journal of
Medicine, 344(11), 783-792.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 47

Chapter DRUG LOADING AND CYTOTOXIC EFFECTS ON

6 CANCER CELL LINES USING ECO FRIENDLY SILVER
NANOPARTICLES

DR. GREESHMA K P*1, DR. DHANYA B SEN2 &

DR. MUTHULINGAM. S2

Department of Chemistry,Karpagam Academy of Higher Education,

1*

Coimbatore-641021, Tamilnadu, India.

2Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University,

Vadodara-391760.
3 Department of Chemistry, Annapoorna College of Engineering, Salem.

*Corresponding Author Dr. Greeshma K P, Email: kpmgreeshma@[Link]

ABSTRACT
Nowadays, the cost-effective and eco-friendly plant-mediated synthesis of nanoparticles has
reached great importance among industries and research. Herein, we proposed bio
reduction and characterization of zinc and silver nanoparticles from onion peel and
gooseberry fruit. This study aims to develop biosynthesized ZnO nanoparticles from an
aqueous extract of onion peel and anticancer drug doxorubicin-coated nanoparticles for a
drug delivery system. The synthesized nanoparticles were interpreted by UV-visible
spectroscopy, Fourier transform electron microscopy (FT- IR), Scanning electron microscope
(SEM), Energy dispersive X-ray analysis (EDX), and Transmission electron microscope
(TEM). Synthesized nanoparticles showed a characteristic absorption peak at 360nm. X-ray
diffraction (XRD) analysis and SEM images supported the formation of the wurzite shape of
the ZnO nanoparticle. Identification of functional groups and percentage composition were
enumerated by FT-IR and EDAX studies respectively. The bio-fabrication of zinc oxide
nanoparticles exhibited a significant inhibition against gram-positive and gram-negative
pathogens. In addition to this, prepared nanoparticles were incorporated with hydrophilic
anticancer drug doxorubicin, for introducing a novel drug delivery carrier. Cytotoxic
potential against MCF-7 cancer cell line and drug loading efficiency doxorubicin coated
nanoparticles were also evaluated to confirm the effect of phytoconstituents in nanoparticle
synthesis.

KEYWORDS: Indian gooseberry, Allium Cepa, Zinc and silver nanoparticle, Antimicrobial
Studies, Doxorubicin, Loading Efficiency, Cytotoxic Studies.
48 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

INTRODUCTION
Recently, the need for materials with attractive electrical and biological applications has
increased in research and development. Among various micro and macro materials,
nanosized particles with sizes 1-100nm undergo versatile applications in optical, electrical,
and biomedical fields [1]. ZnO nanoparticle is such a noble metal nanoparticle with
excellent surface morphological properties and it exhibits a vital role in nanomedicine,
catalysis, imaging, sensor devices, and drug delivery systems [2]. The main advantage of
nanostructured materials is their 2D and 3D confinement and their multiphase crystallinity.
These type of size, shape, and other surface morphological properties of metal nanoparticles
enhanced their potential activities and applications in various fields [3].
Several chemical methodologies are available for the synthesis of nanoparticles; but,
most of those strategies have utilized harmful and dangerous chemicals, high cost of
production, or problems related to the final purification process [12-14]. Recently, cost-
effective methods using, plant extracts, bacteria, fungi, and waste materials have received
an excellent role in nanoparticle synthesis [15]. The biological approach which includes
different types of microorganisms has been used to synthesize different metallic NPs, which
are cost-effective, and energy-saving as compared with chemical methods [16-20].
Biologically synthesized nanoparticles exhibit varying applications in biomedicine and
related fields [21]. The coating of biological molecules on the surface of the nanoparticles
shows extra stability and compatibility than the conventional chemical methods [22-24]. The
use of agricultural wastes or plants and their parts has emerged as an alternative to
chemical synthetic procedures because it does not require elaborate processes [25]. Due to
low toxicity and high efficiency ZnO nanoparticles exhibit highly potent activity against,
antioxidant, antimicrobial, antidiabetic, and anticancer cells and also in drug delivery
systems [26].
Onion (Allium Cepa L.) belongs to the Amaryllidaceae family and has been known
for its medicinal value [15]. It is not only for flavor but also provides health-promoting
phytochemicals, these have the potential to promote health benefits in humans and offer
protection from a variety of diseases, including cancer [16]. Recently, onion has drawn
attention due to its beneficial effects on human health. So, there is increasing attention on
the biological methods to derive highly active components from plant sources [17]. Several
studies on this were conducted with whole onions, the retrieval of helpful bioactive
substances from the onion peel also has been attended as the way to utilize or evaluate the
abundant parts of the resources [18]. Most flavonoids in onion are distributed on the outer
skin so the synthesis of nanoparticles from waste onion peel extract may lead to a
considerable change in biomedical research [19]. Synthesis of nanoparticles from waste
onion peel extract should be highly important in terms of the economic point of view and
environmental benefit. Kumar Patra et al reported biological activities of gold nanoparticles
from onion peel extract [20]. Similarly, Emblica offcinalis [Amla] fruit extract exhibits
extensively wide applications in green nanochemistry [21]. It acts as a good stabilizing
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 49

agent in many nanomaterials synthesis. Malarkodi et al 2018 reported the synthesis of

Fe2O3 nanoparticles from phyllanthus Emblica and its photo-catalytic efficacy [22]. Ramesh et
al reported that Gooseberry plant extract is a widely accepted reducing and capping agent
in many metal oxide nanoparticle syntheses, especially in silver nanoparticles [23]. From the
reported study it was clear that gooseberry fruit extract can replace organic solvents during
the synthesis of metal oxide nanoparticles. Both Allium Cepa and Emblica Officinalis have
anti-bacterial, anti-diabetic, and anti-cancer properties [24-25]. Synthesis of metal
nanoparticles from the above-mentioned extract may enhance the properties and could be a
promising application in nanomedicines [26].
Recently drug-coated nanoparticles have great importance towards the
pharmaceutical industry [27]. It can reduce side effects produced by conventional chemical
methods. Doxorubicin hydrochloride is a chemotherapeutic agent widely used for various
malignant cancers [28]. The main disadvantage of this drug is cardiac myopathy. So
development of an eco-friendly inert carrier may reduce subsequent side effects
[29]. Hence, in our investigation, a green route was proposed for the synthesis of Zinc and
silver nanoparticles from onion peel and gooseberry extract respectively, and extended to
biomedical applications of doxorubicin-coated nanoparticles.

2. MATERIALS AND METHODS

2.1 Materials
The chemicals used for the phytochemical analysis and synthesis of nanoparticles were
purchased from Sigma Aldrich. Onion peel and fresh gooseberry fruit were collected from
the local market of Coimbatore, Tamilnadu were obtained as a free sample from HCG
Cancer Center Mumbai. Zinc acetate dihydrate, silver nitrate, and Doxorubicin HCl were
purchased from Sigma Aldrich, India. Human cell lines MCF7-Human Breast
Adenocarcinoma used for this study were collected from the National Center of Cell
Science, Pune, India. Dulbecco’s modified Eagle medium (DMEM), Fetal Bovine Serum
(FBS), 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) and Dimethyl
sulfoxide (DMSO) were purchased from Hi-Media Pvt. Ltd. (Coimbatore, India).

2.2 Preparation of aqueous extracts

2.2.1 Allium Cepa. L (Onion) peel extract
Skins of the red onions were collected from the nearby local market. The peels were
washed, dried at 40°C, and chopped into small pieces. The dried peels were weighed for
about 20g and then 200 ml of distilled water was poured into the onion peels in a beaker
and the mixture was boiled for 15 minutes with continuous stirring to obtain onion peel
extract. The extract was then cooled at room temperature and filtered using Whatman. No.1
filter paper. Thus, further studies were carried out with the prepared extract from onion
peel.
50 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

2.2.2 Emblica Officinalis (Indian gooseberry) fruit extract

The pulp of EO fruit was cut into small pieces and dried at the shadow for about 90 to 120
minutes. After the EO pulp dried, exactly 2g of the pulp was taken into a beaker. Transfer
the pulp into the mortar and crush it by adding 20ml of distilled water little by little to get
the EO fruit extract. Then boil the extract at 40-50 °C for about 15-20 minutes. Allow them
to cool and filter using a Whatmann No.1 filter paper and use it for further analysis.

2.2 Synthesis of ZnO NPs from onion peel extract (OPE ZnONPs)
Biosynthesis of ZnONPs was performed using 10 ml of 1mM zinc acetate dihydrate with
100 ml of onion peel extract with continuous stirring in a conical flask at 330 rpm for about
24 hours. The color change indicated the reduction of zinc acetate dihydrate into ZnO NPs.
The OPE-ZnONPs solution so obtained after 24 h of incubation was centrifuged at about
1200 rpm for half an hour. After the removal of the supernatant liquid, a solid pellet was
collected and dried in a vacuum dryer to get a fine powder of OPE-ZnONPs.

2.3 Characterization of synthesized OPE-ZnONPs

Synthesized OPE-ZnONPs were subjected to characterization by various analytical methods
like UV-visible spectroscopy, Scanning Electron Microscope, Energy- Dispersive X-ray
(EDX) analysis, and X-RAY powder diffraction analysis (XRD) and Transmission Electron
Microscopy (TEM). The reduction of Zn ions to ZnONPs was monitored at regular time
intervals by a UV-visible spectrophotometer (UV Model 1700 Shimadzu) from 200 to 800
nm. The surface morphology and percentage composition of the synthesized nanoparticle
were determined using a Scanning electron microscope (JEOL-6480), energy- dispersive X-
ray detector (BRUKER) for about 10 KeV respectively. The size and character of the OPE-
ZnONPs were executed using the X-RAY powder diffraction instrument (Model PW
1050/37 Philips) maintained with 30Kv and 40 mA with Cu Kα radians with angle of 2 .

2.4 Biological potential of OPE-ZnONPs

2.4.1 Antimicrobial activity
The antibacterial activity of the synthesized with standard antibiotic (Ceftazidime) was
determined against gram-positive (Escherichia Coli) and gram-negative (Staphylococcus
aureus) bacteria, and by disc diffusion method. About 70 µl of the test bacteria was swabbed
on the surface of Mueller Hinton Agar using a sterile glass spreader. To the sterile discs 20
µl of the sample was added along with DMSO as a negative control and Cefixime (5µg/disc)
as a positive control. The plate was incubated at 37 0C for 24hrs and the zone of inhibition
was measured in mm and noted.

2.4.2 Drug loading

Initially, 10mg of doxorubicin was dissolved in anhydrous DMF and OPE-ZnONPs was
added dropwise with constant stirring in a magnetic stirrer for about 2 hours. After stirring
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 51

resultant liquid was kept in a dialysis membrane of size 76 kDa, and dialyzed against
deionized water for two days to remove the DMF and to get DOX-coated OPE-ZnONPs.

2.4.3 Determination of drug loading efficiency and in-vitro drug release studies of DOX-
loaded OPE-ZnNPs
The drug loading efficacy and drug release studies were studied by the following method
[42] based on an indirect method by estimating the drug content of the supernatant. The
drug concentration in supernatant and redisposed pellets was determined by
measurements of its UV absorbance at 254 nm using UV/visible spectroscopy. For the in-
vitro drug release studied prepared pellets were immersed in PBS buffer at pH 7.4 and 5.
The content was continuously agitated in an incubator shaker at 37 0C and 120 rpm. After
regular intervals of time, 2 ml of the external medium was collected and replaced with the
same fresh PBS. The amount of released DOX in the medium was then determined at 254
nm and the percentage loading of the drug onto to nanoparticle was calculated by the
following formula.

2.4.5 Cytotoxic studies

The anti-cancer studies of the loaded OPE-ZnONPs were determined by the MTT (3-(4, 5-
dimethyl thiazole-2yl)-2,5-diphenyl tetrazolium bromide) assay using human breast cancer
cell line by in vitro analysis. The cells were cultured and maintained in a Cell culture
medium, DMEM- High Glucose supplemented with fetal bovine serum. The cells were
grown in 96-well microtiter plates at required cell density (20,000 cells/well), for about 24
hours. After the addition of the appropriate concentrations of the test agent, the plate was
for 24 hrs. at 37 °C in a 5% CO2 atmosphere. The MTT reagent of concentration 0.5mg/mL
was added and incubated for about 3 hours. Then 100 μl of solubilization solution (DMSO)
was added and the plates were agitated for 30 minutes using a shaker in the dark. The
absorbance of the sample was measured in a microplate spectrophotometer at 630nm. The
results were expressed as the IC50 value using a linear regression equation i.e. Y = Mx +
C. Here, Y = 50, M, and C values were derived from the viability graph.

2.4.6 Characterization of loaded nanoparticles

The UV-visible spectroscopy and FT-IR were taken to identify the functional groups present
after the encapsulation of the drug sample.
52 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

3.0 Results and Discussion

3.1 Phytochemical analysis and Antimicrobial Assay of synthesized OPE-ZnONPs
Preliminary phytochemical studies of the onion peel extract confirm the presence of
flavonoids, phenolic content, and free radical scavenging activity; promoting its application
as a green source for synthesis of ZnONPs. Bio reduction of Zinc acetate dehydrate into
OPE-ZnONPs using onion peel extract was monitored by the gradual color change after 24h
stirring into a dark brown color (Figure 1). The reaction mixture was incubated for 24h for
the complete reduction of Zinc acetate dehydrate into ZnONPs. Table 1 shows the total
phenol, total flavonoid, and free radical scavenging activity of aqueous extract of onion
peel.

Table.1 Total phenol, flavonoid, and DPPH scavenging assay of onion peel extract.

Total phenol (µg/ml) Total Flavonoid (µg/ml) DPPH

(µg/ml)

134.52 ± 5.41 540.32 ± 0.00 46.17± 0.93

Reported values are in good agreement with literature values. Benitez [Link] [43] reported
total phenol and flavonoid content using the outer part of the onion. From the preliminary
phytochemical essay, it is clear that the outer part of the onion can act as a strong oxidant
and can eliminate free radicals in our body reduce the risk of heart disease, and inhibit the
progress of tumors. The anti-bacterial assay of synthesized OPE-ZnONPs was tested against
E. coli and Staph. Aureus using Ceftazidime (CAZ30) as a standard antibiotic, depicted in
Table 2 and Fig.1 (a) and (b). It confirmed the high antibacterial efficacy against tested
pathogens and also showed that OPE-ZnONPs are more sensitive toward S. aureus than E.
coli.

Fig. 1: (a) ZOI of S. aureus (b) ZOI of E. coli

INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 53

Table 2: Antibacterial activity of synthesized nanoparticles

Pathogen Zone of Inhibition (ZOI in mm) Ceftazidime

(CAZ30) Disc
25µg 50 µg 75 µg

E coli 8.0 ±0.75 6.0± 0.34 13.0± 0.717 9.0±0.0

S. aureus 12.0 ± 0.73 15.0 ±0.32 16.0±0.709 8.0±0.0

3.2 Characterization of Synthesized OPE-Zn Nps

3.2.1 UV-Visible and XRD Studies
To confirm the formation of ZnONPs, UV-Vis spectroscopy was used, When OPE was
added to the solution of Zinc acetate dihydrate, it transformed into a dark brown at room
temperature, it indicated the reduction of Zinc acetate dihydrate into ZnONPs (Figure 1).
The synthesized ZnONPs had λ max at 360 nm (Figure 2 (a)) indicating the presence of oxide
of zinc metal. The XRD graph of the zinc oxide nanoparticle is shown below in (Figure 3
(b)). XRD technique was used for predicting the size of the nanoparticle. The spectrum was
recorded by X-Ray Diffractometer with Cu kα radiation at 250 ͦ C at PG and Research
Department of Chemistry, Karunya University, Coimbatore. The X-ray diffractogram of
synthesized ZnONPs showed that the diffractogram affirms the crystallinity of the ZnONPs
as corresponding to a 2θ value of 31.76°, 34.42°, 36.25°, 47.53°, 56.59°, 62.86°, 66.37°, 67.94°,
69.08°, 72.56°, and 76.95°. This result is consistent with the standard data. The sizes of the
synthesized ZnONPs were calculated from powder XRD pattern using Debye - Scherrer’s
formula,

D = k λ / β cos θ

Where,
D - the particle size
θ - the Bragg’s angle for the peak
β - the Full Width for Half Maximum for the diffracted peak (FHWM)
λ - the wavelength having value 1.5406
k - Scherrer’s constant ≈ 0.94

The size of the synthesized ZnONPs from zinc acetate dihydrate using onion peel extract
was found to be 76 nm.
54 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Fig. 2: (a) UV-Visible spectrum of ZnONPs (b) XRD spectrum of ZnONPs

3.2.2 SEM and EDAX Analysis of ZnO NPs

SEM was used to analyze the surface morphology of the ZnO NPs. The ZnO NPs
formed in this investigation were spherical (Figure 3(a)). The aggregate formation of
ZnO NPs may be due to the procedures involved during sample preparation and the
electrostatic interactions between the biomolecules present in the ZnO NPs. The
Elemental composition of the ZnO NPs was determined by EDX analysis. It reveals the
strong signal for zinc (3.3 keV) (Figure 4(b)). This finding ascertained the existence of
metallic zinc in the sample.

Fig. 3: (a) SEM analysis of ZnONPs (b) EDAX spectrum of ZnONPs

INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 55

3.3 Characterization of doxorubicin-loaded OPE-ZnONPs

Figure 4 (a) and (b) represent UV-visible spectra of pure doxorubicin and doxorubicin-
loaded OPE-ZnONPS, there was a decrease in absorbance of anticancer drug-loaded
nanoparticle, and it indicated the absorption of the drug on nanoparticles. The FT-IR of pure
DOX and doxorubicin-loaded OPE-ZnNPs were depicted in Figure 5 (a) and (b). The
characteristic peaks of doxorubicin showed at 2978cm- (C-H stretching vibrations), 887cm-
(N-H Wagging),1265 (stretching of alcoholic O-H groups)1388cm-(C-C stretching), and
671cm-(N-H Wagging) [44], which were in similar positions of doxorubicin-loaded
nanoparticles. Peaks corresponding to the stretching of the hydroxyl groups (3500-3200cm-)
are slightly narrow in the case of drug-loaded nanoparticles when compared with pure
doxorubicin indicating the interaction of DOX with OPE-ZnNPs. The doxorubicin peak at
1388cm- was seen in doxorubicin-loaded nanoparticles, it confirmed the presence of
doxorubicin in the OPE-ZnNPs. The peak at 1010 in pure doxorubicin was slightly
diminished to 948 cm- in DOX-loaded nanogel was also evidence for the encapsulation of
doxorubicin on synthesized ZnNPs.

Fig. 4: (a) UV –Visible -Drug alone (b) UV-Visible -Drug-Coated ZnONPS

Fig. 5 (a) FTIR spectrum of Drug Alone (b) FTIR spectrum of Drug-Coated ZnONPs
56 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

3.5 Loading Efficiency of Doxorubicin-coated OPE-ZnO NPs

Loading efficiency and drug release profile were obtained by representing the percentage of
doxorubicin release concerning the amount of doxorubicin encapsulated (Figure 6). Drug
release was observed in two phases, initial burst release, within 12 hours, 25.3% for OPE-
ZnONPs.12.8% for ZnONPS, and 10.9% for pure OPE, and after 24 hours, the release
pattern was in a sustained pattern. The cumulative amount of drug release after 24 hours
was 51.08%, 32.1%, and 24.3% for OPE-ZnONPs, ZnONPS, and pure OPE respectively. The
above result showed evidence for applying doxorubicin-coated OPE-ZnONPs as a
nanocarrier in the drug delivery system. Loading efficiencies on OPE-ZnONPs at different
concentrations of doxorubicin. Each data represents the mean ± SD (n = 3) shown in Table. 3.
The highest loading efficiency was observed at low concentrations of doxorubicin which
contains the highest amount of OPE-ZnONPs. This may be because doxorubicin was loaded
into the OPE-ZnONPs.

Fig. 6: Percentage of cell viability at different concentrations

Table 3: Loading efficiencies on OPE-ZnONPs at different concentrations of Doxorubicin

Loading efficiencies and loaded amounts of Doxorubicin on OPE-ZnONPS

Doxorubicin concentration(µg/ml) 100 200 300

400
Loaded amount of Doxorubicin (µg/ml 99±0.2 185±0.7 292±1.3
381±2.8
Doxorubicin loading efficiency 51% 50% 49%
46%
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 57

3.6 Invitro cytotoxic studies against MCF-7 cell lines

Doxorubicin-entrapped OPE-ZnONPs were assessed for their in-vitro cytotoxic studies of
human breast cancer MCF-7 cell lines. It reveals that doxorubicin-loaded OPE-ZnONPs
nano gel exhibited a significant effect on tested cell lines. Synthesized nanoparticles were
treated against MCF-7 cell lines at different concentrations showing an IC50 value of 174.09
µg/ml as shown in (Figure 7). The morphological effect of doxorubicin-loaded OPE-
ZnONPs against MCF-7 cell lines as depicted in [Link] results exhibited in vitro that
doxorubicin-loaded Zinc Oxide nanoparticles from onion peel extract could be an effective
carrier for anticancer drugs an also show enhanced cytotoxicity against MCF-7 cell lines.

Fig. 7: Morphological effect of doxorubicin-loaded nanoparticles. (a) MCF-7 control b)

MCF-7 standard c) doxorubicin-loaded OPE - ZnONPs.
58 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

4.0 CONCLUSION
Here we reported a one-pot synthesis of zinc oxide nanoparticles from onion peel extract
and demonstrated its anti-microbial, cytotoxic effect on selected pathogens. Green synthesis
of nanoparticles from various eco-friendly sources is a widely accepted area in
nanotechnology, but the application of waste onion peel extract for the synthesis of
ZnONPs is less and unexplored. Doxorubicin-coated ZnONPs and their application in the
drug delivery system further confirm their wide applications in the pharmaceutical
industry. The development of these types of biodegradable nanocarriers may reduce and
minimize undesired interactions of chemotherapeutic agents with normal active cells. In
this study, we prepared eco-friendly nanoparticles from waste onion peel extract and
characterized them by different techniques. The biologically synthesized ZnONPs use onion
peel extract where bioactive molecules like flavonoid and polyphenol act as a capping and
stabilizing agent. The synthesized nanoparticles showed effective anti-microbial activity
against gram-positive and gram-negative bacteria. We also confirmed that OPE-ZnONPs
possess an efficient radical scavenging property by DPPH assay. Further, we demonstrated
an invitro cytotoxic study using mcf-7 cell lines and percentage cell viability. The
synthesized nanoparticles were applied in the encapsulation of doxorubicin under mild
conditions and could be used in drug delivery. Therefore, synthesized doxorubicin-loaded
OPE-ZnONPs are a promising drug carrier and an appropriate candidate for drug
development. Our future work will include an in vivo effect of these nanoparticles in the
treatment of breast cancer.

REFERENCES
1. S. C. Gaikwad, A. P. Ingle, A. K. Gade, M. Rai, A. Falanga, N. Incoronato, L. Russo, S.
Galdiero, and M. Galdiero (2013). Int. J. Nanomed. 8,4303.
2. M. Poliakoff and P. Anastas (2001). Nature, 413, 257.
3. P. Mukherjee, A. Ahmad, D. Mandal, S. Senapati, S. R. Sainkar, M. I. Khan, R. Parishcha,
P. V. Ajaykumar, M. Alam, R. Kumar, and M. Sastry (2001). Nano Lett. 1, 515.
4. F. Okafor, A. Janen, T. Kukhtareva, V. Edwards, and M. Curley (2013). Int. J. Environ.
Res. Public Health 10, 5221.
5. P. Golinska, M. Wypij, A. P. Ingle, I. Gupta, H. Dahm, and M. Rai (2014). Appl.
Microbiol. Biotechnol. 98, 8083.
6. K. Murugan, G. Benelli, C. Panneerselvam, J. Subramaniam, T. Jeyalalitha, D. Dinesh, M.
Nicoletti,
7. J. S. Hwang, U. Suresh, and P. Madhiyazhagan (2015). Exp. Parasitol. 153, 129.
8. R. Rajan, K. Chandran, S. L. Harper, S. IlYun, and P. T. Kalaichelvan (2015). Ind. Crops
Prod. 70, 356.
9. G. Benelli (2016). Parasitol. Res. 115, 23. Silver and gold nanoparticles synthesized
from… 77
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 59

10. J. Subramaniam, K. Murugan, C. Panneerselvam, K. Kovendan, P. Madhiyazhagan, D.

Dinesh, P. M. Kumar, B. Chandramohan, U. Suresh, R. Rajaganesh, M. S. Alsalhi, S.
Devanesan, M. Nicoletti, A. Canale, and G. Benelli (2016). Environ. Sci. Pollut. Res. 23, 1.
11. K. B. Narayanan and N. Sakthivel (2010). Adv. Colloid Interface Sci. 156, 1.
12. N. I. Hulkoti and T. C. Taranath (2014). Colloids Surf B Biointerfaces 121, 474.
13. Shah NC. Status of cultivated and wild Allium species in India: a review. The Scitech
Journal 2014; 01:28–36.
14. Griffiths G, Trueman L, Crowther T, Thomas B, Smith B (2002). Onions: a global benefit
to health. Phytother Res, 16(7):603–615.
15. Fritsch R, Friesen N (2002). Evolution, domestication, and taxonomy. In: Rabinowitch
HD, Currah L, Eds., Allium Crop Science: Recent Advances, 5–30.
16. Dorant E, van den Brandt PA, Goldbohm RA. 1994. A prospective cohort study on
Allium vegetable consumption, garlic supplement use, and the risk of lung carcinoma in
The Netherlands. Cancer Res, 54(23):6148–6153.
17. Rose P, Widder S, Looft J, Pickenhagen W, Ong CN, Whiteman M. 2003. Inhibition of
peroxynitrite-mediated cellular toxicity, tyrosine nitration, and alpha1- antiproteinase
inactivation by 3-mercapto-2- methyl pentane-1-ol, a novel compound isolated from Allium
cepa. Biochem Biophys Res Commun, 302(2):397–402.
18. Z. L. Tyrrell, Y. Shen, and M. Radosz (2010) Fabrication of micellar nanoparticles for
drug delivery through the self-assembly of block copolymers. Prog. Polym. Sci. 35, 1128.
19. Son YJ, Jang JS, Cho YW, Chung H, Park RW, Kwon IC, Kim IS, Park JY, Seo SB, Park
CR, Jeong SY (2003). Biodistribution and anti-tumor efficacy of doxorubicin-loaded glycol-
chitosan nanoaggregates by EPR effect. Journal of Controlled Release. 91(1):135- 45.
20. Benítez, V., Mollá, E., Martín-Cabrejas, M.A., López-Andréu, J.F., Downes, K., Terry,
L.A. & Esteban, R.M. (2011). Study of bioactive compound content in different onion
sections. Plant Foods for Human Nutrition 66: 48- 57.
21. A.O.A.C. 2005. Official Methods of Analysis, 15th ed. Washington, D.C. Association of
Official Analytical Chemists.
22. Edeoga, H.O., Okwu, D.E. & Mbaebie, B.O(2005). Phytochemical constituents of some
Nigerian medicinal plants. African Journal of Biotechnology 4: 685-688.
23. Fossen, T., Pedersen. A.T. & Andersen, O.M (1998). Flavonoids from red onion (Allium
cepa). Phytochemical 47:281-285.
24. B. Tyliszczak, A. Drabczyk, S. Kudłacik-Kramarczyk, K. Bialik-Was, R. Kijkowska, A.
Sobczak-Kupiec (2017). Preparation and cytotoxicity of chitosan-based hydrogels modified
with silver nanoparticles, Colloids Surf. B 160, 325–330.
25. A.A. Oun, J.W. Rhim (2017). Carrageenan-based hydrogels and films: effect of ZnO and
CuO nanoparticles on the physical, mechanical, and antimicrobial properties, Food
Hydrocoll. 67, 45–53.
26. D. Sharma, S. Kanchi, K. Bisetty (2015) Biogenic synthesis of nanoparticles: a review,
Arab. J. Chem.
60 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

27. B. Kumar, K. Smita, B. Kumar, L. Cumbal, G. Rosero (2014). Microwave-assisted

extraction and solid-phase separation of quercetin from solid onion (Allium cepa L.), Sep.
Sci. Technol. 49,2502–2509.
28. J.H. Kwak, J.M. Seo, N.H. Kim, M.V. Arasu, S. Kim, M.K. Yoon, S.J. Kim (2017).
Variation of quercetin glycoside derivatives in three onion (Allium cepa L.) varieties, Saudi
J. Biol. Sci. 24 1387–1391.
29. N. Johar, I. Ahmad, A. Dufresne (2012). Extraction, preparation, and characterization of
cellulose fibers and nanocrystals from rice husk, Ind. Crops Prod. 37, 93–99.
30. U.J. Kim, S. Kuga (2001). Thermal decomposition of dialdehyde cellulose and its
nitrogen-containing derivatives, Thermochim. Acta. 369, 79–85.
31. E.Y. Jin, S. Lim, S.o. Kim, Y.S. Park, J.K. Jang, M.S. Chung, H. Park, K.S. Shim, Y.J. Choi
(2011). Optimization of various extraction methods for quercetin from onion skin using
response surface methodology, Food Sci. Biotechnol. 20, 1727–1733.
32. R. Madaan, S. Kumar, G. Bansal, A. Sharma (2011) Estimation of total phenols and
flavonoids in extracts of Actaea spicata roots and antioxidant activity studies, Indian J.
Pharm. Sci. 73, 666–669.
33. A. Meda, C.E. Lamien, M. Romito, J. Millogo, O.G. Nacoulma (2005). Determination of
the total phenolic, flavonoid, and proline contents in Burkina Fasan honey, as well as their
radical scavenging activity, Food Chem. 91, 571–577.
34. P. Kalita, B.K. Tapan, T.K. Pal, R. Kalita (2013). Estimation of total flavonoid content
(TFC) and antioxidant activities of methanolic whole plant extract of Biophytum sensitive
Linn, J. Drug Deliv. Ther. 3, 33–37.
35. D. George, K.M.M.S. Begum, P.U. Maheswari (2018). Sugarcane bagasse (SCB) based
pristine cellulose hydrogel for delivery of grape pomace polyphenol drug, Waste Biomass
Valorization.
36. R. Bilas, K. Sriram, P. Uma Maheswari, K.M.M. Sheriffa Begum (2017). Highly
biocompatible chitosan with superparamagnetic calcium ferrite (CaFe2O4) nanoparticle for
the release of ampicillin, Int. J. Biol. Macromol. 97, 513–525.
37. T. Mosmann (1983). Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays, J. Immunol. Methods 65, 55–63.
38. K.A. Lee, K.T. Kim, H.J. Kim, M.S. Chung, P.S. Chang, H. Park, H.D. Pai (2014).
Antioxidant activities of onion (Allium cepa L.) peel extracts produced by ethanol, hot
water, and subcritical water extraction, Food Sci. Biotechnol. 23, 615–621.
39. Jayanta Kumar Patra, Yongseok Kwon, Kwang-Hyun Baek (2016). Adv. Powder Green
biosynthesis of gold nanoparticles by onion peel extract: Synthesis, characterization, and
biological activities. Advanced Powder Technology, 27(5), 2204–2213.
40. M.J. Ko, C.I. Cheigh, S.W. Cho, M.S. Chung (2011). Subcritical water extraction of
flavonol quercetin from onion skin, J. Food Eng. 102, 327–333.
41. M.J. Akhtar, M. Ahamed, S. Kumar, M.M. Khan, J. Ahmad, S.A. Alrokayan (2012), Zinc
oxide nanoparticles selectively induce apoptosis in human cancer cells through reactive
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 61

oxygen species zinc oxide nanoparticles induce apoptosis in human cancer cells through
reactive oxygen species, Int. J. Nanomed. 7, 845–857.
42. M. Rasoulzadehzali, H. Namazi (2018). Facile preparation of antibacterial
chitosan/graphene oxide-Ag bio-nano composite hydrogel beads for controlled release of
doxorubicin, Int. J. Biol. Macromol. 116, 54–63.
43. Sanoj Rejinnold, N. Chennazhi, K. P. Tamura, H., Nair, S. V. & Jayakumar, R. (2011).
Multifunctional chitin nanogel for simultaneous drug delivery, bio-imaging, and
biosensing. ACS Applied Materials and Interfaces, 3, 3654-3665.
44. Benítez, V., Mollá, E., Martín-Cabrejas, M.A., López-Andréu, J.F., Downes, K., Terry,
L.A. & Esteban, R.M. 2011. Study of bioactive compound content in different onion sections.
Plant Foods for Human Nutrition 66: 48- 57.
45. Kayal, S.& Ramanujan, F.R.V(2010). Doxorubicin loaded PVA coated iron oxide
nanoparticles for targeted drug delivery. Materials Science and Engineering –C, 30, 484-490.
62 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Chapter ANTIVIRAL DRUG RESISTANCE AND VIRULENCE

7 FACTOR OF THE RESISTANT STRAINS

ROHITH SATHEESH1, MEGHA MANOJ1, LAYA R GANESH1 &

SUBHAJIT NATH1*

1 Department of Medical & Molecular Virology, University of Manchester,

Manchester, United Kingdom
*Corresponding Author: Subhajit Nath, Email: writetosbhajit@[Link]

ABSTRACT
Antiviral drug resistance has emerged as a critical challenge in the management of viral
infections, particularly among immunocompromised patients. This phenomenon arises
from genetic mutations in viruses that diminish the efficacy of antiviral medications,
leading to treatment failures and persistent infections. The rapid replication and high
mutation rates of viruses facilitate the development of resistant strains, which can
significantly impact patient outcomes and public health. This study explores the
mechanisms underlying antiviral resistance, including drug target alterations, efflux
pumps, and enzymatic degradation. It highlights the complex relationship between
resistance and virulence, where resistant strains may exhibit enhanced pathogenicity due to
mutations that increase their ability to evade immune responses or invade host tissues. To
combat this growing threat, a multifaceted approach is essential. Strategies such as
combination therapies, which utilize multiple drugs to reduce the likelihood of resistance
development, have shown promise. Additionally, ongoing surveillance and rapid detection
of resistant strains are crucial for effective management. The study emphasizes the need for
novel antiviral agents targeting different stages of viral replication and the importance of
vaccination in preventing resistance by limiting viral transmission. By understanding the
dynamics of antiviral resistance and implementing comprehensive strategies, we can
improve treatment outcomes for affected patients while safeguarding public health against
emerging resistant strains.

KEYWORDS: Antiviral, Virulence, Drug Resistance

INTRODUCTION
Antiviral drug resistance is a growing challenge in treating viral infections, especially in
immunocompromised patients [1]. Widespread use of antiviral medications has led to the
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 63

emergence of resistant viral strains, which can undermine the effectiveness of these
therapies. This resistance occurs when viruses mutate, allowing them to replicate even in
the presence of antiviral drugs, causing treatment failure and persistent infections [2].
The primary cause of drug resistance lies in the genetic variability of viruses. Their
rapid replication and error-prone nature enable mutations in viral proteins targeted by
antiviral drugs, such as enzymes or structural proteins. For instance, in HIV, resistance can
develop against all major classes of antiretroviral drugs [3]. Contributing factors include
prolonged drug exposure, suboptimal drug levels, high viral replication rates, and
weakened immune systems. The clinical impact of resistance is particularly severe in
immunocompromised patients, often leading to persistent infections, increased morbidity,
and mortality.
Resistance can affect viral virulence, sometimes reducing a virus’s replication
efficiency, but in other cases, resistant strains may retain or enhance their virulence.
Addressing this challenge requires strategies like combination therapy, novel drug targets,
better diagnostics, and personalized medicine [4]. Understanding resistance mechanisms
and managing them effectively is vital to preserving antiviral drug efficacy in the future.

Table 1: Antiviral Drugs in Clinical Use or Progressive Stages of Development [33]

64 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

WHAT IS ANTVIRAL DRUG RESISTANCE AND HOW HAS IT BEEN OCCURRING?

Antiviral drug resistance occurs when viruses acquire genetic mutations that reduce or
eliminate the effectiveness of antiviral medications. This is particularly concerning in
immunocompromised patients, where prolonged drug exposure and ongoing viral
replication increase the likelihood of resistance. As viruses mutate, targeted viral proteins
change, making antiviral drugs less effective or even ineffective. The consequences of drug
resistance include treatment failure, persistent infections, and higher morbidity and
mortality. Resistance also limits treatment options, often requiring alternative, more toxic,
or expensive medications [5]. Additionally, resistant viral strains can spread to others,
posing a public health threat.
Historically, several incidents highlight the impact of antiviral resistance. For
example, acyclovir-resistant herpes simplex virus (HSV) emerged in the early 1980s after the
introduction of systemic acyclovir, with resistance rates reaching 36% in some
immunocompromised patients [6]. Similarly, during the 2008-2009 influenza season,
oseltamivir-resistant H1N1 influenza viruses saw global resistance rates exceeding 90%,
prompting changes in treatment guidelines [7]. In HIV treatment, early monotherapy
regimens in the 1990s led to rapid resistance, driving the development of combination
antiretroviral therapy, which is now the standard of care [7][8].
Managing antiviral drug resistance is crucial for maintaining the efficacy of current
treatments and guiding the development of new therapies.

VIRULENCE FACTORS OF RESISTANT STRAINS

Virulence factors of resistant strains can significantly impact their pathogenicity and ability
to cause severe infections. Enhanced pathogenicity in resistant strains often results from
mutations that not only confer drug resistance but also increase the organism's ability to
invade host tissues or evade immune responses [9]. For instance, some antibiotic-resistant
Staphylococcus aureus strains have been found to produce higher levels of virulence
factors, such as toxins and adhesins, compared to their susceptible counterparts [10].
Immune evasion mechanisms in resistant strains can include alterations in surface proteins
that help the pathogen avoid recognition by the host immune system or the ability to
suppress immune responses. Biofilm formation is another crucial virulence factor that
contributes to both antibiotic resistance and chronic infections. Resistant strains often
exhibit enhanced biofilm-forming capabilities, creating a protective environment that
shields them from antibiotics and host immune defenses. This is particularly evident in
Pseudomonas aeruginosa infections in cystic fibrosis patients, where biofilm formation
contributes to persistent lung infections. Increased toxin production is also observed in
some resistant strains, potentially leading to more severe disease outcomes. For example,
certain antibiotic-resistant Clostridium difficile strains have been associated with higher
toxin production, resulting in more severe and recurrent infections. The combination of
these virulence factors in resistant strains can lead to infections that are not only more
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 65

difficult to treat but also potentially more severe and persistent, posing significant
challenges for clinical management and public health.

MECHANISMS OF ANTIVIRAL DRUG RESISTANCE

Antiviral drug resistance emerges through various mechanisms, primarily driven by genetic
mutations in viral genomes. These mutations can occur spontaneously during viral
replication or under selective pressure from antiviral drugs [11]. Drug target alterations are
a common form of resistance, where changes in viral proteins reduce the efficacy of
antivirals. For example, mutations in the HIV reverse transcriptase gene can confer
resistance to nucleoside reverse transcriptase inhibitors [12]. Some viruses develop
resistance through efflux pumps, which actively expel antiviral drugs from infected cells,
though this mechanism is more common in bacteria than viruses. Enzymatic degradation is
another strategy employed by viruses, where viral enzymes evolve to break down antiviral
drugs. This is exemplified by the development of resistance to neuraminidase inhibitors in
influenza viruses [13].
The complexity of antiviral resistance mechanisms necessitates multi-pronged
approaches to combat them. Combination therapies, targeting different stages of the viral
life cycle, have proven effective in reducing the emergence of resistant strains. For instance,
highly active antiretroviral therapy (HAART) for HIV combines multiple drug classes to
minimize resistance development. Additionally, ongoing surveillance and rapid detection
of resistant strains are crucial for the effective management of antiviral resistance [14].

Fig. 1: Influenza Virus showing different types of resistance to drugs [34]

66 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

CO-SELECTION AND COMPENSATORY MUTATIONS

Co-selection and compensatory mutations are key in the evolution of antibiotic resistance
and viral fitness. Co-selection occurs when resistance and virulence genes are linked,
leading to the inadvertent selection of more virulent pathogens through antibiotic use[15].
This happens when resistance genes are physically close to virulence factors on the same
genetic element, such as a plasmid or chromosome, allowing selective pressure to maintain
virulence genes in bacterial populations.
Resistance mutations often come with fitness costs, which can vary greatly, but
compensatory mutations help maintain pathogen viability. For instance, in HIV-1, the
fitness cost of the M184V mutation in reverse transcriptase can be mitigated by other
mutations like D67N and K219Q [16]. In Escherichia coli, horizontally transferred resistance
genes impose a smaller fitness burden than chromosomal mutations, explaining the
prevalence of plasmid-mediated resistance in many species [17].
Compensatory mutations can restore fitness in both antimicrobial and non-
antimicrobial environments, although the fitness gains may differ [18]. These dynamics
influence treatment outcomes and the persistence of resistant strains. Understanding the
relationship between resistance, fitness, and compensatory adaptations is essential for
developing strategies to combat antimicrobial resistance and predict pathogen evolution.

CLINICAL SIGNIFICANCE OF ANTIVIRAL RESISTANCE

Antiviral drug resistance presents significant challenges in treating viral infections,
especially in immunocompromised patients. Prolonged drug exposure and ongoing viral
replication foster the emergence of resistant strains, which can lead to persistent infections,
severe disease progression, and even death when alternative treatments are unavailable
[19].
The prevalence of resistance varies across viruses and patient populations. For
example, acyclovir-resistant herpes simplex virus (HSV) is rare in immunocompetent hosts
but more common in immunocompromised patients [20]. In contrast, widespread resistance
to HIV antivirals requires combination therapies and careful monitoring. The spread of
drug-resistant viruses, such as resistant influenza strains, is a growing public health concern
[21].
Managing resistance is complicated by diagnostic challenges. Rapid detection of
resistant strains is essential, but current methods often rely on specialized laboratory tests.
Phenotypic assays determine drug susceptibility, while genotypic assays identify resistance
mutations, though interpreting these results can be complex.
Antiviral resistance poses risks beyond individual patients, necessitating ongoing
surveillance and the development of new strategies, including combination therapies,
optimized dosing, and novel antivirals targeting different stages of viral replication to
combat resistance [22].
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 67

STRATEGIES TO COMBAT RESISTANCE

Combating antiviral drug resistance requires a multifaceted approach, combining strategies
to prevent, detect, and overcome resistant strains. Combination therapies are a key method,
particularly for HIV and hepatitis C treatment. By using multiple drugs with different
mechanisms, the virus must mutate at multiple sites simultaneously to evade treatment,
significantly reducing resistance [23]. This approach has greatly improved patient outcomes
and curb the rise of resistant strains.
Identifying novel drug targets is another vital strategy. Researchers are exploring
new viral proteins and pathways, such as SARS-CoV-2 protease, which led to the
development of drugs like Paxlovid [24]. These new targets offer promise for treating
resistant strains and expanding combination therapy options.
Vaccination also plays a critical role in preventing resistance by reducing viral transmission
and replication, indirectly limiting the chances for resistance to develop [25]. Some vaccines
are designed to target conserved viral regions, making it harder for resistant strains to
emerge [26].
Surveillance programs are essential for tracking antiviral resistance. Global
initiatives like the WHO’s Global Influenza Surveillance and Response System (GISRS) help
monitor resistant strains, enabling early detection and response.
Through coordinated efforts—combining therapies, novel drugs, vaccination, and
surveillance—we can effectively combat antiviral resistance and ensure the continued
efficacy of these treatments.

CASE STUDIES AND EXAMPLES

Case studies and examples of antiviral resistance provide valuable insights into the
mechanisms and clinical management of drug-resistant viral infections across various
pathogens. In HIV, resistance can develop rapidly due to the virus's high mutation rate and
the long-term nature of antiretroviral therapy. For instance, the emergence of the M184V
mutation confers resistance to lamivudine and emtricitabine, while the K103N mutation
leads to resistance against first-generation non-nucleoside reverse transcriptase inhibitors
[27]. Management of HIV drug resistance often involves genotypic testing to guide the
selection of active drugs for salvage regimens [28].
Influenza viruses, both seasonal and pandemic strains, can develop resistance to
antiviral drugs. The 2009 H1N1 pandemic saw the emergence of oseltamivir-resistant
strains, highlighting the need for continuous surveillance and development of new
antivirals [29]. In chronic hepatitis B infections, long-term nucleos(t)ide analog therapy can
lead to the selection of resistant variants. For example, the rtM204V/I mutation in the HBV
polymerase gene confers resistance to lamivudine and telbivudine [30]. Hepatitis C virus
(HCV) resistance has become less problematic with the advent of direct-acting antivirals,
but certain baseline polymorphisms can still affect treatment outcomes.
68 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Herpesviruses pose a particular challenge in immunocompromised patients, where

prolonged antiviral exposure and impaired immune responses create ideal conditions for
resistance development. Acyclovir-resistant herpes simplex virus (HSV) infections, while
rare in immunocompetent hosts, occur more frequently in transplant recipients and HIV
patients [31][32]. These resistant strains often harbor mutations in the viral thymidine
kinase gene, necessitating the use of alternative therapies like foscarnet.
These case studies underscore the importance of understanding resistance
mechanisms, implementing appropriate diagnostic testing, and developing strategies to
prevent and manage antiviral resistance. They also highlight the need for ongoing research
into novel antiviral targets and combination therapies to stay ahead of evolving viral
resistance.

CONCLUSION
Antiviral drug resistance remains a significant challenge in the management of viral
infections, with far-reaching implications for individual patient care and public health. The
complex mechanisms underlying resistance development, including genetic mutations and
compensatory adaptations, highlight the need for continued research and innovation in
antiviral strategies. The case studies across various viral pathogens underscore the
importance of tailored approaches to resistance management, considering the unique
characteristics of each virus and patient population. Moving forward, a multifaceted
approach combining improved diagnostics, novel drug development, combination
therapies, and global surveillance efforts will be essential in mitigating the impact of
antiviral resistance. By staying ahead of evolving viral resistance mechanisms, we can hope
to maintain the effectiveness of current antiviral therapies while developing new strategies
to combat resistant strains, ultimately improving patient outcomes and protecting public
health.

REFERENCES
[1] Kimberlin, D. W., & Whitley, R. J. (1996). Antiviral resistance: mechanisms, clinical
significance, and future implications. Journal of Antimicrobial Chemotherapy, 37(3), 403-
421.
[2] NERVTAG: Antiviral drug resistance and the use of directly acting antiviral drugs
(DAAs) for COVID-19, 8 December 2021. [Link].
[3] Pillay, D. (2007). The emergence and epidemiology of resistance in the nucleoside-
experienced HIV-infected population. Antiviral Therapy, 12(Supplement 1), S15-S20.
[4] Menéndez-Arias, L. (2013). Molecular basis of human immunodeficiency virus drug
resistance: an update. Antiviral Research, 98(1), 93-120.
[4] Piret, J., & Boivin, G. (2011). Resistance of Herpes Simplex Viruses to Nucleoside
Analogues: Mechanisms, Prevalence, and Management. Antimicrobial Agents and
Chemotherapy, 55(2), 459-472.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 69

[5] Bacon, T. H., Levin, M. J., Leary, J. J., Sarisky, R. T., & Sutton, D. (2003). Herpes simplex
virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clinical
Microbiology Reviews, 16(1), 114-128.
[6] Meijer, A., et al. (2009). Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007–08
season. Emerging Infectious Diseases, 15(4), 552-560.
[7] Clavel, F., & Hance, A. J. (2004). HIV drug resistance. New England Journal of Medicine,
350(10), 1023-1035.
[8] Beceiro, A., Tomás, M., & Bou, G. (2013). Antimicrobial resistance and virulence: a
successful or deleterious association in the bacterial world? Clinical Microbiology Reviews,
26(2), 185-230.
[9] Rudkin, J. K., et al. (2012). Methicillin resistance reduces the virulence of healthcare-
associated methicillin-resistant Staphylococcus aureus by interfering with the agr quorum
sensing system. Journal of Infectious Diseases, 205(5), 798-806.
[10] Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350(10):1023-1035.
[11] Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogs.
Gastroenterology. 2009;137(5):1593-1608.
[12] Hurt AC, Holien JK, Parker MW, Barr IG. Oseltamivir resistance and the H274Y
neuraminidase mutation in seasonal, pandemic, and highly pathogenic influenza viruses.
Drugs. 2009;69(18):2523-2531.
[13] New and Emerging Respiratory Virus Threats Advisory Group. NERVTAG: Antiviral
drug resistance and the use of directly acting antiviral drugs (DAAs) for COVID-19, 8
December 2021. [Link]. 2021.
[14] World Health Organization. Global Influenza Surveillance and Response System
(GISRS). [Link]. 2021.
[15] Yang W-L, et al. (2015) PLoS Pathog 11(3): e1004722.
[16] Martínez JL, et al. (2007) FEMS Microbiol Rev 31(4): 474-487.
[17] Franke EK, et al. (2005) J Virol 79(6): 3624-3632.
[18] Durão P, et al. (2023) Front Microbiol 14: 1186920.
[19] Schulz zur Wiesch P, et al. (2010) Antimicrob Agents Chemother 54(6): 2085-2095.
[20] Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin
Microbiol Rev. 2010;23(4):689-712.
[21] New and Emerging Respiratory Virus Threats Advisory Group. NERVTAG: Antiviral
drug resistance and the use of directly acting antiviral drugs (DAAs) for COVID-19, 8
December 2021. [Link]. 2021.
[22] Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogs.
Gastroenterology. 2009;137(5):1593-1608.
[23] Hojabri Z, Pajand O, Bonura C, et al. Phylogenetic group, antibiotic resistance,
virulence gene, and genetic diversity of Escherichia coli causing bloodstream infections in
Iran. Front Microbiol. 2024; 15:1426510.
70 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

[24] Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin
Microbiol Rev. 2010;23(4):689-712.
[25] New and Emerging Respiratory Virus Threats Advisory Group. NERVTAG: Antiviral
drug resistance and the use of directly acting antiviral drugs (DAAs) for COVID-19, 8
December 2021. [Link]. 2021.
[26] Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogs.
Gastroenterology. 2009;137(5):1593-1608.
[27] World Health Organization. Global Influenza Surveillance and Response System
(GISRS). [Link]. 2021.
[28] Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin
Microbiol Rev. 2010;23(4):689-712.
[29] Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance
testing. Infect Genet Evol. 2016; 46:292-307.
[30] Hurt AC, Holien JK, Parker MW, Barr IG. Oseltamivir resistance and the H274Y
neuraminidase mutation in seasonal, pandemic, and highly pathogenic influenza viruses.
Drugs. 2009;69(18):2523-2531.
[31] Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogs.
Gastroenterology. 2009;137(5):1593-1608.
[32] Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogs:
mechanisms, prevalence, and management. Antimicrob Agents Chemother. 2011;55(2):459-
472.
[33] Jain, S., Vyas, R., Pandit, P., & Dalai, A. (2013). Occurrence and removal of antiviral
drugs in the environment: A review. Water, Air, & Soil Pollution, 224, 1410.
[Link]
[34] Ley, S. (2022). Understanding anti-influenza antiviral drugs (Version 1). Preprints.
[Link]
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 71

Chapter
In Silico DRUG DESIGN
8

DR. K. SANTHANALAKSHMI1*

1 Guest Lecturer, Department of Biotechnology, Government Arts & Science College,

Kumulur, Lalgudi, Tiruchirappalli
*Corresponding Author: Dr. K. Santhanalakshmi, Email: santhuviro@[Link]

ABSTRACT
The drug discovery process is a struggling path and full of challenges, with the result that
very few only from hit compound to a commercially available product, often due to factors,
such as poor binding affinity, off-target effects, or physicochemical properties, such as
solubility or stability. This path of process is very complicated by high research
development costs and time requirements. Every step of the path is to make a success and
as a result we move recent advancements in computer power and technology, computer-
aided drug design (CADD) has become an integral part of modern drug discovery to guide
and accelerate the process. In this review, we present an overview of the important CADD
methods and applications such as in silico structure prediction, modeling, and designing
that are commonly used in this area.

KEYWORDS: Insilico, drug design, protein, ligand,

INTRODUCTION
The development of drugs is a sumptuous process and complex process that
development and identify the new chemical compounds used to treat the diseases. A labor-
intensive and time-consuming are taken by traditional drug design. Limited cost and
limited manpower are the quick approaches followed in modern drug technology. In new
drug discovery and development, high demand, and reduction of toxicity, several
challenges are there. The design of the drugs majorly investigates the mechanisms,
interactions, and effective pharmacological responses or actions. The major pitfalls of drugs
are high toxicity, poor efficiency, and poor pharmacokinetics observed in clinical trials [1,2].
Wong et al. reported that 4,06,038 trials were conducted from January 2000 to October 2015
and showed that the probability of success of drugs being developed and marketed was
only 13.8% [3]. DiMasi and R&D teams estimated the new drug cost around USD 2.8 billion
based on data for 106 randomly selected new drugs developed by 10 pharmaceutical
72 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

companies [4]. The essential process of drug designing is to create tiny molecules that are
charged and complementary forms to interact with biomolecules and attached to them.
There are various difficult strategies can be used to screen the drugs such as the mass
spectrometry method [5], nuclear magnetic resonance screening [6,7], fragment screening
method [8], DNA encoded libraries [9], high throughput screening (HTS) such as protein or
cells [10] or in silico methods such as virtual screening (VS) [11]. The successful drug
candidates progress to the development stage and pass to different phases of clinical trials
stage by stage and eventually submission for approval to launch the market [Figure.1].

Stage 1 • Target identification & Validation

Stage 2 • Hit Discovery

Stage 3 • Lead Optimization

Satge 4 • Pre Clinical development

Stage 5 • Phase I

Stage 6 • Phase II

Stage 7 • Phase III

Stage 8 • Submission

Stage 9 • Marketing

Fig. 1. Different Stages Drug Discovery

The drug discovery process considered the absorption, distribution, metabolisms, and
excretions (ADME) to identify the properties of the drug after optimization. The
unfavorable pharmacokinetic and toxicity profile of a drug candidate is one of the hurdles
that often lead to failure in clinical trials [12].
Computer-aided drug design (CADD) utilizes this information and knowledge to
screen for novel drug candidates. In recent years, the advanced technology
Such as CADD has proven a successful tool for the drug discovery process and reduces the
time. The review aims to give an overview of the various in silico techniques that are used in
the drug discovery process (Figure 2).
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 73

Fig. 2: CADD – Computer-Aided Drug Designing

Various Insilico techniques – DFT – Density functional theory; MM- Molecular Mechanical;
MM –GBSA- Molecular mechanisms Generalised Born and surface area; QM – Quantum
mechanical; QSAR – Quantitative structure active relationship.
Computer-aided drug design (CADD) using the techniques and models to identify
drug-like molecules using bioinformatics tools. In silico methods analyze and predict the
biological activity of potential drug candidates, and also predict their physicochemical
properties.

1. LIGAND-BASED DRUG DESIGN [LBDD]

New drugs were designed by the LBDD method and drug structure, and functions of
ligands that bind to target molecules. The ligand serves an important role in
designing molecules to the starting point of the similar structures, features, and interactions
of target molecules. The LBDD approaches are pharmacophore modeling, quantitative
structure-activity relationship (QSAR), and similarity searches [13].

1.1 Similarity Search

This hypothesis is based on the molecular similarity of the molecule that has similar
physical properties and biological activities. The quantitative measurement of similarity
molecule’s structure analysis represents the two different chemical molecules measured by
1D, 2D, and 3D molecular fingerprints. The molecular fingerprints include pharmacophore
74 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

fingerprints, circular fingerprints, structural keys, and topological fingerprints. These

fingerprints are used to compare to assess the similarities [14]. TGD fingerprints [15] and
MACCS fingerprints [16] are the types of structural key fingerprints that can be used to
search the presence of structures/features of the molecules based on the pre-defined list of
structural keys. Analysis molecule connectivity path has been analyzed by topological
fingerprints (e.g., Daylight fingerprints) [17]. This pattern helps to search each atom of the
molecules ie. nearest neighbours and connecting bonds of the molecules. Heavy atoms of
the molecules are assigned by atom type and starting point. This heavy atom and the
neighboring atoms of the central heavy atoms are monitored at a certain radius level by
circular fingerprints such as Molprint2D [18] and extended connectivity fingerprints (ECFP)
[19]. The heavy atom and the number of atoms are recorded by descriptor values [20]. The
Natural Compound Molecular Fingerprint (NC-MFP) was developed by Seo et al. to better
represent natural products [21]. The novel CDK8 inhibitors identified by Wang and co-
workers used a combination of docking-based techniques and 2D similarity techniques [22].
The docking-based technique and 2D similarity technique were performed on W-18 and W-
37 of the candidate to find the similar structure of inhibitory effects.

Fig. 3: Discovery of W2 – CDK8 inhibitor

CDK8 inhibitory effects were performed by similarity search and out by ECFP_6
fingerprints, WS-2 was similar with withW-18 andW-37, respectively, and was identified as
potent to parental molecules.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 75

1.2 Quantitative Structure-Activity Relationship (QSAR)

Hansch and Fujita in 1964 proposed the QSAR methodology, which is the correlation of
biological activity and chemical structure [23]. 1D- and 2D-QSAR models are called
“classical QSAR” methodologists used to correlate biological activity with molecular
properties [24]. Cramer et al. [25] proposed the 3D-QSAR methodologies are the
Comparative Molecular Field Analysis (CoMFA) and the Comparative Molecular Similarity
Indices Analysis (CoMSIA) proposed by Klebe et al., a modified version of CoMFA [26].
This 3D chemical structure was applied in structure-activity relationship analysis (SAR) and
identifies the anticancer activity [27].

1.3 Pharmacophore validation

To identify the common structure of ligands that bind to the target, a technique followed in
pharmacophore modeling. The major features are used to design the new molecules that
mimic interactions of ligands with target molecules. The physicochemical properties and
similar chemical structures were identified and screened by this model. These models will
help to make libraries and to identify the computed to generate stable confirmations, then
they are arranged to identify the similar functional groups to active ligands. This will help
to identify the new drugs. Before employing this model, it helps to validate and evaluate the
predictivity of the model. Decoy databases such as DUD-E [28], MUV [29], and DEKOIS [30]
are often used to test the model’s ability to differentiate between active and inactive
compounds.

2. STRUCTURE-BASED DRUG DESIGN [SBDD]

The structure-based drug design (SBDD) relies on the 3D structural information of the
target protein function, which can be acquired from experimental methods such as NMR
spectroscopy, cryo-electron microscopy, and X-ray crystallography.
The binding affinity of the ligands to the binding site of the protein was predicted
by SBCC. Molecular docking [31], de novo drug design [32], and fragment-based docking
[33]. Figure.4. describe the workflow of molecular docking

2.1 Protein structure prediction

The Protein Data Bank (PDB) recorded the 1, 93,000 structural data available and the
number of sequences stored in genetic information such as the UniProtKB/TrEMBL
database contained over 231 million sequence entries [34,35].
76 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Fig. 4: The flow of molecular docking

2.1.1. Homology Modelling

Homology modeling involves predicting the structure of a protein by aligning the
sequences to a homologous protein and constructing the models. The Universal Protein
Resource (UniProt) identifies modeling templates that have high sequence similarity and
resolution by performing a BLAST search against the Protein Data Bank, PSI-BLAST [36].
This method was useful for identifying patterns of residue conservation, which can be more
useful and accurate than simply comparing raw sequences, as protein functions are
predominately determined by the structural arrangement rather than the amino acid
sequence. Another alignment method, global and local alignment comes under Pairwise
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 77

alignment. EMBOSS Needle and EMBOSS Stretcher use the Needleman–Wunsch algorithm
to perform in global alignment. The ligand-based homology modeling approaches have
been used for G protein-coupled receptors (GPCRs), including serotonin receptors [36],
dopamine receptors [37], cannabinoid receptors [38], neurokinin-1 receptor [39], -
aminobutyric acid (GABA) receptor [40] and histamine H3 receptors [41].

2.1.2. Ab initio Protein Structure Prediction

Ab initio modeling is also known as free modeling, or de novo modeling [42,43]. The amino
acid sequences are predicted by protein structure to provide information on complex
formation and protein-protein interaction. The principle of Ab initio protein structure
prediction is based on the thermodynamic hypothesis. The 3D structure of protein and
Gibbs free energy is determined by inter-atomic interactions and amino acid sequence [44].
ASTRO-FOLD, CASP9 [45,46], and UNRES [47] are used to predict the critical assessment of
protein structure, this is purely based on physics approaches, high computational cost, and
time requirement to predict the small proteins. Other knowledge-based approaches I-
TASSER [48] and QUARK [49] methods help to improve the accuracy of de nova protein
structure prediction is the use of co-evolutionary data for targets with many homologous.
The structure of a protein is the key to its biological function, and through the evolutionary
process, amino acids in direct physical contact, or proximity, tend to co-evolve together to
maintain these interactions and hence preserve the function of the protein. Furthermore,
residues that have a high number of evolutionary constraints could indicate important
functionalities. A prediction approaches are, Deep learning methods Raptor X [50], ProQ3D
[51], D-I-TASSER [52], D-QUARK [53], and trRosetta [54], High accuracy models predicted
by Alpha Fold 2 are also published in Alpha Fold Protein Structure Database
([Link] [55], Knowledge-based methods, such as I-TASSER and
QUARK were not tested in CASP14 [56], Physics-based methods, such as UNRES
(previously described above), using 3 different approaches (UNRES-template, UNRES-
contact, and UNRES) achieved GDT_TS scores of 56.37, 39.3 and 29.2, respectively.

2.1.3. Protein Model Validation

The accuracy and quality of the predicted structures can be validated and verified using
different methods. The stereochemistry of the model can be verified by analyzing bond
lengths, torsion angles, and rotational angles with tools, such as WHATCHECK [57] and
Ramachandran plots [58].

2.2. Docking-Based Virtual Screening

To discover new drugs, Docking-based virtual screening is useful to find out the binding
modes of both ligands and receptors, study their interaction patterns, and estimate binding
affinity. Many docking programs are AutoDock [59], GOLD [60], Glide [61,62], SwissDock
[63], DockThor [64], CB-Dock [65] and Molecular Operating Environment (MOE) [66]. The
78 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

X-ray crystallography and NMR spectroscopy derived the structures such as missing
hydrogen atoms, incomplete side chains and loops, ambiguous protonation states, and
flipped residues [67].

2.2.1. Binding Site Detection

Firestar [68], 3DLigandSite [69], and Libra [70,71] were template-based methods utilize
protein sequences to locate residues that are conserved and important for binding.
CurPocket [72], Surfnet [73], and SiteMap [74,75] search for clefts and pockets based on the
size and depths of these cavities. Energy-based methods such as FTMap [76] and Q-
SiteFinder [77] locate sites on the surface of a protein that is energetically favorable for
binding. Hybrid methods, such as ConCavity [78] and MPLs-Pred [79], as well as machine-
learning methods, such as DeepSite [80], Kalasanty [81], and DeepCSeqSite [82], are some of
the newer approaches that are under rapid development in recent years.

2.2.2. Ligand Flexibility

ZINC [83], DrugBank [84], PubChem [85], or commercial (e.g., Maybridge, ChemBridge,
and Enamine) are virtual screenings that can be obtained from small molecule databases
like ligand structures. PDB data are a knowledge base of allowed torsion angles and ring
conformations, which are used to guide the sampling [86,87]. Balloon [88], a free conformer
generator, uses distance geometry to generate an initial conformer for a ligand, followed by
a multi-objective genetic algorithm approach to modify torsion angles around rotatable
bonds, the stereochemistry of double bonds, chiral centers, and ring conformations. Some
other tools that were developed for ligand preparation include Prepflow [89], VSPrep [90],
Gypsum-DL [91], Frog2 [92], and UNICON [93].

3. De Novo and Fragment-Based Drug Design

The novel molecules with new scaffolds, especially when the majority of small molecule
libraries have been exhausted for virtual screening by De novo drug design. Fragment-based
approaches are more synthetically feasible but the resulting molecules are relatively less
diverse [94]. LUDI [95], LigBuilder [96], ACFIS [97], and SEED [98] are some examples of de
novo/fragment-based drug design programs, linking, growing, and lattice-based sampling.
The linking approach links the building blocks that are positioned at the interaction sites
with the linker to form a complete molecule [95, 99].

4. Hierarchical Virtual Screening (HLVS)

The molecular docking and hierarchical combination of pharmacophore modeling were
employed for the HLVS and identification of matrix metalloproteinase 2 (MMP2) inhibitors
by Di Pizio et al. [100] as well as the discovery of novel PKR-like endoplasmic reticulum
kinase (PERK) inhibitors by Wang et al. [101,102].
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 79

5. Molecular Mechanical/Generalised Born Surface Area (MM-GBSA)

MM-GBSA is the combination of the Molecular Mechanical/Generalised Born Surface Area
(MM-GBSA) approach [103]. Free energies of protein, ligand and the complex of the
solution were binding based on the force field of MM-GBSA. The free energy is calculated
by using a combination of gas-phase molecular mechanics (MM) energy, electrostatic
solvation energy (GB), and non-electrostatic contribution to solvation energy (SA).

6. Molecular Dynamics
Molecular dynamics (MD) is an in-silico simulation method based on molecular mechanics
(MM), to study the individual particle motions of model systems over time [104]. MD can
provide insights into biomolecular processes, such as protein folding, conformational
changes, ligand binding, and disassociation by simulating the interactions between atoms
and molecules at an atomic level [105–108]. The major MD software packages are Gromacs
[109], AMBER [110], Lammps [111], NAMD [112], CHARMM [113] and Desmond [114].

7. QM/MM and DFT Approaches

QM and MM approaches are used in two main ways to study ligand–protein interactions
the first of which only utilizes QM to analyze a small region of interest such as the binding
site, while the second method also uses QM to analyze the region of interest while using the
less computationally expensive MM approach to model the remainder of the system
[115,116]. The application of pure Density Functional Theory (DFT) or ab initio work is
limited due to the expensive computational cost, and as such it is limited to small systems,
or for exploring derivable properties [117,118]. However, the application of the hybrid
approach allows larger systems to be partitioned with the area of interest (i.e., the active
site) being analyzed with QM [119]. DFT is a well-established technique, and the
experimental design needs to be in line with size, and property being explored for the
system. DFT is computationally more efficient and accurate relative to QM (ab initio)
methods. DFT explores the electronic behavior of a molecule or system as a function of the
electronic density, with the energy being directly relatable [120]. This approach allows for a
much faster generation of a wavefunction to review and the accuracy is dependent on the
function applied. Recently, Bursch et al. provided a thorough review of the functionals and
basis set selection for DFT applications [121].

CONCLUSION
In this review, the in-silico methods are highlighted and commonly used in the hit
identification and lead optimization stages of the drug design process, yet computational
methods are also applied in other areas in the pipeline. Some examples include drug
repurposing [122,123], protein-protein docking, de novo protein design, inverse docking
[124,125], adverse events prediction, physiologically-based pharmacokinetic modeling, and
guiding chemical synthesis [122,123]. Recent advanced computational software and
80 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

hardware have revolutionized drug design. The development of machine learning-based

CADD methodologies will be one of the major focuses in the future to continue improving
current strategies and to overcome existing challenging barriers in the drug discovery
process.

REFERENCES
1. (FDA), U.S.F.D.A. The Drug Development Process. Available online:
[Link]
Approvals/drug development process (accessed on 2 February 2022).
2. Wouters, O.J.; McKee, M.; Luyten, J. Estimated research and development investment
needed to bring a new medicine to market,2009–2018. Jama 2020, 323, 844–853. [CrossRef]
[PubMed]
3. DiMasi, J.A.; Grabowski, H.G.; Hansen, R.W. Innovation in the pharmaceutical industry:
New estimates of R&D costs. J. Health
Econ. 2016, 47, 20–33. [PubMed]
4. Paul, S.M.; Mytelka, D.S.; Dunwiddie, C.T.; Persinger, C.C.; Munos, B.H.; Lindborg, S.R.;
Schacht, A.L. How to improve R&D
productivity: The pharmaceutical industry’s grand challenge. Nat. Rev. Drug Discov. 2010,
9, 203–214. [PubMed]
5. Maple, H.J.; Garlish, R.A.; Rigau-Roca, L.; Porter, J.; Whitcombe, I.; Prosser, C.E.;
Kennedy, J.; Henry, A.J.; Taylor, R.J.; Crump, M.P.
Automated protein-ligand interaction screening by mass spectrometry. J. Med. Chem. 2012,
55, 837–851. [CrossRef] [PubMed]
6. Dalvit, C. NMR methods in fragment screening: Theory and a comparison with other
biophysical techniques. Drug Discov. Today
2009, 14, 1051–1057. [CrossRef] [PubMed]
7. O’Reilly, M.; Cleasby, A.; Davies, T.G.; Hall, R.J.; Ludlow, R.F.; Murray, C.W.; Tisi, D.;
Jhoti, H. Crystallographic screening using
ultra-low-molecular-weight ligands to guide drug design. Drug Discov. Today 2019, 24,
1081–1086. [CrossRef]
8. Madsen, D.; Azevedo, C.; Micco, I.; Petersen, L.K.; Hansen, N.J.V. Chapter Four—An
overview of DNA-encoded libraries: A versatile tool for drug discovery. In Progress in
Medicinal Chemistry; Witty, D.R., Cox, B., Eds.; Elsevier: Amsterdam, The Netherlands,
2020; Volume 59, pp. 181–249.
9. Shuker, S.B.; Hajduk, P.J.; Meadows, R.P.; Fesik, S.W. Discovering high-affinity ligands
for proteins: SAR by NMR. Science 1996,
274, 1531–1534. [CrossRef]
10. Macarron, R.; Banks, M.N.; Bojanic, D.; Burns, D.J.; Cirovic, D.A.; Garyantes, T.; Green,
D.V.S.; Hertzberg, R.P.; Janzen, W.P.; Paslay, J.W.; et al. Impact of high-throughput
screening in biomedical research. Nat. Rev. Drug Discov. 2011, 10, 188–195. [CrossRef]
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 81

11. Shoichet, B.K. Virtual screening of chemical libraries. Nature 2004, 432, 862–865.
[CrossRef]
12. Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev.
Drug Discov. 2004, 3, 711–716. [CrossRef]
13. Vázquez, J.; López, M.; Gibert, E.; Herrero, E.; Luque, F.J. Merging ligand-based and
structure-based methods in drug discovery: An overview of combined virtual screening
approaches. Molecules 2020, 25, 4723. [CrossRef] [PubMed].
14. Gao, K.; Nguyen, D.D.; Sresht, V.; Mathiowetz, A.M.; Tu, M.; Wei, G.-W. Are 2D
fingerprints still valuable for drug discovery. Phys. Chem. Chem. Phys. 2020, 22, 8373–8390.
[CrossRef]
15. Sheridan, R.P.; Miller, M.D.; Underwood, D.J.; Kearsley, S.K. Chemical Similarity Using
Geometric Atom Pair Descriptors. J. Chem.
Inf. Comput. Sci. 1996, 36, 128–136. [CrossRef]
16. Durrant, J.D.; Cao, R.; Gorfe, A.A.; Zhu, W.; Li, J.; Sankovsky, A.; Oldfield, E.;
McCammon, J.A. non-bisphosphonate inhibitors of
isoprenoid biosynthesis identified via computer-aided drug design. Chem. Biol. Drug Des.
2011, 78, 323–332. [CrossRef]
17. Daylight Chemical Information Systems, I. Fingerprints—Screening and Similarity.
Available online: [Link]
(accessed on 25 February 2022).
18. Bender, A.; Mussa, H.Y.; Glen, R.C.; Reiling, S. Similarity Searching of Chemical
Databases Using Atom Environment Descriptors (MOLPRINT 2D): Evaluation of
Performance. J. Chem. Inf. Comput. Sci. 2004, 44, 1708–1718. [CrossRef]
19. Rogers, D.; Hahn, M. Extended-connectivity fingerprints. J. Chem. Inf. Model. 2010, 50,
742–754. [CrossRef] [PubMed]
20. Glem, R.C.; Bender, A.; Arnby, C.H.; Carlsson, L.; Boyer, S.; Smith, J. Circular
fingerprints: Flexible molecular descriptors with
applications from physical chemistry to ADME. Idrugs 2006, 9, 199–204. [PubMed]
21. Seo, M.; Shin, H.K.; Myung, Y.; Hwang, S.; No, K.T. Development of Natural Compound
Molecular Fingerprint (NC-MFP) with the Dictionary of Natural Products (DNP) for natural
product-based drug development. J. Cheminformatics 2020, 12, 6. [CrossRef]
[PubMed]
22. Wang, T.; Yang, Z.; Zhang, Y.; Yan, W.; Wang, F.; He, L.; Zhou, Y.; Chen, L. Discovery of
novel CDK8 inhibitors using multiple crystal structures in docking-based virtual screening.
Eur. J. Med. Chem. 2017, 129, 275–286. [CrossRef]
23. Biovia, D.S. Discovery Studio; Dassault Systems: San Diego, CA, USA, 2021.
24. Overton, C.E. Studien über die Narkose: Zugleich ein Beitrag zur Allgemeinen
Pharmakologie; G. Fischer: Schaffhausen, Switzerland,1901.
82 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

25. Cramer, R.D.; Patterson, D.E.; Bunce, J.D. Comparative molecular field analysis
(CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc.
1988, 110, 5959–5967. [CrossRef] [PubMed]
26. Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indices in a comparative
analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J.
Med. Chem. 1994, 37, 4130–4146. [CrossRef] [PubMed]
27. Ehrlich, P. Über den jetzigen Stand der Chemotherapie. Ber. Der Dtsch. Chem. Ges. 1909,
42, 17–47. [CrossRef]
28. Mysinger, M.M.; Carchia, M.; Irwin, J.J.; Shoichet, B.K. Directory of useful decoys,
enhanced (DUD-E): Better ligands and decoys
for better benchmarking. J. Med. Chem. 2012, 55, 6582–6594. [CrossRef]
29. Rohrer, S.G.; Baumann, K. Maximum unbiased validation (MUV) data sets for virtual
screening based on PubChem bioactivity
data. J. Chem. Inf. Model. 2009, 49, 169–184. [CrossRef]
30. Bauer, M.R.; Ibrahim, T.M.; Vogel, S.M.; Boeckler, F.M. Evaluation and optimization of
virtual screening workflows with DEKOIS
2.0–a public library of challenging docking benchmark sets. J. Chem. Inf. Model. 2013, 53,
1447–1462. [CrossRef].
31. Shoichet, B.K.; McGovern, S.L.; Wei, B.; Irwin, J.J. Lead discovery using molecular
docking. Curr. Opin. Chem. Biol. 2002, 6, 439–446. [CrossRef] [PubMed]
32. Chen, Y.; Shoichet, B.K. Molecular docking and ligand specificity in fragment-based
inhibitor discovery. Nat. Chem. Biol. 2009, 5,358–364. [CrossRef] [PubMed]
33. Schneider, G.; Fechner, U. Computer-based de novo design of drug-like molecules. Nat.
Rev. Drug Discov. 2005, 4, 649–663. [CrossRef] [PubMed]
34. EMBL-EBI UniProtKB/TrEMBL Protein Database Release 2022_02 Statistics. Available
online: [Link] (accessed on 27 July 2022).
35. Bank, R.P.D. PDB Statistics: Overall Growth of Released Structures Per Year. Available
online: [Link] (accessed on 27 July
2022). Pharmaceutics 2023, 15, 49 37 of 52.
36. Gacasan, S.B.; Baker, D.L.; Parrill, A.L. G protein-coupled receptors: The evolution of
structural insight. AIMS Biophys. 2017, 4, 491. [CrossRef] [PubMed]
37. Rodríguez, D.; Ranganathan, A.; Carlsson, J. Strategies for improved modeling of GPCR-
drug complexes: Blind predictions of serotonin receptors bound to ergotamine. J. Chem. Inf.
Model. 2014, 54, 2004–2021. [CrossRef] [PubMed]
38. Kołaczkowski, M.; Bucki, A.; Feder, M.; Pawłowski, M. Ligand-optimized homology
models of D1 and D2 dopamine receptors: Application for virtual screening. J. Chem. Inf.
Model. 2013, 53, 638–648. [CrossRef]
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 83

39. Cichero, E.; Menozzi, G.; Guariento, S.; Fossa, P. Ligand-based homology modeling of
the human CB2 receptor SR144528 antagonist binding site: A computational approach to
explore the 1, 5-diaryl pyrazole scaffold. Med Chem Comm 2015, 6, 1978–1986. [CrossRef]
40. Evers, A.; Klebe, G. Successful virtual screening for a sub micromolar antagonist of the
neurokinin-1 receptor based on a ligand-supported homology model. J. Med. Chem. 2004,
47, 5381–5392. [CrossRef]
41. Freyd, T.; Warszycki, D.; Mordalski, S.; Bojarski, A.J.; Sylte, I.; Gabrielsen, M. Ligand-
guided homology modelling of the GABAB2 subunit of the GABAB receptor. PLoS ONE
2017, 12, e0173889. [CrossRef]
42. Hameduh, T.; Haddad, Y.; Adam, V.; Heger, Z. Homology modeling in the time of
collective and artificial intelligence. Comput. Struct. Biotechnol. J. 2020, 18, 3494–3506.
[CrossRef]
43. Bonneau, R.; Strauss, C.E.; Rohl, C.A.; Chivian, D.; Bradley, P.; Malmström, L.;
Robertson, T.; Baker, D. De novo prediction of three-dimensional structures for major
protein families. J. Mol. Biol. 2002, 322, 65–78. [CrossRef] [PubMed]
44. Schaller, D.; Hagenow, S.; Stark, H.; Wolber, G. Ligand-guided homology modeling
drives identification of novel histamine H3
receptor ligands. PLoS ONE 2019, 14, e0218820. [CrossRef]
45. Klepeis, J.L.; Floudas, C.A. ASTRO-FOLD: A Combinatorial and Global Optimization
Framework for Ab Initio Prediction of
Three-Dimensional Structures of Proteins from the Amino Acid Sequence. Biophys. J. 2003,
85, 2119–2146. [CrossRef] [PubMed]
46. Subramani, A.; Wei, Y.; Floudas, C.A. ASTRO-FOLD 2.0: An Enhanced Framework for
Protein Structure Prediction. AIChE J 2012,
58, 1619–1637. [CrossRef] [PubMed]
47. Ołdziej, S.; Czaplewski, C.; Liwo, A.; Chinchio, M.; Nanias, M.; Vila, J.; Khalili, M.;
Arnautova, Y.; Jagielska, A.; Makowski, M.O. Physics-based protein-structure prediction
using a hierarchical protocol based on the UNRES force field: Assessment in two blind tests.
Proc. Natl. Acad. Sci. USA 2005, 102, 7547–7552. [CrossRef]
48. Bowie, J.U.; Eisenberg, D. An evolutionary approach to folding small alpha-helical
proteins that uses sequence information and an empirical guiding fitness function. Proc.
Natl. Acad. Sci. USA 1994, 91, 4436–4440. [CrossRef]
49. Hart, T.N.; Read, R.J. A multiple-start Monte Carlo docking method. Proteins Struct.
Funct. Bioinform. 1992, 13, 206–222. [CrossRef]
50. Zheng, W.; Li, Y.; Zhang, C.; Zhou, X.; Pearce, R.; Bell, E.W.; Huang, X.; Zhang, Y.
Protein structure prediction using deep learning distance and hydrogen-bonding restraints
in CASP14. Proteins Struct. Funct. Bioinform. 2021, 89, 1734–1751. [CrossRef]
84 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

51. Du, Z.; Su, H.; Wang, W.; Ye, L.; Wei, H.; Peng, Z.; Anishchenko, I.; Baker, D.; Yang, J.
The rosetta server for fast and accurate protein structure prediction. Nat. Protoc. 2021, 16,
5634–5651. [CrossRef]
52. Baek, M.; DiMaio, F.; Anishchenko, I.; Dauparas, J.; Ovchinnikov, S.; Lee, G.R.; Wang, J.;
Cong, Q.; Kinch, L.N.; Schaeffer, R.D. Accurate prediction of protein structures and
interactions using a three-track neural network. Science 2021, 373, 871–876. [CrossRef]
53. Senior, A.W.; Evans, R.; Jumper, J.; Kirkpatrick, J.; Sifre, L.; Green, T.; Qin, C.; Žídek, A.;
Nelson, A.W.; Bridgland, A. Protein structure prediction using multiple deep neural
networks in the 13th Critical Assessment of Protein Structure Prediction (CASP13). Proteins
Struct. Funct. Bioinform. 2019, 87, 1141–1148. [CrossRef] [PubMed]
54. Zemla, A. LGA: A method for finding 3D similarities in protein structures. Nucleic
Acids Res. 2003, 31, 3370–3374. [CrossRef]
55. Antoniak, A.; Biskupek, I.; Bojarski, K.K.; Czaplewski, C.; Giełdo ´ n, A.; Kogut, M.;
Kogut, M.M.; Krupa, P.; Lipska, A.G.; Liwo, A. Modeling protein structures with the coarse-
grained UNRES force field in the CASP14 experiment. J. Mol. Graph. Model. 2021,108,
108008. [CrossRef] [PubMed]
56. Varadi, M.; Anyango, S.; Deshpande, M.; Nair, S.; Natassia, C.; Yordanova, G.; Yuan, D.;
Stroe, O.; Wood, G.; Laydon, A. AlphaFold Protein Structure Database: Massively
expanding the structural coverage of protein-sequence space with high-accuracy models.
Nucleic Acids Res. 2022, 50, D439–D444. [CrossRef] [PubMed]
57. Hooft, R.W.; Vriend, G.; Sander, C.; Abola, E.E. Errors in protein structures. Nature 1996,
381, 272. [CrossRef] [PubMed]
58. Ramachandran, G.T.; Sasisekharan, V. Conformation of polypeptides and proteins. In
Advances in Protein Chemistry; Elsevier: Amsterdam, The Netherlands, 1968; Volume 23,
pp. 283–437.
59. Trott, O.; Olson, A.J. AutoDock Vina: Improving the speed and accuracy of docking with
a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010,
31, 455–461. [CrossRef] [PubMed]
60. Verdonk, M.L.; Cole, J.C.; Hartshorn, M.J.; Murray, C.W.; Taylor, R.D. Improved protein-
ligand docking using GOLD. Proteins Struct. Funct. Bioinform. 2003, 52, 609–623. [CrossRef]
[PubMed]
61. Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Repasky,
M.P.; Knoll, E.H.; Shelley, M.; Perry, J.K. Glide: A new approach for rapid, accurate docking
and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem.2004, 47, 1739–
1749. [CrossRef]
62. Halgren, T.A.; Murphy, R.B.; Friesner, R.A.; Beard, H.S.; Frye, L.L.; Pollard, W.T.; Banks,
J.L. Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in
database screening. J. Med. Chem. 2004, 47, 1750–1759. [CrossRef]
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 85

63. Grosdidier, A.; Zoete, V.; Michielin, O. Swiss Dock, a protein-small molecule docking
web service based on EADock DSS. Nucleic Acids Res. 2011, 39 (Suppl. S2), W270–W277.
[CrossRef]
64. Santos, K.B.; Guedes, I.A.; Karl, A.L.; Dardenne, L.E. Highly flexible ligand docking:
Benchmarking of the DockThor program on the LEADS-PEP protein–peptide data set. J.
Chem. Inf. Model. 2020, 60, 667–683. [CrossRef] [PubMed]
65. Liu, Y.; Grimm, M.; Dai, W.-t.; Hou, M.-c.; Xiao, Z.-X.; Cao, Y. CB-Dock: A web server for
cavity detection-guided protein-ligand blind docking. Acta Pharmacol. Sin. 2020, 41, 138–
144. [CrossRef] [PubMed]
66. Chemical Computing Group Inc. Molecular Operating Environment (MOE); Chemical
Computing Group Inc.: Montreal, QC,
Canada, 2022.
67. Sastry, G.M.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. Protein and ligand
preparation: Parameters, protocols, and influence on virtual screening enrichments. J.
Comput. Aided Mol. Des. 2013, 27, 221–234. [CrossRef] [PubMed]
68. López, G.; Valencia, A.; Tress, M.L. Firestar—Prediction of functionally important
residues using structural templates and alignment reliability. Nucleic Acids Res. 2007, 35
(Suppl. S2), W573–W577. [CrossRef]
69. Wass, M.N.; Kelley, L.A.; Sternberg, M.J. 3DLigandSite: Predicting ligand-binding sites
using similar structures. Nucleic Acids Res.
2010, 38 (Suppl. S2), W469–W473. [CrossRef]
70. Toti, D.; Viet Hung, L.; Tortosa, V.; Brandi, V.; Polticelli, F. LIBRA-WA: A web
application for ligand binding site detection and protein function recognition.
Bioinformatics 2018, 34, 878–880. [CrossRef]
71. Viet Hung, L.; Caprari, S.; Bizai, M.; Toti, D.; Polticelli, F. Libra: Ligand binding site
recognition application. Bioinformatics 2015, 31, 4020–4022. [CrossRef]
72. Laskowski, R.A. SURFNET: A program for visualizing molecular surfaces, cavities, and
intermolecular interactions. J. Mol. Graph.1995, 13, 323–330. [CrossRef]
73. Halgren, T. New method for fast and accurate binding-site identification and analysis.
Chem. Biol. Drug Des. 2007, 69, 146–148. [CrossRef] [PubMed]
74. Halgren, T.A. Identifying and characterizing binding sites and assessing draggability. J.
Chem. Inf. Model. 2009, 49, 377–389. [CrossRef] [PubMed]
75. Brenke, R.; Kozakov, D.; Chuang, G.-Y.; Beglov, D.; Hall, D.; Landon, M.R.; Mattos, C.;
Vajda, S. Fragment-based identification of druggable ‘hot spots’ of proteins using Fourier
domain correlation techniques. Bioinformatics 2009, 25, 621–627. [CrossRef]
76. Laurie, A.T.; Jackson, R.M. Q-SiteFinder: An energy-based method for the prediction of
protein-ligand binding sites. Bioinformatics 2005, 21, 1908–1916. [CrossRef]
86 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

77. Capra, J.A.; Laskowski, R.A.; Thornton, J.M.; Singh, M.; Funkhouser, T.A. Predicting
protein-ligand binding sites by combining evolutionary sequence conservation and 3D
structure. PLoS Comput. Biol. 2009, 5, e1000585. [CrossRef]
78. Lu, C.; Liu, Z.; Zhang, E.; He, F.; Ma, Z.; Wang, H. MPLs-Pred: Predicting membrane
protein-ligand binding sites using hybrid sequence-based features and ligand-specific
models. Int. J. Mol. Sci. 2019, 20, 3120. [CrossRef]
79. Jiménez, J.; Doerr, S.; Martínez-Rosell, G.; Rose, A.S.; De Fabritiis, G. DeepSite: Protein-
binding site predictor using 3Dconvolutional neural networks. Bioinformatics 2017, 33,
3036–3042. Pharmaceutics 2023, 15, 49 40 of 52. [CrossRef] [PubMed]
80. Stepniewska-Dziubinska, M.M.; Zielenkiewicz, P.; Siedlecki, P. Improving detection of
protein-ligand binding sites with 3D segmentation. Sci. Rep. 2020, 10, 5035. [CrossRef]
81. Cui, Y.; Dong, Q.; Hong, D.; Wang, X. Predicting protein-ligand binding residues with
deep convolutional neural networks. BMC
Bioinform. 2019, 20, 93. [CrossRef]
82. Doñate-Macian, P.; Duarte, Y.; Rubio-Moscardo, F.; Pérez-Vilaró, G.; Canan, J.; Díez, J.;
González-Nilo, F.; Valverde, M.A. Structural determinants of TRPV4 inhibition and
identification of new antagonists with antiviral activity. Br. J. Pharmacol. 2022, 179, 3576–
3591. [CrossRef] [PubMed]
83. Irwin, J.J.; Tang, K.G.; Young, J.; Dandarchuluun, C.; Wong, B.R.; Khurelbaatar, M.;
Moroz, Y.S.; Mayfield, J.; Sayle, R.A. ZINC20—A free ultra large-scale chemical database for
ligand discovery. J. Chem. Inf. Model. 2020, 60, 6065–6073. [CrossRef]
84. Wishart, D.S.; Feunang, Y.D.; Guo, A.C.; Lo, E.J.; Marcu, A.; Grant, J.R.; Sajed, T.;
Johnson, D.; Li, C.; Sayeeda, Z. DrugBank 5.0: A major update to the DrugBank database for
2018. Nucleic Acids Res. 2018, 46, D1074–D1082. [CrossRef]
85. Kim, S.; Chen, J.; Cheng, T.; Gindulyte, A.; He, J.; He, S.; Li, Q.; Shoemaker, B.A.;
Thiessen, P.A.; Yu, B. PubChem in 2021: New data content and improved web interfaces.
Nucleic Acids Res. 2021, 49, D1388–D1395. [CrossRef]
86. Beusen, D.D.; Shands, E.B.; Karasek, S.; Marshall, G.R.; Dammkoehler, R.A. Systematic
search in conformational analysis. J. Mol. Struct. THEOCHEM 1996, 370, 157–171.
[CrossRef]
87. Smellie, A.; Stanton, R.; Henne, R.; Teig, S. Conformational analysis by intersection:
CONAN. J. Comput. Chem. 2003, 24, 10–20. [CrossRef]
88. Vainio, M.J.; Johnson, M.S. Generating conformer ensembles using a multiobjective
genetic algorithm. J. Chem. Inf. Model. 2007, 47, 2462–2474. [CrossRef] [PubMed]
89. Jones, G.; Willett, P.; Glen, R.C.; Leach, A.R.; Taylor, R. Development and validation of a
genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727–748. [CrossRef]
90. Sisquellas, M.; Cecchini, M. Prep Flow: A Toolkit for Chemical Library Preparation and
Management for Virtual Screening. Mol. Inform. 2021, 40, 2100139. [CrossRef]
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 87

91. Gally, J.-M.; Bourg, S.; Fogha, J.; Do, Q.-T.; Aci-Sèche, S.; Bonnet, P. VSPrep: A KNIME
workflow for the preparation of molecular
databases for virtual screening. Curr. Med. Chem. 2020, 27, 6480–6494. [CrossRef]
92. Ropp, P.J.; Spiegel, J.O.; Walker, J.L.; Green, H.; Morales, G.A.; Milliken, K.A.; Ringe, J.J.;
Durrant, J.D. Gypsum-DL: An opensource program for preparing small-molecule libraries
for structure-based virtual screening. J. Cheminformatics 2019, 11, 34. [CrossRef]
93. Miteva, M.A.; Guyon, F.; Tufféry, P. Frog2: Efficient 3D conformation ensemble
generator for small compounds. Nucleic Acids Res.2010, 38 (Suppl. S2), W622–W627.
[CrossRef]
94. Vinkers, H.M.; de Jonge, M.R.; Daeyaert, F.F.; Heeres, J.; Koymans, L.M.; van Lenthe,
J.H.; Lewi, P.J.; Timmerman, H.; Van Aken, K.; Janssen, P.A. Synopsis: Synthesize and
optimize the system in silico. J. Med. Chem. 2003, 46, 2765–2773. [CrossRef]
95. Jorgensen, W.L.; Ruiz-Caro, J.; Tirado-Rives, J.; Basavapathruni, A.; Anderson, K.S.;
Hamilton, A.D. Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse
transcriptase. Bioorganic Med. Chem. Lett. 2006, 16, 663–667. [CrossRef]
96. Wang, R.; Gao, Y.; Lai, L. LigBuilder: A multi-purpose program for structure-based drug
design. Mol. Model. Annu. 2000, 6, 498–516. [CrossRef]
97. Hao, G.-F.; Jiang, W.; Ye, Y.-N.; Wu, F.-X.; Zhu, X.-L.; Guo, F.-B.; Yang, G.-F. ACFIS: A
web server for fragment-based drug discovery. Nucleic Acids Res. 2016, 44, W550–W556.
[CrossRef]
98. Marchand, J.-R.; Caflisch, A. In silico fragment-based drug design with SEED. Eur. J.
Med. Chem. 2018, 156, 907–917. [CrossRef]
99. Clark, D.E.; Frenkel, D.; Levy, S.A.; Li, J.; Murray, C.W.; Robson, Waszkowycz, B.;
Westhead, D.R. PRO_LIGAND: An approach to de novo molecular design. 1. Application to
the design of organic molecules. J. Comput. Aided Mol. Des. 1995, 9, 13–32. [CrossRef]
100. Di Pizio, A.; Laghezza, A.; Tortorella, P.; Agamennone, M. Probing the S1’ Site for the
Identification of Non-Zinc-Binding MMP-2 Inhibitors. Chem med chem 2013, 8, 1475–1482.
[CrossRef]
101. Wang, Q.; Park, J.; Devkota, A.K.; Cho, E.J.; Dalby, K.N.; Ren, P. Identification and
Validation of Novel PERK Inhibitors. J. Chem. Inf. Model. 2014, 54, 1467–1475. [CrossRef]
102. Kumar, A.; Zhang, K.Y.J. Hierarchical virtual screening approaches in small molecule
drug discovery. Methods 2015, 71, 26–37. [CrossRef]
103. Kollman, P.A.; Massova, I.; Reyes, C.; Kuhn, B.; Huo, S.; Chong, L.; Lee, M.; Lee, T.;
Duan, Y.; Wang, W. Calculating structures and free energies of complex molecules:
Combining molecular mechanics and continuum models. Acc. Chem. Res. 2000, 33, 889–897.
[CrossRef]
104. Karplus, M.; McCammon, J.A. Molecular dynamics simulations of biomolecules. Nat.
Struct. Biol. 2002, 9, 646–652. [CrossRef] [PubMed]
88 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

105. Piana, S.; Klepeis, J.L.; Shaw, D.E. Assessing the accuracy of physical models used in
protein-folding simulations: Quantitative evidence from long molecular dynamics
simulations. Curr. Opin. Struct. Biol. 2014, 24, 98–105. [CrossRef] [PubMed]
106. Latorraca, N.R.; Fastman, N.M.; Venkatakrishnan, A.; Frommer, W.B.; Dror, R.O.; Feng,
L. Mechanism of substrate translocation in an alternating access transporter. Cell 2017, 169,
96–107.e12. [CrossRef]
107. Wacker, D.; Wang, S.; McCorvy, J.D.; Betz, R.M.; Venkatakrishnan, A.; Levit, A.; Lansu,
K.; Schools, Z.L.; Che, T.; Nichols, D.E. Crystal structure of an LSD-bound human serotonin
receptor. Cell 2017, 168, 377–389.e12. [CrossRef]
108. Clark, A.J.; Tiwary, P.; Borrelli, K.; Feng, S.; Miller, E.B.; Abel, R.; Friesner, R.A.; Berne,
B.J. Prediction of protein-ligand binding poses via a combination of induced fit docking and
meta dynamics simulations. J. Chem. Theory Comput. 2016, 12, 2990–2998. [CrossRef]
109. Abraham, M.J.; Murtola, T.; Schulz, R.; Páll, S.; Smith, J.C.; Hess, B.; Lindahl, E.
GROMACS: High-performance molecular simulations through multi-level parallelism from
laptops to supercomputers. Software X 2015, 1–2, 19–25. [CrossRef]
110. Salomon-Ferrer, R.; Case, D.A.; Walker, R.C. An overview of the Amber biomolecular
simulation package. Wiley Interdiscip. Rev. Comput. Mol. Sci. 2013, 3, 198–210. [CrossRef]
111. Thompson, A.P.; Aktulga, H.M.; Berger, R.; Bolintineanu, D.S.; Brown, W.M.; Crozier,
P.S.; in ‘t Veld, P.J.; Kohlmeyer, A.; Moore, S.G.; Nguyen, T.D.; et al. LAMMPS—A flexible
simulation tool for particle-based materials modeling at the atomic, meso, and continuum
scales. Comput. Phys. Commun. 2022, 271, 108171. [CrossRef]
112. Phillips, J.C.; Hardy, D.J.; Maia, J.D.; Stone, J.E.; Ribeiro, J.V.; Bernardi, R.C.; Buch, R.;
Fiorin, G.; Hénin, J.; Jiang, W. Scalable
molecular dynamics on CPU and GPU architectures with NAMD. J. Chem. Phys. 2020, 153,
044130. [CrossRef]
113. Brooks, B.R.; Brooks III, C.L.; Mackerell Jr, A.D.; Nilsson, L.; Petrella, R.J.; Roux, B.;
Won, Y.; Archontis, G.; Bartels, C.; Boresch, S. CHARMM: The biomolecular simulation
program. J. Comput. Chem. 2009, 30, 1545–1614. [CrossRef]
114. Bowers, K.J.; Chow, D.E.; Xu, H.; Dror, R.O.; Eastwood, M.P.; Gregersen, B.A.; Klepeis,
J.L.; Kolossvary, I.; Moraes, M.A.; Sacerdoti, F.D. Scalable Algorithms for Molecular
Dynamics Simulations on Commodity Clusters. In Proceedings of the 2006 ACM/IEEE
Conference on Supercomputing, Tampa, FL, USA, 11–17 November 2006; IEEE: Piscataway,
NJ, USA, 2006; p. 43.
115. Fernandes, H.S.; Sousa, S.F.; Cerqueira, N.M. New insights into the catalytic
mechanism of the SARS-CoV-2 main protease: An ONIOM QM/MM approach. Mol. Divers.
2022, 26, 1373–1381. [CrossRef]
116. Yildiz, I.; Yildiz, B.S. Computational Analysis of the Inhibition Mechanism of NOTUM
by the ONIOM Method. ACS Omega 2022,7, 13333–13342. [CrossRef]
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 89

117. Vuppala, S.; Kim, J.; Joo, B.-S.; Choi, J.-M.; Jang, J. A Combination of Pharmacophore-
Based Virtual Screening, Structure-Based Lead Optimization, and DFT Study for the
Identification of S. epidermidis TcaR Inhibitors. Pharmaceuticals 2022, 15, 635. [CrossRef]
118. Elkaeed, E.B.; Yousef, R.G.; Elkady, H.; Gobaara, I.M.M.; Alsfouk, B.A.; Husein, D.Z.;
Ibrahim, I.M.; Metwaly, A.M.; Eissa, I.H. Design, Synthesis, Docking, DFT, MD Simulation
Studies of a New Nicotinamide-Based Derivative: In Vitro Anticancer and VEGFR-2
Inhibitory Effects. Molecules 2022, 27, 4606. [CrossRef] [PubMed]
119. Chung, L.W.; Sameera, W.M.C.; Ramozzi, R.; Page, A.J.; Hatanaka, M.; Petrova, G.P.;
Harris, T.V.; Li, X.; Ke, Z.; Liu, F.; et al. The ONIOM Method and Its Applications. Chem.
Rev. 2015, 115, 5678–5796. [CrossRef] [PubMed]
120. Kohn, W.; Sham, L.J. Self-consistent equations including exchange and correlation
effects. Phys. Rev. 1965, 140, A1133. [CrossRef]
121. Bursch, M.; Mewes, J.-M.; Hansen, A.; Grimme, S. Best Practice DFT Protocols for Basic
Molecular Computational Chemistry. Angew. Chem. 2022, 134, e202205735. [CrossRef]
122. Guedes, I.A.; Costa, L.S.; Dos Santos, K.B.; Karl, A.L.; Rocha, G.K.; Teixeira, I.M.;
Galheigo, M.M.; Medeiros, V.; Krempser, E.; Custódio, F.L. Drug design and repurposing
with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-
synonym variants. Sci. Rep. 2021, 11, 5543. [CrossRef]
123. Hodos, R.A.; Kidd, B.A.; Shameer, K.; Readhead, B.P.; Dudley, J.T. In silico methods for
drug repurposing and pharmacology. Wiley Interdiscip. Rev. Syst. Biol. Med. 2016, 8, 186–
210. [CrossRef]
124. Xu, X.; Huang, M.; Zou, X. Docking-based inverse virtual screening: Methods,
applications, and challenges. Biophys. Rep. 2018, 4, 1–16. [CrossRef]
125. McNutt, A.T.; Francoeur, P.; Aggarwal, R.; Masuda, T.; Meli, R.; Ragoza, M.; Sunseri, J.;
Koes, D.R. GNINA 1.0: Molecular docking with deep learning. J. Cheminformatics 2021, 13,
43. [CrossRef]
90 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Chapter RNAi AND siRNA IN CANCER TREATMENT: A

9 PROMISING THERAPEUTIC APPROACH

ASHISH RANJAN BHARADWAJ1 & PRIYANKA SHANKARISHAN1*

1
Department of Applied Biology, University of Science and Technology Meghalaya
(USTM), Ri-Bhoi, Techno City, Killing Road, Baridua, Meghalaya-783101
*Corresponding Author: Dr. Priyanka Shankarishan, Email: [Link]@[Link]

ABSTRACT
The natural biological mechanism, RNA interference (RNAi), silences particular mRNA
transcripts to control gene expression. Double-stranded RNA molecules known as small
interfering RNAs (siRNAs) start RNA interference (RNAi), which silences genes. This
mechanism has drawn a lot of interest as a possible cancer treatment approach. Aberrant
gene expression, frequently involving the overexpression of oncogenes and the under-
expression of tumor suppressors, is a hallmark of cancer. By specifically targeting and
silencing these genes, RNAi-based therapeutics may be able to stop tumor development and
metastasis. Since siRNAs can be made to target almost any gene, they are incredibly
adaptable for treating a variety of malignancies. Furthermore, compared to conventional
treatments, RNAi-based medicines may be more targeted, limiting toxicity and off-target
consequences. However, there are several obstacles to the clinical use of siRNA therapies,
such as potential immunogenicity, stability inside the body, and delivery to target tissues.
By creating effective delivery mechanisms and refining siRNA design, researchers are
actively attempting to overcome these constraints. Notwithstanding these difficulties,
RNAi-based treatments have a lot of potential as a cutting-edge method of treating cancer.
SiRNA therapies could be a useful addition to the toolkit of strategies to fight this
debilitating illness with more study and development.

KEYWORDS: Cancer, RNAi, siRNA, treatment, therapeutic

INTRODUCTION
The condition known as cancer starts when certain cells undergo genetic and epigenetic
changes, some of which can spread and migrate to other tissues (Hanahan et al.,2011). The
study of the entire DNA sequence and how it manifests in tumor cells is known as cancer
genomics. It appears that this study only makes sense when contrasted with normal cells. In
addition to being revolutionary in terms of our understanding of our gene pool, the 2003
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 91

completion of the human genome sequencing revolutionized the field of cancer research. In
the post-genomic era, numerous global initiatives, including the Pan-Cancer Analysis
Working Group (PCAWG), the International Cancer Genome Consortium, the Human
Cancer Genome Project, and the Cancer Genome ATLAS (TCGA), have helped characterize
thousands of primary tumors from various neoplasias, producing more than 2.5 petabytes
(1015) of genomic, epigenomic, and proteomic data. This has aided in changing the
classification and therapy of different neoplasms and resulted in the development of
databases and analytical tools available for the study of cancer from an "omic" perspective
(Creighton et al., 2018; Yang et al., 2015). Recent research, such as that conducted by the
PCAWG, has demonstrated that cancer typically starts with four or five driving mutations
in certain genes, such as tumor-suppressor genes and oncogenes. For instance, precancerous
lesions are characterized by mutations in the tumor-suppressor gene TP53, which are
detected early in over half of all cancer types (Aaltonen et al., 2020; Gerstung et al., 2020).
One in six fatalities today is attributable to some form of cancer, making it the second
leading cause of mortality globally. The International Agency for Research on Cancer
(IARC) estimates that there were 10.3 million cancer-related deaths and 19.3 million new
cases in 2020 (Sung et al., 2021) and that by 2030, there will be 23.8 million cases and 13.0
million deaths from the disease (Ferlay et al., 2020). Accordingly, it is evident that
environmental variables, such as processed foods and environmental toxins, are becoming
more and more important as causes and promoters of cancer (Turner et al., 2020).

RNAi
Through the suppression of transcription (transcriptional gene silencing [TGS]) or the
initiation of a sequence-specific RNA degradation process (posttranscriptional gene
silencing [PTGS]/RNA interference [RNAi]), RNA silencing is a unique gene regulation
mechanism that restricts the transcript level. Even though TGS and PTGS have a
mechanistic relationship, TGS is still a relatively new field, whereas PTGS is experiencing a
massive increase in the amount of information it contains. We have restricted our discussion
to phenomena relating to PTGS/RNAi here.
Although PTGS/RNAi was first observed in plants, RNAi-related processes were
later documented in nearly all eukaryotic organisms, including parasites, flies, nematodes,
insects, protozoa, and human and mouse cell lines. RNA interference (RNAi) has been
described in three phenotypically distinct but mechanistically comparable forms: quelling in
fungi, cosuppression or PTGS in plants, and RNAi in animals. More recently, various
aspects of the naturally occurring RNAi processes of eukaryotic cells have been identified,
such as heterochromatinization and micro-RNA production.
Double-stranded RNA (dsRNA) molecules function as inducers or activators of
RNAi/PTGS by first breaking down the inducer molecules into smaller fragments (Bender et
al., 2001) and then destroying the viral or cellular cognate mRNA molecules (referred to as
the target) (Bernstein et al., 2001). As a result, the target mRNAs are still detectable by
92 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

nuclear run-on tests but are unable to accumulate in the cytosol (Fagard et al., 2000). In
some cases, the degradation process also results in the methylation of the DNA encoding
the target mRNA (Wassenegger et al., 1998).
The defense of the genome against invasion by mobile genetic elements like viruses
and transposons, as well as the coordinated operation of the developmental programs of
eukaryotic organisms, appear to be the natural activities of RNA interference (RNAi) and its
associated processes. Many outstanding recent studies address various facets of RNA
interference in isolation (Hammond et al., 2001; Sharp et al., 2001). Here, we have compiled
the different facets of the RNAi process that are now understood, noted the mechanistic
parallels and discrepancies that exist among different eukaryotic life forms, and
concentrated on the experimental findings that have sparked conceptual breakthroughs in
this area.

MECHANISM OF RNA INTERFERENCE (RNAi)

With the ability to break down exogenously invasive genetic material, including viruses,
RNA interference (RNAi) is a crucial defense mechanism for eukaryotic cells (Downward et
al., 2004). MicroRNAs (miRNAs) and small interfering RNAs (siRNAs), which are essential
for gene regulation, are the two primary types involved in the mechanism of RNA
interference. Endogenous genes produce miRNAs, and Drosha and DGCR8 process the
principal transcripts of these genes (pri-miRNA) in the cell nucleus to create precursor
miRNA (pre-miRNA). Exportin 5 transports pre-miRNA to the cytoplasm, where it
undergoes further processing by the enzyme Dicer to eliminate the hairpin structure. After
processing, the pre-miRNA is loaded into the Argonaute 1–4 (Ago1–Ago4) protein-
containing RNA-induced silencing complex (RISC), which separates from the
complementary RNA strand. In the end, mRNA degradation or mRNA translation
suppression results from the miRNA-RISC complex's poorly complementary binding to the
target mRNA's 3' untranslated region (UTR) (Rev et al., 2019). On the other hand, double-
stranded RNA (dsRNA) is introduced into the cell to start siRNA-mediated RNA
interference. This dsRNA can come from a variety of sources, such as synthesized siRNAs
or external genetic material like viruses. Dicer identifies and processes the dsRNA upon
arrival, cleaving it into smaller pieces that are usually about 20 nucleotides long. The RISC
protein complex is subsequently loaded with these fragments. To guide the complex to its
target mRNA, one of the dsRNA strands—known as the guide strand—is chosen within the
RISC. Through base pairing, the RISC's guide strand attaches itself to the target mRNA's
complementary sequence. Proteins like Argonaute 2 (Ago2) are drawn in and activated as a
result of this contact, which makes it easier for the target mRNA to be cleaved or degraded.
As a result, the relevant protein's production is either stopped or drastically decreased. As
shown in Figure 1, RNA interference (RNAi) is a formidable research technique with
potential therapeutic uses (Lim et al., 2022; Kanasty et al., 2013).
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 93

Fig. 1: Mechanism of RNA Interference (RNAi)

Mechanism of action of small interfering RNA (siRNA) and microRNA (miRNA). miRNA:
In the cell nucleus, the miRNA gene is converted to pri-mRNA, which is subsequently
processed by DGCR8 and Drosha to create pre-miRNA. Exportin 5 carries the pre-miRNA
into the cytoplasm, where Dicer processes it further to eliminate the stem-loop structure and
create mature miRNA. After that, the passenger strand is removed and the miRNA is put
into the RISC that makes up Argonaute 1–4 (Ago1–Ago4). Translational repression or
mRNA degradation results from the miRNA-RISC's poorly complementary pairing with the
94 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

target mRNA. siRNA: Dicer is the first to identify and process the precursor of siRNA, such
as double-stranded RNA (dsRNA). The precursor molecules are broken down by Dicer into
tiny siRNA pieces, usually ranging in length from 21 to 23 nucleotides. The RNA-induced
silencing complex (RISC) is then formed by integrating these siRNA pieces. Once
established, base matching between the siRNA and the mRNA sequence allows the siRNA-
RISC complex to attach to a particular target mRNA molecule. The target mRNA is then
cleaved at a precise location by the siRNA-RISC complex, more especially by the
Argonaute-2 endonuclease (Ago2) within RISC. The target protein expression is eventually
decreased as a result of this breakage, which stops the target mRNA from being translated
into protein. [Link] was used to create the icons for the cell, mitochondria,
endoplasmic reticulum, miRNA gene, genomic DNA, and mRNA.

THE ROLES OF RNA INTERFERENCE IN CANCER THERAPY

High efficiency and potential, inducing silencing in advanced stages of growth, passing on
silenced genes to the following generation, low cost in comparison to other gene therapy
techniques, and high specificity in comparison to other cancer therapy techniques like
chemotherapy are all characteristics of RNA interference's effectiveness in cancer therapy
(Yazdi et al., 2013). One of the primary targets of RNAi-based therapy is cancer. Because
RNAi-based therapy has a precise functional mechanism, high potential, high specificity,
and no side effects compared to chemotherapies, it is a good target for gene silencing
oncogenes, mutated tumor suppressor genes, and several other genes involved in tumor
progression. Targeting several genes of different cellular pathways involved in tumor
progression is RNA interference's primary benefit in cancer treatment (Bora et al., 2001). A
successful method of treating cancer and lowering the risk of treatment resistance brought
on by chemical medication overload is the simultaneous inhibition of several genes. The
creation of appropriate, customized medications for a given patient is an additional benefit
of this kind of therapy. When it comes to regulating tumor growth, personalized
medications are probably more successful than others (Bora et al., 2001). Numerous
investigations into RNAi-based medications have resulted in the development of a number
of these medications, which are currently being investigated in clinical trials. According to
research on animal models, using particular siRNA to target key cell cycle proteins like
polo-like kinase 1 (PLK1) and kinesin spindle protein (KSP) has demonstrated strong
antitumor activity in both subcutaneous and hepatic tumor models (Judge et al., 2009).
Similar to how PLK1 inhibition induces apoptosis (Bora et al., 2001), KSP inhibition results
in cell cycle termination and apoptosis promotion (Tao et al., 2005). In cancer, protein kinase
N3 (PKN3) has been proposed as a legitimate therapeutic target. In orthotopic prostate
cancer models, PKN3 inhibition decreases lymph node metastases (Leenders et al., 2004). In
non-human primates, mice, and rats, Atu027 (siRNA-lipoplex targeted against PKN3) has
been administered. Additionally, inhibiting PKN3 expression led to a considerable
reduction in tumor development and lymph node metastases (Tao et al., 2005). When
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 95

Atu027 was administered to animal models of metastatic lung cancer, the results
demonstrated that metastasis was inhibited (Tao et al., 2005). Furthermore, Atu027 was
assessed in an animal model of lung metastases from breast cancer, and the findings
indicated that lung metastasis was inhibited (Santel et al., 2010). The next round of clinical
testing has just begun, following the conclusion of a phase I clinical trial for the treatment of
solid tumors in late 2012. The current state of RNAi-based medications is detailed in Table 3
(Burnett et al., 2012; Rao et al., 2013). Another RNAi-based medication being evaluated in a
phase I clinical trial is called CALAA-01. The M2 subunit of ribonucleotide reductase
(RRM2) is the target of this particular siRNA against transferrin that is enclosed by non-
chemical nanoparticles. The gene plays a role in the replication of DNA. Following
endocytosis, CALAA-01 attaches to the transferrin receptor, and siRNA releases RRM2-
specific, which ultimately results in the suppression of RRM2 expression and the
suppression of tumor cell proliferation that expresses the transferrin receptor. Biopsies from
melanoma patients receiving the medication were obtained as part of a phase I clinical
study. The results revealed the presence of nanoparticles within the biopsies as well as a
decrease in RRM2 mRNA and RRM2 protein levels. It was found after the phase I clinical
study that siRNA treatment can specifically target tumor cells and systemically quiet
carcinogenic genes (Davis et al., 2010). Currently undergoing phase I therapeutic trials is
ATN-RNA, a 160-bp double-stranded RNA that targets Tenasion-c and is delivered locally
(Rao et al., 2013). When glioma surgery is performed, it is administered directly into the
malignant tissues. Following treatment, the patient's survival increased from 48.2 weeks to
106.8 weeks. Additionally, the scientists found no neurological harm with this medication.
Furin can be silenced ex vivo with the FANGTM vaccination, which was created using
bishRNA technology. Furin is a calcium-dependent, non-functional proprotein that is
necessary for the maturation of TGF-β isoforms (β1, β2) through proteolytic processing. The
FANGTM vaccination increases GM-CSF and inhibits Furin. The body responds to the
FANGTM vaccine in three ways: the antigens are widely presented, GM-CSF stimulates the
immune system, and immunosuppressive protein (TGF-β1, β2) is inhibited. Clinical trials
for the medication are still ongoing. Clinical trials involve the collection of cancer cells from
the body and the electroporation method of transfecting GM-CSF/bishRNA furin into an
expression plasmid. A phase I clinical trial for 68 bishRNA-STMN1, an RNAi-based
medication that targets Stathmin1, has just begun. Stathmin1, a 149-amino acid protein
involved in tubulin-microtubule compartmentalization, is elevated in tumor tissues. It
affects cell motility as well as M-phase entry and exit. It has been demonstrated that siRNA
and ribozyme can target stathmin1 and that their suppression of stathmin1 increases the
number of cells arrested in the G2/M phase, inhibits cell cloning, and inhibits the induction
of apoptosis (Rao et al., 2013).
96 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Table 1: Current Status of cancer siRNA-based drug

(Burnett et al., 2012; Rao et al., 2013)

Company Drug Target Vehicle Disease Phase

Cyclodextrin
Calando CALAA-
RRM2 nanoparticle, TF, Solid tumors I
Pharmaceuticals 01
and PEG
Silence Advanced
Atu027 PKN3 siRNA-lipoplex I
Therapeutics AG solid cancer
Alnylam ALN- VEGF,
SNALP Solid tumors I
Pharmaceuticals VSP02 KSP
siG12D
Silenseed Ltd. KRAS LODER polymer PDAC I
LODER
Sataris Pharma Advanced
EZN- HIF-1,
and Enzon Nacked solid tumor I
2968 survivin
Pharmaceuticals or lymphoma
SNALP-
Tekmira PLK1 SNALP Solid tumors I
PLK1
Duisburg Bcr-Abl
Bcr-Abl Anionic liposome CML
University siRNA
FANG Furin and
Gradalis Inc. Electroporation Solid tumors I
vaccine GM-CSF
LMP2,
Metastatic
Duke University iPsiRNA LMP7, Transfection I
melanoma
MECL1
Polish academy of ATN- Astrocytic
Tenascin-c Nacked I
sciences RNA tumor

RRM2, M2 subunit of ribonucleotide reductase; PKN3, protein kinase N3; KSP, kinesin
spindle protein; KRAS, V-ki-ras2 Kirsten rat sarcoma viral oncogene homolog; PLK1, polo-
like kinase 1; VEGF, vascular endothelial growth factor; HIF-1, hypoxia-induced factor;
Investigational novel drug, or IND. MECL1 (Multicatalytic Endopeptidase Complex-Like 1),
GM-CSF (granulocyte-macrophage colony-stimulating factor), LMP (latent membrane
protein), and Bcr-Abl (breakpoint cluster region-Abelson).

siRNA
In 1998, Fire and Mello discovered that the silencing effectors in Caenorh abditis elegans
were double-stranded RNAs, which opened the door to the field of RNA interference and
transformed our current knowledge of gene regulation (Fire et al., 1998).
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 97

Sequence-dependent endonucleolytic cleavage of the mRNAs they regulate in mammalian

cells is guided by siRNAs, which were first identified in plants in 1999 (Tomari et al., 2005).
With at least dozens of representatives in each of numerous animal and plant species,
miRNAs were discovered to compose a large class of short RNA regulators by 2001 (Bartel
et al., 2004). Since this discovery, two types of small RNAs have solidified our
understanding of the gene regulatory landscape: miRNAs, which regulate endogenous
genes, and siRNAs, which protect genome integrity against foreign or invasive nucleic acids
like viruses, transposons, and transgenes (Meister et al., 2004).
The groundwork for creating RNAi applications was laid in 2001 when Elbashir et
al. effectively employed synthetic siRNAs for silencing and identified the fundamentals of
siRNA structure and RNAi mechanics (Elbashir et al., 2001).

MECHANISMS OF GENE SILENCING BY siRNA

The starting and impacting stages are the two phases of siRNA production. In the initial
phase, Dicer cleaves a lengthy double-stranded RNA (500–200 bp) into fragments that are
23–21 nucleotides long, producing siRNA. SiRNA is a useful chemical. The bacterial DNA,
viral genome, or synthetic RNA made from bioinformatic data can all yield double-stranded
RNA (Figure 2) (Agrawal et al., 2003; Matzke et al., 2005). During the affecting stage,
helicase separates the double-stranded siRNA, endogenous endonucleases demarcate the
sense strand, and the antisense strand is directed to the RNA-induced silencing complex
(RISC). The target mRNA is thus the target of this complex. Argonate, a RISC member,
breaks down the target mRNA by its ribonuclease activity from the piwi region. As long as
RISC breaks the target mRNA, gene expression stops. There are two ways that mRNA can
be broken. Firstly, ribonuclease may break them. Second, RNA polymerase can create
double-stranded RNA when they attach to the homologous strand, which starts the ongoing
interference cycle (Figure 2). Post-transcriptional gene silencing (PTGS) is the process of
suppressing the expression of the target gene by causing mRNA to degrade (Agrawal et al.,
2003; Matzke et al., 2005). Another post-transcriptional silencing method controlled by a
vector called shRNA was created after it was discovered that siRNA targets gene expression
in an unstable and transient manner and that there is evidence that these molecules increase
the innate immune response, such as interferon. This method works by often silencing
genes after vectors have transfected them into the genome (Cullen et al., 2006; Rubinson et
al., 2003).
98 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Fig. 2: Mechanisms of gene silencing by siRNA

siRNA silencing mechanism. An endo-ribonuclease is known as Dicer cleaves long dsRNA,

which can originate from the hairpin, complementary RNAs, and RNA-dependent RNA
polymerases. Dicer allows the molecules to form the RNA-induced silencing Complex
(RISC) by cutting the long dsRNA into short interfering RNA, or siRNA. After entering the
cell, siRNA is combined with other proteins to create the RISC. Single-stranded siRNA is
created when the siRNA unwinds after joining the RISC complex. Because of its base
pairing at the 5´end, the strand that is thermodynamically less stable is selected to stay in
the RISC complex. It is now possible for the RISC complex's single-stranded siRNA to
search for a complementary mRNA. The RISC complex's single-stranded siRNA causes
mRNA cleavage after attaching to its target mRNA. The cell now recognizes the mRNA as
aberrant and cuts it. As a result, the mRNA is degraded and cannot be translated into amino
acids and proteins. Consequently, the gene encoding that mRNA is silenced.

THE ROLES OF SIRNA IN CANCER THERAPY

Many illnesses, including cancer, may be cured by the therapeutic use of siRNA. The
development of altered genes within tumor cells is the genetic etiology of cancer; many
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 99

gene mutations in cancer both inactivate tumor suppressor genes and activate disease-
driving oncogenes. The ability of small interfering RNAs to deactivate particular genes that
cause cancer has demonstrated significant promise as a novel cancer treatment. Clinical
trials have begun for several anti-cancer siRNA-based medications, and preclinical research
is actively pursuing many more.
Although siRNA therapy has shown promise in the treatment of cancer, there are
still many issues that need to be resolved before siRNAs may be used effectively in clinical
settings. Ensuring that siRNA is delivered to the tumor cells from the injection site is the
first and most important step in making this therapy effective. When given systemically,
siRNAs encounter physiological and biological obstacles that hinder their distribution to the
active site. Intravascular breakdown, immune system detection, renal clearance,
obstructions to tumor tissue penetration and uptake into tumor cells, endosomal escape
once in tumor cells, and off-target effects are a few examples of these barriers.
To get beyond these obstacles and make it easier for siRNAs to reach their target
cells, delivery formulations and chemical modification of siRNA are needed. Additionally,
choosing the right gene targets for cancer is essential for developing siRNA treatment plans.
Findings on the pathways behind cancer provide siRNA therapy novel targets that are
sometimes unattainable with traditional medications. However, the specific gene pool that
causes cancer differs based on the tumor kinds and sources. Therefore, in siRNA therapy
techniques, it is crucial to carefully identify gene targets based on their kind of cancer.

KEY APPLICATIONS OF SIRNAS IN CANCER THERAPY INCLUDE

• Targeting oncogenes: Cancer cells commonly overexpress several oncogenes, including
RAS, MYC, and BCL-2. SiRNAs can be engineered to target these oncogenes and block their
activity, which will cause cancer cells to proliferate less rapidly and undergo apoptosis
(Mahmoodi Chalbatani et al., 2019).
• Silencing tumor suppressor genes: Tumor suppressor genes may be deleted or rendered
inactive in some malignancies. By restoring the expression of these genes, siRNAs can aid in
the suppression of tumors.
• Targeting pathways linked to cancer: siRNAs can also be employed to target particular
signaling pathways implicated in the initiation and spread of cancer. For instance, the
PI3K/AKT pathway, which is commonly active in a variety of malignancies, can be inhibited
by siRNAs.
• Combination therapy: To increase their effectiveness and lower their toxicity, siRNAs can
be used in conjunction with other cancer treatments including radiation therapy or
chemotherapy (Zhao et al., 2022).

CHALLENGES AND FUTURE PROSPECTS

Two promising therapeutic approaches for the treatment of cancer are RNA interference
(RNAi) and small interfering RNA (siRNA) (Zhang et al., 2023a). RNA interference (RNAi)
100 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

provides a tailored approach to cancer treatment by either restoring the activity of tumor
suppressor genes or selectively suppressing the production of oncogenes. However, several
obstacles and restrictions prevent them from being widely used in clinical settings (Hu et
al., 2020a).

CHALLENGES
1. Delivery and Biodistribution: Effectively delivering siRNA to cancer cells is one of the
main challenges (Tian et al., 2021). The circulation quickly breaks down siRNA molecules,
and cells frequently absorb them inefficiently (Zhang et al., 2023b). To overcome this
obstacle, efficient delivery mechanisms such as exosomes, polymeric carriers, and lipid
nanoparticles must be developed.
2 Off-Target Effects: siRNA may target unwanted genes, which could result in negative
side effects and off-target consequences. To reduce off-target binding, careful sequence
design and validation are necessary (Buehler et al., 2012).
3. Immunogenicity: siRNA may cause an immunological reaction, which could result in
toxicity and removal from the body (Kang et al., 2023). To lessen immunogenicity, siRNA
molecule modifications or immune-modulating drugs may be required (Hu et al., 2020b).
4. Drug Resistance: Target gene mutations or changes to the RNAi machinery are two ways
that cancer cells can become resistant to RNAi-based treatments. For RNAi-based cancer
treatments to be successful in the long run, overcoming drug resistance is a crucial obstacle.

FUTURE PROSPECTS
RNAi and siRNA have great potential for cancer treatment despite these obstacles (Afrin et
al., 2023). Addressing these constraints and investigating novel applications are the main
goals of ongoing research (Singh et al., 2018).
1. Advanced Delivery Systems: One of the main areas of research is the creation of more
effective and selective delivery systems, such as cell-penetrating peptides and tailored
nanoparticles (Timotievich et al., 2023).
2. Combination Therapies: RNAi-based medicines may be more effective and overcome
drug resistance when combined with other cancer treatments like immunotherapy or
chemotherapy.
3. Personalized Medicine: RNAi-based medicines can be customized for each patient
according to their unique genetic profile, resulting in more individualized and successful
care (Krzyszczyk et al., 2018).
4. New Targets: Research is still being done to find new cancer-related genes that can be
targeted with RNA interference.
5. Clinical Trials: To assess the safety and effectiveness of RNAi-based treatments for
different cancer types, more clinical trials are necessary.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 101

CONCLUSION
In the fight against cancer, RNA interference (RNAi) and small interfering RNA (siRNA)
offer a promising treatment strategy. siRNA may offer a focused and efficient therapeutic
alternative by specifically inhibiting the expression of oncogenes or genes implicated in
tumor growth. Compared to conventional chemotherapeutic drugs, the capacity to alter
gene expression at the post-transcriptional stage provides a high degree of selectivity,
decreasing off-target effects and lowering toxicity.
Even while siRNA-based treatments have advanced significantly, there are still
many obstacles to overcome, including effective target cell delivery, stability in vivo, and
possible immunological reactions. Nevertheless, these obstacles are being addressed by
continuing research and technical developments, opening the door for the practical use of
RNA interference in the treatment of cancer. RNAi and siRNA are positioned to be crucial
in creating innovative and individualized treatments that give patients with this debilitating
illness hope as our knowledge of the molecular pathways underlying cancer continues to
expand.

REFERENCES
1. Aaltonen, L. A., Abascal, F., Abeshouse, A., Aburatani, H., Adams, D. J., Agrawal,
N., Ahn, K. S., Ahn, S.-M., Aikata, H., Akbani, R., Akdemir, K. C., Al-Ahmadie, H.,
Al-Sedairy, S. T., Al-Shahrour, F., Alawi, M., Albert, M., Aldape, K., Alexandrov, L.
B., Ally, A., … von Mering, C. (2020). Pan-cancer analysis of whole genomes. Nature,
578(7793), 82–93. [Link]
2. Afrin, H., Geetha Bai, R., Kumar, R., Ahmad, S. S., Agarwal, S. K., & Nurunnabi, M.
(2023). Oral delivery of RNAi for cancer therapy. In Cancer and Metastasis Reviews
(Vol. 42, Issue 3, pp. 699–724). Springer. [Link]
3. Agrawal N, Dasaradhi PV, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK.
RNA interference: biology, mechanism, and applications. Microbiol Mol Biol
Rev. 2003;67(4):657–85.
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;
116:281–297.
5. Bender, J. 2001. A vicious cycle: RNA silencing and DNA methylation in
plants. Cell 106:129-132.
6. Bernstein, E., A. A. Caudy, S. M. Hammond, and G. J. Hannon. 2001. Role of a
bidentate ribonuclease in the initiation step of RNA interference. Nature 409:363-
366.
7. Burnett JC, Rossi JJ. RNA-based therapeutics: current progress and prospects. Chem
Biol. 2012;19(1):60–71.
8. Cioca D, Aoki Y, Kiyosawa K. RNA interference is a functional pathway with
therapeutic potential in human myeloid leukemia cell lines. Cancer Gene Ther.
2003;10(2):125–33.
102 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

9. Cooper GM, Sunderland (MA): Sinauer Associates; [Link] Cell: A Molecular

Approach, 2nd edition
10. Creighton CJ. Making use of cancer genomic databases. Curr Protoc Mol Biol. 2018;
121:13-19.
11. Cullen BR. Induction of stable RNA interference in mammalian cells. Gene
Ther. 2006;13(6):503–8.
12. Downward J. RNA interference. BMJ. 2004;328(7450):1245–1248. doi:
10.1136/bmj.328.7450.1245.
13. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, et al. Duplexes of 21-nucleotide
RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;
411:494–498.
14. Fagard, M., and H. Vaucheret. 2000. (Trans) Gene silencing in plants: how many
mechanisms? Annu. Rev. Plant Physiol. Plant Mol. Biol. 51:167-194.
15. Fang J., Nakamura H., Maeda H. (2011). The EPR effect: unique features of tumor
blood vessels for drug delivery, factors involved, and limitations and augmentation
of the effect. Adv. Drug Deliv. Rev. 63, 136–151. 10.1016/[Link].2010.04.009.
16. Ferlay J, Laversanne M, Ervik M, et al. Global Cancer Observatory: Cancer Tomorrow.
International Agency for Research on Cancer, 2020. Accessed on June 13, 2021.
17. Fire A, Xu S, Montgomery MK, Kostas SA, et al. Potent and specific genetic
interference by double-stranded RNA in Caenorhabditis
elegans. Nature. 1998;391(6669):806–811.
18. Gerstung M, Jolly C, Jolly C, et al. The evolutionary history of 2,658 cancers. Nature.
2020;578(7793):122-128.
19. Hammond, S. M., A. A. Caudy, and G. J. Hannon. 2001. Post-transcriptional gene
silencing by double-stranded RNA. Nat. Rev. Genet. 2:110-119.
20. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell.
2011;144(5):646-674.
21. Hnisz D, Weintraub AS, Day DS, Valton AL, Bak RO, Li CH, et al. Activation of
proto-oncogenes by disruption of chromosome neighborhoods. Science.
2016;351(6280):1454.
22. Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X. J. (2020a).
Therapeutic siRNA: state of the art. In Signal Transduction and Targeted Therapy (Vol.
5, Issue 1). Springer Nature. [Link]
23. Kang, H., Ga, Y. J., Kim, S. H., Cho, Y. H., Kim, J. W., Kim, C., & Yeh, J. Y. (2023).
Small interfering RNA (siRNA)-based therapeutic applications against viruses:
principles, potential, and challenges. In Journal of Biomedical Science (Vol. 30, Issue 1).
BioMed Central Ltd. [Link]
24. Katoh M, Terada M. Oncogenes and tumor suppressor genes. Gastric Cancer.
1993:196–208.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 103

25. Krzyszczyk, P., Acevedo, A., Davidoff, E. J., Timmins, L. M., Marrero-Berrios, I.,
Patel, M., White, C., Lowe, C., Sherba, J. J., Hartmanshenn, C., Balter, M. L., Fritz, Z.
R., Androulakis, I. P., Schloss, R. S., & Yarmush, M. L. (2018). The growing role of
precision and personalized medicine for cancer treatment. Technology, 6(3-4), 79.
[Link]
26. Lim SA, Cox A, Tung M, Chung EJ. Clinical progress of nanomedicine-based RNA
therapies. Bioact Mater. 2022; 12:203–213 doi: 10.1016/[Link].2021.10.018.
27. Mahmoodi Chalbatani, G., Dana, H., Gharagouzloo, E., Grijalvo, S., Eritja, R.,
Logsdon, C. D., Memari, F., Miri, S. R., Rad, M. R., & Marmari, V. (2019). Small
interfering RNAs (siRNAs) in cancer therapy: a nano-based approach. In
International Journal of nanomedicine (Vol. 14, pp. 3111–3128). NLM (Medline).
[Link]
28. Matzke MA, Birchler JA. RNAi-mediated pathways in the nucleus. Nat Rev
Genet. 2005;6(1):24–35.
29. Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded
RNA. Nature. 2004; 431:343–498.
30. Nieth C, Priebsch A, Stege A, Lage H. Modulation of the classical multidrug
resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett. 2003; 545:144–
50.
31. Rao DD, Wang Z, Senzer N, Nemunaitis J. RNA interference and personalized
cancer therapy. Discov Med. 2013;15(81):101–10.
32. Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J., et al. A
lentivirus-based system to functionally silence genes in primary mammalian cells,
stem cells and transgenic mice by RNA interference. Nat Genet. 2003;33(3):401–6.
33. Scomparin A, Tiram G, Satchi-Fainaro R. Nanoscale-based delivery of RNAi for
cancer therapy. In: Erdmann VA, Barciszewski J, editors. DNA and RNA
nanotechnologies in medicine. Diagnosis and treatment of diseases. Berlin: Springer;
2013:349–372.
34. Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based
therapeutics. Nat Rev Drug Discov. 2019;18(6):421–446. doi: 10.1038/s41573-019-
0017-4.
35. Sharp, P. A. 2001. RNA interference. Genes Dev. 15:485-490.
36. Singh, A., Trivedi, P., & Jain, N. K. (2018). Advances in siRNA delivery in cancer
therapy. In Artificial Cells, Nanomedicine and Biotechnology (Vol. 46, Issue 2, pp.
274–283). Taylor and Francis Ltd. [Link]
37. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA
A Cancer J Clin. 2021;71(3):209-249.
38. Therapy Zhao Y, Liu T, Thurecht, Investigation of a Dual siRNA/Chemotherapy
Delivery System for Breast Cancer KACS Omega (2022) 7(20) 17119-17127
104 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

39. Tian, Z., Liang, G., Cui, K., Liang, Y., Wang, Q., Lv, S., Cheng, X., & Zhang, L.
(2021). Insight Into the Prospects for RNAi Therapy of Cancer. In Frontiers in
Pharmacology (Vol. 12). Frontiers Media S.A.
[Link]
40. Timotievich, E. D., Shilovskiy, I. P., & Khaitov, M. R. (2023). Cell-Penetrating
Peptides as Vehicles for Delivery of Therapeutic Nucleic Acids. Mechanisms and
Application in Medicine. In Biochemistry (Moscow) (Vol. 88, Issue 11, pp. 1800–
1817). [Link]
41. Tomari Y, Zamore PD. Perspective: machines for RNAi. Genes Dev. 2005; 19:517–
529.
42. Turner MC, Andersen ZJ, Baccarelli A, et al. Air pollutants and cancer: an overview
of current evidence and public health recommendations. CA Cancer J Clin. 2020; 0:
1-20.
43. Vicentini F. T., Borgheti-Cardoso L. N., Depieri L. V., de Macedo Mano D., Abelha T.
F., Petrilli R., et al. (2013). Delivery systems and local administration routes for
therapeutic siRNA. Pharm. Res. 30, 915–931. 10.1007/s11095-013-0971-1.
44. Wang K, Zhang X, Liu Y, Liu C, Jiang B, Jiang YY. Tumor penetrability and anti-
angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
Biomaterials. 2014;35(30):8735–47.
45. Wassenegger, M., and T. Pelissier. 1998. A model for RNA-mediated gene silencing
in higher plants. Plant Mol. Biol. 37:349-362.
46. Wilda M, Fuchs U, Wossmann W, Borkhardt A. Killing of leukemic cells with a
bcr/abl fusion gene by RNA interference (RNAi). Oncogene. 2002;21(37):5716–24.
47. Yang Y, Dong X, Xie B, et al. Databases and web tools for cancer genomics
study. Dev Reprod Biol. 2015;13(1):46-50.
48. Zhang, J., Chen, B., Gan, C., Sun, H., Zhang, J., & Feng, L. (2023a). A Comprehensive
Review of Small Interfering RNAs (siRNAs): Mechanism, Therapeutic Targets, and
Delivery Strategies for Cancer Therapy. In International Journal of Nanomedicine
(Vol. 18, pp. 7605–7635). Dove Medical Press Ltd.
[Link]
49. Zhao J, Feng SS. Nanocarriers for delivery of siRNA and co-delivery of siRNA and
other therapeutic agents. Nanomedicine. 2015;10(14):2199–228.
50. Zhao, Y., Liu, T., Ardana, A., Fletcher, N. L., Houston, Z. H., Blakey, I., & Thurecht,
K. J. (2022). Investigation of a Dual siRNA/Chemotherapy Delivery System for
Breast Cancer Therapy. ACS Omega, 7(20), 17119–17127.
[Link]
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 105

Chapter REVOLUTIONIZING MEDICINE: THE RISE OF

10 BIOLOGICS, BIOSIMILARS, AND M-RNA THERAPIES

MR. NEIL B. PANCHAL1*

1
Assistant Professor, Department of Pharmacy, Sumandeep Vidyapeeth
Deemed to be University, Piparia, Waghodia, Vadodara, Gujarat, India
*Corresponding Author: Mr. Neil B. Panchal,
Email: [Link]@[Link]

ABSTRACT
This chapter explores the rapidly advancing fields of biological drugs, biosimilars, and
mRNA-based therapies, highlighting their critical role in modern medicine. Biologics have
transformed treatment in areas like oncology and autoimmune diseases, while biosimilars
offer cost-effective alternatives, with discussions on their development, regulatory
pathways, and challenges, particularly immunogenicity and manufacturing. The chapter
also examines mRNA therapies, focusing on their action mechanism, success with COVID-
19 vaccines, and future potential. Key regulatory and manufacturing considerations are
addressed, underscoring the role of innovation in overcoming challenges and advancing
healthcare possibilities.

KEYWORDS: Biologics, Biosimilars, M-Rna Therapies.

INTRODUCTION
Biologics: A New Frontier In Medicine
A breakthrough in medicine, biologics are specifically directed and highly effective
therapies for a multitude of complex conditions. Biologics are large, complex molecules
generated from living cells rather than chemically synthesized the way traditional small-
molecule drugs typically are. These include monoclonal antibodies, vaccines, and gene
therapies as well as recombinant proteins.[1] The complex nature of biologics enables them
to focus on specific elements within the human body, such as proteins or cells, providing
personalized and highly effective therapeutic solutions.[2] However, this complexity also
introduces challenges in their production, storage, and administration.
106 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Biosimilars: The Cost-Effective Alternative

When many biologic drugs face patent expirations, biosimilars seem like a more cost-
effective alternative. Biosimilars are not like traditional generics, which would be
chemically identical copies of their brand-name counterparts; they cannot be identical with
their reference biologics because biological systems are variably inexact. Even so,
biosimilars undergo much testing to show that they are just as safe, pure, and efficacious as
the reference biologics.[3] Biosimilars will make it possible to lower the cost of healthcare
and offer lifesaving treatment to every patient in the world, though development and
approval are much more complex and expensive than for traditional generics.[4]

mRNA-Based Therapies: A Revolution in Vaccinology

The COVID-19 pandemic has highlighted mRNA-based therapies, especially through the
swift creation of mRNA vaccines. Unlike traditional vaccines, which use weakened viruses,
mRNA vaccines instruct cells to produce a viral protein that elicits an immune response.
This method allows for faster development and quick adaptation to new variants.[5] The
potential of mRNA technology extends far beyond vaccines, showing promise in a broad
spectrum of therapeutic applications. This innovative approach could revolutionize
treatments for cancer and various genetic disorders, opening up new possibilities in medical
science.[6] The rapid progress and the demonstrated impact of mRNA vaccines have
heralded a transformative period in the field of biological therapies. This technological
breakthrough has the potential to redefine the landscape of modern medicine, paving the
way for more targeted, effective, and personalized treatment options for patients.

Biologic Drugs: Definition, Types, Mechanisms, and Therapeutic Applications

Introduction to Biologic Drugs
Biologics are a distinct class of medications that are sourced from living entities,
encompassing humans, animals, and microorganisms.[7] In contrast to traditional,
chemically synthesized drugs composed of small molecules, biologics stand out as large,
intricate molecules. They are often proteins, nucleic acids, or even cells and tissues.[8,9] The
intricacy of their structure, often involving hundreds of amino acids or nucleotides, makes
biologics distinct in their mechanism of action and therapeutic application.

Definition of Biologics
The category of biologics encompasses a wide-ranging assortment of medical products. This
diverse group includes vaccines, which stimulate immune responses; blood and its various
components; innovative gene therapies; tissue-based treatments; and recombinant
therapeutic proteins.[10] What sets biologics apart from traditional pharmaceuticals is their
origin—biologics are produced using biotechnology and involve biological processes,
making them more closely related to the natural substances found in the human body.[11] As
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 107

a result, biologics often provide more targeted treatment options, with the potential for
fewer side effects compared to chemical-based drugs.

Types of Biologics
Biologics can be categorized into several types, each with unique characteristics and
applications in modern medicine:
1. Monoclonal Antibodies (mAbs): Monoclonal Antibodies (mAbs) are artificially
created molecules designed in laboratory settings. These engineered antibodies are
crafted to function as substitutes for natural antibodies, with the capability to
restore, enhance, or imitate the immune system's ability to attack foreign cells. By
replicating and augmenting the body's natural defense mechanisms, mAbs serve as
powerful tools in targeted medical treatments.[12] Monoclonal antibodies are
engineered to selectively target and bind to specific antigens, including those on
cancer cells. This precise binding mechanism enables mAbs to exhibit high
specificity, allowing for targeted therapeutic interventions with minimal impact on
surrounding healthy tissues, and delivering potent treatments that exploit unique
diseased cell characteristics. They are widely used in treating various types of
cancer, autoimmune diseases, and chronic inflammatory conditions.[13]
2. Gene Therapy Products: Gene therapies encompass the insertion, deletion, or
modification of genetic material in a patient's cells to combat or prevent diseases.
This innovative approach directly targets the genetic root of health conditions,
offering potential treatments for previously untreatable disorders.[14–16] This category
of biologics has shown promise in treating genetic disorders, certain types of
cancers, and viral infections by correcting or compensating for defective genes
responsible for disease development.[17]
3. Therapeutic Proteins: These include hormones, enzymes, and antibodies produced
through recombinant DNA technology.[18] A well-known example is insulin, used to
manage diabetes. Therapeutic proteins are utilized to replace or augment the
function of a protein that is deficient or abnormal in patients, offering crucial
treatment options for a variety of chronic and acute conditions.[19,20]

Mechanisms of Action
How biologic drugs work can differ significantly based on the specific type of biologic and
what it is designed to target. For example, monoclonal antibodies work by attaching
themselves to specific molecules on cells, like markers on cancer cells, signaling the immune
system to destroy them. Conversely, gene therapies operate by directly modifying the
genetic material within a patient's cells, enabling the repair or replacement of faulty genes
that contribute to disease.[21]
Therapeutic proteins often work by supplementing or replacing endogenous
proteins. For instance, in the case of insulin, the recombinant protein functions by
108 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

regulating blood glucose levels in individuals with diabetes, thereby mimicking the action
of naturally occurring insulin.[22]

Key Therapeutic Areas

Biologics have revolutionized treatment across multiple therapeutic areas, offering new
hope where traditional treatments have fallen short:
1. Oncology: Monoclonal antibodies like trastuzumab (Herceptin) and checkpoint
inhibitors such as pembrolizumab (Keytruda) have transformed cancer treatment by
specifically targeting tumor cells or modulating the immune response against
cancer.[23]
2. Autoimmune Diseases: Biologic medications such as adalimumab (Humira) and
infliximab (Remicade) are employed in the treatment of autoimmune disorders
including rheumatoid arthritis, Crohn's disease, and psoriasis. These biologics
function by suppressing specific pro-inflammatory cytokines that play a crucial role
in driving the disease process. By targeting these inflammatory mediators, these
drugs help to alleviate symptoms and slow disease progression in patients suffering
from these chronic conditions.[24,25]
3. Endocrinology: Therapeutic proteins such as recombinant insulin are essential in
the management of diabetes, providing life-saving treatment for millions of people
worldwide.[26]
4. Rare Diseases: Gene therapies offer revolutionary progress in medicine, as
exemplified by treatments like onasemnogene abeparvovec (Zolgensma) for spinal
muscular atrophy (SMA). These therapies provide effective solutions for genetic
disorders that were once considered untreatable.[27,28]

Biosimilar Development: Definition, Challenges, and Regulatory Pathways

Definition and Importance of Biosimilars
Biosimilars are essentially biological copies of existing drugs. They are very similar in
safety, purity, and effectiveness to the original drug, often referred to as the "innovator" or
"originator" product. Unlike simpler drugs with a defined chemical structure, biologics are
complex molecules produced using living organisms.[29] Consequently, even slight
alterations in the manufacturing process can result in variations in the end product. This
means that biosimilars are not exact replicas, but rather highly comparable versions of their
reference products. Despite these minor differences, biosimilars are designed to have no
clinically significant distinctions from the original biologics they're based on
The importance of biosimilars lies in their potential to increase access to biologic
therapies by offering more affordable alternatives to expensive originator biologics. The
advent of biologics has transformed the treatment landscape for various diseases, including
cancer, autoimmune disorders, and chronic inflammatory conditions. However, the high
cost associated with these innovative therapies has imposed a substantial burden on
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 109

healthcare systems and patients alike, creating a pressing concern that needs to be
addressed.[30,31] Biosimilars can help reduce these costs, improve patient access to essential
treatments, and stimulate competition in the pharmaceutical market, leading to further
innovation.

Comparison Between Biosimilars and Generics

While both biosimilars and generics are developed to be alternatives to existing approved
drugs, there are key differences between the two. Generics are exact chemical copies of
small-molecule drugs and are typically less expensive to develop and produce than their
branded counterparts. The production of generics involves straightforward chemical
synthesis, which allows for the creation of identical copies of the original drug.
The regulatory approval process for generics focuses primarily on verifying that
they contain the identical active ingredient, in the same dosage form and strength, as the
original product, thereby ensuring their bioequivalence and interchangeability.
Biosimilars, on the other hand, are much more complex. They are developed
through a rigorous process that requires extensive characterization and comparison to the
reference biologic. Because biologics are produced in living cells, slight differences in the
manufacturing process can lead to variations in the final product's structure.[32,33] As a result,
biosimilars must undergo comprehensive analytical, non-clinical, and clinical studies to
demonstrate their similarity to the reference product, including studies on
pharmacokinetics, pharmacodynamics, immunogenicity, and clinical efficacy.

The Process of Biosimilar Development

The development of a biosimilar is a highly complex and lengthy process that typically
spans several years and involves multiple stages:
1. Characterization and Analytical Comparability: The initial phase of developing a
biosimilar entail a comprehensive analysis of the reference biologic's molecular
structure. This includes examining its primary amino acid sequence, higher-order
structure, post-translational modifications, and glycosylation patterns.[34] Advanced
analytical techniques, such as spectroscopy, and chromatography, ensure the
biosimilar closely replicates the reference product.[35]
2. Process Development and Optimization: The production process for the biosimilar
is developed and optimized to ensure consistency and scalability. This process
encompasses the careful selection of a suitable cell line, fine-tuning of cell culture
conditions, and development of effective purification methods. The goal is to
produce a biosimilar that closely mimics the reference biologic in terms of structure
and function.[36]
3. Preclinical Studies: Non-clinical studies are performed to compare the biosimilar
with the reference product regarding pharmacokinetics, and pharmacodynamics.
The animal models are used for this type of study.[37]
110 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

4. Clinical Trials: Clinical studies are undertaken to establish the biosimilar's

equivalence to the original product regarding safety, effectiveness, and potential to
trigger immune responses. These investigations typically involve direct
comparisons between the biosimilar and the reference biologic, often focusing on a
carefully selected group of patients who are likely to be sensitive to any differences
between the two products.[38] Clinical endpoints are chosen to show that the
biosimilar does not have any significant clinical differences from the reference
product.
5. Regulatory Submission and Approval: Once the biosimilar has completed the
necessary studies, a regulatory submission is prepared, including all the data
generated during development.[39] This submission is reviewed by regulatory
authorities, such as the FDA or EMA, to determine whether the biosimilar can be
approved for use.

Regulatory Considerations: EMA and FDA Guidelines

Various Regulatory bodies across the globe have set forth specific guidelines for the
development and approval of biosimilars. The European Medicines Agency (EMA)
pioneered the development of a regulatory framework for biosimilars, releasing its first set
of guidelines in 2005. The EMA's approach mandates a step-by-step mandate that biosimilar
development follows a stepwise progression, commencing with comprehensive analytical
comparability studies, and then proceeding to non-clinical and clinical evaluations.[40] The
EMA's guidelines emphasize the importance of demonstrating biosimilarity through a
combination of quality, non-clinical, and clinical data.
In the United States, the Biologics Price Competition and Innovation Act (BPCIA) of
2009 paved the way for a regulatory framework governing biosimilars under the Public
Health Service Act (PHSA). The FDA mandates that biosimilars demonstrate a high level of
similarity to the reference product, with no differences that could impact patient care. This
stringent requirement ensures that biosimilars meet the highest standards for safety,
efficacy, and quality, providing patients with trustworthy and affordable treatment
alternatives.[41,42] The FDA has issued guidance documents outlining requirements for
biosimilar development, including clinical trials, immunogenicity, and data submission
procedures.[43]

Challenges in Biosimilar Development

The development of biosimilars presents several unique challenges, including
immunogenicity and manufacturing complexities.
1. Immunogenicity: A major hurdle in developing biosimilars is the risk of
immunogenicity, where either the biosimilar or the original product elicits an
immune response in patients. Such reactions can potentially diminish the
treatment's effectiveness or cause unwanted side effects.[44] To mitigate this risk,
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 111

biosimilars undergo rigorous immunogenicity testing during development,

including both in vitro assays and clinical studies.[45]
2. Manufacturing Complexities: Biologic manufacturing is intricate and sensitive.
Slight process changes can alter the product's structure, potentially impacting safety
and efficacy. This complexity underscores the challenges in producing consistent
biologics.[46] Consistent biosimilar production requires advanced manufacturing
techniques, stringent quality control, and extensive validation to ensure close
similarity to reference products.

Examples of Approved Biosimilars and Their Impact on Healthcare

Several biosimilars have been approved worldwide, providing more affordable treatment
options for patients. For example, the biosimilar Trastuzumab-dkst (marketed as Ogivri) is
used to treat HER2-positive breast cancer and has offered a more cost-effective alternative
to the originator biologic, Herceptin.[47] Similarly, Infliximab-dyyb (marketed as Inflectra) is a
biosimilar to Remicade, used to treat autoimmune diseases like rheumatoid arthritis and
Crohn's disease.[48]
The introduction of biosimilars has had a significant impact on healthcare by
reducing drug costs and increasing access to life-saving biological therapies. As more
biosimilars enter the market, competition is expected to drive down prices further,
benefiting healthcare systems and patients alike.

mRNA-Based Therapies: Development, Mechanism, and Applications

Introduction to mRNA Technology
mRNA technology marks a major medical advancement, introducing a novel approach to
developing therapies and vaccines. It utilizes genetic material that directs bodily cells to
produce specific proteins.[49] Unlike DNA, which contains the complete genetic blueprint of
an organism, mRNA serves as a temporary template, carrying the instructions from DNA to
the cell's protein-making machinery.[50] This technology has garnered immense attention
due to its role in the rapid development of COVID-19 vaccines, highlighting its potential for
revolutionizing healthcare.

Mechanism of Action for mRNA Vaccines and Therapies

mRNA-based therapies leverage cellular protein synthesis. For example, COVID-19
vaccines use mRNA encoding the SARS-CoV-2 spike protein. Once injected, cells near the
injection site absorb the mRNA. Inside these cells, ribosomes translate the mRNA,
producing the spike protein. This protein is then displayed on the cell surface, triggering an
immune response. This process mimics viral infection, training the immune system without
using live viruses.[51] The body's immune system identifies the foreign protein, triggering
antibody production and T-cell activation. This creates immune memory, enabling future
recognition and defense against the actual virus.
112 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

mRNA therapies extend beyond vaccines, offering potential treatments for various
diseases. By encoding specific proteins, mRNA can address genetic disorders, metabolic
conditions, cardiovascular issues, and even cancer. This approach enables the body to
produce therapeutic proteins internally, potentially treating conditions caused by protein
deficiencies or dysfunctions.[49][52]

Success Stories: The Role of mRNA in COVID-19 Vaccines

The COVID-19 crisis accelerated mRNA vaccine development, marking a significant
medical milestone. Pfizer-BioNTech and Moderna's mRNA vaccines were among the first
approved for emergency use. These innovative vaccines have shown impressive
effectiveness in preventing symptomatic infections and significantly reducing severe cases,
hospitalizations, and fatalities related to COVID-19.[53] The speed with which these vaccines
were developed—from sequencing the virus to large-scale clinical trials—was
unprecedented, showcasing the flexibility and scalability of mRNA technology.
mRNA vaccines' success against COVID-19 confirms their potential for broader use.
This technology's rapid design and production capabilities offer a powerful tool against
future pandemics.[51][54]

Potential Future Applications of mRNA-Based Therapies Beyond Vaccines

The promise of mRNA technology extends far beyond vaccines. Researchers are exploring a
variety of potential applications, including cancer immunotherapy, where mRNA could be
used to encode tumor-specific antigens, thereby training the immune system to recognize
and destroy cancer cells.[52] Additionally, mRNA-based treatments are being investigated
for rare genetic disorders, where mRNA could provide a source of functional protein that is
missing or defective due to a genetic mutation.[55]
Another promising application is in the field of regenerative medicine, where
mRNA could be used to promote tissue repair and regeneration by encoding growth factors
or other therapeutic proteins.[56] The versatility of mRNA technology, combined with
advances in delivery systems and formulation, opens the door to a wide array of novel
treatments.

Current Research and Development Trends in mRNA Therapies

The success of mRNA vaccines has spurred a surge in research and development aimed at
expanding the applications of this technology. Multiple clinical trials are currently testing
mRNA therapies for various conditions, including cancer, infectious diseases, and genetic
disorders.[57,58] Companies and research institutions are also working to optimize mRNA
delivery systems, improve stability and translation efficiency, and reduce the risk of adverse
reactions.
A major hurdle in mRNA therapy is ensuring the mRNA reaches target cells intact.
Lipid nanoparticles (LNPs) have proven effective as delivery vehicles, shielding the mRNA
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 113

and enhancing cellular uptake.[59,60] Current research focuses on improving delivery systems
for better targeting and reduced side effects.

Regulatory and Manufacturing Considerations for Biologics, Biosimilars, and mRNA

Therapies
Key Regulatory Frameworks for Biologics, Biosimilars, and mRNA Therapies
Biologics, biosimilars, and mRNA therapies have the complex task of being regulated by
processes that protect safety, efficacy, and quality. These agencies (including the FDA in the
USA and EMA in EU countries, as well as many others at the national level) are key players
in monitoring the process of development/ approval for all these advanced medical
products. [39,61]
Biologics are under much stronger regulations compared to traditional drugs owing
to their wide complexity. In the US, biologics are governed by the Biologics Control Act and
PHSA. Approval requires hundreds of millions or more, along with a Biologics License
Application supported by significant clinical data to demonstrate safety, purity, and
potency. Because of their complexity, biologics are more highly regulated than traditional
small-molecule drugs. In the United States, biologics are overseen by both Biologic Control
Act and PHSA. Licenses need Biologics License Applications, which involve mountains of
trial data to ensure safety and potency. [62,63]
Biosimilars, which closely resemble approved biologics (reference products), follow
a distinct regulatory route. In the United States, the 351(k) pathway of the Public Health
Service Act, established by the Biologics Price Competition and Innovation Act of 2009,
governs biosimilar approval.[64]
This pathway permits biosimilars to be licensed by demonstrating they are highly
similar to the reference product, with no clinically significant differences in safety, purity, or
potency. The EMA also follows stepwise patterns, incorporating analytical, preclinical, and
clinical studies to verify biosimilarity.[65]
The landscape is also changing for mRNA therapies. As mRNA technology is
relatively new, regulators also had to adjust their frameworks. The FDA directs the
development of mRNA vaccines, emphasizing regulatory rigor in manufacturing and
evidence from clinical trials as well as continuous monitoring of safety and effectiveness
post-licensure. [66,67]
The EMA has also released guidance on clinical trials of vaccines, including those
based on mRNA technology to ensure they are safe and effective. [68]

Manufacturing Challenges for Biologics and mRNA Therapies

Manufacturing biologics and mRNA therapies pose unique challenges due to their
complexity and sensitivity. Unlike chemically synthesized small-molecule drugs, biologics
are produced using living organisms, resulting in a more variable and sensitive
manufacturing process.[31]
114 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

One of the primary challenges in biological manufacturing is maintaining

consistency in the final product. As biologics are produced by living cells, minor changes in
manufacturing—like cell culture conditions, purification, or storage—can alter the final
product's composition, potentially impacting its safety and effectiveness.[69,70] This requires
rigorous quality control measures, including thorough characterization of the biologic at
multiple stages of production.
The manufacturing of mRNA therapies presents its own set of challenges. mRNA's
instability requires advanced delivery systems like lipid nanoparticles (LNPs) to protect it
and ensure efficient uptake by target cells.[71] mRNA production demands precise
transcription control and thorough purification to eliminate impurities that might provoke
immune responses or diminish the therapy's effectiveness.[67]
Scale-up is another significant challenge for both biologics and mRNA therapies. As
these therapies move from the laboratory to large-scale production, maintaining product
consistency and quality becomes increasingly difficult.[72]
Biologics and mRNA therapies require specialized equipment and facilities, adding
significant costs and complexity. Cold-chain storage and distribution further complicate the
supply chain.[67,70]

Innovations and Technologies Addressing Manufacturing Challenges

So, as the manufacturing demand and needs went on increasing over time significant
discoveries in technology evolved to fulfill such giant production tasks. Progress in cell
culture technology, including the advent of single-use bioreactors and continuous
production options [9], has improved the efficiency and consistency of biologics
manufacturing. For example, single-use bioreactors can decrease the risks of contamination
enable easy scale-up as well as do not require extensive cleaning and validation between
manufacture runs. [73,74]
Advances in analytical technologies have made it possible to characterize biologics
more accurately throughout the lifecycle. With advances in techniques like mass
spectrometry, high-performance liquid chromatography (HPLC), and next-generation
sequencing providing more detailed structural analysis of the biologic, each final product
may have to meet stricter specifications. [75,76]
These innovations with delivery systems have been paramount in the domain of
mRNA therapies. The creation of lipid nanoparticles (LNPs) has revolutionized the ability
to deliver mRNA securely and efficiently into cells. Developments in delivery systems are
being actively pursued to enhance their stability, minimize side effects, and target specific
tissues/cells more effectively. [77,78]
In addition, improvements in synthetic biology and automation slowly evolve how
manufacturing is done. Synthetic biology methods enable the systematic engineering of
biological parts, and automation serves to facilitate manufacturing processes by eliminating
errors associated with human intervention. [79]
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 115

CONCLUSION
The regulatory and manufacturing considerations for biologics, biosimilars, and mRNA
therapies are complex and multifaceted, reflecting the challenges and opportunities
presented by these advanced therapies. As the field continues to evolve, ongoing
innovations in manufacturing technologies and regulatory frameworks will be essential to
ensuring the continued success and expansion of these life-saving treatments. By addressing
these challenges head-on, the pharmaceutical industry is paving the way for the next
generation of therapies, offering new hope for patients with a wide range of conditions.

ACKNOWLEDGEMENT
I extend my heartfelt thanks to Mr. Biren S. Panchal for his expert mentorship and
continuous encouragement throughout the research process.

CONFLICTS OF INTEREST
The research and its outcomes are solely motivated by scientific pursuit and academic
integrity, free from any conflicting interests that could influence the work.

REFERENCES
1. Walsh G. Biopharmaceutical benchmarks 2014. Nat Biotechnol [Internet] 2014 [cited
2024 Sep 7];32(10):992–1000. Available from:
[Link]
2. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological
classification. Nat Rev Drug Discov [Internet] 2008 [cited 2024 Sep 7];7(1):21–39.
Available from: [Link]
3. McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin
Pharmacol Ther [Internet] 2012 [cited 2024 Sep 7];91(3):405–17. Available from:
[Link]
4. Ramanan S, Grampp G. Drift, evolution, and divergence in biologics and biosimilar
manufacturing. BioDrugs [Internet] 2014 [cited 2024 Sep 7];28(4):363–72. Available
from: [Link]
5. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in
vaccinology. Nat Rev Drug Discov [Internet] 2018 [cited 2024 Sep 7];17(4):261–79.
Available from: [Link]
6. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics--developing a new class of
drugs. Nat Rev Drug Discov [Internet] 2014 [cited 2024 Sep 7];13(10):759–80.
Available from: [Link]
7. Ogbru O, Davis CP. Biologics: definition, side effects, uses & drug list [Internet].
Med. Net2019 [cited 2024 Sep 7]; Available from:
[Link]
8. Rang HP, Hill RG. Assessing drug safety. Drug Discov Dev Technol Transit
116 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

2013;211–25.
9. Rang HP, LeVine H, Hill RG. Therapeutic modalities. Drug Discov Dev Technol
Transit 2013;33–40.
10. Geigert J. Biopharmaceutical Landscape. Chall C Regul Compliance Biopharm
[Internet] 2023 [cited 2024 Sep 7];1–30. Available from:
[Link]
11. MORROW T, Felcone LH. Defining the difference: What Makes Biologics Unique.
Biotechnol Healthc [Internet] 2004 [cited 2024 Sep 7];1(4):24. Available from:
/PMC/articles/PMC3564302/
12. Bayer V. An Overview of Monoclonal Antibodies. Semin Oncol Nurs
2019;35(5):150927.
13. [Link]. Immunotherapy for Cancer - NCI [Internet]. 2019 [cited 2024 Sep 7];
Available from: [Link]
cancer/treatment/types/immunotherapy
14. Gene Therapy Definition, Pros & Cons [Internet]. 2023 [cited 2024 Sep 7]; Available
from: [Link]
15. What is Gene Therapy- - FDA. [cited 2024 Sep 7]; Available from:
[Link]
gene-therapy
16. Shchaslyvyi AY, Antonenko S V., Tesliuk MG, Telegeev GD. Current State of Human
Gene Therapy: Approved Products and Vectors. Pharmaceuticals [Internet] 2023
[cited 2024 Sep 7];16(10). Available from: /PMC/articles/PMC10609992/
17. Gonçalves GAR, Paiva R de MA. Gene therapy: advances, challenges, and
perspectives. Einstein [Internet] 2017 [cited 2024 Sep 7];15(3):369. Available from:
/PMC/articles/PMC5823056/
18. Dimitrov DS. Therapeutic Proteins. Methods Mol Biol [Internet] 2012 [cited 2024 Sep
7];899:1. Available from: /PMC/articles/PMC6988726/
19. Antar SA, Ashour NA, Sharaky M, Khattab M, Ashour NA, Zaid RT, et al. Diabetes
mellitus: Classification, mediators, and complications; A gate to identify potential
targets for the development of new effective treatments. Biomed Pharmacother
2023;168:115734.
20. Ansari MA, Chauhan W, Shoaib S, Alyahya SA, Ali M, Ashraf H, et al. Emerging
therapeutic options in the management of diabetes: recent trends, challenges, and
future directions. Int J Obes 2023 4712 [Internet] 2023 [cited 2024 Sep 7];47(12):1179–
99. Available from: [Link]
21. Bishnoi M. Pharmacodynamics: Drug mechanisms of action. Pharma Innov
2019;8(1):875–8.
22. Kumar V, Barwal A, Sharma N, Mir DS, Kumar P, Kumar V. Therapeutic proteins:
developments, progress, challenges, and future perspectives. 3 Biotech 2024 144
[Internet] 2024 [cited 2024 Sep 7];14(4):1–32. Available from:
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 117

[Link]
23. Jin S, Sun Y, Liang X, Gu X, Ning J, Xu Y, et al. Emerging new therapeutic antibody
derivatives for cancer treatment. Signal Transduct Target Ther 2022 71 [Internet] 2022
[cited 2024 Sep 7];7(1):1–28. Available from: [Link]
021-00868-x
24. Reimold AM. The role of adalimumab in rheumatic and autoimmune disorders:
comparison with other biologic agents. Open Access Rheumatol Res Rev [Internet]
2012 [cited 2024 Sep 7];4:33. Available from: /PMC/articles/PMC5045097/
25. Lu XQ, Hu R, Peng L, Liu MS, Sun Z. Efficacy and Safety of Adalimumab
Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis. Front Immunol
[Internet] 2021 [cited 2024 Sep 7];12. Available from: /PMC/articles/PMC8055954/
26. Landgraf W, Sandow J. Recombinant Human Insulins – Clinical Efficacy and Safety
in Diabetes Therapy. Eur Endocrinol [Internet] 2016 [cited 2024 Sep 7];12(1):12.
Available from: /PMC/articles/PMC5813452/
27. Yasinski E. With Zolgensma, Gene Therapy Takes Step Forward in Treating SMA,
Other Rare Diseases [Internet]. SMA News Today2019 [cited 2024 Sep 7];Available
from: [Link]
rare-diseases/
28. Ogbonmide T, Rathore R, Rangrej SB, Hutchinson S, Lewis M, Ojilere S, et al. Gene
Therapy for Spinal Muscular Atrophy (SMA): A Review of Current Challenges and
Safety Considerations for Onasemnogene Abeparvovec (Zolgensma). Cureus
[Internet] 2023 [cited 2024 Sep 7];15(3). Available from: /PMC/articles/PMC10104684/
29. Ghia C, Shah D, Rambhad G, Mubashir A, Upadhyaya S. Biologics, biosimilars,
intended copies and the era of competitive medicine. Apollo Med [Internet] 2015
[cited 2024 Sep 7];12(2):103–11. Available from:
[Link]
_copies_and_the_era_of_competitive_medicine
30. Adami G, Saag KG, Chapurlat RD, Guañabens N, Haugeberg G, Lems WF, et al.
Balancing benefits and risks in the era of biologics. Ther Adv Musculoskelet Dis
[Internet] 2019 [cited 2024 Sep 7];11. Available from: /PMC/articles/PMC6820177/
31. Makurvet FD. Biologics vs. small molecules: Drug costs and patient access. Med
Drug Discov 2021;9:100075.
32. Mascarenhas-Melo F, Diaz M, Gonçalves MBS, Vieira P, Bell V, Viana S, et al. An
Overview of Biosimilars—Development, Quality, Regulatory Issues, and
Management in Healthcare. Pharmaceuticals [Internet] 2024 [cited 2024 Sep 7];17(2).
Available from: /PMC/articles/PMC10892806/
33. Kaushik K, Amaral C, Rodrigues AR, Veiga F, Bell V. Biosimilar Medicines: From
Development Process to Marketing Authorization by the EMA and the FDA. Appl
Sci 2024, Vol 14, Page 7529 [Internet] 2024 [cited 2024 Sep 7];14(17):7529. Available
from: [Link]
118 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

34. AL-Sabbagh A, Olech E, McClellan JE, Kirchhoff CF. Development of biosimilars.

Semin Arthritis Rheum 2016;45(5):S11–8.
35. Labine LM, Simpson MJ. The use of nuclear magnetic resonance (NMR) and mass
spectrometry (MS)–based metabolomics in environmental exposure assessment. Curr
Opin Environ Sci Heal 2020;15:7–15.
36. Developing BIOSIMILARS [Internet]. Process Qual. Stand. AMGEN
BiosimilarsAvailable from: [Link]
37. O’Connor A, Rogge M. Nonclinical development of a biosimilar: the current
landscape. Bioanalysis [Internet] 2013 [cited 2024 Sep 7];5(5):537–44. Available from:
[Link]
38. Alten R, Cronstein BN. Clinical trial development for biosimilars. Semin Arthritis
Rheum 2015;44(6):S2–8.
39. Gherghescu I, Delgado-Charro MB. The Biosimilar Landscape: An Overview of
Regulatory Approvals by the EMA and FDA. Pharmaceutics [Internet] 2021 [cited
2024 Sep 7];13(1):1–16. Available from: /PMC/articles/PMC7824407/
40. Biologics development & regulatory approval – EMA perspective - DDReg Pharma
[Internet]. [cited 2024 Sep 7]; Available from:
[Link]
approval-ema-perspective/
41. Biological Product Innovation and Competition [Internet]. [cited 2024 Sep 7].
Available from: [Link]
innovation-and-competition
42. Carver KH, Elikan J, Lietzan E. An unofficial legislative history of the Biologics Price
Competition and Innovation Act of 2009 [Internet]. Food Drug Law J.2010 [cited 2024
Sep 7];65(4). Available from: [Link]
43. Vandivort TC, Horton DB, Johnson SB. Regulatory and strategic considerations for
addressing immunogenicity and related responses in biopharmaceutical
development programs. J Clin Transl Sci [Internet] 2020 [cited 2024 Sep 7];4(6):547.
Available from: /PMC/articles/PMC8057416/
44. Civoli F, Kasinath A, Cai XY, Wadhwa M, Exley A, Oldfield P, et al.
Recommendations for the Development and Validation of Immunogenicity Assays in
Support of Biosimilar Programs. AAPS J [Internet] 2019 [cited 2024 Sep 7];22(1).
Available from: [Link]
45. Kaida-Yip F, Deshpande K, Saran T, Vyas D. Biosimilars: Review of current
applications, obstacles, and their future in medicine. World J Clin Cases [Internet]
2018 [cited 2024 Sep 7];6(8):161. Available from: /PMC/articles/PMC6107532/
46. Conner J, Wuchterl D, Lopez M, Minshall B, Prusti R, Boclair D, et al. The
Biomanufacturing of Biotechnology Products. Biotechnol Entrep Leading, Manag
Commer Innov Technol 2020;447–80.
47. Triantafyllidi E, Triantafillidis JK. Systematic Review on the Use of Biosimilars of
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 119

Trastuzumab in HER2+ Breast Cancer. Biomedicines [Internet] 2022 [cited 2024 Sep
7];10(8). Available from: /PMC/articles/PMC9405693/
48. Blair HA, Deeks ED. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in
Autoimmune Inflammatory Diseases. BioDrugs [Internet] 2016 [cited 2024 Sep
7];30(5):469–80. Available from: [Link]
49. Qin S, Tang X, Chen Y, Chen K, Fan N, Xiao W, et al. mRNA-based therapeutics:
powerful and versatile tools to combat diseases. Signal Transduct Target Ther 2022
71 [Internet] 2022 [cited 2024 Sep 7];7(1):1–35. Available from:
[Link]
50. Baptista B, Carapito R, Laroui N, Pichon C, Sousa F. mRNA, a Revolution in
Biomedicine. Pharmaceutics [Internet] 2021 [cited 2024 Sep 7];13(12). Available from:
/PMC/articles/PMC8707022/
51. Chavda VP, Soni S, Vora LK, Soni S, Khadela A, Ajabiya J. mRNA-Based Vaccines
and Therapeutics for COVID-19 and Future Pandemics. Vaccines [Internet] 2022
[cited 2024 Sep 7];10(12). Available from: /PMC/articles/PMC9785933/
52. Wei HH, Zheng L, Wang Z. mRNA therapeutics: New vaccination and beyond.
Fundam Res 2023;3(5):749–59.
53. Patel R, Kaki M, Potluri VS, Kahar P, Khanna D. A comprehensive review of SARS-
CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson. Hum Vaccin Immunother
[Internet] 2022 [cited 2024 Sep 7];18(1). Available from: /PMC/articles/PMC8862159/
54. Ye Z, Harmon J, Ni W, Li Y, Wich D, Xu Q. The mRNA Vaccine Revolution: COVID-
19 Has Launched the Future of Vaccinology. ACS Nano [Internet] 2023 [cited 2024
Sep 7];17(16):15231–53. Available from: [Link]
55. Shen G, Liu J, Yang H, Xie N, Yang Y. mRNA therapies: Pioneering a new era in rare
genetic disease treatment. J Control Release 2024;369:696–721.
56. Balmayor ER. Synthetic mRNA - an emerging new class of drug for tissue
regeneration. Curr Opin Biotechnol [Internet] 2022 [cited 2024 Sep 8];74:8–14.
Available from: [Link]
57. Al Fayez N, Nassar MS, Alshehri AA, Alnefaie MK, Almughem FA, Alshehri BY, et
al. Recent Advancement in mRNA Vaccine Development and Applications.
Pharmaceutics [Internet] 2023 [cited 2024 Sep 8];15(7). Available from:
/PMC/articles/PMC10384963/
58. Zhang G, Tang T, Chen Y, Huang X, Liang T. mRNA vaccines in disease prevention
and treatment. Signal Transduct Target Ther 2023 81 [Internet] 2023 [cited 2024 Sep
8];8(1):1–30. Available from: [Link]
59. Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid Nanoparticles─From Liposomes to
mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS
Nano [Internet] 2021 [cited 2024 Sep 8];15(11):16982–7015. Available from:
[Link]
60. Ma R, Li Y, Wei Y, Zhou J, Ma J, Zhang M, et al. The dynamic process of mRNA
120 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

delivery by lipid nanoparticles in vivo. Nano Today 2024;57:102325.

61. Mascarenhas-Melo F, Diaz M, Gonçalves MBS, Vieira P, Bell V, Viana S, et al. An
Overview of Biosimilars—Development, Quality, Regulatory Issues, and
Management in Healthcare. Pharmaceuticals [Internet] 2024 [cited 2024 Sep 8];17(2).
Available from: /PMC/articles/PMC10892806/
62. Cosenza ME. Biologics. An Overv FDA Regul Prod From Drugs Cosmet to Food Tob
2018;85–104.
63. Baylor NW, Tillman DB. Regulatory Approval and Compliances for Biotechnology
Products. Biotechnol Entrep Leading, Manag Commer Innov Technol 2020;429–46.
64. Gherghescu I, Delgado-Charro MB. The Biosimilar Landscape: An Overview of
Regulatory Approvals by the EMA and FDA. Pharmaceutics [Internet] 2021 [cited
2024 Sep 8];13(1):1–16. Available from: /PMC/articles/PMC7824407/
65. Biosimilar medicines: Overview | European Medicines Agency (EMA) [Internet].
[cited 2024 Sep 8]; Available from: [Link]
regulatory-overview/biosimilar-medicines-overview
66. Knezevic I, Liu MA, Peden K, Zhou T, Kang HN. Development of mRNA Vaccines:
Scientific and Regulatory Issues. Vaccines [Internet] 2021 [cited 2024 Sep 8];9(2):1–11.
Available from: /PMC/articles/PMC7910833/
67. Whitley J, Zwolinski C, Denis C, Maughan M, Hayles L, Clarke D, et al.
Development of mRNA manufacturing for vaccines and therapeutics: mRNA
platform requirements and development of a scalable production process to support
early phase clinical trials. Transl Res [Internet] 2022 [cited 2024 Sep 8];242:38–55.
Available from: [Link]
68. Clinical evaluation of new vaccines - Scientific guideline | European Medicines
Agency (EMA) [Internet]. [cited 2024 Sep 8]; Available from:
[Link]
69. Nathan JJ, Ramchandani M, Kaur P. Manufacturing of Biologics. Biol Syst Agents
Dermatology [Internet] 2018 [cited 2024 Sep 8];101–10. Available from:
[Link]
70. Sampathkumar K, Kerwin BA. Roadmap for Drug Product Development and
Manufacturing of Biologics. J Pharm Sci 2024;113(2):314–31.
71. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev
Mater 2021 612 [Internet] 2021 [cited 2024 Sep 8];6(12):1078–94. Available from:
[Link]
72. Jiang Z, Dalby PA. Challenges in scaling up AAV-based gene therapy
manufacturing. Trends Biotechnol 2023;41(10):1268–81.
73. Jacquemart R, Vandersluis M, Zhao M, Sukhija K, Sidhu N, Stout J. A Single-use
Strategy to Enable Manufacturing of Affordable Biologics. Comput Struct Biotechnol
J [Internet] 2016 [cited 2024 Sep 8];14:309. Available from: /pmc/articles/PMC4990569/
74. Matanguihan C, Wu P. Upstream continuous processing: recent advances in
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 121

production of biopharmaceuticals and challenges in manufacturing. Curr Opin

Biotechnol 2022;78:102828.
75. Vervoort N, Goossens K, Baeten M, Chen Q. Recent advances in analytical
techniques for high throughput experimentation. Anal Sci Adv [Internet] 2021 [cited
2024 Sep 8];2(3–4):109–27. Available from:
[Link]
76. Kaur H, Bhagwat SR, Sharma TK, Kumar A. Analytical techniques for
characterization of biological molecules - Proteins and aptamers/oligonucleotides.
Bioanalysis 2019;11(2):103–17.
77. Pozzi D, Caracciolo G. Looking Back, Moving Forward: Lipid Nanoparticles as a
Promising Frontier in Gene Delivery. ACS Pharmacol Transl Sci [Internet] 2023 [cited
2024 Sep 8];6(11):1561–73. Available from:
[Link]
78. Su K, Shi L, Sheng T, Yan X, Lin L, Meng C, et al. Reformulating lipid nanoparticles
for organ-targeted mRNA accumulation and translation. Nat Commun 2024 151
[Internet] 2024 [cited 2024 Sep 8];15(1):1–12. Available from:
[Link]
79. Wegener K, Damm O, Harst S, Ihlenfeldt S, Monostori L, Teti R, et al.
Biologicalisation in manufacturing – Current state and future trends. CIRP Ann
2023;72(2):781–807.
122 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Chapter REVOLUTIONIZING HEALTHCARE: ADVANCED DRUG

11 DELIVERY PLATFORMS AND ETHICAL
CONSIDERATIONS

MR. NEIL B. PANCHAL1*

1
Assistant Professor, Department of Pharmacy, Sumandeep Vidyapeeth
Deemed to be University, Piparia, Waghodia, Vadodara, Gujarat, India
*Corresponding Author: Mr. Neil B. Panchal,
Email: [Link]@[Link]

ABSTARCT
From microfluidic devices to hydrogels, advanced drug delivery platforms have the power
to revolutionize healthcare as they facilitate precise and localized treatment administration
custom-fitted for every patient. Although these technologies offer the promise of
transforming drug delivery, they are subject to long clinical testing cycles for regulatory
approval ensuring safety and efficacy. However, once we talk about AI coming into the
picture and affecting how these weapons are used, you get to kind of this ethical discussion
around transparency and fairness. These challenges must be tackled head-on to leverage
these developments in the continuing development of truly smart, targeted healthcare and
the establishment of valuable trust amongst patients.

KEYWORDS: Healthcare, Drug delivery, Ethical Practices.

INTRODUCTION
Advanced drug delivery systems represent a significant leap forward in modern medicine,
addressing the limitations of traditional drug administration methods. Conventional
delivery approaches often face challenges such as poor drug solubility, rapid degradation,
and non-specific targeting, leading to reduced efficacy and increased side effects.[1]
Advanced drug delivery systems are one of the hallmark developments in modern
medicine. They have overcome the problems of traditional delivery methods. Poor
solubility and rapid degradation of drugs along with poor specificity are the major
limitations in conventional delivery strategies, resulting in reduced efficacy and increased
side effects. These issues have been addressed by innovative platforms developed like
microfluidic devices, hydrogels, and wearable systems. The novel technologies have
enabled controlled and patient-specific drug delivery with accuracy to improve therapeutic
outcomes.[2] Microfluidic devices enable meticulous control over drug release,[3] hydrogels
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 123

provide responsive and sustained delivery,[4] and wearable systems ensure continuous, real-
time medication administration,[5] making these advanced platforms essential tools in the
future of personalized medicine.

MICROFLUIDIC DEVICES
Definition and Overview
Microfluidic devices are newly designed systems that manipulate small volumes of fluids,
typically in the range of microliters to picoliters, through channels with dimensions
measured in micrometers. These devices operate on the principles of fluid dynamics at a
microscale, where the behavior of fluids is influenced by factors like capillary forces, surface
tension, and laminar flow.[6] These systems have been found to comprise channels of
microsized dimensions, usually in glass, silicon, or polymers, integrated with pumps,
valves, and sensors in ways that can manipulate and mix fluids.[7] The ability to precisely
manipulate fluids at such a small scale has made microfluidic devices a cornerstone in the
development of advanced drug delivery systems.

Advantages
They have several very important advantages in drug delivery. The specific control of fluid
flow that it enables also leads to dosing accuracy, and assured targeted delivery of the
therapeutic agent.[8] It minimizes the effects of side effects as it introduces drugs accurately.
The microfluidic devices also have another advantage: they consume minimal amounts of
samples and reagents. This is very convenient when using expensive and priceless drugs.[9]
Small quantities reduce waste and all the costs hence making the treatments cheap.
Microfluidic systems can further be designed to achieve controlled release, in which drugs
are administered to patients for long periods at a constant rate, increasing patients'
compliance and hence the therapeutic efficacy.[10]
Another advantage is that it has the possibility of integrating technology. The microfluidic
devices can be combined with biosensors, making a lab-on-a-chip system in which
conditions can be diagnosed and appropriate treatments provided simultaneously. It opens
up the possibility of personalized medicine, taking into consideration the specific needs of
the patient, based on real-time data collected from the microfluidic system.[11]

Applications
Applications of microfluidic devices in drug delivery are very broad. Targeted drug
delivery minimizes systemic exposure and side effects as drugs are delivered to the site in
the body where they are required, for example, tumors or sites of inflammation. [3,12] In
oncology, for example, collateral damage from the high doses of chemotherapy drugs given
is substantial in healthy tissues.
The treatment plans may be tailored to the specific patient through the use of
microfluidic devices. Clinicians can analyze the biological samples of a patient on a
124 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

microfluidic chip to define the most optimal drug and dosage regimen corresponding to
their unique genetic and molecular profile. [13,14] It not only enhances treatment outcomes but
also diminishes the trial-and-error procedure that often accompanies conventional therapy.
Microfluidic devices also have their use in diagnostics whereby they are used as a point-of-
care testing platform. They rapidly test small samples of blood, saliva, and other body fluids
for the presence of biomarkers associated with different diseases.[15] Since diagnostics can be
delivered on the same platform as drug delivery, microfluidic devices become powerful
tools for managing chronic conditions that require continuous monitoring and adjustments
in the treatment course.[16]

Challenges
Mass commercialization of microfluidic devices in drug delivery presents various technical
challenges. First, large-scale production will come with the challenges of producing and
duplicating microfluidic devices. Accurate engineering of the above-mentioned devices is
normally very expensive and involves complicated processes [12]. The other major challenge
they should face at a large scale is to be reliable and reproducible.
Other challenges include the integration of microfluidic devices with already
existing medical technologies and infrastructure.[17] These devices need to be compatible
with already available standard diagnostic and therapeutic tools for wider acceptance in
clinical settings. Compatibility requires technical innovation but, in addition, regulatory
approval which is a long-winding process.[18]
Lastly, there are issues with the commercialization and market adoption of
microfluidic devices.[19] The technology has many benefits but still is relatively new, and
healthcare providers and patients are not yet ready to change to unfamiliar systems. Such
challenges require continued research and development as well as education to
demonstrate the added value that microfluidic devices add to patient outcomes.[20]
Therefore, microfluidic devices are an extremely important innovation in drug
delivery technology that brings precision and efficiency but also the possibility of
personalized medicine. However, technical, manufacturing, and market-related challenges
associated with their application will be pivotal to unlocking their full potential in clinical
use.

HYDROGELS
Introduction to Hydrogels
Hydrogels are three-dimensional, hydrophilic polymer networks capable of holding a
significant amount of water within their structures. Due to their high water content, which
can be up to 90% of their weight, hydrogels resemble natural tissue, making them highly
biocompatible and suitable for various biomedical applications. These polymers can be
synthetic, such as polyacrylamide, or natural, like gelatin and alginate.[21,22] The unique
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 125

properties of hydrogels, including their softness, flexibility, and ability to respond to

environmental stimuli, make them ideal candidates for use in drug delivery systems.[23]

Mechanism of drug delivery

Hydrogels can be prepared to release drugs in a way that is controlled and normally in
response to a stimulus such as pH changes, temperature changes, or other enzyme-based
changes. Responsiveness is due to polymer chains in the hydrogels, which may expand or
shrink depending on given conditions to control the release of the drug within its
encapsulation. [24,25]
pH-sensitive hydrogels are prepared to release the drug load in environments at
specific pH values. This is, for instance, those prevailing in acidic conditions in some disease
sites, including tumors or inflamed tissues. [26] Temperature-sensitive hydrogels can release
drugs when exposed to body heat, hence useful in localized drug delivery systems. [27] The
composition of the polymer and cross-linking density allow researchers to fine-tune the rate
and duration of drug release, thus providing sustained therapeutic effects with minimal
side effects.

APPLICATIONS
Hydrogels have a wide range of applications in the biomedical field, particularly in wound
healing, tissue engineering, and controlled drug delivery. In wound healing, hydrogels are
used as dressings that provide a moist environment, promoting faster healing and reducing
pain. Their high water content helps to cool the wound site, while their porous structure
allows for the exchange of oxygen and the removal of exudates.[28] Additionally, hydrogels
can be loaded with antimicrobial agents or growth factors to enhance the healing process.
In tissue engineering, hydrogels serve as scaffolds that mimic the extracellular matrix,
providing structural support to growing cells and tissues. Their biocompatibility and ability
to encapsulate cells make them ideal for regenerating damaged tissues or organs.[29]
Researchers are exploring the use of hydrogels in creating artificial skin, cartilage, and even
heart tissue, where they can provide a framework for cells to proliferate and form functional
tissues.[30]
In the realm of controlled drug delivery, hydrogels offer a versatile platform for
delivering a wide range of therapeutic agents, from small molecules to proteins and nucleic
acids. Their ability to respond to specific stimuli makes them particularly useful in targeting
drugs to specific sites within the body, reducing systemic exposure and minimizing side
effects. For example, injectable hydrogels can be used to deliver chemotherapy drugs
directly to a tumor site, where they slowly release the drug over time, enhancing the
therapeutic effect while reducing toxicity.[31]
126 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

RECENT DEVELOPMENTS
Recent advancements in hydrogel technology have led to the development of "smart"
hydrogels, which are capable of more sophisticated drug delivery functions.[32] These smart
hydrogels are designed to respond to multiple stimuli or to release their drug load in a
pulsatile manner, providing more precise control over drug delivery.[33] For instance, some
smart hydrogels can release drugs in response to both pH and temperature changes,
offering dual-triggered drug release for complex therapeutic needs.[34]
Another exciting development is the use of injectable hydrogels that can form in
situ, meaning they solidify upon injection into the body. These hydrogels can conform to
the shape of the target site, providing localized and sustained drug delivery.[35] Researchers
are also exploring the use of hydrogels in combination with other materials, such as
nanoparticles, to create hybrid systems with enhanced drug delivery capabilities.[36]
Furthermore, advances in bioprinting technology have enabled the creation of
hydrogel-based structures with intricate designs and patterns, allowing for the precise
placement of cells and drugs within the scaffold.[37] This approach is particularly promising
in the field of regenerative medicine, where printed hydrogels could be used to create
complex tissues or organs for transplantation.[38]
In conclusion, hydrogels represent a versatile and promising platform for drug
delivery and tissue engineering, with their unique properties and adaptability making them
suitable for a wide range of applications. The ongoing research and development of smart
hydrogels and other innovative hydrogel-based systems continue to push the boundaries of
what is possible in modern medicine, offering new possibilities for targeted and controlled
therapeutic interventions.

WEARABLE DELIVERY SYSTEMS

Introduction: Wearable drug delivery systems represent a significant advancement in
modern healthcare, enabling continuous and controlled administration of therapeutics.
These systems typically consist of a wearable device that delivers medication through the
skin or into the bloodstream at a programmed rate. Key components include sensors,
pumps, and drug reservoirs, all integrated into a compact, portable design that can be
comfortably worn by patients.[39–41]

Advantages: The primary benefit of wearable drug delivery systems is the ability to provide
continuous medication, ensuring consistent therapeutic levels and improving treatment
outcomes. This continuous delivery can be particularly beneficial for chronic conditions like
diabetes, where maintaining steady insulin levels is crucial.[39][42] Additionally, these systems
enhance patient compliance by reducing the need for multiple daily doses and minimizing
the burden of treatment. Real-time monitoring is another significant advantage, as many
wearable devices are equipped with sensors that track physiological parameters,[43][44]
allowing for timely adjustments to therapy based on the patient’s needs.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 127

Applications: Wearable drug delivery systems have found widespread use in various
therapeutic areas. Insulin pumps are among the most well-known examples, providing
diabetics with a steady supply of insulin throughout the day.[45] Transdermal patches are
another common application, delivering drugs like nicotine or pain relief medications
through the skin.[46] Wearable injectors, such as those used for the administration of
biologics in conditions like rheumatoid arthritis, offer a convenient alternative to traditional
injections, allowing patients to self-administer treatment with ease.

Future Trends: The future of wearable delivery systems is likely to be closely intertwined
with the growth of digital health technologies. Integration with mobile apps and cloud-
based platforms could enable more sophisticated monitoring and management of chronic
conditions.[47] Additionally, advancements in materials science and miniaturization are
expected to lead to even more discreet and comfortable wearable devices.[48] Innovations
such as closed-loop systems, where the device automatically adjusts drug delivery based on
real-time data, hold the promise of further enhancing the precision and effectiveness of
treatment.[41]

COMPARISON OF PLATFORMS
When considering drug delivery systems, it becomes crucial to contrast hydrogels,
microfluidic devices, and wearable delivery systems. Microfluidic devices get the upper
hand when targeted delivery is needed and the amount of a drug quantity is limited. In the
case of personalized medicine and diagnostics, they are useful as everything needs to be
precise and tailored. [14,49] On the downside, their complex design and medical systems
integration are large barriers.[50]
There is a wide array of applications for hydrogels as they are well-biocompatible
and have tissue-like properties as well. Considering their elastomeric nature, they can be
custom-designed to swarm certain parameters such as pH or temperature which permit
controlled drug release. [21,51,52] Quite the opposite, hydrogels have the concerns of instability
and uneven rate of drug release as issues.
Wearable systems offer the capability of efficient, safe, continuous, and passive
delivery of a drug while also enhancing patient compliance since real-time monitoring is a
viable option. For certain diseases such as diabetes where steady treatment is a necessity,
these systems bring more efficiency and effectiveness. However, regular refilling and the
possibility of device-induced pain or irritation may be considered disadvantages.
Suitability for Different Conditions: Each platform is well suited to particular
medical conditions or types of patients. Microfluidic devices are suitable for Therapies
where precision is required such as in the treatment of cancer, because interference with the
surrounding cells is not needed.[53] Hydrogels are ideal for wound healing and tissue
engineering since they can offer moist, biocompatible conditions optimal for healing.[54,55]
128 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Wearable systems are most suited for chronic diseases like diabetes or heart ailments where
continuous drug delivery and observation are required to maintain a balanced state.[56,57]

REGULATORY AND MANUFACTURING CONSIDERATIONS

Regulatory Pathways: Advanced drug delivery platforms such as microfluidic devices,
hydrogels, and wearable systems are challenging in regulatory terms since their nature is
innovative. In this respect, the FDA and the EMA demand a full assessment of such
technologies on safety, efficacy, and quality. Their greatest difficulty in classification
remains because they do not fit well within any of the categories that currently exist. For
example, microfluidic devices would be classified as a combination product under both
drug and device regulations and therefore complicate both approval processes. [58–61]
Regulatory pathways for advanced drug delivery platforms require extensive
validation beyond traditional systems, including rigorous preclinical studies, clinical trials,
and post-market surveillance to ensure long-term safety.[62] Clear guidelines are needed for
evaluating new materials like hydrogels' biocompatibility and the long-term stability of
wearable devices.

Manufacturing Challenges: The production of advanced drug delivery systems,

particularly novel platforms, comes with difficulties related to large-scale manufacturing.
Microfluidic systems, for example, are not only intricate but also necessitate unique
processes of manufacture. In particular, the microfabrication techniques required for the
development of microfluidic chips are both expensive and challenging to scale up in terms
of volume without loss of quality. It is also worth stressing that the reproducibility of these
devices is important since any variation could affect their function and therefore patient
care. [18,63]
While progressing towards mass production of hydrogels, pertinent issues also
arise. The properties of such hydrogels must be consistent, volume and porosity render
mass-scale production significant for reliable therapeutic effects.[55] The process of sterilizing
hydrogels, on the other hand, must be optimized to ensure that they perform their duties
without risk of damage, which adds to the difficulties in manufacturing.[21]
Wearable systems, even though are comparatively simple in their design, pose
quality assurance issues related to mass manufacturing. In most cases, interaction with
other electronic devices is required which provides the life expectancy needed to be at least
functional over extended periods. Significant skill is needed in the areas of attention to
detail to ensure that both the performance of wearable devices and their comfort to the
patients are optimal. [47,64]
To conclude this section, drug delivery platforms do have significant barriers
regarding both regulatory concerns and ease of manufacturing.
It is imperative to tackle these challenges to ensure that patients receive the
beneficial effects of these novel therapies safely, effectively, and reliably.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 129

FUTURE DIRECTIONS AND INNOVATIONS

Emerging Technologies: Nanotechnology and artificial intelligence will be emerging
technologies that will revolutionize future drug delivery platforms. Nanotechnology can
produce drug delivery systems operating at the molecular level, thus diseased cells are
targeted more accurately, and side effects are lessened.[65] For example, nanoparticles, in
which drugs are delivered directly to the cancer cells, hence increasing efficacy, and harm to
healthy tissues is minimized.[66]
Another disruptive technology is AI which is supposed to advance drug delivery:
through personalized treatment plans, for instance, AI algorithms implanted in wearable
devices could continuously monitor patients' data in real time so that dosages may be
adjusted for the best therapeutic effects.[67,68] AI will also be part of designing and
developing new drug delivery systems: the prediction of exactly how different materials
and structures will behave in the body may facilitate innovation.[69]

Challenges to Overcome: There is, however, a backward mentality that needs to be

completely overcome before these nascent technologies can be truly realized. One such
major barrier is the absence of broad and robust legal regulatory mechanisms that would be
able to keep pace with emerging technologies. As drug delivery systems get more
sophisticated, there will be a need to explore and test new ways for their validation and
verification. [70,71]
One more main hurdle is the scale-up of manufacturing processes. To achieve the
level of nanotechnology, artificial intelligence, and other processes that are currently
deployed in medicine, and meet customers’ demand to switch to large-scale production,
substantial investments into the improvement of manufacturing technologies will be
necessary. [72,73]
Tackling ethics, in particular, about AI, is crucial for achieving acceptance of AI-based drug
delivery systems from society.[70] These systems should be built in such a way that everyone
can harness their full strength without risks, such that systems are fully transparent,
equitable, and devoid of bias, which would ensure their widespread adoption as
intended.[74]

CONCLUSION
In this chapter, we explored the advancements in drug delivery platforms, focusing on
microfluidic devices, hydrogels, and wearable systems. Each of these technologies offers
unique advantages in addressing the limitations of traditional drug delivery methods, from
precise control and targeted delivery to enhanced patient compliance and real-time
monitoring. However, challenges such as regulatory hurdles and manufacturing scalability
remain.
Looking ahead, the integration of emerging technologies like nanotechnology and
AI promises to further transform drug delivery, offering even more personalized and
130 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

efficient therapies. As these platforms continue to evolve, their potential to improve patient
outcomes and revolutionize healthcare delivery is immense, marking a promising future for
the field.

ACKNOWLEDGEMENT:
I sincerely thank Mr. Biren S. Panchal for his invaluable guidance and unwavering support
during the course of this research.

CONFLICTS OF INTEREST
This research was conducted purely in the spirit of academic inquiry and scientific integrity,
with no conflicts of interest that could have affected the outcomes.

REFERENCES
1. He S, Liu Z, Xu D. Advance in oral delivery systems for therapeutic protein. J Drug
Target 2019;27(3):283–91.
2. Lou J, Duan H, Qin Q, Teng Z, Gan F, Zhou X, et al. Advances in Oral Drug Delivery
Systems: Challenges and Opportunities. Pharmaceutics [Internet] 2023 [cited 2024
Sep 9];15(2). Available from: /PMC/articles/PMC9960885/
3. Rawas-Qalaji M, Cagliani R, Al-Hashimi N, Al-Dabbagh R, Al-Dabbagh A, Hussain
Z. Microfluidics in drug delivery: a review of methods and applications. Pharm Dev
Technol [Internet] 2023 [cited 2024 Sep 9];28(1):61–77. Available from:
[Link]
4. Suhag D, Kaushik S, Taxak VB. Hydrogels in Drug Delivery. 2024 [cited 2024 Sep
9];213–46. Available from: [Link]
1_8
5. Bian S, Zhu B, Rong G, Sawan M. Towards wearable and implantable continuous
drug monitoring: A review. J Pharm Anal [Internet] 2021 [cited 2024 Sep 9];11(1):1.
Available from: /PMC/articles/PMC7428759/
6. Maghsoudi S, Rabiee N, Ahmadi S, Rabiee M, Bagherzadeh M, Karimi M. An
overview of microfluidic devices. Biomed Appl Microfluid Devices 2021;1–22.
7. Verma N, Prajapati P, Singh V, Pandya A. An introduction to microfluidics and their
applications. Prog Mol Biol Transl Sci 2022;186(1):1–14.
8. Rabiee M, Namaei Ghasemnia N, Rabiee N, Bagherzadeh M. Microfluidic devices
and drug delivery systems. Biomed Appl Microfluid Devices 2021;153–86.
9. Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA. Targeted drug
delivery strategies for precision medicines. Nat Rev Mater 2021 64 [Internet] 2021
[cited 2024 Sep 9];6(4):351–70. Available from:
[Link]
10. Ma Z, Li B, Peng J, Gao D. Recent Development of Drug Delivery Systems through
Microfluidics: From Synthesis to Evaluation. Pharm 2022, Vol 14, Page 434 [Internet]
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 131

2022 [cited 2024 Sep 9];14(2):434. Available from: [Link]

4923/14/2/434/htm
11. Nikoleli GP, Siontorou CG, Nikolelis DP, Bratakou S, Karapetis S, Tzamtzis N.
Biosensors Based on Microfluidic Devices Lab-on-a-Chip and Microfluidic
Technology. Nanotechnol Biosens 2018;375–94.
12. Damiati S, Kompella UB, Damiati SA, Kodzius R. Microfluidic Devices for Drug
Delivery Systems and Drug Screening. Genes (Basel) [Internet] 2018 [cited 2024 Sep
9];9(2). Available from: /PMC/articles/PMC5852599/
13. Alavi SE, Alharthi S, Alavi SF, Alavi SZ, Zahra GE, Raza A, et al. Microfluidics for
personalized drug delivery. Drug Discov Today 2024;29(4):103936.
14. Maurya R, Gohil N, Bhattacharjee G, Khambhati K, Alzahrani KJ, Ramakrishna S, et
al. Advances in microfluidics devices and their applications in personalized
medicines. Prog Mol Biol Transl Sci 2022;186(1):191–201.
15. Kumar AS, Venkatesalu S, Dilliyappan S, Pasupulla AP, Prathap L, Palaniyandi T, et
al. Microfluidics as diagnostic tools. Clin Chim Acta 2024;556:117841.
16. Yang SM, Lv S, Zhang W, Cui Y. Microfluidic Point-of-Care (POC) Devices in Early
Diagnosis: A Review of Opportunities and Challenges. Sensors (Basel) [Internet] 2022
[cited 2024 Sep 9];22(4). Available from: /PMC/articles/PMC8875995/
17. Rivet C, Lee H, Hirsch A, Hamilton S, Lu H. Microfluidics for medical diagnostics
and biosensors. Chem Eng Sci 2011;66(7):1490–507.
18. Pattanayak P, Singh SK, Gulati M, Vishwas S, Kapoor B, Chellappan DK, et al.
Microfluidic chips: recent advances, critical strategies in design, applications and
future perspectives. Microfluid Nanofluidics [Internet] 2021 [cited 2024 Sep
9];25(12):99. Available from: /PMC/articles/PMC8547131/
19. Volpatti LR, Yetisen AK. Commercialization of microfluidic devices. Trends
Biotechnol 2014;32(7):347–50.
20. Shimali, Chamoli S, Kumar P. Current challenges and prospects of next-generation
microfluidics. Next-Generation Smart Biosensing Nano-Platforms, Nano-
Microfluidics Interfaces, Emerg Appl Quantum Sens 2024;307–15.
21. Mehta P, Sharma M, Devi M. Hydrogels: An overview of its classifications,
properties, and applications. J Mech Behav Biomed Mater 2023;147:106145.
22. Ho TC, Chang CC, Chan HP, Chung TW, Shu CW, Chuang KP, et al. Hydrogels:
Properties and Applications in Biomedicine. Molecules [Internet] 2022 [cited 2024
Sep 10];27(9). Available from: /PMC/articles/PMC9104731/
23. Liu B, Chen K. Advances in Hydrogel-Based Drug Delivery Systems. Gels 2024, Vol
10, Page 262 [Internet] 2024 [cited 2024 Sep 10];10(4):262. Available from:
[Link]
24. Li J, Mooney DJ. Designing hydrogels for controlled drug delivery. Nat Rev Mater
2016 112 [Internet] 2016 [cited 2024 Sep 10];1(12):1–17. Available from:
[Link]
132 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

25. Hameed H, Faheem S, Paiva-Santos AC, Sarwar HS, Jamshaid M. A Comprehensive

Review of Hydrogel-Based Drug Delivery Systems: Classification, Properties, Recent
Trends, and Applications. AAPS PharmSciTech [Internet] 2024 [cited 2024 Sep
10];25(4):1–27. Available from: [Link]
02786-x
26. Rizwan M, Yahya R, Hassan A, Yar M, Azzahari AD, Selvanathan V, et al. pH-
sensitive hydrogels in drug delivery: Brief history, properties, swelling, and release
mechanism, material selection, and applications. Polymers (Basel) 2017;9(4).
27. Zhang K, Xue K, Loh XJ. Thermo-Responsive Hydrogels: From Recent Progress to
Biomedical Applications. Gels [Internet] 2021 [cited 2024 Sep 10];7(3). Available from:
/PMC/articles/PMC8293033/
28. Tavakoli S, Klar AS. Advanced Hydrogels as Wound Dressings. Biomolecules
[Internet] 2020 [cited 2024 Sep 10];10(8):1–20. Available from:
/PMC/articles/PMC7464761/
29. Mantha S, Pillai S, Khayambashi P, Upadhyay A, Zhang Y. Smart Hydrogels in
Tissue Engineering and. Materials (Basel) 2019;12(3323):33.
30. Zhou L, Guo P, D’Este M, Tong W, Xu J, Yao H, et al. Functionalized Hydrogels for
Articular Cartilage Tissue Engineering. Engineering 2022;13:71–90.
31. Xu N, Wang J, Liu L, Gong C. Injectable hydrogel-based drug delivery systems for
enhancing the efficacy of radiation therapy: A review of recent advances. Chinese
Chem Lett 2024;35(8):109225.
32. Narayanaswamy R, Torchilin VP. Hydrogels and Their Applications in Targeted
Drug Delivery. Molecules [Internet] 2019 [cited 2024 Sep 10];24(3). Available from:
/PMC/articles/PMC6384686/
33. Zhang Y, Wu BM. Current Advances in Stimuli-Responsive Hydrogels as Smart
Drug Delivery Carriers. Gels [Internet] 2023 [cited 2024 Sep 10];9(10). Available from:
/PMC/articles/PMC10606589/
34. Bordbar-Khiabani A, Gasik M. Smart Hydrogels for Advanced Drug Delivery
Systems. Int J Mol Sci [Internet] 2022 [cited 2024 Sep 10];23(7). Available from:
[Link]
35. Dimatteo R, Darling NJ, Segura T. In situ forming injectable hydrogels for drug
delivery and wound repair. Adv Drug Deliv Rev 2018;127:167–84.
36. Baishya G, Parasar B, Limboo M, Kumar R, Dutta A, Hussain A, et al. Advancements
in nanocomposite hydrogels: a comprehensive review of biomedical applications.
Discov Mater 2024 41 [Internet] 2024 [cited 2024 Sep 10];4(1):1–23. Available from:
[Link]
37. Muskan, Gupta D, Negi NP. 3D bioprinting: Printing the future and recent advances.
Bioprinting 2022;27:e00211.
38. Dey M, Ozbolat IT. 3D bioprinting of cells, tissues, and organs. Sci Reports 2020 101
[Internet] 2020 [cited 2023 Jul 26];10(1):1–3. Available from:
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 133

[Link]
39. Kar A, Ahamad N, Dewani M, Awasthi L, Patil R, Banerjee R. Wearable and
implantable devices for drug delivery: Applications and challenges. Biomaterials
2022;283:121435.
40. Smuck M, Odonkor CA, Wilt JK, Schmidt N, Swiernik MA. The emerging clinical
role of wearables: factors for successful implementation in healthcare. npj Digit Med
2021 41 [Internet] 2021 [cited 2024 Sep 12];4(1):1–8. Available from:
[Link]
41. Manikkath J, Subramony JA. Toward closed-loop drug delivery: Integrating
wearable technologies with transdermal drug delivery systems. Adv Drug Deliv Rev
2021;179:113997.
42. Pons-Faudoa FP, Ballerini A, Sakamoto J, Grattoni A. Advanced implantable drug
delivery technologies: transforming the clinical landscape of therapeutics for chronic
diseases. Biomed Microdevices [Internet] 2019 [cited 2024 Sep 12];21(2):47. Available
from: /PMC/articles/PMC7161312/
43. Guk K, Han G, Lim J, Jeong K, Kang T, Lim EK, et al. Evolution of Wearable Devices
with Real-Time Disease Monitoring for Personalized Healthcare. Nanomaterials
[Internet] 2019 [cited 2024 Sep 12];9(6). Available from: /PMC/articles/PMC6631918/
44. Dias D, Cunha JPS. Wearable Health Devices—Vital Sign Monitoring, Systems and
Technologies. Sensors (Basel) [Internet] 2018 [cited 2024 Sep 12];18(8). Available
from: /PMC/articles/PMC6111409/
45. Freckmann G, Buck S, Waldenmaier D, Kulzer B, Schnell O, Gelchsheimer U, et al.
Insulin Pump Therapy for Patients With Type 2 Diabetes Mellitus: Evidence, Current
Barriers, and New Technologies. J Diabetes Sci Technol [Internet] 2021 [cited 2024
Sep 12];15(4):901. Available from: /PMC/articles/PMC8258526/
46. Isaac M, Holvey C. Transdermal patches: the emerging mode of drug delivery
system in psychiatry. Ther Adv Psychopharmacol [Internet] 2012 [cited 2024 Sep
12];2(6):255. Available from: /PMC/articles/PMC3736952/
47. Canali S, Schiaffonati V, Aliverti A. Challenges and recommendations for wearable
devices in digital health: Data quality, interoperability, health equity, fairness. PLOS
Digit Heal [Internet] 2022 [cited 2024 Sep 12];1(10):e0000104. Available from:
/PMC/articles/PMC9931360/
48. Hossain N, Mahmud MZ Al, Hossain A, Rahman MK, Islam MS, Tasnim R, et al.
Advances of materials science in MEMS applications: A review. Results Eng
2024;22:102115.
49. Bhattacharjee G, Gohil N, Shukla M, Sharma S, Mani I, Pandya A, et al. Exploring the
potential of microfluidics for next-generation drug delivery systems. OpenNano
2023;12:100150.
50. Ejeta F. Recent Advances of Microfluidic Platforms for Controlled Drug Delivery in
Nanomedicine. Drug Des Devel Ther [Internet] 2021 [cited 2024 Sep 12];15:3881.
134 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Available from: /PMC/articles/PMC8439440/

51. Ahmad Z, Salman S, Khan SA, Amin A, Rahman ZU, Al-Ghamdi YO, et al.
Versatility of Hydrogels: From Synthetic Strategies, Classification, and Properties to
Biomedical Applications. Gels [Internet] 2022 [cited 2024 Sep 12];8(3). Available from:
/PMC/articles/PMC8950628/
52. Ho TC, Chang CC, Chan HP, Chung TW, Shu CW, Chuang KP, et al. Hydrogels:
Properties and Applications in Biomedicine. Molecules [Internet] 2022 [cited 2024
Sep 12];27(9). Available from: /PMC/articles/PMC9104731/
53. Coluccio ML, Perozziello G, Malara N, Parrotta E, Zhang P, Gentile F, et al.
Microfluidic platforms for cell cultures and investigations. Microelectron Eng
2019;208:14–28.
54. Gounden V, Singh M. Hydrogels and Wound Healing: Current and Future
Prospects. Gels [Internet] 2024 [cited 2024 Sep 12];10(1). Available from:
/PMC/articles/PMC10815795/
55. Khan MUA, Aslam MA, Abdullah MF Bin, Al-Arjan WS, Stojanovic GM, Hasan A.
Hydrogels: Classifications, fundamental properties, applications, and scopes in
recent advances in tissue engineering and regenerative medicine – A comprehensive
review. Arab J Chem 2024;17(10):105968.
56. Kazanskiy NL, Khonina SN, Butt MA. A review on flexible wearables – Recent
developments in non-invasive continuous health monitoring. Sensors Actuators A
Phys 2024;366:114993.
57. Guo Y, Liu X, Peng S, Jiang X, Xu K, Chen C, et al. A review of wearable and
unobtrusive sensing technologies for chronic disease management. Comput Biol Med
2021;129:104163.
58. Komala MG, Ong SG, Qadri MU, Elshafie LM, Pollock CA, Saad S. Investigating the
Regulatory Process, Safety, Efficacy and Product Transparency for Nutraceuticals in
the USA, Europe, and Australia. Foods [Internet] 2023 [cited 2024 Sep 12];12(2).
Available from: /PMC/articles/PMC9857896/
59. Lottes AE, Cavanaugh KJ, Chan YYF, Devlin VJ, Goergen CJ, Jean R, et al.
Navigating the Regulatory Pathway for Medical Devices—a Conversation with the
FDA, Clinicians, Researchers, and Industry Experts. J Cardiovasc Transl Res
[Internet] 2022 [cited 2024 Sep 12];15(5):927. Available from:
/PMC/articles/PMC8920055/
60. What is Genomic Surveillance? | CDC [Internet]. [cited 2023 Apr 16]; Available from:
[Link]
61. Van Norman GA. Drugs and Devices: Comparison of European and U.S. Approval
Processes. JACC Basic to Transl Sci 2016;1(5):399–412.
62. Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ, et al. Advances
in drug delivery systems, challenges, and future directions. Heliyon [Internet] 2023
[cited 2024 Sep 15];9(6). Available from: /PMC/articles/PMC10320272/
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 135

63. Cardoso S, Silverio V. Introduction to microfabrication techniques for microfluidics

devices. Drug Deliv Devices Ther Syst 2021;19–30.
64. Chan M, Estève D, Fourniols JY, Escriba C, Campo E. Smart wearable systems:
Current status and future challenges. Artif Intell Med 2012;56(3):137–56.
65. Srinivasan S, Elumalai K. The new frontier of drug delivery through nanotechnology.
Intell Pharm 2023;1(4):169–74.
66. Elumalai K, Srinivasan S, Shanmugam A. Review of the efficacy of nanoparticle-
based drug delivery systems for cancer treatment. Biomed Technol 2024;5:109–22.
67. Li YH, Li YL, Wei MY, Li GY. Innovation and challenges of artificial intelligence
technology in personalized healthcare. Sci Reports 2024 141 [Internet] 2024 [cited
2024 Sep 15];14(1):1–9. Available from: [Link]
70073-7
68. Shajari S, Kuruvinashetti K, Komeili A, Sundararaj U. The Emergence of AI-Based
Wearable Sensors for Digital Health Technology: A Review. Sensors (Basel) [Internet]
2023 [cited 2024 Sep 15];23(23). Available from: /PMC/articles/PMC10708748/
69. Gholap AD, Uddin MJ, Faiyazuddin M, Omri A, Gowri S, Khalid M. Advances in
artificial intelligence for drug delivery and development: A comprehensive review.
Comput Biol Med 2024;178:108702.
70. Mennella C, Maniscalco U, De Pietro G, Esposito M. Ethical and regulatory
challenges of AI technologies in healthcare: A narrative review. Heliyon
2024;10(4):e26297.
71. Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, Chavda VP. Artificial
Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics
[Internet] 2023 [cited 2024 Sep 15];15(7). Available from:
/PMC/articles/PMC10385763/
72. Naik GG, Jagtap VA. Two heads are better than one: Unravelling the potential
Impact of Artificial Intelligence in nanotechnology. Nano TransMed 2024;3:100041.
73. Elzein B. Nano Revolution: “Tiny tech, big impact: How nanotechnology is driving
SDGs progress". Heliyon 2024;10(10):e31393.
74. Al-Khulaidy Stine A, Kavak H. Bias, fairness, and assurance in AI: overview and
synthesis. AI Assur Towar Trust Explain Safe, Ethical AI 2022;125–51.
136 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Chapter HARNESSING PLANT GENOMICS FOR PERSONALIZED

12 MEDICINES: INNOVATIONS IN DRUG FORMULATIONS

VAISHNAVI. V.V1 & DR. S. UMA GOWRIE2*

Ph.D Research Scholar, Department of Plant Biology and Plant Biotechnology,

1

Ethiraj College for Women (Autonomous),

Affiliated to the University of Madras, Chennai – 600 008, Tamil Nadu, India.
2Head of the Department, Department of Plant Biology and Plant Biotechnology, Principal

& Secretary, Ethiraj College for Women (Autonomous),

Affiliated to the University of Madras, Chennai – 600 008, Tamil Nadu, India.
*Corresponding Author: Dr. S. Uma Gowrie, Email: umagowrie_s@[Link]

ABSTRACT
Plant genomics, which integrates cutting-edge genetic research with herbal knowledge, has
become a revolutionary force in personalized medicine and drug development. The
groundbreaking impact of plant genomics on healthcare is examined in this chapter, which
also highlights significant technological developments and their uses in the study of
medicinal plants. The technologies such as CRISPR/Cas9, transcriptomics, metabolomics,
and next-generation sequencing are speeding up the search for the improvement of
bioactive compounds in plants. Using case studies of notable medicinal plants such as
Cannabis sativa, Catharanthus roseus, and Artemisia annua, the study shows how genomic
approaches have improved drug production and efficacy. This chapter also focuses on how
plant-based medicine and pharmacogenomics can work together to create customized
herbal remedies. Innovative drug delivery systems influenced by plant genomics are
developed and demonstrating improvements in targeted therapy and bioavailability.
The objective of the study concludes by highlighting the significant influence of plant
genomics on contemporary medicine and providing fresh insights into drug development,
customized care, and the environmental use of natural resources in the medical field.

KEYWORDS: Plant Genomics, Personalized Medicine, Drug Formulations

INTRODUCTION
The powerful fusion of botany with molecular genomic technology which is transforming
medicine and drug development is plant genomics. Researchers are uncovering the
molecular foundation of the therapeutic potentials, thereby enhancing the production of
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 137

novel bioactive compounds [1]. This holds a significant role in improving global health by
addressing the medical needs in the new era of personalized plant-based medicines.

PLANT GENOMICS IN MODERN MEDICINE

Plants play an important role in the field of medicine by providing numerous remedies that
form the basis of many modern drugs. However, the ability to understand and utilize plants
at the genetic level has recently emerged [2]. The advancements in plant genomics have led
researchers to discover the biochemical pathway that has led to the production of
therapeutic compounds. This insight has enabled researchers to manipulate genetic
information to enhance the yield of natural compounds [3].
For example, in Artemisia annua, the powerful anti-malarial drug artemisin has
undergone extensive genome analysis. Scientists have engineered plants to produce the
drug in higher yield by identifying the genes involved in biosynthesis making the malarial
treatment more affordable [4]. This example not only highlights the potential to address
global health challenges but also demonstrates the benefits of plant genomics in improving
drug availability.

REGULATORY
APPROVAL

PERSONALIZED
MEDICINE
DEVELOPMENT

PHARMACOLOG
ICAL TESTING

BIOACTIVE
COMPOUND
IDENTIFICATION

MULTI-OMICS
INTEGRATION

GENOMIC
ANALYSIS

PLANT
SELECTION

Fig. 1: Plant Genomics in Modern Medicine

138 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

REVOLUTIONARY TECHNOLOGY IN GENOMIC RESEARCH

Several technological innovations play an important role in the advancements of genomic
research in plants. One of the most significant innovations is Next-Generation Sequencing
(NGS), which has revolutionized the field by enabling rapid sequencing of entire plant
genomes. This technology provides researchers with a comprehensive map of a plant’s
genetic makeup, facilitating the discovery of medicinal compounds.
Another key innovation is Transcriptomics, which allows scientists to analyze gene
expression patterns. By understanding these patterns, researchers can manipulate
conditions to enhance the production of desired compounds in plants, optimizing their
medicinal potential. Metabolomics is another important tool, focusing on the study of
chemical fingerprints generated during cellular processes. By mapping these metabolites,
researchers can identify compounds with potential medicinal uses, advancing drug
discovery from plant sources.
CRISPR/Cas9 technology has enabled precise gene editing in plants. This technique
has been applied to Catharanthus roseus to enhance the production of vinblastine and
vincristine, two potent anti-cancer drugs. The ability to target and modify specific plant
genes has paved the way for developing more efficient treatments, offering new avenues in
medicinal research [5].

DISCOVERY OF MEDICINAL COMPOUNDS THROUGH GENOMIC APPROACH:

Genomic Research is a rapidly expanding field for understanding the medicinal potential
which are locked within the plants. Scientists can discover new bioactive compounds by
analyzing the bio-synthetic pathways that are involved in secondary metabolite production
[6]. For example, in the genomic study of Capsella bursa pastoris, various pharmacologically
important active metabolites like flavonoids, polypeptides, choline, acetylcholine,
histamine, and tyramine have been discovered [7].

PHARMACOGENOMICS & PLANT-BASED MEDICINE

The important application of plant genomics is its intersection with pharmacogenomics
which leads to the genetic variations affecting the drug response. By integrating both
pharmacogenomics and plant genomics, researchers can develop personalized plant-based
medicines. This approach has optimized the treatment efficacy by minimizing adverse
reactions. One such example is the Cannabinoid-based treatment from Cannabis sativa. The
effectiveness of cannabinoids in treating neurological disorders varies among individuals
due to their genetic differences in the receptors [8].

DRUG DELIVERY SYSTEM

Plant genomics is gaining attention in drug delivery systems. For example, in
nanostructured lipid carriers, the bioavailability of plant-derived compounds like silymarin,
an extract obtained from Silybum marianum has been discovered [9]. This discovery has
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 139

improved the solubility of the compounds and the absorption in the body thereby reducing
the hepatoprotective activity. Such advancements not only enhance the therapeutic
potential of plant-based drugs but also for effective treatments.

REGULATORY & ETHICAL CONSIDERATIONS

The applications of plant genomics are vast and therefore it also has important regulatory
and ethical considerations. One such ethical issue is the production of phytocompounds to
formulate medicines by genetically modifying the plants which must be carefully regulated
to ensure environmental sustainability and biodiversity conservation. The governance
framework needed to balance innovation with the ethical use of genetic technologies
ensures that the modified plants do not impact the ecosystems [10].

FUTURE TRENDS AND CHALLENGES IN PLANT GENOMICS

The future of plant genomics lies in the integration of multi-omics data i.e., combining
genomics, transcriptomics, and metabolomics to create a broad knowledge of medicinal
plants. This integrated approach is applied to plants like Silybum marianum in which new
therapeutic strategies have been discovered by mapping the intricate network of
biochemical reactions that are taking place within the plants [11 &12].
Plant genomics poses several challenges. One of the primary challenges is the
complexity of the genome, which is large and polyploid, complicating the sequences and
subsequent analysis. The high levels of repetitive DNA cause challenges in the genome
assembly. Additionally, the various diversity among plant species has its own sets of
challenges, variation in the genomic features across species makes the comparison very
challenging and the lack of well-characterized genomes for many plants limits the scope of
research [13]. Another critical challenge is with functional genomics because identifying the
gene functions was found to be difficult because of the complex interactions. Further,
understanding the gene interaction with environmental factors poses another challenge in
the research. Addressing these challenges is important for the advancement of
biotechnology and in the improvement of crops at the global agricultural demands [14].

CASE STUDIES IN PLANT GENOMICS

 Artemisia annua: Antimalarial Properties
Artemisia annua, commonly known as sweet wormwood, is renowned for its production of
artemisinin, a potent antimalarial compound. The sequencing of its genome has provided
significant insights into the biosynthetic pathway of artemisinin. Key genes involved in this
pathway include those encoding enzymes such as amorpha-4,11-diene synthase (ADS),
cytochrome P450 monooxygenase (CYP71AV1), double-bond reductase 2 (DBR2), and
aldehyde dehydrogenase 1 (ALDH1). These discoveries have facilitated genetic engineering
efforts to enhance artemisinin yield, making it more cost-effective and accessible for malaria
140 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

treatment. This is particularly crucial for addressing drug-resistant malaria strains prevalent
in many developing countries [15].

 Catharanthus roseus: Anti-Cancer Alkaloids

Catharanthus roseus, or Madagascar periwinkle, produces vital anti-cancer alkaloids such as
vincristine and vinblastine. The complete genome sequencing of C. roseus has elucidated
the complex biosynthetic pathways responsible for these compounds. Researchers have
identified key regulatory genes and metabolic bottlenecks that can be targeted to enhance
alkaloid production. These advancements have led to improved yields of vincristine and
vinblastine, making cancer treatments more efficient and cost-effective [16].

 Withania somnifera: Adaptogens

Withania somnifera, commonly known as Ashwagandha, is a prominent herb in Ayurvedic
medicine, known for its adaptogenic properties. Genomic studies have identified genes
involved in the biosynthesis of withanolides, the primary bioactive compounds responsible
for their therapeutic effects. This knowledge has enabled selective breeding and genetic
modification to increase withanolide content, enhancing its efficacy in treating stress,
anxiety, and neurodegenerative disorders [17].

 Curcuma longa: Anti-Inflammatory Compounds

Curcuma longa, or turmeric, is valued for curcumin, an active compound with strong anti-
inflammatory and antioxidant properties. Genome sequencing has revealed the genes
involved in curcumin biosynthesis, allowing researchers to optimize its production through
targeted breeding and biotechnological interventions. These efforts have increased
curcumin yield, boosting the therapeutic potential of turmeric in modern medicine [18].

 Moringa oleifera: Nutraceuticals

Moringa oleifera is recognized for its high nutritional value and wide range of medicinal
properties. Genomic studies have identified genes involved in the biosynthesis of bioactive
compounds like quercetin and chlorogenic acid. This understanding has facilitated selective
breeding and genetic engineering to enhance these health-promoting compounds, aiding in
nutraceutical development aimed at addressing malnutrition and preventing chronic
diseases [19].

 Glycyrrhiza glabra: Antiviral and Anti-inflammatory Uses

Licorice from Glycyrrhiza glabra contains glycyrrhizin, which exhibits antiviral and anti-
inflammatory properties. Genome sequencing has provided insights into glycyrrhizin
biosynthesis, enabling genetic modifications to increase its production. This research
supports the development of enhanced antiviral drugs and supplements that promote liver
health and reduce inflammation [20].
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 141

 Musa Flowers: Bioactive Stigmasterol

Musa flowers are a rich source of stigmasterol, which has potential therapeutic effects
including anti-inflammatory and antioxidant properties. Genomic studies have mapped
genes responsible for stigmasterol biosynthesis, allowing for genetic modifications to
increase its yield. This advancement holds promise for developing natural therapies for
cancer treatments and creating functional foods that combat oxidative stress [21].

CONCLUSION
Plant genomics holds a significant role in the development of personalized medicines,
which have the unique genetic and biochemical properties of plants. The integration of
plant-derived compounds into personalized medicine strategies can increase the treatment
efficacy and minimize the adverse effects. The vast genetic diversity found in plants allows
for the identification of novel bioactive compounds that can be optimized for specific health
conditions. Many pharmaceutical compounds are derived from plants and by
understanding the genomic basis of these compounds, researchers can improve extraction
methods, enhance yield, and develop alternatives that are more effective and sustainable.
The genomic study of medicinal plants used in medicine can lead to the discovery of new
therapeutic agents and by validating the efficacy of these plants through genomic analysis,
personalized medicine approaches can be developed. In conclusion, the integration of plant
genomics and personalized medicine poses a transformative opportunity to enhance
healthcare. As research continues to grow, plant genomics will likely play a vital role in the
future of personalized medicine.

REFERENCES
1. Sanger, F., Nicklen, S., & Coulson, A. R. (1977). DNA sequencing with chain-terminating
inhibitors. Proceedings of the national academy of sciences, 74(12), 5463-5467.
2. Liu, Y., Wang, B., Shu, S., Li, Z., Song, C., Liu, D., & Nie, J. (2021). Analysis of the Coptis
chinensis genome reveals the diversification of protoberberine-type alkaloids. Nature
communications, 12(1), 3276.
3. Ghazal, H., Adam, Y., Idrissi Azami, A., Sehli, S., Nyarko, H. N., Chaouni, B., & Adebiyi,
E. (2021). Plant genomics in Africa: present and prospects. The Plant Journal, 107(1), 21-36.
4. Chen, T., Yang, M., Cui, G., Tang, J., Shen, Y., Liu, J., & Huang, L. (2024). IMP: bridging
the gap for medicinal plant genomics. Nucleic Acids Research, 52(D1), D1347-D1354.
5. Yonekura-Sakakibara, K., & Saito, K. (2009). Functional genomics for plant natural
product biosynthesis. Natural product reports, 26(11), 1466-1487.
6. Yamazaki, M., Rai, A., Yoshimoto, N., & Saito, K. (2018). Perspective: functional genomics
towards new biotechnology in medicinal plants. Plant Biotechnology Reports, 12, 69-75.
7. Kersey, P. J. (2019). Plant genome sequences: past, present, future. Current opinion in plant
biology, 48, 1-8.
142 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

8. Sharma, N., Muthamilarasan, M., Prasad, A., & Prasad, M. (2020). Genomics approaches
to synthesize plant-based biomolecules for therapeutic applications to combat SARS-CoV-
2. Genomics, 112(6), 4322-4331.
9. Hao, D. C., & Xiao, P. G. (2015). Genomics and evolution in traditional medicinal plants:
road to a healthier life. Evolutionary Bioinformatics, 11, EBO-S31326.
10. Auffray, C., Chen, Z., & Hood, L. (2009). Systems medicine: the future of medical
genomics and healthcare. Genome medicine, 1, 1-11.
11. Baima, S. (2005). Plant genomics and plant breeding: at the root of human nutrition and
health. Current Topics in Nutraceutical Research, 3(2), 95-112.
12. Chaney, L., Sharp, A. R., Evans, C. R., & Udall, J. A. (2016). Genome mapping in plant
comparative genomics. Trends in plant science, 21(9), 770-780.
13. Briggs, S. P. (1998). Plant genomics: more than food for thought. Proceedings of the
National Academy of Sciences, 95(5), 1986-1988.
14. Thudi, M., Li, Y., Jackson, S. A., May, G. D., & Varshney, R. K. (2012). Current state-of-
art sequencing technologies for plant genomics research. Briefings in functional
genomics, 11(1), 3-11.
15. Gao, L., Xu, W., Xin, T., & Song, J. (2023). Application of third-generation sequencing to
herbal genomics. Frontiers in plant science, 14, 1124536.
16. Mittler, R., & Shulaev, V. (2013). Functional genomics, challenges and perspectives for
the future. Physiologia plantarum, 148(3), 317-321.
17. Stokes, M. E., & McCourt, P. (2014). Towards personalized agriculture: what chemical
genomics can bring to plant biotechnology. Frontiers in Plant Science, 5, 344 – 349.
18. Mehta, A., & Hasija, Y. (2018). Bioinformatics approaches for genomics and post-
genomics applications of anticancer plants. Anticancer Plants: Mechanisms and Molecular
Interactions: Volume 4, 283-317.
19. Bennetzen, J. L. (1999). Plant genomics takes root, and branches out. Trends in
genetics, 15(3), 85-87.
20. Nützmann, H. W., Huang, A., & Osbourn, A. (2016). Plant metabolic clusters–from
genetics to genomics. New Phytologist, 211(3), 771-789.
21. Duvick, J., Fu, A., Muppirala, U., Sabharwal, M., Wilkerson, M. D., Lawrence, C. J., &
Brendel, V. (2007). PlantGDB: a resource for comparative plant genomics. Nucleic acids
research, 36(1), D959-D965.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 143

Chapter AI-DRIVEN DRUG DISCOVERY AND DEVELOPMENT: A

13 NEW ERA IN THERAPEUTICS

DR. SHARAD SINGH LODHI1, DR. PRATIBHA YADAV1 &

DR. ATUL KUMAR SINGH2
1 Mata Jijabai Govt PG College, Indore, M.P., India
Indian Institute of Technology-Delhi, Sonipat Campus, Sonipat, Haryana, India
2

*Corresponding Author: Dr. Pratibha Yadav, Email: pratibhayadav23@[Link]

ABSTRACT
Artificial intelligence (AI) is poised to revolutionize the pharmaceutical industry by
streamlining drug discovery and development. By leveraging advanced algorithms and
vast datasets, AI can accelerate the identification of promising drug targets, optimize lead
compounds, and enhance clinical trial design. AI-driven target identification leverages
machine learning to analyze genomic, proteomic, and clinical data, identifying potential
drug targets more efficiently than traditional methods. Lead optimization benefits from AI's
ability to predict molecular properties, design novel compounds, and simulate drug-target
interactions, reducing the time and cost of drug development. In clinical trials, AI can
optimize patient selection, monitor treatment responses, and predict adverse events,
improving trial efficiency and patient safety. However, the successful adoption of AI in
drug discovery and development requires addressing challenges such as data quality,
model interpretability, and regulatory considerations. As AI technologies continue to
advance, their integration into the pharmaceutical industry is expected to lead to more
efficient drug development and improved patient outcomes.

KEYWORDS: AI, drug discovery, drug development, target identification, lead

optimization, clinical trials, machine learning, deep learning, generative models, predictive
analytics.

INTRODUCTION
The pharmaceutical industry has traditionally been a slow and expensive process, with the
development of new drugs taking over a decade and costing billions of dollars. This lengthy
and costly process has hindered the development of treatments for many diseases,
particularly rare diseases and neglected tropical diseases. However, the advent of artificial
144 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

intelligence (AI) has the potential to revolutionize drug discovery and development,
accelerating the process and reducing costs.
This chapter will explore the role of AI in drug discovery and development,
focusing on the key areas where AI is making a significant impact. These areas include
target identification, lead optimization, and clinical trials. We will also discuss the timeline,
case studies, challenges, and limitations of AI-driven drug discovery and development and
the prospects for this technology.

AI IN TARGET IDENTIFICATION
Target identification is the first step in drug discovery, involving the identification of
biological molecules, such as proteins or genes, that are involved in disease processes.
Traditionally, target identification has been a time-consuming and labor-intensive process,
relying on experimental methods such as high-throughput screening.
AI can significantly accelerate target identification by analyzing vast amounts of
biological data, including genomic, proteomic, and clinical data. Machine learning
algorithms can identify patterns and correlations in this data that are indicative of potential
drug targets. For example, AI can be used to predict the protein-protein interactions that are
involved in disease pathways or to identify genetic mutations that are associated with
disease susceptibility.

Specific examples of AI applications in target identification:

 Deep learning for protein structure prediction: Deep learning models, such as
AlphaFold, can accurately predict the 3D structure of proteins, which is essential for
understanding their function and identifying potential drug targets.
 Natural Language Processing (NLP) for literature mining: NLP algorithms can
extract relevant information from vast amounts of scientific literature, identifying
potential drug targets and their associated biological pathways.
 Network analysis for disease pathway identification: Network analysis algorithms
can identify key nodes and pathways in complex biological networks, providing
insights into disease mechanisms and potential drug targets.

AI IN LEAD OPTIMIZATION
Once a potential drug target has been identified, the next step is to develop lead compounds
that can interact with the target and modulate its function. This process, known as lead
optimization, is also time-consuming and expensive, involving the synthesis and testing of
thousands of compounds.
AI can streamline lead optimization by using computational methods to predict the
properties of potential drug candidates, such as their binding affinity to the target,
solubility, and toxicity. This allows researchers to focus their efforts on compounds that are
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 145

most likely to be successful, reducing the number of compounds that need to be synthesized
and tested.
AI can also be used to design new molecules with desired properties, such as
increased potency or reduced side effects. This is achieved through generative models that
can generate novel chemical structures based on the properties of known drug molecules.

Specific examples of AI applications in lead optimization:

 Generative models for de novo drug design: Generative models, such as variational
autoencoders and generative adversarial networks, can generate novel chemical
structures with desired properties, such as high potency and low toxicity.
 Quantum computing for drug discovery: Quantum computing has the potential to
accelerate lead optimization by simulating complex molecular interactions more
efficiently than classical computers.
 Machine learning for property prediction: Machine learning models can predict
the properties of drug candidates, such as binding affinity, solubility, and toxicity,
based on their chemical structures.

AI IN CLINICAL TRIALS
Clinical trials are the final stage of drug development, involving the testing of new drugs in
humans to assess their safety and efficacy. Clinical trials are often lengthy and expensive,
and many drugs fail to make it through this stage.
AI can help to improve the efficiency and success rate of clinical trials by using
predictive analytics to identify patients who are most likely to benefit from a particular
drug. This can help to reduce the number of patients who are exposed to ineffective or
harmful treatments.
AI can also be used to monitor patients' responses to treatment and to detect
adverse events early. This can help to improve patient safety and reduce the risk of clinical
trial failures.

Specific examples of AI applications in clinical trials:

 Predictive analytics for patient selection: Predictive analytics can identify patients
who are most likely to benefit from a particular drug based on their genetic, clinical,
and sociodemographic characteristics.
 Wearable devices for patient monitoring: Wearable devices, such as smartwatches
and fitness trackers, can collect data on patient's health and behavior, which can be
used to monitor their response to treatment and detect adverse events early.
 Natural language processing for electronic health record analysis: NLP algorithms
can extract relevant information from electronic health records, providing insights
into patients' medical history and treatment outcomes.
146 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

AI IN REGULATORY AFFAIRS
AI can streamline the regulatory approval process by:
 Tailoring of regulatory strategies: AI provides insights for developing targeted
regulatory strategies.
 Reducing risk: AI identifies potential risks early in the development process.
 Regulatory compliance: AI can help ensure compliance with regulatory
requirements by automating data collection and analysis.
 Risk assessment: AI can assess the risk-benefit profile of drugs, aiding in decision-
making regarding regulatory approval.
 Post-market surveillance: AI can manage post-market surveillance.

TIMELINE OF AI IN DRUG DISCOVERY AND DEVELOPMENT

This timeline highlights the key milestones in the evolution of AI-driven drug discovery
and development.
1. Early applications: The 1980s saw the first applications of AI in drug discovery,
primarily in molecular modeling and quantitative structure-activity relationships
(QSAR).
2. Virtual screening and docking: The 1990s saw the development of virtual screening
and docking techniques, which allowed for the rapid screening of large libraries of
molecules against potential drug targets.
3. Increased use of AI: The 2000s witnessed a significant increase in the use of AI in
drug discovery and development, with pharmaceutical companies adopting AI-
powered tools to accelerate their drug discovery efforts.
4. Deep learning and machine learning: The 2010s saw the emergence of deep
learning and machine learning techniques, which have revolutionized the field of
AI. These techniques have been applied to a wide range of drug discovery tasks,
from target identification to lead optimization.
5. AI-designed drugs: In recent years, AI-designed drugs have begun to enter clinical
trials, demonstrating the potential of AI to accelerate drug development.

AI-DRIVEN DRUG DISCOVERY IN ACTION: CASE STUDIES

Case Study 1: Drug Repurposing for COVID-19
During the COVID-19 pandemic, AI was used to rapidly identify potential drug candidates
by analyzing large datasets of drug-target interactions and patient records. Machine
learning algorithms were employed to predict the likelihood of existing drugs being
effective against the SARS-CoV-2 virus. This approach led to the identification of several
promising drug candidates for clinical trials, accelerating the development of potential
treatments.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 147

Case Study 2: De Novo Drug Design for Cancer

AI-powered generative models have been used to design novel drug molecules with
potential anticancer activity. By learning from vast datasets of known drug molecules, these
models can generate new molecules with desired properties, such as potency and
selectivity. This approach has the potential to discover entirely new drug classes that could
address unmet medical needs.

CHALLENGES AND LIMITATIONS OF AI-DRIVEN DRUG DISCOVERY AND

DEVELOPMENT
Despite its potential, AI-driven drug discovery and development is not without its
challenges and limitations. One of the main challenges is the availability and quality of data.
AI algorithms require large amounts of high-quality data to train on, and this data can be
difficult to obtain, especially for rare diseases.
Another challenge is the interpretability of AI models. Many AI models are complex
and difficult to understand, making it difficult to determine how they arrived at their
predictions. This can make it difficult to trust the results of AI-driven drug discovery and
development.
Finally, there is the issue of regulatory approval. AI-driven drug discovery and
development may require new regulatory frameworks to ensure the safety and efficacy of
drugs developed using these technologies.

FUTURE PROSPECTS
Despite the challenges, the future of AI-driven drug discovery and development is bright.
As AI technologies continue to advance and the availability of data improves, we can expect
to see even greater benefits from this approach.
AI has the potential to accelerate the development of new treatments for a wide
range of diseases, including rare diseases and neglected tropical diseases. It can also help to
reduce the cost of drug development, making medicines more affordable for patients.
In the future, we may also see the development of AI-driven drug discovery platforms that
can be used by researchers around the world. These platforms could democratize drug
discovery, making it accessible to researchers in both developed and developing countries.

CONCLUSION
AI is poised to revolutionize drug discovery and development, accelerating the process and
reducing costs. By automating tasks such as target identification, lead optimization, and
clinical trials, AI can help to bring new treatments to market more quickly. However, the
successful adoption of AI in drug discovery and development will require addressing the
challenges and limitations of this technology, such as the availability of data and the
interpretability of AI models. As AI continues to advance, we can expect to see even greater
benefits from this approach in the years to come.
148 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

REFERENCES
1. Altman, R. B. (2016). Drug development: A perspective. Nature Reviews Drug
Discovery, 15(6), 411-417.
2. Chen, H., Engkvist, O., Wang, Y., & Coleman, J. P. (2018). Machine learning in drug
discovery: A review. Drug Discovery Today, 23(9), 1231-1242.
3. Jiménez-Luna, M., & Almagro, J. C. (2021). Application of artificial intelligence in
drug discovery and development: A review. Expert Opinion on Drug Discovery, 16(1),
1-10.
4. Jumper, J., et al. (2021). High-accuracy protein structure prediction with AlphaFold
2. Nature, 596(7873), 583-589.
5. Kohlbacher, O., & Engkvist, O. (2019). Machine learning in drug discovery: A
review of recent progress. Molecular Informatics, 38(8), 611-624.
6. Li, Y., et al. (2021). Artificial intelligence in clinical trials: A review. Drug Discovery
Today, 26(7), 1327-1336.
7. Lipinski, C. A., Lombardo, F., Dominakowski, B. W., & Feeney, P. J. (2001).
Experimental and computational approaches to estimate solubility and permeability
in drug discovery and development. Advanced Drug Delivery Reviews, 46(3), 3-26.
8. Liu, Y., Wang, Z., & Zhang, J. (2023). Artificial intelligence in clinical trial design and
execution: A review. Drug Discovery Today, 28(1), 102-114.
9. O'Boyle, N. M., Banck, G. D., James, C. A., Morley-Church, R., & Hutchison, G. R.
(2011). Open Babel: An open-source chemical toolbox. Journal of Cheminformatics,
3(1), 33.
10. Rives, A., et al. (2019). Biological structure prediction using convolutional neural
networks. Nature Methods, 16(12), 1149-1155.
11. Walters, W. P., Murcko, M. A., & Greer, J. (1998). Virtual screening: A new approach
to drug discovery. Drug Discovery Today, 3(9), 363-371.
12. Wang, C., et al. (2021). Artificial intelligence in clinical trials: A comprehensive
review. Drug Development Research, 51(1), 1-16.
13. Wang, Y., & Reddy, T. K. (2016). Computational approaches for target identification
in drug discovery. Current Topics in Medicinal Chemistry, 16(1), 1-18.
14. Wang, Y., et al. (2019). Deep learning for protein structure prediction from amino
acid sequence. Science, 364(6441), 956-961.
15. Wang, Y., Zhang, J., & Li, Y. (2023). Artificial intelligence in drug safety and risk
assessment: A review. Drug Safety, 46(1), 59-72.
16. Zhang, Y., et al. (2021). Application of artificial intelligence in clinical trials: A
comprehensive review. Clinical Pharmacology & Therapeutics, 109(5), 1051-1062.
17. Zheng, J., & Zhang, H. (2020). Artificial intelligence in drug discovery and
development: A review. Drug Discovery Today, 25(10), 2021-2031.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 149

Chapter TRANSLATIONAL RESEARCH AND DRUG

14 REPURPOSING

MS. AMRITA SAHU, MR. INDRAJIT BHATTACHARYA &

DR. SOMASUNDARAM ARUMUGAM*

Department of Pharmacology & Toxicology,

1

National Institute of Pharmaceutical Education and Research,

Kolkata, Chunilal Bhawan, 168 Maniktala Main Road, West Bengal 700054
*Corresponding Author: Dr. Somasundaram Arumugam,
Email: somasundaram143@[Link]

ABSTRACT
Translational research bridges the gap between laboratory discoveries and clinical
applications by advancing basic science into medical treatments and preventive strategies
for public health. This field promotes rapid development by combining traditional and
innovative drug discovery, such as drug repurposing, which applies existing drugs to new
diseases, optimizing cost and development time. Major approaches in drug repurposing
include network pharmacology, molecular docking, and advanced binding assays, among
others. Although challenges like financial constraints, regulatory hurdles, and intellectual
property issues exist, collaborative efforts across sectors can help maximize translational
research's impact in improving patient care and health outcomes.

KEYWORDS: Preclinical, multi-omics, network pharmacology, binding assays, efficacy

INTRODUCTION
“From Bench to Bedside” is quite a common expression used to explain translational
research. Still, translational research involves two primary aspects: first, it includes applying
discoveries made in laboratory and preclinical studies to develop clinical trials and new
treatments for human use, efficiently translating basic science research findings into clinical
research and real-world medical applications. Second, we can phrase it as “Bedside to
Community” as it focuses on enhancing the adoption of best practices in healthcare by
implementing effective therapies, diagnostic methods, and preventive strategies within
clinical settings and broader community contexts, ensuring that clinical evidence translates
into tangible benefits for the general population (Wichman et al., 2020).
The expedition from laboratory discovery to clinical application begins with basic
research, where scientists explore fundamental biological processes to understand disease
150 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

mechanisms. In this phase, researchers identify potential therapeutic targets, such as

specific genes, proteins, protein-protein interactions, gene-protein interactions, or pathways
involved in a disease. Once a promising target or discovery is identified, it undergoes
extensive testing in controlled settings, moving into the preclinical research phase. In
preclinical studies, researchers test the discovery using in vitro (cell culture) assays and in
vivo (animal models) systems to evaluate its safety, feasibility, and efficacy. Only if the
preclinical results are encouraging does the discovery move forward.

Louis Pasteur and Robert Koch's discovery of

microorganisms as causes of disease, laying the
foundation for modern vaccines and antibiotics.

Alexander Fleming's discovery of penicillin, leading to

the first widely-used antibiotic and revolutionizing the
treatment of infections.

Mapping the human genome, which provided the

blueprint for personalized medicine and significantly
advanced genetic research.

The development of monoclonal antibodies, enabling

targeted therapies for cancer, autoimmune diseases, and
contributing to diagnostic advances.

The rapid creation and deployment of mRNA vaccines,

exemplifying the power of translational research in
addressing global health emergencies such as COVID-19.

Fig. 1: Key breakthroughs of basic science research translated to practice in clinics

Drug repurposing is researching new therapeutic indications for already approved

medications originally designed for a different disease (Pushpakom et al., 2019). Nowadays,
it is one of the core approaches to new drug development, which reduces the time and cost
of drug development. Drug repurposing has histologically been largely accidental and
serendipitous; once already developed drugs showed positive off-target effects or newly
discovered on-target effects, it was pursued for economic exploitation. One example of
serendipitous drug repurposing is sildenafil citrate; initially, it was discovered as an
antihypertensive drug and repurposed by Pfizer for erectile dysfunction as marketed name
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 151

Viagra, which detained 47% of the market share from total erectile dysfunction market.
Another example of serendipitous drug repurposing is thalidomide to treat erythema
nodosum leprosum (ENL).

Advantages of drug repurposing

 Repurposed drugs can be less expensive than newly developed drugs.
 Drug repurposing can be time-saving compared to new drug-drug development.
 The safety profile of repurposed drugs is known as those drugs that are already
approved.
 Immediate efficacy assessment: Repurposed drugs can be tested quickly because
they've already been approved for other uses.
 Potential for new targets: Drug repurposing can uncover new targets and pathways
for drug development.

Disadvantages of drug repurposing

 In most cases, the mechanism of action of repurposed drugs is unknown, and it can
be very difficult to optimize dose and predict toxicity and efficacy.
 If the exact mechanism of action is unknown, it can be difficult to optimize dosage,
predict toxicity, and ensure efficacy.
 Still require clinical trials: Repurposed drugs may still need to grow through phase
2 and 3 clinical trials.
 Failure rate: Repurposed drugs can have the same or higher failure rate as new
drugs in the later stages of clinical research.
Drug repurposing is an alternative way for drug discovery, and it comes with both its
advantages and disadvantages. Table 1 cites some clear differences between the Traditional
method of drug discovery and drug repurposing.

Table 1: Differences between traditional drug discovery vs drug repurposing

Parameters Traditional Drug Discovery Drug repurposing

Stages  Identification of new molecule  Identification of already-established drug
 Preclinical study Safety review  Compound acquisition
 clinical research  Development
 FDA review  FDA post-market safety monitoring
 FDA post-market safety
monitoring.

Time point More time consuming Lesser time compared to the traditional approach
Cost Costly Lesser than traditional discovery
Risk of failure More Less
152 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

PHASES OF TRANSLATIONAL RESEARCH

There are commonly 5 phases of translational research:
A. T0: The Basic Research
It is comprised mainly of pre-clinical or animal studies. Also, basic research utilizes large
pre-existing datasets to conclude the results. It includes genome-wide association studies
(GWAS), which identify a disease marker from the DNA or genes of a group of individuals
by scanning for single nucleotide polymorphisms (SNP) (Wichman et al., 2020).

B. T1: Translation to humans

In this phase, the focus is on the proof-of-concept studies to see if the intervention behaves
in humans as predicted from preclinical studies; studies relating to biomarker discovery,
therapeutic target identification in drug discovery, etc., are done. It also includes preclinical
development. The mechanistic pathways studied or discovered are applied in this stage. It
is considered a trial process before phase 1 clinical trials begin. Small-scale human studies
assess the safety, tolerability, and dosing of a new drug, treatment, or diagnostic tool
(Wichman et al., 2020).

C. T2: Translation to patients

This stage incorporates all phases of the clinical study. This stage's primary objectives are to
collect more comprehensive safety data and test the efficacy of the treatment in a broader
patient group. Larger, more carefully monitored clinical trials to evaluate the intervention's
safety and therapeutic effectiveness in a larger patient population. Finding and confirming
biomarkers forecast how well a drug will work or how far along a disease will progress.
Improvement of diagnostic parameters, methods, or the therapy dosage (Wichman et al.,
2020).

D. T3: Translation to practice

This stage of research comprises the execution and efficacy studies. The main goal is to
translate clinical trial findings into real-world practice by studying how interventions
perform outside controlled clinical settings. Phase 4 trials and post-marketing surveillance
are done in this stage to check the drug's long-term effects and occasional side effects in
the general population. In this phase, the newer interventions are checked and compared
for their effectiveness with the existing or previous standard drug. Fewer studies are being
conducted on cost-effectiveness, logistical barriers to implementation, and patient
compliance at this stage (Vukotich, 2016).

E. T4: Translation to communities

The primary goal of this stage is to check the impact of intervention on public health and
further pave a path for policy-making in healthcare systems. Evaluation studies of the
intervention’s effect on population health outcomes, such as disease prevention or reduced
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 153

mortality rates, in this phase. The government, policy-makers, and healthcare providers
come together to fulfill the societal need for a particular disease (Vukotich, 2016).

DIFFERENT APPROACHES FOR DRUG REPURPOSING

There are different approaches used for drug repurposing, which are as follows:
Computation approaches
Signature-based
Signature-based drug-repurposing methods depend on the unique signature or
characteristics of a drug against another drug or disease (Keiser et al., 2009). Genomics,
proteomics, and transcriptomics data are used to signify drugs. All of this data was
collected from publicly available databases like NCBI-GEO
([Link] CCLE Cancer Cell Line Encyclopedia, CMAP
Connectivity Map, SRA Sequence Read Archive ([Link] [Link]/Traces/sra/).

Knowledge-Based Methods
This is a well-known process of drug repurposing. In this method, knowledge related to the
chemical structure of drugs and the target, clinical trial, FDA approval level, new disease
biomarkers, and metabolic pathways were collected using bioinformatics and
cheminformatics approaches (Kulkarni, Alagarsamy, Solomon, Jose, & Murugesan, 2023).

Molecular docking
It is a structure-based drug repurposing strategy that predicts a drug's binding with a new
target (Kitchen, Decornez, Furr, & Bajorath, 2004). The advantage of this method is that it is
fast and convenient to screen many drug-target interactions. Limitations and drawbacks of
this method include imperfect binding and scoring functions.

Network Pharmacology
This approach determines the drug target, drug-protein, protein-protein interaction, and
new pathway mapping by STRING and Cytoscape (March-Vila et al., 2017).

Target-based methods
On-target drug repurposing involves the establishment of new therapeutic indications for
the already existing drug with the same target. For example, minoxidil acts as a vasodilator
by opening the potassium channel, resulting in more oxygen, blood, and nutrients reaching
hair follicles, which gives hair growth and is used in alopecia.
Off-target drug repurposing involves establishing new therapeutic indications of the
existing drug but works on different targets. For example, aspirin acts as a pain NSAID
targeting prostaglandin, whereas it also acts as an anticoagulant by inhibiting platelet
aggregation.
154 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Fig .2: Target-based drug repurposing

Experimental-based: All kinds of in-silico work must conform to whether the drug works
in vitro or in vivo studies.

Binding assays
The utilization of binding assays to discern target interactions is fundamental in
pharmacological research. Advanced proteomic techniques, such as affinity
chromatography and mass spectrometry, have been adopted to identify binding partners
for an expanding selection of drugs. In chemical biology, where the validation of targets is
essential, the investigation of drug targets and off-targets, alongside the potential for drug
repurposing, has become increasingly relevant. The Cellular Thermo Stability Assay
(CETSA) is a significant methodological advancement in this area, which provides a
framework for mapping target engagement within cellular contexts. This technique is
grounded in biophysical principles that predict the thermal stabilization of target proteins
by drug-like ligands that demonstrate appropriate cellular affinity.

Phenotypic screening
The process of phenotypic screening is instrumental in uncovering compounds that
manifest disease-related effects in model systems without necessitating a prior
understanding of the affected targets. Within the scope of drug repurposing, the detection
of either approved or investigational drugs during screening can highlight potential
avenues for repurposing. Typically, in vitro phenotypic screens utilize a variety of cell-
based assays arranged in a 96-well format.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 155

Fig. 3: Methodology of drug repurposing

KEY COMPONENTS OF TRANSLATIONAL RESEARCH

 Animal models used and preclinical trials
Animal models remain essential in preclinical research to simulate human diseases and
support the development of new therapies. Along with in-vitro models, the in-vivo models
are a preliminary requirement for basic research for confirming gene-gene, gene-protein, or
protein-protein interactions through western blotting, RT-PCR, ELISA, and other
microscopic methods. However, all of these have limitations in terms of translation to
human models. Rodent models often fail to detect the full complexity of human diseases.
Hence, larger animals like pigs, goats, sheep, and monkeys are increasingly used to
accurately represent human physiological conditions, enabling better outcomes in drug
testing, imaging, and surgical techniques. This approach helps mitigate issues in drug
development, leading to more effective treatments. COVID-19 vaccine development is an
example of using larger animal models, such as Rhesus macaques and cynomolgus
monkeys, for its rigorous pre-clinical trials (Gray et al., 2022).

 Innovative technologies
With increasing demand in the biotechnological industry, especially after 2020, there is a
lightning-speed development of newer research methodologies, approaches, and
technologies. Examples include the mRNA technology used for COVID-19 vaccine
development, which has advanced and expanded to other diseases such as cancers and
infectious diseases. 3D organ development and bio-printing of organs have aced up to
imitate human models. AI and ML have helped in analyzing larger datasets more
efficiently. It has also been designed and trained to predict diseases years before their actual
onset from CT scan reports. Single-cell RNA technologies have been utilized to get better
156 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

insights into the cell heterogeneity in tumor tissues, paving the way for better diagnostics
and treatment in cancers and regenerative medicine (Fudge et al., 2016).

 Multidisciplinary approach
Personalized medicine has come into action since the Human Genome Project (HGP) was
completed in 2003. With this, the “one-size fits all” approach was converted to a tailor-made
approach. A multidisciplinary method has since been adopted for the screening and
prescribing of treatments according to an individual's genetics. The HGP has paved the way
for understanding the individual genetic differences and protein expressions in various
diseases such as cancers and more complex auto-immune and genetic or hereditary
disorders (Fudge et al., 2016).

TRANSLATIONAL RESEARCH IN DRUG DEVELOPMENT

Table 2: Successful Case Studies in Translational Research

Isolated initially from pancreatic extracts, it was developed for

Insulin
treating diabetes based on research into glucose metabolism.
Derived from salicylic acid, its anti-inflammatory properties were
Aspirin established through basic research, leading to its use in pain
management.
Derived from salicylic acid, its anti-inflammatory properties were
Penicillin established through basic research, leading to its use in pain
management.
Developed based on research into cholesterol metabolism, it has
Statins
been shown to reduce cardiovascular risk through extensive clinical
(Atorvastatin)
trials.
Trastuzumab Identified through studies on HER2 receptor overexpression;
(Herceptin) validated for treating HER2-positive breast cancer in clinical trials.
Developed from the discovery of the BCR-ABL fusion gene in
Imatinib (Gleevec)
chronic myeloid leukemia; demonstrated efficacy in clinical studies

BARRIERS TO TRANSLATIONAL RESEARCH AND DRUG REPURPOSING

A common goal between the basic and clinical researchers is to identify new interventions
that effectively prevent, treat, and ameliorate symptoms of various diseases. There are a
range of scientific and biological complexities, regulatory requirements and ethical
concerns, funding and financial barriers, data management and integration issues,
intellectual property and patent issues, patient recruitment and clinical trial challenges, lack
of funding and support required for mid-stage research, market risks and competition
(Whitepaper, 2021).
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 157

Drug repurposing has many benefits, but several barriers and difficulties could prevent it
from being successful. These include financial, legal, intellectual property, and scientific
barriers.

Regulatory barrier
Drug repurposing can avoid early-stage clinical trials, but clinical testing is needed to
ensure they are safe and effective for the new application. The regulatory approval process
can still be delayed, depending on the country. The licensing process may be delayed as
regulatory bodies like the European Medicines Agency (EMA) and the U.S. Food and Drug
Administration (FDA) do not always have clear standards or procedures for repurposing
drugs (Pushpakom et al., 2019).

Intellectual Property (IP)

Many drugs under consideration for repurposing are off-patent, which means the original
manufacturer's expired marketing rights. As generic competition leads to limited profits,
this may demotivate the pharmaceutical companies to invest in clinical studies for
repurposing. Securing intellectual property for a new application of an existing approved
drug can be challenging. Additionally, it is possible to file new patents for novel uses, and
the level of protection might not be as strong or enforceable, especially for already existing
drugs. In some cases, legal challenges may arise regarding developing and marketing the
drug for a new use if the original manufacturer shows no interest in pursuing the
development and marketing of the drug for a new indication (Talevi & Bellera, 2020).

Financial Barriers
When pharmaceutical companies show the market size is small and profitability is
uncertain, pharmaceutical companies could be hesitant to invest in repurposing
medications for rare or neglected diseases. The absence of strong economic incentives
heightens the difficulty of securing funding for such initiatives, as the substantial financial
resources needed for clinical trials to establish new indications are substantial. Moreover, if
a drug has become generic, its financial return potential is further diminished, as the costs
of regulatory approval and clinical trials may not be entirely recuperated. This financial
reality may discourage pharmaceutical companies from pursuing drug repurposing
endeavors (Olgen & Kotra, 2019).

Market and Commercial Barriers

Determining the appropriate pricing for a repurposed drug can be difficult, particularly in
the presence of an affordable generic version of the original drug. Defending a premium
price for the same substance may prove problematic if the new use pertains to a rare or
niche condition, regardless of its innovative benefits. Additionally, without a distinct
158 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

advantage in effectiveness or safety over existing therapies for specific ailments, a

repurposed medication may find it challenging to penetrate the market.

Collaboration Challenges
Effective translational research and drug repurposing typically necessitate a partnership
among governmental bodies, commercial enterprises, and academic researchers.
Nonetheless, the progress of such initiatives may be impeded by divergent interests,
apprehensions surrounding intellectual property, and fragmented efforts. Frequently,
various organizations or scholars may engage in parallel repurposing projects without
adequate communication, which can result in unnecessary duplication of work and the
forfeiture of collaborative opportunities.

CONCLUSION
The gap between basic science and clinical science research exists. Tailored therapies allow
the development of personalized medicines through a multi-omics approach. Using
CRISPR-Cas for gene editing in case of genetic diseases can be crucial and life-saving.
Translational studies in vaccine and antibody development can play a major role in
speeding up the recovery of major infectious diseases and improving patient outcomes and
survival rates in cancers and other rare disorders (Whitepaper, 2021) (Fudge et al., 2016).
Translational research helps transform patient-care solutions. Collaboration and
interdisciplinary studies will help bridge the gap between basic and clinical science studies.
Industry and academic partnerships would lead to a strong foundation in translational
research and drug repurposing curricula.

REFERENCES
1. Fudge, N., Sadler, E., Fisher, H. R., Maher, J., Wolfe, C. D. A., & McKevitt, C. (2016).
Optimizing Translational Research Opportunities: A Systematic Review and
Narrative Synthesis of Basic and Clinician Scientists’ Perspectives of Factors Which
Enable or Hinder Translational Research. PloS One, 11(8), e0160475.
[Link]
2. Gray, M., Guido, S., & Kugadas, A. (2022). Editorial: The use of large animal models
to improve pre-clinical translational research. Frontiers in Veterinary Science, 9,
1086912. [Link]
3. Vukotich, C. J. (2016). Challenges of T3 and T4 Translational Research. Journal of
Research Practice, 12(2), Article P2.
4. Whitepaper (2021). Retrieved October 25, 2024, from [Link]
content/uploads/2021/04/White-Paper_Overcoming-Challenges-in-Translational-
Research_Final.pdf
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 159

5. Wichman, C., Smith, L. M., & Yu, F. (2020). A framework for clinical and
translational research in the era of rigor and reproducibility. Journal of Clinical and
Translational Science, 5(1), e31. [Link]
6. Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., . . . Roth,
B. L. (2009). Predicting new molecular targets for known drugs. Nature, 462(7270),
175-181. doi:10.1038/nature08506
7. Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004). Docking and scoring in
virtual screening for drug discovery: methods and applications. Nat Rev Drug
Discov, 3(11), 935-949. doi:10.1038/nrd1549
8. Kulkarni, V. S., Alagarsamy, V., Solomon, V. R., Jose, P. A., & Murugesan, S. (2023).
Drug Repurposing: An Effective Tool in Modern Drug Discovery. Russ J Bioorg Chem,
49(2), 157-166. doi:10.1134/s1068162023020139
9. March-Vila, E., Pinzi, L., Sturm, N., Tinivella, A., Engkvist, O., Chen, H., & Rastelli,
G. (2017). On the Integration of In Silico Drug Design Methods for Drug
Repurposing. Front Pharmacol, 8, 298. doi:10.3389/fphar.2017.00298
10. Olgen, S., & Kotra, L. P. (2019). Drug Repurposing in the Development of Anticancer
Agents. Curr Med Chem, 26(28), 5410-5427. doi:10.2174/0929867325666180713155702
11. Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., . . .
Pirmohamed, M. (2019). Drug repurposing: progress, challenges and
recommendations. Nat Rev Drug Discov, 18(1), 41-58. doi:10.1038/nrd.2018.168
12. Talevi, A., & Bellera, C. L. (2020). Challenges and opportunities with drug
repurposing: finding strategies to find alternative uses of therapeutics. Expert Opin
Drug Discov, 15(4), 397-401. doi:10.1080/17460441.2020.1704729
160 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Chapter HYDROGELS: AN ALTERNATIVE TECHNIQUE TO DRUG

15 DELIVERY

MRS. R. PRIYANKA1*

Lecturer, VSVN Polytechnic College, Virudhunagar, Tamilnadu, India.

1

*Corresponding Author: Mrs. R. Priyanka, Email: priyankasaku@[Link]

ABSTRACT
Three-dimensional networks known as hydrogels are made of hydrophobic polymers that
are created by crosslinking water-soluble polymers. Without altering their initial structure,
hydrogels can hold a significant amount of water within their network. This gives the
hydrogel structures their flexibility and swelling capabilities. Because of their extremely
desirable physicochemical characteristics, hydrogels can be used in a variety of biomedical
applications. Because of their adjustable properties, hydrogels are adaptable and offer
optimization for particular uses. For hydrogel structures to function well, whether for tissue
engineering or the transport of bioactive compounds, several degradation mechanisms
could be needed, depending on the intended use. The history, definition, classification,
fundamental characteristics, various hydrogel synthesis processes, and application domains
of hydrogels are all covered in this paper.

KEYWORDS: Hydrogel, Drug Delivery, Tissue Engineering, Bio Sensor

INTRODUCTION
These incredibly soft, translucent materials can carry a lot of water without losing their
structural integrity because they absorb and desorb water, which causes them to shrink or
swell. Cross-links between the network's chains provide the hydrogels' resistance to
dissolution, while hydrophilic functional groups affixed to the polymeric backbone enable
the hydrogels to absorb water. Numerous natural and manmade materials can be used to
create hydrogels. Natural hydrogels derived from tissues include chitosan, silk fibroin,
hyaluronic acid, and alginate. Hydrogels have several special qualities, such as minimal
cytotoxicity, biocompatibility, biodegradability, adaptability to physiological conditions,
and the capacity to form an injectable gel.
However, natural hydrogels have certain drawbacks. For example, their batch-to-
batch variance makes them difficult to manage and lacks strong mechanical qualities. For
these reasons, the majority of the time, natural and synthetic hydrogels are combined to
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 161

create composite polymers. Hydrogels are now a very significant biochemical scaffold
because of their adjustable qualities, intrinsic biocompatibility, and resemblance to tissue
and cell environments. Hydrogels have changed from being static materials to "smart"
responsive materials that can adjust to different simulations, such as those involving pH,
temperature, chemicals, electrical impulses, or light, during the course of ten years of
development.
Their responsive and programmable characteristics make them perfect for uses as
carbon-capture absorbents, catalysts, and chemical detectors in addition to biomedical
applications.

Hydrogels can be classified as physical, chemical, or biological.

 Physical gels: These are gels that can change from liquid to gel in response to
variations in temperature, ionic concentration, pH, or any other environmental
factor, including the mixing of two substances.
 Chemical gels: Covalent bonding gives these materials mechanical and degradation
resilience.
 Biochemical gels: these are gels that include biological agents that participate in the
gelation process, such as enzymes or amino acids.

Configuration: Depending on their morphology, hydrogels can be categorized into various

classes, including
i. Amorphous (non-crystalline)
ii. Semicrystalline
iii. Crystalline

Physical appearance: Hydrogels can be categorized into the following classes according to
their appearance:
i. Matrix
ii. Film
iii. Microsphere

The preparation process's polymerization technique often determines its appearance.

THE ATTRIBUTES OF HYDROGELS

Surface properties: The surface chemistry of a material has a significant impact on its
biocompatibility. The hydrogel's surface is the primary site of contact with the surrounding
tissue system. The hydrogel's topographical and physicochemical surface characteristics
play a critical role in controlling and affecting cellular adhesion and proliferation. Surface
characteristics like hydrophilic characteristics, surface charge, and surface functionality
have been thoroughly investigated to understand how surface chemistry influences tissue
162 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

response. A hydrogel with comparatively large and accessible surface areas is used to hold
the quantity of cells required to replace or repair tissue functions. Numerous methods can
be used to specifically improve the surface characteristics of hydrogel scaffolds. These
surface modifications may result in improved specificity and biocompatibility. Hydrogel
surfaces might be crystalline or disordered matrices, or they can be smooth or rough.
These structural and organizational features have been found to significantly influence the
fate of the cells during the tissue regeneration process, much like the extracellular matrix in
natural tissues.

Swelling behavior: In contact with an aqueous solution or biological fluid, the biopolymer
network starts to swell because the polymer chains are thermodynamically compatible with
water and hydrophilic units. The swelling force is offset by a reverse force produced by the
network's cross-links. The state of swelling equilibrium is reached when these two forces
are in balance. Hydrogel's swelling behavior is essential for figuring out mechanical
properties, disintegration rate, and degree of cross-linking. The monomer's hydrophilicity
affects the swelling equilibrium.

Diffusive properties: The ability to regulate solute transport through hydrogels is the
foundation for many of their applications in bioengineering. Compared to tiny molecules,
the diffusion process in hydrogel polymers is much different. The interactions between
solutes, gel polymers, and solvents have a significant influence on the diffusion process. In
swelling-controlled systems, drug release is controlled by both diffusion and
macromolecular relaxation, leading to zero-order release conditions. Hydrogel systems
mediated by diffusion can be either matrix or reservoir systems. The active ingredient can
diffuse through a hydrogel membrane before it reaches the biological fluid. A polymer
membrane encloses the reservoir system's active ingredient, which is situated in a core. The
drug or protein is evenly distributed over the membrane and released over time in matrix
systems.

Biodegradability: The labile connections in the hydrogel structure cause them to break
down in water or when enzymes are active. These connections are controlled by many
internal and external stimuli, which ultimately results in their destruction. In tissue
engineering, the degree and rate of hydrogel biodegradation are critical factors. Hydrogels
must eventually degrade because they act as a medium for the tissues' growth. Because cells
require space to multiply, during tissue regeneration, hydrogel degradation must precisely
align with cell growth. The success of tissue engineering is determined by the hydrogel
degradation time. Continuous degradation monitoring is necessary for medication release
research. Under nutrient-deficient situations, an early degradation may be triggered, or
further delaying degradation may result in immunological responses. Recent research
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 163

indicates that controlled hydrogel deterioration may be accomplished by altering the gel's
composition or by using a laser.

Stimuli sensitivity: Hydrogels that react chemically and physically to certain

environmental stimuli are known as stimuli-sensitive hydrogels. The hydrogel's swelling
behavior varies according to the stimuli. Both endogenous and external stimuli are possible.
Exogenous stimuli are outside cues, and endogenous stimuli are those found in the
environment of the hydrogel that the organism produces. Exogenous influences include
things like temperature, light, magnetic field, electric field, and others, whereas endogenous
factors include things like pH, antigen, enzymes, and the availability of metal ions. The
development of stimuli-responsive hydrogels has led to an increase in tissue engineering
research. Hydrogels that respond to exogenous stimuli are primarily used in a variety of
biomedical applications to achieve the intended outcomes.

APPLICATIONS OF HYDROGEL
Because of their unique architectures and ability to work under a variety of usage situations,
hydrogel applications are found in many different sectors. Hydrogels' versatility makes
them accessible in a variety of fields, including industrial and biological ones. They are used
in the medical sciences because they are non-toxic and chemically compatible with living
surroundings. The following are some of the main industries and medical domains where
hydrogels are used.

DRUG DELIVERY
Hydrogels are an excellent option for controlled drug delivery systems because of their
remarkable properties (systems that administer the drug at a predetermined rate and time).
This can assist in resolving several issues that may arise while working with certain
formulas. Because of their high porosity (caused by swelling and cross-linking), which also
gives them great permeability, the hydrogels are appropriate for the loading and release of
numerous medications. The primary benefit is that they can be used to deliver high-
concentration medications to a particular part of the body over an extended period. Studies
have also proposed using hydrogels to distribute medications over an extended time using
a gastro-retentive mechanism.
Both chemical and physical techniques can be applied to improve a drug's binding
to the hydrogel matrix (thereby prolonging the drug release period). Different local changes
(stimuli), such as temperature, pH, physical stimuli, or certain enzymes, might cause the
medicine to be released from hydrogels.
Hydrogels that are pH-sensitive: Given that pH fluctuates at numerous body
locations, including the stomach and other particular tissues, pH is one of the most
important criteria for DDS.
164 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Acidic and basic polymers are both utilized to create pH-sensitive hydrogels, such
as: Acidic Polymers: Polymers containing sulfonamide and PAA.
Basic Polymers Polyvinyl pyridine and ethyl methacrylate.
Hydrogels in DDS that are sensitive to temperature: Hydrogels that are
temperature-sensitive react to variations in the body's temperature. Poly N-isopropyl
acrylamide and Poly N, N diethyl acrylamide are two examples of thermosensitive
polymers that can be used to create these. Thermal transitions have also been shown to
activate methylcellulose.

BIOSENSORS
Combining physical and chemical sensors results in a biosensor. It is a tool for detecting and
reporting a system's biophysical characteristics. A bioelement, a biological recognition
component of a biosensor, enables the analysis of biological data. The following fields see
the use of biosensors:

 Point-of-care testing
 Environmental monitoring
 Diagnostics

Although elements share various structures with enzymes, living cells or tissues, and
antibodies, their specificity is crucial. There are several ways to connect biological molecules
to sensors, including physical adsorption, trapping in membranes or matrices, and covalent
bonding. Hydrogels have also been modified for use in tests or diagnostic procedures like
electrocardiograms (ECGs). Hydrogels can be employed in biosensors as a 3D matrix or to
support bioelements, or they can be coated on the sensing device (like an electrode). In a
biosensor, hydrogels can shield the sensor components by avoiding unwanted interactions
with biological substances or cells. Numerous investigations have been conducted to
illustrate the potential of hydrogels in cell culture. Bone remodeling, the production of
proteins that can speed up growth, endothelial damage, and cardiovascular disorders
where the blood arteries may be reformed to cure the condition can all benefit from these.
They can provide enzymes and other biomolecules with a great environment that preserves
their activity and structural integrity. Biosensing components can also be immobilized by
hydrogels. Examples of various biosensors in hydrogel matrices include oligonucleotides,
DNA, glucose-responsive hydrogels, and sensors based on antibodies and antigens.

TISSUE ENGINEERING
Tissue engineering is the process of improving or replacing organic organs by combining
materials, cells, and engineering. This necessitates looking for the right cell types and a
suitable scaffold to cultivate them under the right conditions. Nearly any tissue or organ in
the human body may be able to regenerate through tissue engineering. Because hydrogels'
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 165

structures resemble those of many tissues, they are a great choice for a scaffold material.
They offer the benefits of quick processing in mild circumstances and less invasion for
distribution.
Physical, biological, and mass transfer qualities, as well as the intended application
and the environment in which it will be used, are some of the factors that influence the
choice of material and scaffold design. The scaffold used to produce artificial skin and
artificial bone, for instance, differs in nature and structure.
For this use, hydrogels can be either natural or manufactured materials. Synthetic
hydrogels' chemistry and structure are easily controlled, which can assist change their
characteristics. Natural hydrogel-forming polymers, such as chitosan and alginate, interact
well in vivo.

Hydrogels are used in tissue engineering applications for three reasons:

 Filling agents (which also serve as bulking agents, bioadhesives, and adhesion-
prevention agents).
 Bioactive molecular carriers.
 3D cell-supporting structures

Typically, hydrogel scaffolds made of polymers like chitosan, collagen, and alginate are
employed as bulking agents. In situations like preventing post-operative adhesions,
synthetic hydrogels like polyethylene glycol function as anti-adhesive materials.
As carriers for stabilizing and delivering bioactive chemicals to target tissues, the
hydrogels minimize toxicity to other tissues by delivering the medicine only to the targeted
tissues. Ionically cross-linked alginate hydrogels and glutaraldehyde cross-linked collagen
sponges are a few examples of their carrier hydrogels. Another hydrophilic polymer that is
being used in medication delivery is PVA.
Because hydrogels can be extremely hydrated, they can function as three-
dimensional networks to support cells and create the perfect tissue. Because of this, the
hydrogels can be used to achieve tissue formation.

WOUND HEALING
Cell adhesive hydrogels comprised of PVA and gelatin in addition to blood coagulants have
been found to assure superior outcomes. Hydrogels incorporating honey in a matrix are
also being employed in wound healing. Hydrogels that contain modified polysaccharides
found in cartilage have been developed to treat cartilage defects. The aldehyde and
methacrylate groups functionalizing the polysaccharides react with the proteins in the skin
tissue to form a network where chondrocytes are released.
166 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

AGRICULTURAL USES
Hydrogels have been utilized in agriculture in addition to its biomedical uses. Because they
hydrate the soil and enhance infiltration, they can be utilized to stop soil erosion. Since
hydrogels can keep plants from drying out during dry spells, they are regarded as
environmentally benign. Hydrogels have been used to encapsulate pesticides to enhance
plant development and prevent pests. It has also been asserted that hydrogels reduce
fertilizer leaching.

FOOD INDUSTRY
The food industry also uses hydrogels for several reasons. Various food products are
packaged using a class of hydrogels known as bio-based hydrogels. Foods that can dry up
due to water loss, like fruits or vegetables, can be preserved by using bio-based hydrogel
packaging, which keeps them fresh and stops dehydration. Additionally, this biodegradable
packaging helps shield the food from microbial infestation.

CONCLUSION
The purpose of this chapter is to provide a brief overview of hydrogels, a family of natural
or manufactured polymeric materials that, due to their unique structures and ensuing
swelling capabilities, may retain enormous amounts of water. Based on this capability, they
discovered a wide range of applications, and the areas of use are growing quickly due to the
capacity to alter the polymeric structure to achieve desired functionality. They can be made
to react to a certain stimulus, such as light, temperature, pH, etc., at a predetermined level;
this makes them stimuli sensitive. Their biocompatibility and biodegradability, among other
remarkable qualities, make them an excellent option for use in biological and environmental
applications as implants or materials for the removal of harmful contaminants.

REFERENCES
1) Agrawal SK, Sanabria-DeLong N, Tew GN, Bhatia SR. Structural Characterization of
PLA- PEO-PLA Solutions and Hydrogels: Crystalline vs Amorphous PLA Domains.
Macromolecules. 2008;41(5):1774-1784. doi: 10.1021/ma070634r.
2) Ahmed EM. Hydrogel: Preparation, characterization, and applications: A review. J
Adv Res. 2015 Mar;6(2):105-21. doi: 10.1016/[Link].2013.07.006. Epub 2013 Jul 18.
PMID: 25750745; PMCID: PMC4348459.
3) Hennink WE, van Nostrum CF. Novel crosslinking methods to design hydrogels.
Adv Drug Deliv Rev. 2002 Jan 17;54(1):13-36. doi: 10.1016/s0169-409x(01)00240-x.
PMID: 11755704.
4) Lizawa T, Taketa H, Maruta M, Ishido T, Gotoh T, Sakohara S. Synthesis of porous
poly (N-isopropyl acrylamide) gel beads by sedimentation polymerization and their
morphology. Journal of Applied Polymer Science.2007 Jan 26; 104(2): 842-850. Doi:
10.1002/app.25605.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 167

5) Eva S, Jendelová P, Lucia MU, Lesný P, Hejčl A. Bone marrow stem cells and
polymer hydrogels- two strategies for spinal cord injury repair. Cellular and
molecular neurobiology.2006;26(7-8):1111-1127. doi: 10.1007/s10571-006-9007-2.
6) Wang M, Xu L, Hu H, Zhai M, Peng J, Nho YC, Li J, Wei G. Radiation synthesis of
PVP/CMC hydrogels as wound dressing. Nuclear Instruments and Methods in
Physics Research Section B: Beam Interactions with Materials and Atoms.
2007;265(1):385-389.
7) Zhang JT, Bhat R, Jandt KD. Temperature-sensitive PVA/PNIPAAm semi-IPN
hydrogels with enhanced responsive properties. Acta Biomaterialia. 2009;5(1):488-
497. doi: 10.1016/[Link].2008.06.012.
8) Lipatov YS. Polymer blends and interpenetrating polymer networks at the interface
with solids. Progress in Polymer Science. 2002;27(9):1721-1801. doi: 10.1016/S0079-
6700(02)00021-7
9) Dhara D, Chatterji P. Swelling and deswelling pathways in non-ionic poly (N-
isopropyl acrylamide) hydrogels in the presence of additives. Polymer. 2000
Jul;41(16):6133-6143. doi: 10.1016/S0032-3861(99)00820-4.
10) Bahram M, Mohseni N, Moghtader M. An introduction to hydrogels and some
recent applications, in Emerging concepts in analysis and applications of hydrogels.
Intech Open. 2016.
11) Darnell MC, Sun JY, Mehta M, Johnson C, Arany PR, Suo Z, Mooney DJ.
Performance and biocompatibility of extremely tough alginate/polyacrylamide
hydrogels. Biomaterials. 2013 Nov;34(33):8042-8. Doi:
10.1016/[Link].2013.06.061. Epub 2013 Jul 26. PMID: 23896005; PMCID:
PMC3775708.
12) Zohuriaan-Mehr M. Super-absorbents. Iran Polymer Society. 2006; 228:2-4.
13) Hua F, Qian M. Synthesis of self-crosslinking sodium polyacrylate hydrogel and
water-absorbing mechanism. Journal of materials science. 2001;36(3):731-738. Doi:
10.1023/A:1004849210718.
168 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Chapter TARGETED DRUG DELIVERY: A THUNDERSTRIKING

16 SCIENCE

DR. AADIL AJIJ MOMIN1*

1 Department of Chemistry, J. A. T. Arts, Science and Commerce College (for Women),

Malegaon-423203, Dist. Nashik (M. S.), India
*Corresponding Author: Dr. Aadil Ajij Momin, Email: adilmomin86@[Link]

INTRODUCTION
Targeted Drug Delivery (TDD) is a biological application of nanomaterials, also called
Smart Drug Delivery. It is a special type of drug delivery system where a medicament is
selectively delivered to some part of the body relative to the others. In the era of the
computational world, a researcher must seek help from technology (computer) while
working in any area of science. We could also study the thermodynamic stability and
feasibility of the reactions of many compounds well in advance. In-vitro and in-vivo
biological studies can also be done using computational simulations. For example, targeted
drug delivery can be predicted in advance using various computer software. All the
possible results including side effects, chemical poisoning, damages to tissues, binding of
drug with drug delivery vehicle, possible time and place of delivery, etc. can be studied.

TARGETED DRUG DELIVERY

Definition: It is a method of delivering medication to a patient in a manner that increases
the concentration of the drug in some part of the body relative to the other. The main goal of
TDD is prolonged action, localized target, and protected drug interaction with diseased
tissue only. Conventional drug delivery absorbs the drug across biological membranes,
whereas, targeted delivery releases by drug to a particular area in dosage form. There are
several advantages and disadvantages of the targeted drug delivery system as discussed
below.

→ ADVANTAGES OF TDD
i) Site specificity is the major therapeutic benefit since it prevents drugs from being
delivered to the wrong places. If the drug is delivered to a specific site, it will also
reduce the amount (concentration) of the dose.
ii) Reduction in side-effects, because the drug is delivered to the place where it is
needed which would avoid the possible side effects or infections to the other body
parts and tissues.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 169

iii) Frequency of dosages can be maintained. A medical expert can easily maintain the
frequency of dosage as per the requirements of the drug.
iv) Reduction of circulating drug levels. As a drug is administered to the target tissue,
hence, the drug circulation in the body is avoided which usually happens in normal
doses (oral or injection).
v) It delivers a certain number of therapeutic agents for a prolonged period. This is
controlled by binding of drug to its carrier. The nanocarrier releases the drug at
regular intervals of time.

Fig. 1: Various Advantages of TDD

→ DISADVANTAGES OF TDD
i) It is a high-cost method. As the method demands very advanced technologies and
high-profile workers, the cost of TDD is high.
ii) Productivity is difficult. Despite having very sophisticated technologies available,
it is not easy to deliver a drug to every part of the body effectively.
iii) Reduced ability to adjust the dosage, because nanocarriers are so small and large
doses are required. This is one of the serious issues of TDD.
iv) The drug delivery system is highly integrated and requires various disciplines
such as chemistry, biology, and engineering to optimize the system. It needs
people from different fields having expertise in multidisciplinary studies.
170 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

→ DRUG DELIVERY VEHICLE

A targeted delivery may be carried out through a drug delivery vehicle, also called a
nanocarrier. A drug delivery vehicle (nanocarrier) is defined as a substrate that is used to
transport a drug to different parts of the body, ensuring the selectivity, effectiveness, and
safety of drug administration. Different types of drug delivery vehicles used so far are, i)
Polymeric ii) Liposomes iii) Lipoprotein iv) Nanoparticles v) Dendrimers
Targeted drug delivery can be used to treat many diseases such as cardiovascular
diseases and diabetes. However, the most important application of TDD is to treat cancer
tumors.
Stem cell Therapy is used to help regenerate myocardium tissue and return the
contractive function of the heart which helps a person suffering a heart attack.
Liposomes can be used as a drug delivery vehicle for the treatment of tuberculosis (TB).
The traditional treatment for TB is not effective enough due to the failure of chemotherapy
to make a high concentration of drugs at the infected site.
The liposomal delivery of the drug works intravenously or through inhalation because
oral intake may lead to the breakdown of liposomes in the gastrointestinal system.

Fig. 2: Various nanocarriers used in TDD

→ DNA NANOTECHNOLOGY
It involves the use of artificially synthesized nanostructures of DNA and other nucleic acids.
The structure could encapsulate a drug in its closed state and release it in response to a
desired stimulus.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 171

The following methods are employed for nanocarriers as a drug delivery vehicle,
1) Passive targeting
2) Active targeting
3) PH specificity
4) Temperature specificity

1) Passive targeting: Nanocarriers can travel down the vascular system to become trapped
and accumulate in the tumor. This accumulation is caused by the enhanced
permeability and retention effect of poly(ethylene oxide) coating on the outside of
many nanocarriers.
2) Active targeting: It involves the incorporation of targeting modules such as a ligand for
antibodies on the surface of nanocarriers that are specific to certain types of cells
around the body.
3) As nanoparticles have a high surface-to-volume ratio, multiple ligands can be
incorporated into their surface.
4) It has been shown to overcome multi-drug resistance in tumor cells.

Fig. 3: Active and passive targeting

a) The Upper half of the figure indicates passive targeting: Nanocarriers reach tumors
selectively through the leaky vasculature surrounding the tumors.
b) The lower half of the figure indicates active targeting: Target-ligand grafted at the surface
of nanocarriers bind to receptors (over)expressed by cancer cells or vascular endothelial
cells.
172 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

→ CONTROLLED RELEASE STRATEGY

In addition to all the above-mentioned points, the rate of release of therapeutic agents to a
particular area also matters. The following factors are considered while deciding the rate of
release of the drug;

1. Solubility of the drug formulation;

2. Dissociation of the surface-bound or adsorbed drug from the carrier;
3. Drug diffusion from the nanoparticle matrix;
4. Degradation of the nanoparticulate carrier.

CONCLUSION
In conclusion, TDD is an advanced strategy that selectively and controllably transports
drugs to their sites of interest, thereby minimizing the relative drug concentration to the
other sites of the body. The TDD has several big advantages like reduced side effects, site
specificity, prolonged delivery of the drug, low drug circulation in the body, etc. Although
there are many mesmerizing applications of TDD, it has several disadvantages like high
cost, reduced productivity, requirement of high-skilled workers, etc.

REFERENCES
1. The Chemistry of Nanomaterials edited by C. N. R. Rao, A. Muller, A. K. Cheetham—
Wiley-VCH Verlag GmbH & co., Volumes 1 & 2.
2. Tekade R. K., Maheshwari R., Soni N., Tekade M., Chougule M. B. (2017)
Nanotechnology-based Approaches for Targeting and Delivery of Drugs and Genes;
[Link].
3. WTEC Panel Report on Nanostructure Science and Technology edited by Richard
Siegel, Evelin Hu7M. C. RoCo—Kluwer Academic Publishers, Boston/London.
4. Nanomaterials by Dr. Sulbha Kulkarni.
5. Nanotechnology, G. Timp; Springer, AIP Press, 2012.
6. E. Roduner (2006), Nanoscopic Materials – Size Dependent Phenomenon, RSC
Publishing.
7. Nanochemistry – A Chemical Approach to Nanomaterials, G. A. Ozim, A. C. Arsenault,
L. Cadematiri, RSC Publishing 2009.
8. T. Pradeep, “A Textbook of Nanoscience and Nanotechnology”, Tata McGraw Hill
Education Pvt. Ltd., 2012.
9. Hari Singh Nalwa, “Nanostructured Materials and Nanotechnology”, Academic
Press, 2008.
10. Sahu S. C.; Casciano D. A. (2014) Handbook of Nanotoxicology, Nanomedicine and Stem
Cell Use in Toxicology; Wiley International.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 173

Chapter ARTIFICIAL INTELLIGENCE (AI) AND MACHINE

17 LEARNING (ML)

MRS. MALAKALAIARASI. M , MRS. KAMALATHANGAM. C

1 2

& MRS. SELVAMAHESHWARI. P 3

1Lecturer, Department of Computer Engineering,

V.S.V.N. Polytechnic College, Virudhunagar, Tamilnadu –626001- India
2Lecturer, Department of Electrical and Electronics Engineering,

V.S.V.N. Polytechnic College, Virudhunagar, Tamilnadu – 626001 – India

3Lecturer, Department of Garment Technology,

V.S.V.N. Polytechnic College, Virudhunagar, Tamilnadu – 626001 - India

*Corresponding Author: Mrs. Selvamaheshwari. P, Email: selva14031992@[Link]

ABSTRACT
Artificial Intelligence (AI) represents a transformative technological advancement that is
reshaping industries and redefining the way we interact with the world. By simulating
human intelligence through algorithms and machine learning techniques, AI systems can
analyze vast datasets, recognize patterns, and make informed decisions with remarkable
speed and accuracy. ML focuses specifically on algorithms that learn from and make
predictions based on data. This interplay enables machines to identify patterns, improve
decision-making, and automate processes without explicit programming. This paper
highlights the significant impact of AI across medical fields and emphasizes the
applications of AI in that particular field. It also highlights the intersection of AI and
robotics. As ML continues to evolve, it holds the promise of enhancing human capabilities
and fostering a more innovative and efficient future.

KEYWORDS: Artificial intelligence, Machine Learning, Health Care, Robotics.

INTRODUCTION
AI is a once-in-a-lifetime commercial and defense game changer. Hundreds of billions in
public and private capital are being invested in AI and Machine Learning companies. Since
businesses and nations worldwide have recognized that artificial intelligence (AI) and
machine learning will be a significant disruptor and could alter the balance of military
power, the number of patents submitted in 2021 is more than 30 times higher than in 2015.
174 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Until recently, the hype exceeded reality. Today, however, advances in AI in several
important areas equal and even surpass human capabilities.

WHAT IS AI?
The ability of a digital computer, computer-controlled device, or software to replicate
intellectual traits of intelligent organisms (humans) in their operation is known as
Artificial Intelligence (AI).[1] AI technologies also could be used to provide innovative
real-time virtual reference services through mobile and social networking environments,
by combining the existing library resources and third-party contents. The use of robotics in
library operations, indexing systems, and natural language processing are some more
exciting applications of AI in libraries.

TYPES OF AI
 NARROW AI: AI designed to complete very specific actions; unable to
independently learn.
 ARTIFICIAL GENERAL INTELLIGENCE: AI is designed to learn, think, and
perform at similar levels to humans.
 ARTIFICIAL SUPERINTELLIGENCE: AI can surpass the knowledge and
capabilities of humans.
 REACTIVE MACHINE AI: AI capable of responding to external stimuli in real
time; unable to build memory or store information for the future.
 LIMITED MEMORY AI: AI that can store knowledge and use it to learn and train
for future tasks.
 THEORY OF MIND AI: AI that can sense and respond to human emotions, plus
perform the tasks of limited memory machines.
 SELF-AWARE AI: AI that can recognize others’ emotions, plus has a sense of self
and human-level intelligence; the final stage of AI [12].

Fig. 1.1: Types of Artificial Intelligence [13]

INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 175

WHAT IS ML?
Machine Learning, or ML, focuses on the creation of systems or models that can learn from
data and improve their performance in specific tasks, without the need to be explicitly
programmed, making them learn from past experiences or examples to make decisions on
new data. [3]

TYPES OF MACHINE LEARNING

Fig. 1.2: Types of Machine Learning [3]

 SUPERVISED LEARNING: Inputs and outputs of the model, also known as

variables and labels respectively, are used in training to generalize the model. It
can improve its predictions by learning from errors. It is divided into Regression
and Classification.
 UNSUPERVISED LEARNING: The labels are not known; the model discovers the
patterns and structure in the data. It is divided into two types: Clustering and
Dimensionality Reduction.
 REINFORCEMENT LEARNING: This type of technique is used for which an
agent interacts with its environment and receives rewards or punishments based
on its actions. Through testing and discovery, the agent gains knowledge while
working to gradually increase the total reward obtained. It is most likely to result
in a reward, according to the agent.
 RECOMMENDER SYSTEMS: Recommender systems can be defined as a learning
technique under which online user can customize their sites to meet customer’s
tastes. There are mainly two approaches: content-based recommendation and
collaborative recommendation. Most e-commerce site uses this system. [3]
176 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

APPLICATION OF AI & ML
This application of AI and ML discusses robotics and healthcare. [3]

MEDICINE – HEALTH CARE: Artificial intelligence (AI) has already changed much of
the world as we know it – from automating systems to improving the decisions we make
and the ways we go about making them. However, the application of AI in healthcare to
diagnose and develop individualized treatments is arguably the most significant and
intimate way AI is transforming our environment plans, and even predicting patient
survival rates [9].
AI is currently most frequently used in imaging analysis and clinical decision
assistance in medical contexts. Clinical decision support technologies give clinicians rapid
access to information that helps them make decisions about patient needs, including
mental health, drugs, and therapies. AI technologies are being utilized in medical imaging
to examine CT scans, x-rays, MRIs, and other pictures for abnormalities or other
information that a human radiologist might overlook.
It is used by computers and machine processes to simulate human intelligence and
perform complex automated tasks. While AI-enabled computers aim to mimic human
intelligence, they can also surpass it in a variety of ways, most notably by effectively
sorting through massive amounts of big data to find patterns, anomalies, and trends.

TYPES OF AI IN HEALTHCARE
It is important to determine the immense usefulness of this invention before delving
deeply into the applications of artificial intelligence in healthcare [8].

Fig. 1.3: Types of AI in Healthcare [11]

INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 177

 MACHINE LEARNING (ML): Training algorithms using data sets, such as health
records, to create models capable of performing such tasks as categorizing
information or predicting outcomes.
 DEEP LEARNING: A subset of machine learning that involves greater volumes of
data, training times, and layers of ML algorithms to produce neural networks
capable of more complex tasks.
 NEURAL LANGUAGE PROCESSING (NLP): The use of ML to understand
human language, whether it be verbal or written. NLP is used in the medical field
to understand published studies, notes, reports, and documentation.
 ROBOTIC PROCESS AUTOMATION (RPA): The use of AI in computer
programs to automate administrative and clinical workflows. RPA is used by
several healthcare companies to enhance the daily operations of their facilities and
the patient experience.

APPLICATIONS
 AI IN DISEASE DETECTION AND DIAGNOSIS: Unlike humans, AI never
needs to sleep. Critical care patients' vital signs might be monitored by machine
learning algorithms, which could notify doctors if specific risk indicators rise. Vital
indicators may be tracked by medical devices like heart monitors, but artificial
intelligence (AI) can gather the data and search for more complicated illnesses like
sepsis.
 PERSONALIZED DISEASE TREATMENT: Precision medicine could become
easier to support with virtual AI assistance. Because AI models can learn and
retain preferences, AI
Has the potential to provide customized real-time recommendations to patients
around the clock.
 AI IN MEDICAL IMAGING: AI is already playing a prominent role in medical
imaging. According to research, artificial intelligence (AI) driven by neural
networks can identify breast cancer and other illnesses with an accuracy level
comparable to that of human radiologists.
 CLINICAL TRIAL EFFICIENCY: A lot of time is spent during clinical trials
assigning medical codes to patient outcomes and updating the relevant datasets.
By offering a faster and more intelligent search for medical codes, AI can aid in
expediting this procedure.
 ACCELERATED DRUG DEVELOPMENT: Drug discovery is often one of the
longest and most costly parts of drug development. AI has the potential to lower
the cost of producing new medications in two main ways: by improving drug
designs and identifying viable new drug combinations.
178 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

BENEFITS OF AI IN HEALTH CARE

AI provides several benefits to the field of health care, the professionals working within it,
and the patients who interact with it every day. Healthcare providers can use the
technology to create customized treatment plans and diagnose diseases more rapidly and
precisely than they could on their own, while doctors can anticipate decreased operating
expenses as a result of better decision-making and more effective automated services.
Patients can expect potentially improved health outcomes and lower costs resulting from
more efficient health services [5].

Fig. 1.4: Benefits of AI in health care [11]

2. ROBOTICS
Rapidly emerging cutting-edge technology, new industries, and improved productivity
and efficiency in already-existing sectors are all being fuelled by the convergence of robots
and artificial intelligence (AI). AI is revolutionizing industries and enhancing daily life in a
variety of ways, from self-driving cars to healthcare and customer service to industrial and
service robots. The World Economic Forum (WEF) estimates that by 2025, artificial
intelligence (AI) and robotics will generate 12 million more jobs than they eliminate,
despite worries that these technologies may render some kinds of human labor obsolete.
[6]

HOW AI IS USED IN ROBOTICS

AI has made substantial progress in recent years, and its integration with robotics has
proven to be a natural progression. Robotics and artificial intelligence (AI) have enormous
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 179

potential to boost efficiency and productivity, enhance safety, and provide workers in a
range of occupations with more flexibility. Machine learning is one of the main
applications of AI in robotics. By watching and imitating human behavior, this method
helps robots learn and carry out particular jobs. This enables them to become actual
"cognitive collaborators," going beyond merely carrying out monotonous chores. Edge
computing is another application of AI in robotics.
Massive volumes of data collected by robot-based sensors must be interpreted in
real-time for AI applications in robotics; for this reason, the data is analyzed locally on the
machine rather than being transferred to the cloud for processing. By giving machines
real-time awareness, this method enables robots to make decisions far more quickly than
humans can. AI also uses a variety of sensors, such as the following, to teach robots how to
accomplish particular tasks:

 Time-of-flight optical sensors

 Temperature and humidity sensors
 Ultrasonic sensors
 Vibration sensors
 Millimetre-wave sensors

APPLICATIONS OF AI IN ROBOTICS
AI has shown itself to be a useful tool in the field of robotics for several purposes. AI has
left its imprint and is still changing how we view and interact with robots in a variety of
industries, including manufacturing and customer service. Let's examine some of the main
applications of AI and robots in the modern world [10].

Fig. 1.5: Applications of AI in Robotics [13]

180 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

 CUSTOMER SERVICE: AI-powered chatbots are becoming increasingly common

in customer service applications. These automated service agents can handle
simple, repetitive requests without the need for human involvement. These
algorithms learn more the more they engage with people.
 ASSEMBLY: AI has proven to be an invaluable tool in robotic assembly
applications, especially in complex manufacturing industries such as aerospace.
With the help of advanced vision systems, AI can enable real-time course
correction and can be used to help a robot automatically learn the best paths for
certain processes while in operation.
 PACKAGING: AI is used in the packaging industry to improve efficiency,
accuracy, and cost-effectiveness. By continuously refining and saving certain
motions made by robotic systems, AI helps make installing and moving robotic
equipment easier for everyone.
 IMAGING: Across many industries — including assembly and logistics —
accurate imaging is crucial. With the assistance of AI, robots can achieve enhanced
visual acuity and image recognition competencies, enabling greater accuracy in
even the smallest of details.
 MACHINE LEARNING: Machine learning is a powerful tool for robots. By
exploring their surroundings, robots can learn more about their environment, find
ways around obstacles, and solve problems to complete tasks more efficiently.
From home robots like vacuum cleaners to manufacturing robots in factories,
machine learning is helping robots become more intelligent and adaptable in their
work.[4]

THE FUTURE OF AI IN HEALTHCARE AND ROBOTICS

The biggest obstacle facing AI in these healthcare fields is not if the technologies will be
effective enough, but rather whether or not they will be incorporated into routine clinical
practice. For widespread adoption to take place, AI systems must be approved by
regulators, integrated with EHR systems, standardized to a sufficient degree that similar
products work similarly, taught to clinicians, paid for by public or private payer
organizations, and updated over time in the field.[2]
Therefore, we anticipate a limited application of AI in clinical practice in five years,
followed by more widespread use in ten. Additionally, it's becoming more and more
obvious that AI systems will support human clinicians' attempts to provide patient care
rather than completely replace them. Human clinicians may eventually gravitate toward
assignments and Work plans that utilize distinctively human abilities like empathy,
persuasion, and big-picture integration. Perhaps the only healthcare providers who will
lose their jobs over time may be those who refuse to work alongside artificial intelligence.
[7]
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 181

The future of robotics, underpinned by advancements in Artificial Intelligence (AI)

and Machine Learning (ML), holds promising prospects for humanity. It is expected that
this advancement will be inclusive and cooperative, promoting human-robot
collaboration. According to experts, robots will become more commonplace, influencing
many different sectors of the economy and aspects of our daily lives.
From precision farming to driving with autonomous vehicles, robotics will
revolutionize how we operate. It is anticipated that developments in conversational AI and
computer vision will improve human-robot interactions. Concurrently, the ability to
gather data may result in the deployment of a fleet of robots in industrial environments
that are more effective. Robots will be able to learn from their experiences, accomplish
certain activities more quickly, and engage with the outside world more naturally thanks
to the use of AI models. This will be especially transformative in sectors like healthcare,
manufacturing, and logistics, among others. [6]
AI robots are revolutionizing industries globally by providing increased safety,
accuracy, and efficiency in a range of applications. Although there are challenges such as
initial investment or the lack of a stable regulatory framework, its potential to improve
people’s working conditions and improvements in the efficiency of processes is
indisputable.

CONCLUSION
AI and machine learning have become foundational technologies that are reshaping
industries and influencing daily life. Through data-driven algorithms, ML empowers
machines to perform tasks that previously required human intelligence, from recognizing
patterns to making decisions autonomously. These capabilities have unlocked
advancements in fields like healthcare, finance, retail, and autonomous systems, leading to
unprecedented efficiencies and innovations.
AI's integration into healthcare and robotics has transformed these fields, opening
new possibilities for precision, efficiency, and personalized care. In healthcare, AI-
powered tools for diagnostics, predictive analytics, and patient monitoring have improved
treatment outcomes, streamlined workflows, and empowered medical professionals with
valuable insights. Robotics, guided by AI, has further enhanced surgical precision,
rehabilitation therapies, and assisted living, providing critical support in both clinical and
home settings.
However, the deployment of AI in healthcare and robotics presents challenges,
including data privacy, system interoperability, and the need for ethical guidelines to
prevent bias in decision-making processes. Addressing these challenges is essential to
harness the full potential of AI responsibly. As technology evolves, the synergy between
AI, healthcare, and robotics will continue to advance, promising a future where intelligent,
autonomous systems become integral to patient care and medical practice.
182 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

REFERENCES
1. Raynor, W. J, The International Dictionary of Artificial Intelligence -2020.
2. Mike Thomas, The Future of AI: How Artificial Intelligence Will Change the World
Book
3. Sumit Das, Aritra Dey, Akash Pal, Nabamita Roy JIS College of Engineering,
Kalyani, India, Applications of Artificial Intelligence in Machine Learning: Review
and Prospect, International Journal of Computer Applications (0975 – 8887)
Volume 115 – No. 9, April 2015.
4. A Ramalingam, Dr A. karunamurthy, B Pavithra August 2023, “Impact of Artificial
Intelligence on Healthcare: A Review of Current Applications and Future
Possibilities” Quing International Journal of Innovative Research in Science and
Engineering 2(2):37-49 DOI:10.54368/qijirse.2.2.0005
5. Antonio Chella, Luca Iocchi, Artificial Intelligence And Robotics, Contributi
Scientifici Anno III, N° 1/2, Marzo-Giugno 2006
6. Elitsa Krumova, The Future of Artificial Intelligence for Robotics, Manufacturing
December 6, 2023.

WEB-BASED / ONLINE RESOURCES

1. [Link]
2. AI in Health Care: Applications, Benefits, and Examples | Coursera
3. What is Artificial Intelligence in Medicine? | IBM
4. Applications of AI in Robots: An Introduction ([Link])
5. [Link]
6. [Link]
7. [Link]
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 183

Chapter WEARABLE DRUG DELIVERY SYSTEMS: INNOVATIONS

18 AND APPLICATIONS

MRS. ANITHA B1*

1Lecturer, Department of Garment Technology, V.S.V.N. Polytechnic College,
Virudhunagar, Tamil Nadu – India
*Corresponding Author: Mrs. Anitha B, Email: [Link]@[Link]

ABSTRACT
Wearable drug delivery systems (WDDS) are transforming the landscape of medication
administration by offering continuous, controlled, and personalized therapy options. By
integrating advanced technologies with biocompatible materials, these systems address the
challenges of traditional drug delivery methods, improving patient compliance and
therapeutic outcomes. This article explores the mechanisms, applications, advantages, and
challenges of WDDS, highlighting their significant role in managing chronic diseases, pain
relief, and vaccination. Furthermore, it discusses prospects for these systems, emphasizing
the need for ongoing research to overcome current limitations. As WDDS continues to
evolve, it promises to revolutionize patient care, providing innovative solutions that
enhance treatment efficacy and patient satisfaction.

KEYWORDS: Drug Delivery, Applications, Innovations

INTRODUCTION
The evolution of drug delivery systems has been pivotal in advancing therapeutic
interventions, significantly enhancing the efficacy of medications, and improving patient
outcomes. Among the latest innovations, wearable drug delivery systems (WDDS) have
emerged as a promising solution, offering a novel approach to medication administration
that aligns with the growing emphasis on personalized and patient-centered care. These
systems are designed to deliver therapeutic agents continuously, precisely, and
conveniently, addressing several challenges associated with traditional delivery methods.
Traditionally, patients have relied on oral medications, injections, or infusions, which often
require strict adherence to dosing schedules and can lead to fluctuating drug levels in the
bloodstream. Such variability may result in suboptimal therapeutic outcomes, increased
side effects, and poor patient compliance. Wearable drug delivery systems aim to overcome
184 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

these limitations by providing a steady and controlled release of drugs, minimizing peaks
and troughs in drug concentrations, and thereby enhancing therapeutic effectiveness.
WDDS utilizes innovative technologies and materials that enable transdermal,
subcutaneous, or even intramuscular delivery of drugs. These devices can be integrated
with sensors to monitor physiological parameters in real time, allowing for dynamic
adjustments in drug delivery based on individual patient needs. This real-time feedback
mechanism is particularly advantageous in managing chronic conditions, where timely and
appropriate drug administration is critical for maintaining health.
The applications of wearable drug delivery systems are diverse and span various
therapeutic areas. For instance, in diabetes management, continuous glucose monitors
(CGMs) coupled with insulin delivery systems offer patients a seamless way to regulate
blood glucose levels without the need for frequent finger pricks or injections. Similarly,
WDDS are being developed for chronic pain management, where patients can benefit from
localized delivery of analgesics through wearable patches, reducing the reliance on oral
medications that can lead to systemic side effects.
As healthcare continues to evolve towards more personalized approaches, the
potential of wearable drug delivery systems is increasingly recognized. By enabling self-
administration and facilitating improved adherence to treatment regimens, these systems
promise to enhance the overall patient experience. However, their integration into routine
clinical practice is not without challenges. Issues such as biocompatibility, device longevity,
regulatory approval, and cost-effectiveness must be addressed to ensure successful
implementation.
In this article, we will explore the mechanisms, applications, advantages, and
challenges of wearable drug delivery systems. By examining current research and
technological advancements, we aim to provide a comprehensive overview of how WDDS
is poised to revolutionize the landscape of drug delivery and improve healthcare outcomes
for patients worldwide.

TECHNIQUES IN WEARABLE DRUG DELIVERY

Wearable drug delivery systems operate through various mechanisms that facilitate the
efficient and controlled administration of therapeutic agents. Understanding these
mechanisms is crucial for optimizing drug delivery and enhancing patient outcomes.

1. TRANSDERMAL DRUG DELIVERY

Transdermal drug delivery involves the administration of drugs through the skin for
systemic effect. This method is commonly used in WDDS, where patches deliver
medications over extended periods. The primary advantage of transdermal systems is that
they bypass the gastrointestinal tract and first-pass metabolism, improving bioavailability
[8]. Modern transdermal patches are designed with permeation enhancers that facilitate
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 185

drug absorption through the skin barrier, allowing for a controlled release profile that
maintains steady drug levels in the bloodstream.

2. MICROINFUSION TECHNOLOGY
Microinfusion systems are designed to deliver precise doses of medication at predetermined
intervals. These systems often utilize small pumps that can be programmed to adjust the
infusion rate based on patient-specific parameters, such as blood glucose levels in diabetic
patients. This approach is particularly beneficial for managing chronic conditions, as it
enables patients to maintain optimal drug concentrations without frequent manual dosing
[2].

3. MICRONEEDLE ARRAYS
Microneedles are tiny needles, typically ranging from 100 to 1000 micrometers in length,
that can painlessly penetrate the outer layer of the skin to deliver drugs directly to the
dermal layer. Wearable devices utilizing microneedle arrays are capable of administering
vaccines, hormones, or other therapeutic agents in a minimally invasive manner. This
technique offers the potential for self-administration and is particularly promising for
vaccine delivery, enhancing patient comfort and compliance [3].

4. SMART WEARABLES WITH SENSOR INTEGRATION

Recent advancements have seen the integration of sensors within wearable drug delivery
systems. These sensors can monitor physiological parameters, such as glucose levels, heart
rate, and temperature, in real-time. This data allows for dynamic adjustments to drug
delivery, optimizing treatment based on individual patient needs. For example, smart
insulin pumps can automatically adjust insulin delivery based on real-time glucose
readings, significantly improving glycemic control in diabetic patients [7].

APPLICATIONS OF WEARABLE DRUG DELIVERY SYSTEMS

Wearable drug delivery systems have found applications across a wide range of therapeutic
areas, providing innovative solutions to various healthcare challenges.

1. DIABETES MANAGEMENT
Continuous glucose monitoring systems (CGMs) combined with insulin pumps represent
one of the most successful applications of WDDS. These systems enable real-time
monitoring of blood glucose levels and deliver insulin in response to fluctuations,
improving glycemic control and reducing the risk of complications associated with diabetes
[1]. The integration of automated insulin delivery with CGMs has transformed diabetes
management, providing patients with greater autonomy and better health outcomes.
186 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

2. CHRONIC PAIN MANAGEMENT

Wearable patches that deliver analgesics through the skin offer a non-invasive solution for
chronic pain management. These systems allow for localized delivery of medication,
minimizing systemic exposure and reducing side effects commonly associated with oral
analgesics [5]. The convenience of self-administering pain relief via wearable devices
improves patient adherence and satisfaction.

3. HORMONE REPLACEMENT THERAPY

Wearable drug delivery systems are also being utilized in hormone replacement therapy.
For example, transdermal patches can deliver hormones such as estrogen or testosterone,
providing a steady release and reducing the need for daily dosing [6]. This method
enhances patient comfort and compliance, making it easier for individuals undergoing
hormone therapy to manage their conditions effectively.

4. VACCINE DELIVERY
Microneedle-based wearable devices show promise for vaccine delivery, particularly in
enhancing immunization rates. These devices facilitate the self-administration of vaccines,
making it easier for individuals to receive immunizations without the need for healthcare
provider visits. This approach is especially beneficial in remote areas with limited access to
healthcare facilities [4].

ADVANTAGES OF WEARABLE DRUG DELIVERY SYSTEMS

Wearable drug delivery systems offer several advantages that make them an attractive
option for both patients and healthcare providers.

1. ENHANCED PATIENT COMPLIANCE

By providing continuous and automated drug delivery, wearable systems reduce the
burden of adhering to complex medication schedules. This ease of use improves patient
compliance, particularly for individuals with chronic conditions who require ongoing
therapy [1].

2. REAL-TIME MONITORING AND ADJUSTMENTS

The incorporation of sensors in wearable drug delivery systems allows for continuous
monitoring of physiological parameters, enabling real-time adjustments to drug delivery
based on patient-specific needs. This capability enhances treatment efficacy and minimizes
the risk of adverse effects [7].

3. MINIMIZED SIDE EFFECTS

Targeted and controlled drug delivery reduces the risk of systemic side effects associated
with traditional methods. By delivering drugs directly to the site of action or through the
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 187

skin, wearable systems can improve the therapeutic index of medications, enhancing patient
safety and comfort [5].

4. PERSONALIZED MEDICINE
Wearable drug delivery systems can be tailored to individual patient profiles, optimizing
treatment efficacy and safety. The ability to customize dosing based on real-time data
empowers healthcare providers to deliver more effective and patient-centered care [6].

CHALLENGES
Despite their potential, wearable drug delivery systems face several challenges that must be
addressed to facilitate widespread adoption.

1. BIOCOMPATIBILITY AND SKIN IRRITATION

Prolonged skin contact with wearable devices can lead to irritation or allergic reactions.
Ongoing research into biocompatible materials is essential to mitigate these issues and
ensure patient comfort during extended use [8].

2. DEVICE LONGEVITY AND RELIABILITY

Ensuring the durability and reliability of wearable systems over extended periods remains a
challenge, particularly for devices intended for long-term use. Continued innovation in
materials and engineering design is necessary to enhance the longevity and performance of
these systems [2].

3. REGULATORY HURDLES
The novel nature of wearable drug delivery systems requires navigating complex
regulatory landscapes to ensure safety and efficacy. Regulatory agencies must develop clear
guidelines to evaluate and approve these innovative technologies, balancing patient safety
with the need for rapid innovation [7].

4. COST AND ACCESSIBILITY

The high cost of developing and manufacturing advanced wearable technologies may limit
their accessibility to a broader population. Efforts to reduce costs and improve
manufacturing processes will be crucial in making WDDS available to diverse patient
populations [4].

FUTURE DIRECTIONS
As technology continues to evolve, the future of wearable drug delivery systems looks
promising. Innovations in materials science, microelectronics, and data analytics will drive
advancements in device design and functionality. Emerging trends, such as the integration
of artificial intelligence and machine learning, hold the potential to further enhance the
188 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

personalization and effectiveness of drug delivery systems. Collaborative efforts between

researchers, healthcare providers, and regulatory bodies will be essential to overcome
existing challenges and unlock the full potential of WDDS in clinical practice.

CONCLUSION
Wearable drug delivery systems are at the forefront of modern medicine, offering
innovative solutions for drug administration and patient management. By providing
continuous, controlled, and personalized therapy options, these systems enhance treatment
efficacy and improve patient compliance. The diverse applications of WDDS across
therapeutic areas such as diabetes management, chronic pain control, hormone replacement
therapy, and vaccination highlight their potential to transform patient care.
However, challenges related to biocompatibility, device longevity, regulatory
approval, and cost must be addressed to facilitate the successful integration of these
systems into routine clinical practice. Continued research and development in wearable
drug delivery technology will be crucial in overcoming these barriers and realizing the full
potential of WDDS in improving healthcare outcomes.
As the healthcare landscape evolves towards more personalized approaches,
wearable drug delivery systems are poised to play a significant role in enhancing patient
care and satisfaction, ultimately leading to better health outcomes for individuals
worldwide.

REFERENCES
1. Buse, J. B., et al. (2016). "Insulin Delivery: The Role of Continuous Glucose
Monitoring in Diabetes Management." Diabetes Care, 39(7), 1264-1271.
2. Davis, S. N., et al. (2016). "Insulin Delivery Systems: The Future is
Now." Endocrinology and Metabolism Clinics of North America, 45(3), 603-615.
3. Donnelly, R. F., et al. (2016). "Microneedle-Mediated Transdermal Drug Delivery: A
Review." Journal of Controlled Release, 232, 13-22.
4. Levy, J., et al. (2017). "Microneedle Technology for Vaccine Delivery." Nature Reviews
Drug Discovery, 16(4), 257-258.
5. Pereira, S. A., et al. (2017). "Wearable Devices for Chronic Pain
Management." Nature Reviews Rheumatology, 13(5), 307-319.
6. Simon, S. L., et al. (2018). "Wearable Technologies for Hormone Replacement
Therapy." Journal of Clinical Endocrinology and Metabolism, 103(9), 3410-3421.
7. Tavakol, M., et al. (2019). "Wearable Drug Delivery Devices: Current and Future
Applications." Journal of Pharmaceutical Sciences, 108(4), 1035-1046.
8. Vashist, S. K. (2017). "Wearable Devices: Potential Role in Drug Delivery and
Management." Expert Opinion on Drug Delivery, 14(8), 897-903.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 189

Chapter AN OVERVIEW OF EFFECT OF SIDDHA

19 IMMUNOMODULATORS AGAINST
VARIOUS DISEASES AND INFECTIONS

DR. M. RAMANI1 & DR. S. SELVAKUMAR2

Medical Officer, National Institute of Siddha,

1

Tambaram Sanatorium, Chennai-47, Tamilnadu, India.

2Assistant Professor, Department of Physiology,

Dhanalakshmi Srinivasan Medical College & Hospital, Perambalur, Tamilnadu, India.

*Corresponding Author: Dr. M. Ramani, Email: ramanishanthi@[Link]

ABSTRACT
The immune system is an effective network of cellular elements, such as white blood cells,
proteins, and chemicals that play together to protect the integrity of the organism against
external insults and its correct functioning and balancing are essential to avoid a variety of
disorders. Immuno-modulator means an alteration of immune response may cause an
increase or decrease the immune responses. Numerous medicinal plants are playing in
various systems of medicine to improve immune disorders globally. From time immemorial
in the Siddha system, they have used several plants for rejuvenation and
immunomodulation to prevent various diseases and improve their longevity of life. To date,
evidence from various literature highlights an increase in immunological diseases, and
great attention has been focused on the development of molecules and their ability to
modulate their immune response. There are several global demands for new effective
therapies and researchers are investigating this field. This review explains some of the
medicinal plant sources, descriptions, active components, indications, traditional use, and
recent research about the plant immunomodulatory mechanism and related information of
those plants also few single and compound herbal formulations in the Siddha system of
medicine are also discussed in detail.

KEYWORDS: Immune system, Immuno-modulator, Medicinal plants, Rejuvenator.

INTRODUCTION
1. IMMUNE SYSTEM AND IMMUNOMODULATORS
Now – a - days, humans are exposed to harmful pathogens and environmental pollutants
that can affect their health and homeostasis of the organism. The immune system is a
complex integrated network of cells, tissues, organs, and soluble mediators, evolved to
190 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

defend the organism against any foreign insult that threatens the integrity of the organism.
[1]

Innate and adaptive immunity, which play distinct and specialized roles in immune
defense responses, are the standard classifications for the immune response. The innate
immune system provides an imminent but incomplete defense against a foreign insult and
it has no long-term memory [2]. The adaptive immune response is an antigen-specific system
that includes long-lived lymphocytes and their highly specialized receptors. [3] As a fine-
tuning machine, the inherent and adaptive systems collaborate closely rather than being
completely distinct
The innate system recognizes the infection and “alerts” the adaptive system through
the antigen presentation that occurs to the major histocompatibility complex proteins. The
innate cells release also other chemical signals, such as cytokines and chemokines, to
completely activate the adaptive system. Importantly, specialized B and T lymphocytes,
known as regulatory cells, manage and stop the immune response once the insult has been
responded to, thus avoiding an excessive response of the Immune system. [4,5]
Immunomodulator means an alteration of immune response may cause an increase
or decrease in the immune responses. An immunomodulator is defined as a substance,
biological or synthetic, which stimulates, suppresses, or modulates any of the components
of the immune system including both innate and adaptive arms of the immune response. [6,
7]

Today the reality of life is that a poor and improper diet is the main source of many
diseases such as cardiovascular diseases, osteoporosis, obesity, diabetes, hypertension
cancer, etc. At the same time, a healthy and balanced diet can meet the nutritional needs
while contributing to the prevention of all the above diseases. Hence, in the Siddha system
of medicine, a good and balanced diet is considered the first drug of choice for most
diseases.
The great Tamil poet ‘Thiruvalluvar’ also insisted on the importance of diet in the
causation of disease. According to his statement, not only the adequate energy content of
the food but also its composition plays an important role in keeping the body healthy. So a
healthy body provides the basic platform for all human activities, efficiency, and
performance. Proper foods only contain intrinsic elements allowing the body to remain
healthy. To achieve this health, a proper diet combined with a healthy lifestyle, and many
plant products are mandatory. Strengthening the immune system through proper nutrition
and plant medications is the best way to maintain health.

2. PLANTS FROM THE SIDDHA SYSTEM WITH IMMUNOMODULATOR

POTENTIALS
Medicinal plants from the Siddha system of medicine have been used from time
immemorial to increase and strengthen the defense mechanism naturally without any side
effects. In the Siddha system of medicine, most of the anti-bacterial, anti-viral, anti-cancer,
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 191

anti-histamine, and bronchodilator plants have effective therapeutic potentials with

enhanced immune function, and such drugs are termed immunomodulators.
A lot of scientific effort has been made to validate the many medicinal plants as
immunomodulatory agents. Numerous immune-enhancing substances have been isolated
from plants and opened the door for the development of novel drugs. [8] Hence, the present
study considered the results of different investigations that have focused on medicinal
plants active in the immune system with potential applications in the field of
immunomodulatory action. Though the scientific evidence is still inadequate, this review is
aimed to provide with existing point to the use of safe and effective medicinal plants in the
prevention and treatment aspect of various immune-related disorders.

3. PHYTOCHEMICAL RESEARCH WORK

From ancient times, in traditional medicine phytochemicals have been used for their
properties and health benefits.[9] The majority of these natural compounds possess
biological or pharmacological properties that can be utilized in pharmaceutical medication
design and discovery. For instance, the most prevalent antioxidants in the human diet are
polyphenols, which are secondary metabolites of plants. Numerous research conducted in
recent years has shown the positive health impacts of their dietary contribution. [10 – 12] Some plant
extracts have been proven to modulate the IS response and numerous phytochemicals,
including not only polyphenols but also polysaccharides, flavonoids, and alkaloids, have
been studied for their immunomodulatory activities. [13–17]

MATERIALS AND METHODS

All the data were collected from various Siddha classical texts, and manuscripts,
and the research details were collected from several books and research journals to get
sufficient information.
In this review, we focused on the immunomodulatory activity of some of the
medicinal plants that act as an Immunomodulator.
192 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Table 1: Medicinal plants with their family name and their parts having
Immunomodulatory effects are illustrated

S. No Plant name Family Part used Immunomodulatory mechanism

significantly enhanced the red blood cell
Fruits, seeds, count, white blood cell count,
Aegle marmelos leaves, bark hemoglobin, phagocytic activity, nitro
1. Rutaceae
and root blue tetrazolium chloride assay,
lysozyme, pathogen clearance and
enzyme activity [18]
Increase the production of IL-2,
2. Acorus calamus L. Araceae Rhizome
tumor necrosis factor (TNF) –α [19]
Suppress leukocyte inflammatory
3. Allium sativum L. Alliaceae Bulb
cytokine production [20]
Aloe vera (L.) Burm. Increases phagocytosis and stimulates the
Liliaceae Leaf pulp
4. f. production of superoxide [21]
Andrographis
Increase the production of IL-2,
5. paniculata Acanthaceae Aerial parts
inhibits of NO production [22]
Wall. ex Nees
Increases the production of
Asparagus racemosus
Liliaceae Root tuber leukocytosis, Enhances the phagocytic
6. Willd.
activity of the macrophages [23]
Increase IgM and IgG production,
Azadirachta indica Meliaceae Leaves Inhibits NO synthesis, degranulation
7.
Juss. of neutrophils [24]
Inhibits human NK cell cytotoxicity in
Boerhaavia diffusa
Nyctaginaceae Root vitro, Inhibits production of NO,
8. L.
IL-2 and TNF-α [25]
Boswellia serrata Inhibits passive paw anaphylaxis
9. Burseraceae Bark
Roxb. ex. Colebr reaction and mast cells protection [26]
Calendula officinalis Leaves &
10. Asteraceae Inhibits tumour cell proliferation [27]
L. Flowers
Camellia sinensis (L.) Enhances the neopterin production in
11. Theaceae Leaves
Kuntze peripheral mononuclear cells [28]
Prevents myeloid suppression in mice
Capparis zeylanica
Capparidaceae Leaves with cyclophosphamide & potentiates
12. L.
DTH reaction [29]
Leaves & It enhances the phytohemagglutinins
13. Carica papaya L. Caricaceae
Seeds responsiveness of lymphocytes [30]
It increases the phagocytic index, and total
Centella asiatica
Umbelliferae Leaves WBC count & inhibits human
14. L. Urban.
peripheral blood mononuclear cell [31]
Chrysanthemum Increases DTH reaction, antibody
indicum Asteraceae Aerial parts generation, potentiates the
15.
L. mononuclear phagocytosis function [32]
Citrus Inhibits proliferation of PHA
Fruits &
aurantiifolia Rutaceae activated mononuclear cells,
16. Leaves
(Christm.) Swingle staphylococcal protein [33]
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 193

Shows immunomodulation through

Curcuma longa L. Zingiberaceae Rhizome inhibition of proliferation induced by PMA
17.
and anti-CD28 antibody [34]
Induces phagocytic index, antibody
Eclipta prostrata L. Asteraceae Whole plant titer of mice & increase non-specific
18.
immune response [35]
Decreases the nitric oxide synthase (NOS),
Evolvulus alsinoides
Convolvulaceae Whole plant exerts adaptogenic properties
19. L. [36]

Enhance the phagocytosis of the human

Ficus benghalensis L. Moraceae Whole plant neutrophils in vitro & increase
20.
the antibody titer value [37]
Stimulates immune cells by CD69
Glycyrrhiza glabra L. Fabaceae Root bark expression on CD4 and CD8 T cells
21.
and macrophages function [38]
Increase the antibody titers,
22. Jatropha curcas L. Euphorbiaceae Leaves
lymphocyte and macrophage cells [39]
Increase in humoral antibody titer & DTH,
Mangifera indica L. Anacardiaceae Fruits enhance the production of
23.
IgG1 & IgG2b [40]
Inhibits the release of TNF-α, NO and
Momordica charantia Fruits &
Cucurbitaceae the proliferation of spleen cells induced by
24. L. seeds
PHA and Con A [41]
Stimulating the release TNF-α, IL-β,
25. Morinda citrifolia L. Rubiaceae Fruits
IL-10, IL-12, IFN-γ [42]
Nelumbo nucifera Rhizome & Protects mast cell's degranulation
26. Nymphaeceae
Gaertn. Seed express CD40, CD80, CD86[43]
Inhibited hemagglutination
Nerium oleander L. Apocynaceae Leaves antibodies, DTH reaction, phagocytic
27.
index, etc., [44]
Reduces pancreatic ductal adenocarcinoma
cell (PDA) synthesis of monocyte
Nigella sativa L. Ranunculaceae Seeds chemoattractant protein
28. - 1 (MCP-1), TNF-α, IL-1β and
cyclooxygenase (COX) – 2 [45]
A steam-distilled extract of Ocimum
sanctum leaves has been shown to
enhance anti-sheep red blood cells and
IgE antibody titer. Ocimum sanctum
Whole plant, seed oil produced a significant increase
Ocimum sanctum Lamiaceae leaves, roots, in anti–SRBC antibody titer and caused
29.
seeds. a significant inhibition of antigen-
induced histamine release from the
peritoneal mast cells in non-stressed
animals, radioprotective activity in
mice against 11GY of Co-60γ
irradiation.[46]
Immunosuppressive effects on lymphocyte
Phyllanthus emblica
30. Euphorbiaceae Fruits proliferation &restoration
L.
of IL-2 and IFN-γ production [47]
194 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Increases the total WBC count, bone

Fruits &
Piper longum L. Piperaceae marrow cellularity, enhance the total
31. leaves
antibody production [48]
Up regulates the production of OVA
Psoralea corylifolia L. Fabaceae Seeds – specific Th1 cytokine (IFN-γ) & down-
32.
regulated OVA-specific Th2 cytokine [49]
33. Punica granatum L. Punicaceae Fruits Inhibits the leucocyte migration [50]

Rhinacanthus Whole Increased the production of IL-2 and

34. Acanthaceae
nasutus (L.) Kurz plant TNF –α [51]

35. Salvia officinalis L. Lamiaceae Aerial parts Induce rat thymocyte proliferation [52]
Whole plant,
Immunoprotected activity by increasing
Fruits, seeds,
Solanum the depleted levels of total WBC count,
36. Solanaceae flowers,
xanthocarpum RBC, % Hb, and %neutrophils
leaves, stem
adhesion.[53]
and root.
Inhibits the phorbolmyristate acetate
(PMA) stimulated neutrophil function,
Tamarindus indica L. Fabaceae Fruits
37. neutrophil NADPH oxidase
activity, elastase activity [54]
Terminalia chebula Increase in HA titer and DTH
38. Combretaceae Fruits
Retz. reaction [55]
Increase the total white blood cell
Tinospora cordifolia
Menispermaceae Stem & root count, bone marrow cellularity, and α-
39. (Willd.) Miers
esterase-positive cells [56]
Increases the phagocytic index and
Trigonella foenum–
phagocytic capacity of macrophages,
graecum Fabaceae Seeds
40. enhancement of thymus and bone
L.
marrow cellularities [57]
Increase total WBC count, bone marrow
Withania somnifera cellularity, circulating antibody titer &
Solanaceae Root
41. (L.) Dunal plaques forming cells
in the spleen [58]

CONCLUSION
From this review, immunology is a rapidly developing field of medical research science and
technology to prevent and treat several diseases. Nowadays people are experiencing a lot of
stress, eating unhealthy food, and exposure to toxic substances. This leads to an effect on
our body’s immune system. Immuno modulation is a normal phenomenon that acts as a
weak immune system in our body. The immune system is normally our natural first line of
defense mechanism against illness. However, due to inadequacies and abnormalities,
immune systems can occasionally work abnormally, causing the body to either lose its
natural immunity or turn against the body they are meant to protect. Natural
immunomodulators may provide the key to maintaining a strong and proper functioning of
the immune system.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 195

REFERENCES
1. Yatim, K.M.; Lakkis, F.G. A brief journey through the immune system. Clin. J. Am. Soc.
Nephrol. CJASN 2015, 10, 1274–1281. [CrossRef] [PubMed]
2. Netea, M.G.; Quintin, J.; van der Meer, J.W.M. Trained immunity: A memory for innate
host defense. Cell Host Microbe 2011, 9, 355–361. [CrossRef] [PubMed]
3. Pancer, Z.; Cooper, M.D. The evolution of adaptive immunity. Annu. Rev. Immunol.
2006, 24, 497–518. [CrossRef] [PubMed]
4. Mauri, C.; Bosma, A. Immune regulatory function of B cells. Annu. Rev. Immunol. 2012,
30, 221–241. [CrossRef] [PubMed]
5. Josefowicz, S.Z.; Lu, L.-F.; Rudensky, A.Y. Regulatory T cells: Mechanisms of
differentiation and function. Annu. Rev. Immunol. 2012, 30, 531–564. [CrossRef] [PubMed]
6. Sell S & Max EE. Immunology, Immunopathology Immunity. (ASM Press, USA): 2001.
7. Goldsby RA, Kindt TJ & Osborne BA, Kuby. Immunology. (W. H. Freeman and
Company, New York), 2006; 35-57.
8. Wasser SP 10. Medicinal mushrooms Science: History, current status, future trends and
unsolved problems. Inter J Med Mushrooms, 2010; 12(1): 1- 16.
9. Nilius, B.; Appendino, G. Spices: The savory and beneficial science of pungency. Rev.
Physiol. Biochem. Pharmacol. 2013, 164, 1–76. [CrossRef] [PubMed]
10. Estrela, J.M.; Mena, S.; Obrador, E.; Benlloch, M.; Castellano, G.; Salvador, R.; Dellinger,
R.W. Polyphenolic phytochemicals in cancer prevention and therapy: Bioavailability versus
bioefficacy. J. Med. Chem. 2017, 60, 9413–9436. [CrossRef] [PubMed]
11. Annuzzi, G.; Bozzetto, L.; Costabile, G.; Giacco, R.; Mangione, A.; Anniballi, G.; Vitale,
M.; Vetrani, C.; Cipriano, P.; Della Corte, G.; et al. Diets naturally rich in polyphenols
improve fasting and postprandial dyslipidemia and reduce oxidative stress: A randomized
controlled trial. Am. J. Clin. Nutr. 2014, 99, 463–471. [CrossRef] [PubMed]
12. Afzal, M.; Safer, A.M.; Menon, M. Green tea polyphenols and their potential role in
health and disease. Inflammopharmacology 2015, 23, 151–161. [CrossRef] [PubMed]
13. Farzaei, M.; Rahimi, R.; Abdollahi, M. The role of dietary polyphenols in the
management of inflammatory bowel disease. Curr. Pharm. Biotechnol. 2015, 16, 196–210.
[CrossRef] [PubMed]
14. Andreicut, A.-D.; Pârvu, A.E.; Mot, A.C.; Pârvu, M.; Fischer Fodor, E.; Cătoi, A.F.;
Feldrihan, V.; Cecan, M.; Irimie, A. Phytochemical analysis of anti-inflammatory and
antioxidant effects of Mahonia aquifolium flower and fruit extracts. Oxid. Med. Cell. Longev.
2018, 2018, 1–12. [CrossRef] [PubMed]
15. Ferreira, S.S.; Passos, C.P.; Madureira, P.; Vilanova, M.; Coimbra, M.A. Structure-
function relationships of immunostimulatory polysaccharides: A review. Carbohydr.
Polym. 2015, 132, 378–396. [CrossRef] [PubMed]
16. Gandhi, G.R.; Neta, M.T.S.L.; Sathiyabama, R.G.; de Souza Siqueira Quintans, J.; de
Oliveira e Silva, A.M.; de Souza Araújo, A.A.; Narain, N.; Júnior, L.J.Q.; Gurgel, R.Q.
Flavonoids as Th1/Th2 cytokines immunomodulators: A systematic review of studies on
196 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

animal models. Phytomedicine 2018, 44, 74–84. [CrossRef] [PubMed] Molecules 2018, 23,
2778 13 of 17
17. Boland, J.W.; Foulds, G.A.; Ahmedzai, S.H.; Pockley, A.G. A preliminary evaluation of
the effects of opioids on innate and adaptive human in vitro immune function. BMJ
Support. Palliat. Care 2014, 4, 357–367. [CrossRef] [PubMed]
18. Pratheepa V, Ramesh S and Sukumaran N. Immunomodulatory effect of
Aeglemarmelos, leaf extract on freshwater fish Cyprinus carpio infected by bacterial
pathogen Aeromonas, hydrophila. Pharmaceutical Biology, 2010; 48: 1-16.
19. Mehrotra S. Mishra KP, Maurya R, Srimal RC, Yadav VS, Pandey R & Singh VK,
Anticellular and immunosuppressive properties of ethanolic extract of Acorus calamus
rhizome. Intl Immunopharmaco, 2003; 3: 53-61.
20. Hodge G, Sandy H & Han P. Allium Sativam (Garlic) Suppresses Leukocyte
Inflammatory Cytokine production in Vitro: Potential Therapeutic Use in the treatment of
Inflammatory Bowel Disease. Cytomery, 2002; 48: 209-215.
21. Zhang X, Wang H, Song Y, Nie L, Wang L, Liu B, Shen P & Liu Y. I solution, Structure
elucidation, antioxidative and immunomodulatory properties of two novel
dihydrocoumarines from Aloe Vera. Bioorg Med Chem Let, 2006; 16: 949-953.
22. Chiou WF, Chen CF, Lin JJ. Mechanisms of suppression of inducible nitric oxide
synthase (INOS) expression in RAW 264.7 cells by andrographolide. Br J Pharmocolol, 2000;
129: 1553-1560.
23. Muruganadan S, Garg H, Lal J, Chandra S & Kumar D. Studies on the immunostimulant
and antihepatotoxic activities of Asparagus racemosus. Phytother Res, 2004; 18: 4194-24.
24. Upadhyay SN, Dhawan S, Garg S, &Talwar GP. Immunomodulatory effects of neem
(Azadirachta indica) oil. Int Immuno Pharmocol, 1992; 14: 1187-1193.
25. Mehrotra S, Mishra KP, Maurya R, Srimal RC & Singh VK. Immunomodulation by
ethanolic of Boerhaavia diffusa roots. Int Immuno Pharmacol, 2002; 2: 987-996.
26. Sharma ML, Kaul A, Singh S & Singh GB. Immunomodulatory Activity of Boswellic
Acids (Pentacyclic Triterpene Acids) from Boswellia serrate. Phytother Res, 1998; 10:107-112.
27. Jimenez ME, Garcia LA &Paco L. A new extract of the plant Calendula officinalis
produces a dual in vitro effect: cytotoxic anti-tumor activity and Lymphocyte activation.
BMC Cancer, 2006; 6: 6-8.
28. Zvetkova E, Wirletiner B, Tram NT, Schennach H & Fuchs D. Aqueous extracts of
Crinum latifolium (L.) and Camellia Sinensis show immunomodulatory properties in human
peripheral blood mononuclear cells. Int Immuno Pharmacol, 2001; 1: 2143-2150.
29. Ghule BV, Murugananthan G, Nakhat PD &Yyeole PG. Immunostimulant effects of
Capparis zeylanica Linn. Leaves. J Ethnopharmacol, 2006; 108: 760- 767.
30. Otsuki N, Dang NH, Kumagai E, Kondo A, Iwata S & Morimoto C. Aqueous extract of
Carcia papaya leaves exhibits anti-tumor activity and immunomodulatory effects. J
Ethnopharmacol, 2010; 127:760-767.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 197

31. Punturee K, Wild CP, Kasinrerk W & Vinitketkumnuen U. Immunomodulatory

activities of Centella asiatica and Rhinacanthus nasutus extracts. Asian Pac Org Cancer
Prev,2005;6: 396- 400.
32. Lee DY, Choi G, Yoon T, Cheon MS, Choo BK &Kim HK. Anti-inflammatory activity of
Chrysanthemum indicum extract in acute and chronic cutaneous inflammation. J
Ethnopharmacol, 2009; 123: 149-154.
33. Gharagozloo M &Ghaderi A. Immunomodulatory effect of concentrated lime juice
extract on activated human monocellular cells. J Ethnopharmacol, 2001; 77: 85-90.
34. Yadav VS, Mishra KP, Singh DP, Mehrotra S & Singh VK. Immunomodulatory effects of
curcumin. Immunopharmacol Immunotoxicol, 2005; 27: 485- 497.
35. Christybapita D, Divyagnaneswari M & Dinakaran Micheal R. Oral administration of
Eclipta albha leaf aqueous extract enhances the non-specific immune response and disease
resistance of Oreochromics mossambics. Fish Shellfish Immun, 2007; 23: 840-852.
36. Ganju L, Karan D, Chanda S, Srivastava KK, Sawhney RC & Selvamurthy W.
Immunomodulatory effects of agents of plant origin. Biomed Pharmacother, 2003; 57: 296-
300.
37. Gabhe SY, Tatke PA & Khan TA. Evaluation of the immunomodulatory activity of the
methanol extract of Ficus benghalensis roots in rats. Indian J Pharmacol, 2006; 38: 271-275.
38. Pandit S, Bandyopadhyay A, Ponnusankar S, Ota S & Mukherjee PK. Exploring the
possible metabolism-mediated interaction of Glycyrrhiza glabra extract with CYP3A4 and
[Link] Res, 2011; 25: 1429-1434.
39. Abd-Alla HI, Moharram FA, Gaara AH & EI-Safty MM. Phytoconstituents of Jatropha
curcas L. leaves and their immunomodulatory activity on humoral and cell-mediated
immune response in chicks. ZeitsschriftfurNarurforshhung, J Biosciences, 2009; 64: 495-501.
40. Garcia D, Leiro J, Delgado R, Sanmartin ML & Ubeira FM. Mangifera indica L. extract
(Vimang) and mangiferin modulate mouse humoral immune responses. Phytother Res,
2003; 17: 1182-1187.
41. Pongnikorn S, Fongmoon D, Kasinrerk W & Limtrakul PN. Effect of bitter melon
(Momordica charantia Linn) on level and function of natural killer cells in cervical cancer
patients with radiotherapy. J Med Assoc Thailand, 2003; 86: 61- 68.
42. Hirazumi A & Furusawa E. An immunomodulatory polysaccharide-rich substance from
the fruit juice of Morinda citrifolia (noni) with antitumor activity. Phytother Res, 1999; 13:
380- 387.
43. Mukherjee D, Khatua TN, Venkatesh P, Saha BP & Mukherjee PK. Immunomodulatory
potential of rhizome and seed extracts of Nelumbonucifera Gaertn. J Ethnopharmacol,
2010a; 128: 490-94.
44. Al- Farwachi. In vitro and in vivo immunomodulatory activities of Nerium oleander
aqueous leaf extract in rabbits. J Ani Vet Adv, 2007; 6: 1047-1050.
45. Salem ML. Immunomodulatory and therapeutic properties of the Nigella sativa L. seed.
Int Immuno Pharmacol, 2005; 5: 1749-1770.
198 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

46. Mediratta PK, Sharma KK & Singh S. Evaluation of immunomodulatory potential of

Ocimum sanctum seed oil and its possible mechanism of action. J Ethnopharmacol, 2002; 80:
15-20.
47. Sairam K, Ram CV, Babu MD, Kumar KV, Agarwal VK, &Goel RK. Antiulcerogenic
effect of methanolic extract of Embelica officinalis: An experimental study. J Ethnopharmacol,
2002; 82: 1- 9.
48. Sunila ES & Kuttan G. Immunomodulatory and antitumor activity of Piper longum
Linn. and piperine. J Ethnopharmacol, 2004; 90: 339-346.
49. Lee YC & Kim SH. Immunomodulatory effect of Juglans sinensis, Psoralea corylifolia,
Cheong - a - hwan extract and cyclosporine A on Th1 (IFN- γ)/Th2(IL-4) cytokine balance,
eosinophil accumulation in a murine model of asthma. Phytochem Let, 2008;1: 6-10.
50. Ross GR, Selvasubramanian S & Jayasundar S. Immunomodulatory activity of Punica
granatum in rabbits-a preliminary study. J Ethnopharmacol, 2001; 73: 85-87.
51. Punturee K, Wild CP, Kasinrerk W & Vinitketkumnuen U. Immunomodulatory
activities of Centella asiatica and Rhinacanthus nasutus extracts. Asian Pac Org Cancer Prev,
2005; 6: 396- 400.
52. Capek P, Hribalova V, Svandova E, Ebringerova A, Sasinkova V & Masarova J.
Characterization of immunomodulatory polysaccharides from Salvia officinalis L. Int J Bil
Macromol, 2003; 33: 113 – 119.
53. Rokeya Sultana, Salma Khanam and Kshama Devi. Immunomodulatory effect of
methanol extract of Solanum xanthocarpum fruits. International Journal of Pharma Sciences
and Research (IJPSR), 2011; 2 (2): 93-97.
54. Sreelekha TT, Vijayakumar, T, Ankanthil R, Vijayan KK & Nair MK.
Immunomodulatory effects of a polysaccharide from Tamarindus indica. Anticancer, 1993; 4:
209-212.
55. Shivaprasad HN, Kharya MD, Rana AC, Mohan S. Preliminary Immunomodulatory
Activities of the Aqueous Extract of Terminalia chebula. Pharm Biol, 2006; 44: 32-34.
56. Bishayi B, Roychowdhury S, Ghosh S &Sengupta M. Hepatoprotective and
immunomodulatory properties of Tinospora cordifolia in CCl4 intoxicated mature albino rats.
J Toxicol Sci, 2002; 27: 139 – 146.
57. Hafeez BB, Haque R, Parvez S, Pandey S, Sayeed I &Raisuddin S. Immunomodulatory
effects of fenugreek (Trigonella foenumgraecum L.) extract in mice. Int Immuno Pharmacol,
2003; 3: 257 – 265.
58. Ghosal S, Lal J, Srivastava R, Bhattacharya SK, Upadhyay SN, Jaiswal AK,
Chattopadhyay U. Immunomodulatory and CNS effects of sitoindosides IX and X, two new
glyco with anolides from Withania somnifera. Phytother Res, 1989; 3: 201-206.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 199

Chapter
HERBAL REMEDY FOR VETERINARY AILMENTS
20

DR. M. MENAKA1 & DR. S. SELVAKUMAR2

Principal & Professor, Nandha Siddha Medical College and Hospital,

1

Pitchandampalayam post, Erode- 638052, Tamilnadu, India

2Assistant Professor, Department of Physiology,

Dhanalakshmi Srinivasan Medical College and Hospital, Perambalur, Tamilnadu, India

*Corresponding Author: Dr. M. Menaka, Email: drmenakaravi@[Link]

ABSTRACT
India has a rich and diversified flora. Plants that have active medicinal compounds are
known as herbs. The use of herbs for therapeutic purposes, either alone or in conjunction
with other herbs, is known as herbal therapy. Herbal (botanical) medicine involves the
practice of prescribing Herbal products, or products derived directly from Herbs, for the
treatment of human diseases. Herbal medicine has survived since prehistoric times, and
people have used it for generations because they are relatively nontoxic, cheaper, and eco-
friendly. In contrast to this, synthetic drugs could pose serious problems and are toxic and
costly. Certain plants have biologically active components, and some widely used
pharmaceuticals today are either direct derivatives of or identical to the bioactive
components of traditional medicines from the past. Indeed, up to 30% of all contemporary
pharmaceuticals are said to have originated from herbal and botanical sources. Since
ancient times, veterinary medicine has made use of medicinal plants. Veterinary herbal
pharmaceuticals are plant-based drugs used in animal healthcare for therapeutic,
prophylactic, or diagnostic purposes. They have also been used in day-to-day problems of
healthcare in animals. Numerous herbs, such as catechu, licorice, pepper, garlic, and neem,
are utilized in veterinary treatment. Plants are the source of 25% of all prescribed
medications worldwide. Nearly 75% of medicinal plants are found growing naturally in
various Indian states. Numerous illnesses in animals, including poisoning, coughing,
constipation, and foot and mouth disease, are known to be treated by these plants.
Dermatitis, cataracts, burning, pneumonia, snakebite injuries, bone fractures, stomach
aches, skin conditions, etc. There is not much of a survey of the literature on this topic
(veterinary herbals). Hence this article focuses on the insight of herbal medicines, especially
for livestock animals.
200 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

KEYWORDS: Herbs, Herbal therapy, Veterinary herbal pharmaceuticals. Medicinal plants,

Herbal medicines, Livestock animals

INTRODUCTION
Herbal (botanical) medicine involves the practice of prescribing Herbal products, or
products derived directly from Herbs, for the treatment of human diseases. Many human
societies have been using herbal (botanical) medicine for thousands of years. These cultures
have accumulated a vast amount of clinical knowledge over decades and even millennia
about which plants are effective for particular ailments and how to use them most
effectively. The history of veterinary herbal treatment is similar to that of human therapy
because early civilizations placed a high value on the health of the horses and cattle that
were so essential to their lives, and it is estimated that 75% of the world's population still
uses herbal medicine for basic medical care today. Herbal Medicine or therapy is the use of
herbs for medicinal purposes, either on their own or in combination with other herbs."
Chemists were able to separate and refine the active components in herbs in the late
eighteenth century because of scientific advancements. The production of synthetic
medications was made possible by further developments.
Herbal therapy started to diverge from mainstream medicine at that time because
traditional medical professionals believed that giving specific amounts of the pure, active
chemical—whether synthetic or derived from plants—was safer and more effective.
Proponents of herbal therapy contend that the natural product contains additional elements
that work in concert with the therapeutic principle and that entire herbs or their extracts are
more effective. Veterinary herbal pharmaceuticals are plant-based drugs used in animal
medicine for therapeutic, prophylactic, or diagnostic purposes. The knowledge, skills,
methods, practices, and beliefs of small-scale farmers regarding the care of their livestock
are covered by veterinary drugs in rural India. Since the beginning of human history Herbal
medicine has been utilized. It involves using plants as medications to treat illnesses and
enhance people's general well-being. Since herbal medicines are believed to have few or no
side effects, more and more individuals are using them [1]. A rising number of people are
using herbal treatments since they are thought to have few or no negative effects. Eighty
percent of people in Asian and African nations rely on traditional medicine for their basic
medical needs. Herbal remedies are the most lucrative kind of traditional medicine,
bringing in billions of dollars annually. Because 40% of the plants contain essential
components for prescription medications, researchers turn to traditional remedies for
guidance. Plants that were once utilized in traditional medicine are the source of about 25%
of modern pharmaceuticals. For a variety of symptoms and ailments, three out of four
individuals with HIV/AIDS in Africa, North America, and Europe turn to traditional
medicine in one way or another. Thirty to fifty percent of the medicine consumed in China
is traditional. China produces 1.8 billion US dollar’s worth of herbal goods annually
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 201

through over 800 firms. In India, traditional medicine is widely practiced, especially in rural
areas where 70% of the population resides. [2].
The World Health Organization (WHO) defines traditional medicine (herbal
medicine) as ‚the total of the knowledge, skills, and practices based on the theories, beliefs,
and experiences indigenous to different cultures, whether explicable or not, used in the
maintenance of health as well as in the prevention, diagnosis, improvement or treatment of
physical and mental illness [3]. Herbal remedies used in veterinary medicine include plant-
based medications used for therapeutic, preventative, or diagnostic purposes in animal
healthcare. Long-term use of synthetic drugs can result in hazardous metabolites and
byproducts that should be taken seriously. For instance, animals that have antibiotic
residues in them may acquire antibiotic resistance. Issues like these have prompted the
search for alternatives because herbal remedies are safer and less costly than the present
methods of caring for animals [4][5]. Many times, standard medical treatment has already
been used. As an alternate viewpoint, herbal remedies can often be used in conjunction with
the traditional method, but they can also be employed in place of it in many situations,
especially for complex or long-term diseases. The patient's vitality, dosage, and potential
drug-herb and herb-herb interactions should always be carefully considered.
The Indian Pharmacopoeia (IP) is a formal regulatory document designed to ensure
the total quality control and assurance of pharmaceutical products sold in India, hence
enhancing the medications' safety, effectiveness, and affordability. Based on the Drugs and
Cosmetics Act 1940 and its Rules 1945, the Indian Pharmacopoeia Commission publishes IP,
which includes several well-selected herbal mixtures, extracts, and monographs. Each
monograph of a herb in the IP includes the botanical name, genus, species, variety, and
quality requirement in line with the binomial system of nomenclature [6]. A wide variety of
pharmacologically active substances can be found in medicinal herbs, and each herb has a
special combination and set of characteristics. Many herbs, or whole plants, have
components that work in multiple ways when combined to form a single medication. When
prescribing such herbal remedies for the benefit of animal health, it would be acceptable to
consider the risk-benefit ratio based on scientific evidence and a prescriber's experience.
This article provides an overview of herbal medicines used for veterinary care, along with
further information.

MATERIALS AND METHODS

The various methods for administering or preparing herbal medications for veterinary use
are as follows [7]:
 Fresh herbs are chopped and mixed with food. Chopped fresh herbs are combined
with cuisine. It might be the most effective approach to offer herbs when they are
available.
 Adding dried herbs to food or making decoctions or infusions with hot water are
two ways to use them both internally and externally.
202 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

 Alcoholic tinctures shall be carefully administered orally with a dropper or syringe,

either undiluted or diluted with water.
 Externally given lotions or oil infusions can be applied to aching joints, such as by
rubbing them.
 The most widely used type of herbal treatment is commercially made tablets or
powders.

If a product contains herbal remedies to prevent or treat an animal's illness, the HPRA
considers those products to be veterinary medications.
- It should be noted, nevertheless, that preparations made from dried or crushed
herbs that make up a small portion of a product meant to be given orally to healthy
animals as part of their diet are not considered veterinary medicines as long as: - no
indication is made for the product's use as a veterinary medicine.
- At the dosage given to the target animal, none of the herbal substances have
pharmacological, immunological, or metabolic effects on physiological function, nor
is the amount of herb(s) indicative of what an animal grazing on native pasture
might likely consume.
The accurate conversion of medication dosage from one animal species to another and the
conversion of animal dose to human dose are both critical from the standpoints of
pharmacological safety and efficacy. Furthermore, drugs are usually administered to
animals under duress and mixed with food. The Food and Drug Administration has
recommended that normalization to body surface area (BSA), which is frequently expressed
in milligrams per square meter and A correction factor (Km) listed in Table 1, be used to
accurately extrapolate animal dose to human dose.

Table 1: Relationship Between Animal Dose and Human Dose

Species Weight (kg) BSA (Mg/M2) Km Factor

Hamster 0.008 0.02 5
Mouse 0.02 0.007 3
Rat 0.15 0.025 6
Guinea Pig 0.4 0.05 8
Rabbit 1.8 0.15 12
Monkey 03 0.24 12
Dog 10 0.5 20
Baboon 12 0.6 20
Human
20 0.8 25
Child
60 1.6 37
Adult
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 203

Herbal remedies can be used to treat almost any condition that currently presents a problem
for conventional veterinary medicine, such as epilepsy, chronic kidney failure, chronic
lameness, hormonal imbalances, behavioral problems, allergic skin diseases, liver failure,
and inflammatory bowel diseases; other herbs may only be used as "tonics," promoting the
normal function of healthy organs. Standardization is required before the administration or
use of herbal medications or items for animal use. To guarantee that one or more of the
primary phytochemical constituents or other substances are present in a specified quantity,
veterinary herbal medicines (crude drugs/extracts) must be standardized to confirm their
quality, uniformity, and reproducibility. Because herbal medications contain intricate mixes
of many chemicals, standardizing them is a challenging procedure. Standardization and
validation of active ingredients require knowledge of the physicochemical characteristics of
herbal medicines as well as other preformulation data. For the standardization, a variety of
chemical, spectroscopic, and biological techniques are also used. Nuclear magnetic
resonance, mass spectroscopy, liquid chromatography, high-performance thin-layer
chromatography (HPTLC), infrared spectroscopy, and others are a few examples [8].

Table 2: The most commonly used herbals or Herbal drugs for veterinary practices or
ailments are listed [9-28]

Botanical name Pharmacological action

Acacia catechu astringent
Rubia cordifolia Astringent, diuretic, antidysenteric, antiseptic
Acidum aritiucm Rumen acidifier
Tribulus terrestris Antidysentry, diuretic
Carminative, anti-inflammatory, antibacterial, in
Syzygium aromaticum
dyspepsia, gastric irritation
Antipyretic, anti-ulcer, expulsion of
Withania somnifera
placenta, anticonvulsive, tissue healing,
antibacterial, improves sexual vitality
Adhatoda vasica Expectorant, diuretic and anti-spasmodic
For Chicken pox, intestinal parasites, eye diseases, anti-acidity,
Phyllanthus emblica
antidiarrheal
Andrographis paniculata Antidysentery, Antipyretic
Terminalia arjuna Hemostatic properties, tissue healing, heart diseases
Boswelia serrata Analgesic, Anti-inflammatory, Anticancer
Antidiarrhea, Anti dysentery, Alimentary and digestive disorders,
Picrorhiza kurroa
deworming, tonsil,
Curcuma longa Analgesic, Anti-inflammatory, Anticancer, Antiemetic
Ocimum sanctum Antipurulent, for Cough and cold, rhinitis, body ache.
Capsicum frutescens Analgesic, Circulatory support
Terminalia bellirica Antidiarrhea, anti-acidity
Analgesic, Anti-inflammatory, Antiosteoporotic
Harpagophytum procumbens
Antioxidant, Appetite suppressing.
204 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

Mucuna pruriens Antidiarrhea, ouster induction, wound healing

Anti-inflammatory, Anticonvulsant, Analgesic
Cannabis sativa
Neuroprotective, Antioxidant
Boerhavia diffusa Improve vitality
Pimpinella anisum Aromatic, stimulant, and lessen grippling effect of
cathartics
Anti-inflammatory, antiulcer, laxative, dyspepsia, for prolapsed
Azadirachta indica uterus, as mosquito repellent, Indigestion, liver disorders, tissue
healing, smallpox
Analgesic for aches, Alleviates digestive discomfort
/antispasmodic, Anti-inflammatory
Mentha piperita Anticancer, Hypoglycemic / antidiabetic, Antifungal,
Antibacterial, Antifibrotic, Antioxidant, Anti-infective for GI tract

Tonsillitis, foot and mouth disease,

Tinospora cordifolia
anthrax, bone fracture, blood purification
Ricinus communis Purgative, External Protective
Hemidesmus indicus Anticonvulsive
Piper methysticum Anticonvulsant, Local anesthetic, Skeletal muscle relaxant
Carica papaya Jaundice, Eczema
Carminative, stimulant, and antispasmodic.
Ferula asafoetida
Externally antiseptic
Gymnema sylvestre anti-diabetic, for Eye discharge.
Camphora officunarum Stimulant, carminative and antispasmodic, externally antiseptic
Antiemetic, Purgative, For Tongue sore,
Cassia fistula
constipation, to reduce swelling due to cold
Hypericum perforatum Antidepressant, Neuroprotective, Analgesic for neuropathic pain
Embelia ribes Diuretic, astringent, anti-inflammatory, antibacterial
Glycyrrhiza glabra Expectorant & demulcent
Centella asiatica antipyretic, antidysentery
Cephaelis ipecacuana Antibacterial, emetic, diaphoretic
Claviceps purpurea Uterine stimulant, oxytocic, abortifacient
Catharanthus roseus Stomachic, sedative & tranquilizing property
Laxative, Antipyretic, for hematuria, indigestion, chicken pox,
Coriandrum sativum
dehydration
Piper longum Anti-inflammatory, analgesic, for anorexia
Antidiarrhea, for Mastitis, cough, cold, fever,
Piper nigrum indigestion, throat swelling, intestinal disorder, blood in excreta,
food poisoning
Terminalia chebula Anti-diarrhoea, anti-dysentery, anti-ulcer, for anthrax, anorexia
Analgesic, Anti-inflammatory, Anticancer, Hypoglycemic,
Zingiber officinale Antiemetic, Regulates GI motility.
Anti-infective for GI tract
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 205

Siddha system of medicine is the mother medicine and traditional medical system of the
ancient Dravidians in south India. The southern Indian peninsula's civilization was
dominated by the Siddha medical system, which is as old as humanity. Since ancient times,
veterinary medicine has made use of medicinal plants. The system provides preventive,
promotional, curative, rejuvenating, and rehabilitative healthcare with a thorough and
scientific approach. Additionally, the Siddha system provides efficient remedies for several
common illnesses and enhances the quality of life by managing lifestyle diseases and
illnesses of different bodily systems. The script MAATTU VAGADAM [40] was created
specifically to treat the ailments of horses, cattle, and birds. Drug use in animals raised for
food may result in residues in animal-derived goods (meat, milk, and honey) and endanger
the consumer's health. Many nations have outlawed the use of antibiotics in animal farming
due to rising public awareness and antimicrobial resistance, which poses a hazard to human
health. It makes it necessary to find a substitute for growth boosters and antibiotics. To
address the issue of drug residues, the Tamil Nadu government took the initiative in 1992 to
introduce the idea of Siddha medicine into veterinary science. All veterinary clinics and
dispensaries operating under the jurisdiction of the Department of Animal Husbandry,
Government of Tamil Nadu, get Siddha pharmaceuticals or medicine kits, which contain
eleven medications.

CONCLUSION
The extensive range of herbal medications that can be used to cure animal illnesses is
discussed in this article. When creating veterinary herbal formulations, manufacturers are
urged to adhere to the IP criteria for these herbal medications. These ancient remedies have
remained popular despite the considerable contemporary systems that hospitals and
government organizations have put in place to improve rural health care. There is a wealth
of unrecorded traditional knowledge regarding animal illnesses, herbal remedies,
formulations, etc. in some rural areas. However, this ancient veterinary knowledge is in
danger of disappearing because of industrialization. This information can only be learned
from what has been passed down through the ages, and traditional veterinary knowledge is
vanishing as a result of the present generation's disinterest in it. Thus, it is imperative to
highlight the veterinary herbal industry. Most herbal veterinary treatments are available at
a relatively low cost when compared to existing drugs.
The active compounds in medicinal plants are getting more and more expensive,
even though herbal products are less expensive. Herbal veterinary medications are
therefore becoming less effective than allopathic ones. Encouragement of study/research in
this area is therefore also desperately needed. The Tamil Nadu University for Veterinary
and Animal Sciences and the Central Council for Research in Siddha have signed an
agreement to create traditional medicines for animals. To address animal health care at the
national and international levels, it is also necessary to set quality standards for veterinary
herbal medications and investigate the feasibility of harmonization or collaborative
206 INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES

initiatives. Therefore, it can be said that for these medicinal plants to be developed and used
as veterinary medications, both the validation of traditional claims (in-depth
Pharmacognostical, phytochemical, and pharmacological investigations, etc.) and safety
evaluations in suitable models of these plants are still required. The management of herbal
medications in veterinary health care would be aided by holding additional training
workshops on herbal drugs for veterinarians. Skilled veterinary herbalists can interpret the
patient's reaction to therapy and comprehend how various forms of treatment combine.

REFERENCES
1. Herbal medicine. [Link] WHO.
INT. World Health Organization.
2. Available from:
[Link] Human
resources and advanced infrastructure can spur Indian herbal industry growth.
Available from: [Link] [Link] / News Details. aspx? Aid
=73588&sid=1 [Last accessed on 2014 Jul 10].
3. Phondani PC, Maikhuri RK, Kal CP. Ethnoveterinary uses of medicinal plants
among traditional herbal healers in Alaknanda catchment of Uttarakhand, India.
African Journal of Traditional Complement Alternation Medicine. 2010; 7:195–206.
4. Chattopadhyay MK. Herbal medicines. Current Sciences. 1996; 71:5.
5. Kamboj VP. Herbal Medicine. Current Sciences.2000;78:35–4.
6. IPC. Indian Pharmacopoeia 2014. Vol 3. The Indian Pharmacopoeia Commission.
Ghaziabad; 2014. p. 3165-284.
7. Veterinary herbal therapy. [Link]
herbal-therapy.
8. Chakravarthy BK. Standardization of herbal products. Indian J Nat Prod 1993;
9:23‑6.
9. Takhar HK. Folk herbal veterinary medicines of southern Rajasthan. Indian J Tradit
Knowl 2004; 3:407‑18.
10. Pande PC, Tiwari L, Pande HC. Ethnoveterinary plants of Uttaranchal - A review.
Indian J Tradit Knowl 2007; 6:444‑58.
11. Pandit PK. Inventory of ethnoveterinary medicinal plants of Jhargram division West
Bengal, India. Indian Forester 2010; 136:1183‑94.
12. Jaiswal S, Singh SV, Singh B, Singh HN. Plants are used for tissue healing of
animals. Natural Product Radiance 2004; 3:284‑92.
13. Galav P, Jain A, Katewa SS. Ethnoveterinary medicines used by tribals of
Tadgarh‑Raoli Wildlife Sanctuary, Rajasthan, India. Indian J Tradit Knowl 2013;
12:56‑61.
INNOVATIONS IN DRUG DISCOVERY: FORMULATION AND DELIVERY STRATEGIES 207

14. Sadangi N, Padhya RN, Sahu RK. Traditional veterinary herbal practices of
Kalahandi district, Orissa. In: De Silva T, editor. Traditional and alternative
medicines: Research and policy perceptive. 1st ed. New Delhi: Daya Publishing
House; 2009. p. 424‑31.
15. Mulay JR, Dinesh V, Sharma PP. Study of some ethno‑veterinary medicinal plants of
Ahmednagar district of Maharashtra, India. World J Sci Technol 2012; 2:15‑8.
16. Chakraborty S, Pal SK. Plants for cattle health: A review of ethno‑veterinary herbs in
veterinary health care. Ann Ayurvedic Med 2012; 1:144‑52.
17. Pal DC, Jain SK. Tribal Medicine. Calcutta: Naya Prakash; 1998. p. 317.
18. Ashok S, Reddy PG. Some reports on traditional ethno‑veterinary practices from
savargaon areas of Ashti Taluka in Beed district (m.s.) India. Int J Adv Bio Res 012;
2:115‑9.
19. Varshney JP. Traditional therapeutic resources for management of gastrointestinal
disorders and their clinical evaluation. In: Dwivedi SK, editor. Techniques for
scientific validation and evaluation of ethnoveterinary practices. 1st ed. Izatnagar:
IVRI Publisher; 1998. p. 47‑51.
20. Dey A, De JN. Ethnoveterinary uses of medicinal plants by the Aboriginals of
Purulia District, West Bengal, India. Int J Bot 2010; 6:433‑40.
21. Singh A, Singh MK, Singh S. Traditional medicinal flora of District Buxar (Bihar,
India). J Pharmacogn Phytochem 2013; 2:41‑9.
22. Sharma PK, Singh V. Ethnobotanical studies in North West and trans Himalayas, V
Ethnoveterinary medicinal plants used in Jammu and Kashmir, India. J
Ethnopharmacol 1989; 27:63‑70. 29.
23. Sudarsanam G, Reddy MB, Nagarju N. Veterinary crude drugs in Rayalaseema,
Andhra Pradesh, India. Int J Pharmacog.1995;33:52‑606.
24. Mishra S, Jha V, Shaktinath J. Plants in ethnoveterinary practices in Darbhanga
(North Bihar). In: Jain SK, editor. Ethnobiology in Human Welfare. 1st ed. New
Delhi: Deep Publisher; 1996. p. 189‑93.
25. Wynn SG. Veterinary herbal medicines. St Louis, Missouri: Elsevier Publications;
2007. p. 81.
26. Choodnal C. Some folk medicines for livestock in Kerala. Folklore 1988; 29:193‑201.
27. Mishra S, Sharma S, Vasudevan P, Bhatt RK, Pandey S, Singh M, et al. Livestock
feeding and traditional healthcare practices in the Bundelkhand region of Central
India. Indian J Tradit Knowl 2010; 9:333‑7.
28. Rajan S, Sethuraman M. Traditional veterinary practices in rural areas in Dindigul
district, Tamil Nadu, India. Indig Knowl Dev Monit 1997; 5:7‑9.
29. B. Rathina Naayakar and Sons, (2019), Pathinen siddhargalum sagadhevarum aruli
seydha Pasu Vaithiya Maattu vaagadam, Thirumagal Vilasa Achagam, Chennai-79.
 About the Editor
INNOVATIONS IN DRUG

Innovations in Drug Discovery: Formulation and

DR VISHNU KIRAN MANAM

DISCOVERY
[Link] [Micro-Bio], [Link]. [Biotech], MBA [Finance], PhD [Micro-Bio-Nanotech]
Six Sigma [Yellow, Green & Black Belt] certified professional.
SENIOR SCIENTIST | DEPUTY GENERAL MANAGER - R&D

Formulation and Delivery Strategies

IB GROUP [AQUACULTURE]
CHAIRMAN – UNIVERSAL SOCIETY OF RESEARCH & DEVELOPMENT

Delivery Strategies
Mail Id: [Link]@[Link]
Mobile: +91 9080611328

S. No Domain Experience (Years)

1 Aquaculture 8
2 R&D / Analytical 16
3 Academic 4
Edited by
He is a highly experienced Ph.D. doctorate in Applied Microbiology with a specialization in Nanotechnology.
With 19 years of expertise in Research and Development, Academics, Aquaculture, Analytical, Data
Analysis, Liaison and coordination, and Team Management, He has made significant contributions to Dr. Vishnu Kiran Manam
various organizations. He has been certified with Six Sigma [Yellow Belt, Green Belt & Black Belt]. He has
bagged the BEST SCIENTIST AWARD from IARDO, the YOUNG SCIENTIST AWARD from ELSEVIER
SSRN, the RESEARCH EXCELLENCE AWARD from RES, the BEST RESEARCHER AWARD from ISCAW
– ESM for the year 2021, and the BEST SCIENTIST AWARD from HyEdge for the year 2022. He has a
proven track record of delivering breakthrough improvements in operational excellence by implementing
research improvement techniques and ensuring quality compliance. In senior management roles, He has
successfully aligned resources, developed technology strategies, and evolved innovation management
focus areas to achieve strategic goals. His strengths lie in enhancing process operations, optimizing
resources and capacity utilization, and driving productivity and operational efficiencies while reducing

Dr. Vishnu Kiran Manam

costs and expenses. He has a reputation for high integrity and energy, and he excels in creating service level
agreements (SLAs), standard operating procedures (SOPs), and manuals. Additionally, He has a strong
ability to recruit and train multicultural teams with the latest knowledge and modern skills in Research
and Development and product development fields, enabling the deliv ery of high-quality services. As an
enterprising leader, He has a proven ability to direct personnel and foster a collaborative environment
that leads to the accomplishment of common goals. He is known for his vision and strategic thinking,
ensuring that organizations are positioned for success. Overall, He brings a wealth of experience, expertise,
and leadership skills to drive innovation, ensure quality, and achieve strategic objectives in the areas of
Aquaculture, Applied Microbiology, Research and Development, and Team Management.

SCIENG PUBLICATIONS ISBN: 978-93-94766-50-1

(ISO 9001:2015 Certified Company)

Janani lllam, Maniyakar Street, Anumandai, Marakkanam Taluk
Villupuram District, Tamilnadu 604303
website:[Link] Email:sciengpublications@[Link]
MRP- 1180/-